levodopa has been researched along with carbidopa in 1971 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 600 (30.44) | 18.7374 |
| 1990's | 431 (21.87) | 18.2507 |
| 2000's | 252 (12.79) | 29.6817 |
| 2010's | 500 (25.37) | 24.3611 |
| 2020's | 188 (9.54) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Walker, E | 1 |
| Greer, M | 1 |
| Quik, M; Sourkes, TL | 1 |
| Agnoli, A; Carolei, A; Casacchia, M; Fazio, C; Zamponi, A | 1 |
| Morley, JB | 1 |
| Winkelman, AC | 1 |
| Butler, IJ; Koslow, SH | 1 |
| Halász, N; Hökfelt, T; Ljungdahl, A | 1 |
| Rinne, UK | 1 |
| Bell, RD; Boyar, RM; Carruth, A; Rosenberg, RN | 1 |
| Leibowitz, M; Lieberman, A | 1 |
| Bartholomé, K; Byrd, DJ | 1 |
| Calne, DB; Gielen, AC; Gillespie, MM; Kartzinel, R; Perlow, M; Sadowsky, DA; TEYCHENNE, P | 1 |
| Lipper, S | 1 |
| Elsworth, JD; Kohout, LJ; Lees, AJ; Sandler, M; Shaw, KM; Stern, GM; Youdim, MB | 1 |
| Halikowski, B; Piotropawlowska-Weinert, M | 1 |
| Coxon, A; Greenacre, JK; Petrie, A; Reid, JL | 1 |
| Anderson, DR; Guy, J; Quigley, HA | 1 |
| Klawans, HL; Lupton, MD; Moskovitz, C; Sharf, B | 1 |
| Darwish, SA; Furman, BL | 1 |
| Sears, ES | 1 |
| Caine, E; Carter, AC; Ebert, M; Kartzinel, R | 1 |
| Battista, AF; Goldstein, M; Lew, JY; Lieberman, A; Matsumoto, Y | 1 |
| Baylin, SB; Beaven, MA; Hsu, TH; Kallman, CH; Stevens, SA; Trump, DL | 1 |
| Ishimitsu, H; Nakasone, S; Namba, S | 1 |
| Finn, BW; Mendez, JS | 1 |
| Camanni, F; Mantegazza, P; Massara, F; Molinatti, GM; Müller, EE; Picotti, GB | 1 |
| Caine, ED; Davis, GC; Ebert, MH; Kopin, IJ; Markey, SP; Reichert, CM; Williams, AC | 1 |
| Gale, CC; Garcia, JF; Mixter, RC; Ruch, W; Russell, RM | 1 |
| Hjälmås, K; Rubenson, A; Sillén, U | 2 |
| Savery, F | 2 |
| Bedard, P; Marsden, CD; Parkes, JD | 1 |
| Estey, E; Goldstein, M; Gopinathan, G; Kupersmith, M; Lieberman, A | 1 |
| Battistin, L; Meneghetti, G; Rigotti, S; Saia, A | 1 |
| Diamond, SG; Markham, CH; Treciokas, LJ | 2 |
| van Rossum, JM | 1 |
| Ohlin, H; Stenberg, P; Wadstein, J | 1 |
| Cotzias, GC; Miller, ST; Papavasiliou, PS; Rosal, VL | 1 |
| Dorner, A; Wajsbort, E; Wajsbort, J | 1 |
| Hokkanen, E; Myllylä, VV; Saarinen, A; Tokola, O | 1 |
| Brambilla, F; Guastalla, A; Maffei, C; Nobile, P; Ponzano, M; Rovere, C; Scarone, S | 1 |
| Calne, DB; Eng, N; Nutt, J; Plotkin, C; Williams, A; Ziegler, M | 1 |
| Del Pesce, M; Di Bella, P; Forastieri, L; Paggi, A; Quattrini, A | 1 |
| Gilligan, B; O'Halloran, M; Stark, R; Wodak, J | 1 |
| Lee, LA; Leebaw, WJ; Woolf, PD | 1 |
| Barbieri, S; Bevilacqua, M; Lanfredini, M; Micossi, P; Nitti, F; Norbiato, G; Raggi, U | 1 |
| Chia, YC; Lees, GJ; Waterhouse, MJ | 1 |
| Albizzati, MG; Frattola, L; Scarlato, G; Trabucchi, M | 1 |
| Green, J; Haycook, W; Kilgore, M; Stephens, R | 1 |
| Birkmayer, W; Mentasti, M; Podiwinsky, F; Riederer, P | 1 |
| Falck, B; Hardebo, JE; Owman, C; Rosengren, E | 1 |
| Barone, DA; Martin, HL | 1 |
| Adamkov, J; Drobný, M; Fundárek, J; Svaleková, A | 1 |
| Bernstein, RM | 1 |
| List, SJ; Seeman, P | 1 |
| Bender, DA; Earl, CJ; Lees, AJ | 1 |
| Blair, ML; Ganong, WF; Keil, LC; Reid, IA | 1 |
| Amendt, P; Rohde, W | 1 |
| Commissiong, JW; Sedgwick, EM | 1 |
| Martinelli, P; Montagna, P | 1 |
| Carchedi, F; Casacchia, M; Di Ceglie, M; Meco, G | 1 |
| Fernstrom, JD; Wiggins, JF | 1 |
| Barthal, JS; Garrett, G; Schultz, DR | 1 |
| Ezrin-Waters, C; Seeman, P | 1 |
| Martin, JR; Quock, RM | 2 |
| Johnson, JC; Maeder, MC; Mazzaferri, EL; Spagna, VA | 1 |
| Jotkowitz, S | 1 |
| McDowell, FH; Miller, ST; Papavasiliou, PS; Rosal, V; Wang, YY | 1 |
| Estey, E; Goldstein, M; Goodgold, A; Gopinathan, G; Kupersmith, M; Lieberman, AN | 1 |
| Hershman, JM; Wingert, TD | 1 |
| Mölsä, P; Rinne, UK | 1 |
| Fahn, S; Hutt, CS; Snider, SR | 1 |
| Davidson, DL; Mawdsley, C; Pullar, IA; Wilson, H; Yates, CM | 1 |
| Frohman, LA; Kovathana, N; Nakawatase, C; Szabo, M | 1 |
| Brotchi, J; Dresse, A; Gerebtzoff, MA; Lepot, M; Scuvee-Moreau, J | 1 |
| Feuerstein, C; Gavend, M; Pellat, J; Perret, J; Serre, F; Tanche, M | 2 |
| Cotzias, GC; McDowell, FH; Papavasilliou, PS; Rosal, VL; Sheehan, PJ | 1 |
| Johnels, B; Steg, G; Ungerstedt, U | 1 |
| Coscia, CJ; Mitchell, J | 1 |
| Jenner, PG; Jones, MK; Ramsay, ID | 1 |
| Aprison, B; Besch, HR; Henry, DP; Judy, WV; Watanabe, AM | 1 |
| Fine, SA; Frohman, LA | 1 |
| Airoldi, L; Watkins, CJ; Wiggins, JF; Wurtman, RJ | 1 |
| Bern, SM; Calne, DB; McInturff, D; Pfeiffer, RF; Teychenne, PF | 1 |
| Klawans, HL; Kramer, J; Nausieda, PA; Wiener, WJ | 1 |
| Haddad, S; Kohout, LJ; Lees, AJ; Shaw, KM; Stern, GM | 1 |
| Davis, JM; Helgeson, E; Narasimhachari, N; Prakash, U | 1 |
| Choi, CR | 1 |
| Barkhatova, VP; Markova, ED | 1 |
| Altszuler, N; Hampshire, J; Moraru, E | 1 |
| Bonnet, K; Friedhoff, AJ; Rosengarten, H | 1 |
| Dessi'-Fulgheri, P; Glorioso, N; Monaco, F; Rappelli, A; Tedde, R | 1 |
| Bentin, S; Cooper, G; Lavy, S; Melamed, E | 1 |
| Kuzuya, F; Mori, K; Sakamoto, N; Yoshimine, N | 1 |
| Bodis-Wollner, I; Yahr, MD | 1 |
| Carr, LA; Jimenez, AE; Voogt, JL | 1 |
| Ganong, WF; Grumbach, MM; Holland, FJ; Kaplan, SL; Richards, GE | 1 |
| Agnoli, A; Denaro, A; Lelli, A; Ruggieri, S | 1 |
| Fisher, MA; Milner-Brown, HS; Weiner, WJ | 1 |
| Clemens, R | 1 |
| Chase, TN; Shoulson, I | 1 |
| Deze, J; Völler, GW | 1 |
| Marsden, CD; Mindham, RH; Parkes, JD | 1 |
| Avery, GS; Brogden, RN; Pinder, RM; Sawyer, PR; Speight, TM | 1 |
| McNay, JL | 1 |
| Bissessur, S; De Man, JJ; Lakke, JP; Moll, L; Seegers, J; Wesseling, H; Witt, FG | 1 |
| Hanzal, F | 2 |
| Bronaugh, RL; Garver, DL; Rutledge, CO; Wenger, GR | 1 |
| Berry, CA; Koller, WC | 1 |
| Kishikawa, H; Namba, S; Omoto, T | 1 |
| Lee, MC; Lippert, DM; Loewenson, RB; Martin, WE; Resch, JA; Tolosa, ES | 1 |
| Aarskog, D; Fevang, FO; Stoa, RF; Thorsen, T | 1 |
| Bianchine, JR | 1 |
| McKinney, AS | 1 |
| Anderson, F; Joynt, R; Rivera-Calimlim, L; Tandon, D | 1 |
| Carolei, A; Casacchi, M; Fazio, C | 1 |
| Hayek, J | 1 |
| Celesia, GG; Quaglieri, CE | 1 |
| Ward, HW | 1 |
| Blair, ML; Ganong, WF; Reid, IA | 1 |
| Brodt, B; Grimm, W; Schönberger, W; Ziegler, R | 2 |
| Agnati, L; Fuxe, K; Hökfelt, T; Löfstöm, A | 1 |
| Blum, K; Hirst, M; Marshall, A | 1 |
| Messiha, FS | 1 |
| Rampton, DS | 1 |
| De la Garza, R; Lombardo, L | 1 |
| Burke, W; Coscia, CJ; Jamroz, G; Lasala, JM; McFarlane, J; Mitchell, J; O'Toole, MM; Wilson, ML | 1 |
| Duvoisin, RC | 2 |
| Calne, DB; Pfeiffer, RF; Teychenne, PF | 1 |
| Lin, JT; Ziegler, DK | 1 |
| Goodwin, BL; Johnson, RD; Ruthven, CR; Sandler, M | 1 |
| Goodale, DB; Moore, KE | 1 |
| Carrera, N; Marti-Masso, JF; Martínez-Lage, JM | 2 |
| Bowers, MB; Extein, I; Roth, RH; Van Woert, M | 1 |
| Mizuno, Y; Obayashi, T; Ueki, A; Yoshida, M | 1 |
| Cooper, RL; Linnoila, M | 1 |
| Londoõ, R | 1 |
| Omoto, T | 1 |
| De Léan, J; Hornykiewicz, O; Richardson, JC | 1 |
| Martocci, RJ | 1 |
| Gabreëls, FJ; Joosten, EM; Keyser, A; Korten, JJ | 1 |
| Marsden, CD; Parkes, JD; Tarsy, D | 1 |
| Jaatoul, N; Kertesz, A; McInnis, W; Paty, DW | 1 |
| Goodgold, A; Jonas, S; Leibowitz, M; Lieberman, A | 1 |
| Baker, AB; Lee, MC; Loewenson, RB; Martin, WE; Resch, JA; Tolosa, ES | 1 |
| Critchley, E | 1 |
| Bell-Midura, M; Cotzias, GC; Mendez, JS; Papavasiliou, PS; Tolosa, ES | 1 |
| Barbeau, A | 1 |
| Cotzias, GC; Dahl, K; Finn, BW; Mendez, JS | 1 |
| Strömberg, U; Svensson, TH | 1 |
| Horie, R; Yamori, Y | 1 |
| Muenter, MD; Sharpless, NS; Tyce, GM | 1 |
| McDowell, FH; Stern, PH; Sweet, RD; Wasterlain, CG | 1 |
| Kishikawa, H; Ohmoto, T | 1 |
| Calne, DB; Findley, LJ; Lewis, PJ; Teychenne, PF | 1 |
| McDowell, FH; Sweet, RD | 1 |
| Cohen, HP; Jacobson, RL; Martin, WE; Tolosa, ES | 1 |
| Moore, KE; Thornburg, JE | 1 |
| Barnett, A; Goldstein, JM; Malick, JB | 1 |
| Franks, S; Lawton, NF; Marshall, NJ | 1 |
| Maj, J; Przewlocka, B | 1 |
| Corsini, GU; Mangoni, A; Marrosu, F; Spissu, A | 1 |
| Cerone, G; Nurzia, A; Pirro, R; Vacca, U | 1 |
| Celesia, GG; Wanamaker, WM | 1 |
| Antonaccio, MJ; Kerwin, L | 1 |
| Birket-Smith, E; Dupont, E; Hansen, E; Mikkelsen, B; Pakkenberg, H; Presthus, J; Rautakorpi, I; Riman, E; Rinne, UK | 1 |
| Hirst, M; Marshall, A | 1 |
| Calne, DB; Fermaglich, J | 1 |
| Hildick-Smith, M | 2 |
| Reid, WG | 1 |
| Aicardi, J; Goutières, F; Rondot, P; Ziegler, M | 1 |
| Dyck, PJ; Jaradeh, S | 1 |
| Fredow, G; Löscher, W | 1 |
| Horstink, MW; Jansen, EN; Roos, RA; Wolters, EC | 2 |
| Golubeva, IA; Maslova, LN; Patrusheva, SV; Sklianova, NA | 1 |
| Lieberman, A | 3 |
| Camarata, PJ; Chae, H; Ebner, TJ; Haines, SJ; Park, SK; Parker, RG; Turner, DA | 1 |
| Heninger, GR; Kleber, HD; Kosten, TR; McDougle, CJ; Palumbo, JM; Price, LH | 1 |
| Bernardi, G; Calabresi, P; Mercuri, NB | 2 |
| De Ceballos, ML; Jenner, P; Marsden, CD; Rose, S; Taylor, MD | 1 |
| Blunt, SB; Jenner, P; Marsden, CD | 4 |
| Advenier, C; Brion, N; Grégoire, A; Kollenbach, K; Marion, MH; Pays, M | 1 |
| Golbe, LI; Schiffman, PL | 1 |
| Borisenko, SA; Männistö, PT; Törnwall, M; Tuomainen, P; Tuominen, RK | 1 |
| Eckardt, MJ; George, DT; Lindquist, T; Linnoila, M; Martin, PR; Mathis, C; Moss, H; Rawlings, RR | 1 |
| Ashford, JW; Hargrave, R | 1 |
| Manji, HK; Potter, WZ; Rudorfer, MV | 1 |
| Bramante, L; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Henley, M; Nicholson, PW; O'Neill, CJ; Purkiss, AG; Weller, C | 1 |
| Collin, C; Eckernäs, SA; Grahnén, A; Ling-Andersson, A; Nilsson, M; Tiger, G | 1 |
| Fenton, ML; Harnett, DS; Rosenthal, SH | 1 |
| Furukawa, Y; Kondo, T; Mizuno, Y; Narabayashi, H; Nishi, K | 1 |
| Graff, E; Korczyn, AD; Rabey, JM; Shabtai, H; Vered, Y | 1 |
| Humphreys, TM; Schmidt, CJ; Sorensen, SM; Taylor, VL | 1 |
| Hildebrand, J; Moussa, Z; Przedborski, S; Raftopoulos, C | 1 |
| Caligiuri, MP; Heindel, WC; Lohr, JB | 1 |
| Anderson, TJ; Donaldson, IM; Ewer, TC; Gilchrist, NL | 1 |
| LeWitt, PA | 1 |
| Pfeiffer, R | 1 |
| Koller, WC | 3 |
| Rodnitzky, RL | 1 |
| Hutton, JT; Morris, JL | 2 |
| Marsden, CD; Pires, M; Quinn, NP; Scaravilli, F; Steiger, MJ | 1 |
| Kaakkola, S; Männistö, PT; Tuomainen, P; Wurtman, RJ | 1 |
| Kleedorfer, B; Poewe, W | 1 |
| Gancher, ST; Grandas, F; Lera, G; Nutt, JG; Obeso, JA; Rodriguez, M | 1 |
| Ahlskog, JE; Bailey, PA; Muenter, MD; Stevens, PM | 1 |
| Anderson, JJ; Bravi, D; Chase, TN; Dagani, F; Davis, TL; Ferrari, R; Gillespie, M | 1 |
| Baruzzi, A; Contin, M; Martinelli, P; Riva, R | 1 |
| Cutlip, WD; Makela, EH | 1 |
| Männistö, PT; Tuomainen, P; Tuominen, RK | 1 |
| Schmidt, CJ | 1 |
| Männistö, PT; Törnwall, M | 2 |
| Ahlskog, JE; Bailey, PA; Miller, PM; Muenter, MD | 1 |
| Jenner, P; Marsden, CD; Rose, S | 4 |
| Blandina, P; Grenader, A; Healy, DP; Huo, TL | 1 |
| Barthelmebs, M; Froehly, S; Grima, M; Imbs, JL; Stephan, D; Vailly, B; Velly, J | 1 |
| Balottin, U; Borgatti, R; Lanzi, G; Zambrino, CA | 1 |
| Pleet, AB | 1 |
| Karstaedt, PJ; Pincus, JH | 1 |
| Mark, MH; Sage, JI | 3 |
| Deleu, D; Ebinger, G; Michotte, Y | 1 |
| Bowes, SG; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ | 1 |
| Männistö, PT; Tuomainen, P | 1 |
| Aramendi, T; Argente, J; Cabranes, JA; Calle-Pascual, AL; Catalan, MJ; Charro, AL; Garcia-Mauriño, ML; Martin, P; Uria, J; Yuste, E | 1 |
| Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW | 1 |
| Abe, T; Kikuchi, T; Nozaki, Y; Takahashi, S; Tohgi, H | 1 |
| Deleu, D; Ebinger, G; Michotte, Y; Sarre, S | 4 |
| Carey, RJ | 2 |
| Horvat, J; Janković, BD; Stojić, Z | 1 |
| Jiménez, F; Jurado, J; Olvera, J; Rodríguez Cuevas, H; Velasco, F; Velasco, M | 1 |
| Cedarbaum, JM; Gauger, LL; Olanow, CW | 1 |
| Fritz, VU; Ming, A; Temlett, JA | 1 |
| Goshima, Y; Misu, Y; Nakamura, S | 1 |
| Deleu, D; Ebinger, G; Herregodts, P; Michotte, Y; Sarre, S | 1 |
| Wikberg, T | 1 |
| Findley, L; Prasher, D | 1 |
| Blunt, S; Jenner, P; Marsden, CD | 1 |
| Jacobs, MB; Varon, J | 1 |
| Cedarbaum, JM; Green-Parsons, A; Toy, LH | 1 |
| Azevedo, MS; Coelho, MH; Manso, CF; Silva, IJ | 1 |
| Davis, SS; Evans, DF; Hardy, JG; Melia, CD; Short, AH; Sparrow, RA; Wilding, IR; Yeh, KC | 1 |
| Buhrfiend, CM; Carvey, PM; Goetz, CG; Klawans, HL; Lin, DH; Lo, ES; Ptak, LR | 1 |
| Cedarbaum, JM; Olanow, CW | 1 |
| Argoff, CE; Filling-Katz, M; Fink, JK; Hallett, M; Ravin, PD | 1 |
| Bulling, MT; Burns, RJ; Wing, LM | 1 |
| Ahlskog, JE; Wilkinson, JM | 1 |
| Bédard, PJ; Di Paolo, T; Gagnon, C | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ; Tye, S | 1 |
| Cedarbaum, JM; Clark, M; Green-Parsons, A; Toy, LH | 1 |
| Sporer, KA | 1 |
| Coates, A; Gurney, H; Kefford, R | 1 |
| Glaeske, CS; Hofman, R; Pfeiffer, RF; Wilken, KE | 1 |
| Marsden, CD; Quinn, NP; Steiger, MJ; Toone, B | 1 |
| Lefeber, EJ; Rainer, C; Scheinost, NA | 1 |
| Coughlin, SS; Karstaedt, PJ; Pincus, JH | 1 |
| Hayashi, M; Kitajima, W; Saruta, T; Yamaji, Y | 1 |
| Altus, P; Hencey, MA; Weissman, MS | 1 |
| Bowes, SG; Charlett, A; Clark, PK; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ; Weller, C | 1 |
| Gash, DM; Kim, MH; Kurlan, R | 1 |
| Driver, PS | 1 |
| Bodis-Wollner, I; Chung, E; Ghilardi, MF; Glover, A; Onofrj, M; Pasik, P; Samson, Y | 1 |
| Block, G; Bush, D; Last, B; Liss, C; Manyam, B; Nakano, K; Nausieda, P; Olanow, CW; Tetrud, JA | 1 |
| August, TF; Bayne, WF; Eisenhandler, R; Musson, DG; Titus, DC; Yeh, KC | 1 |
| Messripour, M; Shahidi, Z | 1 |
| Barrio, JR; Luxen, A; Melega, WP; Nissenson, CH; Perlmutter, MM; Phelps, ME | 1 |
| Kaakkola, S; Männistö, PT; Toivonen, M; Törnwall, M; Tuomainen, P | 1 |
| Ito, S; Jimbow, K; Miura, T | 1 |
| Duvoisin, RC; Heikkila, RE; McHale, DM; Sage, JI; Sonsalla, PK | 2 |
| Bodian, CA; Elizan, TS; Mendoza, MR; Moros, DA; Pang, S; Yahr, MD | 1 |
| Korczyn, AD; Rabey, JM; Streifler, M; Treves, T | 1 |
| Barthelmebs, M; Grima, M; Imbs, JL; Vailly, B; Velly, J | 1 |
| Hodges, LC; Rapp, CG | 1 |
| Sanchez-Ramos, J; Singer, C; Weiner, WJ | 1 |
| Shi, YF | 1 |
| Brannan, T; Kaufmann, H; Knott, P; Yahr, M | 1 |
| Appley, AJ; Apuzzo, ML; Boyd, SD; Couldwell, WT; Neal, JH; Waters, CH; Weiner, LP; Wheelock, VH | 1 |
| Bowes, SG; Clark, PK; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ; Weller, C | 1 |
| Cowan, A | 1 |
| Calne, DB; Chu, NS; Lu, CS; Martin, WR; Peppard, RF; Teal, P | 1 |
| Hamaguchi, K; Iwasaki, A; Iwasaki, S; Narabayashi, Y; Takakusagi, M | 1 |
| Yamazaki, N | 1 |
| Belliardo, F; Betto, P; Corradini, C; Giambenedetti, M; Lucarelli, C; Ricciarello, G; Stocchi, F | 1 |
| Abascal, J; Bravo, G; Lopez-Lozano, JJ | 2 |
| Biswas, S; Poddar, MK | 1 |
| Haig, AJ; Ruess, JM | 1 |
| Cedarbaum, JM; Clark, M; Green-Parsons, A; Harts, A; McDowell, FH; Silvestri, M; Toy, L | 1 |
| Abe, T; Nozaki, Y; Takahashi, J; Takahashi, S; Tohgi, H; Ueno, M | 1 |
| Auerbach, G; Bamford, CR; Highkin, DJ; Lee, S; Sandyk, R; Torres, F; Travis, T | 1 |
| Gordin, A; Järvinen, M; Kaakkola, S; Nissinen, E; Pentikäinen, PJ; Rita, H; Schultz, E; Wikberg, T | 1 |
| Cedarbaum, JM; Guttman, M; Léger, G; Reches, A | 1 |
| Medenica, M; Nikolić, K | 1 |
| DeLanney, LE; Irwin, I; Langston, JW; Maze, M; Ricaurte, GA; Segal, IS; Walton, JK | 1 |
| Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM | 1 |
| Bovingdon, M; Frankel, JP; Kempster, PA; Lees, AJ; Pirtosek, Z; Stern, GM; Webster, R | 1 |
| Meltzer, HY; Parsa, MA; Ramirez, LF; Rohr, T | 1 |
| Angrist, B; Wolfsohn, R | 1 |
| Boyce, S; Clarke, CA; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Bakay, RA; Byrd, LD; Colbassani, HJ; Herring, CJ; Iuvone, PM; Mandir, A; Sweeney, KM; Watts, RL | 1 |
| Campbell, NR; Goodridge, AE; Hasinoff, BB; Kara, M; Rankine, D | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; LeWitt, PA; Nelson, MV | 1 |
| Boyson, SJ | 1 |
| Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC | 1 |
| Allen, G; Burns, RS; Calne, DB; Peppard, RF; Petruk, KC; Tsui, JK | 1 |
| Baumann, G; Chin, L; Gopinathan, G; Lieberman, A; Miller, E; Neophytides, A | 1 |
| Frankel, JP; Hughes, A; Lees, AJ; Stern, GM | 1 |
| Dousa, MK; Muenter, MD; Tyce, GM | 1 |
| Brown, LK; Miller, A; Moros, DA; Zupnick, HM | 1 |
| Sollazzo, D | 1 |
| De Léan, J; Rewcastle, NB; Richardson, JC | 1 |
| Rubenson, A; Sillén, U | 1 |
| Biasetti, S; Bracco, G; Ferraris, S; Guardamagna, O; Niederwieser, A; Ponzone, A | 1 |
| Barton, N; Burns, RS; Cohen, W; Fink, JK; Hallett, M; Lovenberg, W | 1 |
| Butler, IJ; Caskey, TC; Jankovic, J; Stout, JT | 1 |
| Calne, DB; Calne, S; Douglas, J; Postnikoff, D; Poulin, K; Ross, S; Tsui, JK; Woodward, W | 1 |
| Bovingdon, M; Frankel, JP; Kempster, PA; Lees, AJ; Stern, GM; Webster, R | 1 |
| Etemadzadeh, E; Kaakkola, S; Koskinen, L | 1 |
| Elizan, TS; Moros, D; Yahr, MD | 1 |
| Chase, TN; Cox, C; Fabbrini, G; Fedio, P; Mohr, E; Schlegel, J; Williams, J | 1 |
| Deleu, D; Ebinger, G; Jacques, M; Michotte, Y | 2 |
| Corenblum, B; Shaffer, EA | 1 |
| Ludatscher, JI | 1 |
| Grinio, LP; Mineeva, MF; Shoshina, LM | 1 |
| Gauger, LL; Olanow, CW; Werner, EG | 1 |
| Hisaka, A; Kasamatsu, S; Ohtawa, M; Takenaga, N | 1 |
| Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| Gilley, DW; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Aymard, N; Rondot, P; Teinturier, A; Ziegler, M | 1 |
| Rinne, JO; Rinne, UK | 1 |
| Aarli, JA; Gilhus, NE | 1 |
| Gerdes, U; Haagen, K; Ulm, G | 1 |
| Dickins, QS; Dobson, J; Rodnitzky, RL | 1 |
| Crossley, J; Ferguson, I; Peachey, RD; Reynolds, NJ | 1 |
| Shi, YF; Xia, P | 1 |
| Davoudi, H; Durso, R; Feldman, RG; Szabo, G | 1 |
| Araki, K; Matsuo, N; Niederwieser, A; Tanaka, Y; Tsuchiya, Y; Tsuzaki, S | 1 |
| Broe, GA; Genge, S; Hely, MA; Morris, JG; O'Sullivan, DJ; Rail, D; Reid, WG; Williamson, PM | 2 |
| Carter, JH; Hatcher, LF; Nutt, JG; Trotman, TL; Woodward, WR | 1 |
| Cedarbaum, JM; Hoey, M; McDowell, FH | 1 |
| Ahlskog, JE; Bell, GN; Carmichael, SW; Kelly, PJ; Stoddard, SL; van Heerden, JA | 1 |
| Ahlskog, JE | 5 |
| Cedarbaum, JM | 2 |
| Jankovic, J; Schwartz, K; Vander Linden, C | 1 |
| Bush, DF; Liss, CL; Morton, A | 1 |
| Dempski, RE; Oberholtzer, ER; Scholtz, EC; Yeh, KC | 1 |
| August, TF; Bush, DF; Lasseter, KC; Musson, DG; Schwartz, S; Smith, ME; Titus, DC; Yeh, KC | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; Kesaree, N; LeWitt, PA; Nelson, MV; Schlick, P | 2 |
| Davis, SS; Evans, DF; Hardy, JG; Melia, CD; Short, AH; Sparrow, RA; Wilding, IR | 1 |
| Bush, DF; Hutton, JT; Liss, CL; Morris, JL; Reines, S; Smith, ME | 1 |
| Baronti, F; Chase, TN; Fabbrini, G; Heuser, IJ; Juncos, JL; Mouradian, MM | 1 |
| Feldman, RG; Kelly, MR; Mosbach, PA; Saint Hilaire, MH; Thomas, CA | 1 |
| Evtushenko, SK; Mogilevskaia, GS; Osadchiĭ, VG; Ostropolets, SS; Prokhorova, LM; Sadekov, IA; Samsonenko, RA; Va'skovskaia, ME | 1 |
| Reynolds, CM; Riklan, M; Stellar, S | 1 |
| Gibb, WR; Kempster, PA; Lees, AJ; Stern, GM | 1 |
| Factor, SA; Ingenito, AM; Sanchez-Ramos, JR; Weiner, WJ | 1 |
| Luquin, MR; Obeso, JA; Vaamonde, J | 2 |
| Baruzzi, A; Contin, M; Martinelli, P; Procaccianti, G; Riva, R | 1 |
| Ingvarsson, PE; Johnels, B; Steg, G; Thorselius, M; Valls, M | 1 |
| Issopoulos, PB | 1 |
| Emskötter, T; Heidenreich, C; Lachenmayer, L | 1 |
| Costeff, H; Gadoth, N; Harel, S; Lavie, P | 1 |
| Friedman, JH; Lannon, MC | 1 |
| Factor, SA; Sanchez-Ramos, JR; Weiner, WJ | 1 |
| Golden, WE; Lavender, RC; Metzer, WS | 1 |
| Factor, SA; Hefti, F; Weiner, WJ | 1 |
| Everest, H; George, CF; Monks, K; Renwick, AG; Robertson, DR; Waller, DG; Wood, ND | 1 |
| Hisaka, A; Ihara, M; Sawasaki, Y; Takehana, H; Tomimoto, K; Tsuchiya, Y; Yano, M | 1 |
| Barter, R; Koller, WC; Vetere-Overfield, B | 1 |
| Douyon, R; Klutchko, B; Rotrosen, J; Serby, M | 1 |
| Aperia, A; Ballermann, BJ; Brenner, BM; Gullans, SR; Kone, BC; Seri, I | 1 |
| Case, TC; Hruby, VJ; Rockway, T; Snider, SR | 1 |
| Maayan, ML; Sellitto, RV; Volpert, EM | 1 |
| Connolly, CE; Donlon, J; O'Reilly, U | 1 |
| Critchley, P; Grandas Perez, FJ; Jenner, PG; Marsden, CD; Nomoto, M; Parkes, JD; Quinn, NP; Stahl, S | 1 |
| Koller, WC; Lang, AE; Marsden, CD; Quinn, NP | 1 |
| Chang, D; Chou, L; Keil, LC; Reid, IA | 1 |
| Butler, IJ; Irons, M; Kaufman, S; Langlais, PJ; Levy, HL; Milstien, S; O'Flynn, ME; Stack, CV | 1 |
| Baumann, G; Chin, L; Lieberman, A | 1 |
| Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM | 1 |
| Simpson, GM; Stephanos, MJ; Yadalam, KG | 1 |
| Cummings, JL; Friedenberg, DL | 1 |
| Brannan, T; Kaufmann, H; Knott, P; Leung, L; Yahr, M | 1 |
| Huber, SJ; Paulson, GW; Shulman, HG; Shuttleworth, EC | 2 |
| Bratton, M; Jost, MG; Lannon, MC; Lockhart-Pretti, P; Thomas, CA | 1 |
| Flauto, C; Groppetti, A; Parati, E; Parenti, M; Rusconi, L; Vescovi, A | 1 |
| Bazan, E; de Yebenes, JG; Mena, MA; Muradas, V; Reiriz, J | 1 |
| Basciani, M; Gambi, D; Ghilardi, MF; Onofrj, M | 1 |
| Jankovic, J | 1 |
| Ahlskog, JE; Bailey, PA; Bell, GN; McManis, PG; Muenter, MD | 1 |
| Ahlskog, JE; Muenter, MD | 2 |
| Herskovits, E; Leston, J; Yorio, A | 1 |
| Cedarbaum, JM; Dhar, AK; Kutt, H; McDowell, FH; Watkins, S | 1 |
| Carlson, HE | 1 |
| Birkmayer, W | 1 |
| Lindström, P; Ohlsson, L | 1 |
| Bodis-Wollner, I; Onofrj, M | 1 |
| Birkmayer, JD; Birkmayer, W | 1 |
| Matsubara, M; Nakagawa, K; Tango, M | 1 |
| Casas, M; Cobos, A; Ferre, S; Garcia, C; Grau, JM; Jane, F | 1 |
| Da Prada, M; Haefely, WE; Kettler, R; Schaffner, R; Zürcher, G | 1 |
| Duvoisin, RC; Golbe, LI | 1 |
| Pulmones, MT; Sansaricq, C; Snyderman, SE | 1 |
| Braz, S; Ferreira, TM; Silveira Filho, NG; Troncone, LR; Tufik, S | 1 |
| Ahlskog, JE; Duvoisin, RC; Foo, SH; Golbe, LI; Gopinathan, G; Lieberman, AN; Muenter, MD; Neophytides, AN | 1 |
| Cannon-Spoor, E; Chuang, LW; Costa, E; Freed, WJ; Karoum, F; Wyatt, RJ | 1 |
| Gillman, MA; Sandyk, R | 1 |
| Bioulac, B; Doudet, D; Gross, C; Lebrun-Grandié, P | 2 |
| Etemadzadeh, E; Kaakkola, S; Lindén, IB; Männistö, P; Nissinen, E; Pohto, P | 1 |
| Lieberman, AN | 2 |
| Albers, JW; Albin, RL; Ellis, CN; Silverman, AK; Voorhees, JJ | 1 |
| Kaakkola, S; Lindén, IB; Männistö, PT; Nissinen, E; Pohto, P; Schultz, E | 1 |
| Cohen, G; Spina, MB | 1 |
| Betto, P; Giambenedetti, M; Lucarelli, C; Ricciarello, G; Ruggeri, S; Stocchi, F | 1 |
| Black, JR; Pruchniewski, JF | 1 |
| Cortese, M; Fix, JA; Leppert, PS | 1 |
| Dyczek, A; Kardas, M; Podolec, Z | 1 |
| Albrecht, JW; Hutton, JT; Kopetzky, MT; Román, GC | 1 |
| Carroll, VS; Carvey, PM; Gilley, D; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM | 1 |
| Bouchard, S; Gawel, MJ; Libman, I; Riopelle, RJ | 1 |
| Denham, MJ; Deshmukh, AA; Dobbs, RJ; Dobbs, SM; Leeman, AL; Nicholson, PW; O'Neill, CJ; Royston, JP | 1 |
| Berger, J; Factor, SA; Sanchez-Ramos, J; Weiner, WJ | 1 |
| Ferraro, TN; Hare, TA; Manyam, BV | 1 |
| Como, P; Kurlan, R | 1 |
| Allain, H; Bentué-Ferrer, D; Reymann, JM; Sabouraud, O; Van den Driessche, J | 1 |
| Förster, I; Junghänel, H; Kropfgans, F | 1 |
| Cedarbaum, JM; Hoey, M; Kutt, H; McDowell, FH | 1 |
| Barton, NW; Cohen, WE; Filling-Katz, MR; Fink, JK; Hallett, M; Macrae, PR | 1 |
| Keller, RW; Kuhr, WG; Wightman, RM; Zigmond, MJ | 1 |
| Elias, JW; Hutton, JT; Imke, SC; Morris, JL; Román, GC | 1 |
| Bergamasco, B; Chiadò, I; De Gennaro, T; Delsedime, M; Gilli, M; Rainero, I; Riccio, A | 1 |
| Carruthers, M; Quinn, N | 1 |
| Duvoisin, RC; Heikkila, R; Sage, JI; Sonsalla, PK; Trooskin, S | 1 |
| Bukhanov, VP | 1 |
| Comella, CL; Goetz, CG; Klawans, HL; Penn, RD; Shannon, KM; Tanner, CM; Witt, TR | 1 |
| Brown, RG; Gotham, AM; Marsden, CD; Nissenbaum, H; Quinn, NP; Toone, B | 1 |
| Byer, DE; Danielson, DR; Messick, JM; Rorie, DK; Tyce, GM; Yaksh, TL | 1 |
| Agnoli, A; Brughitta, G; Ruggieri, S; Stocchi, F | 1 |
| Gopinathan, G; Lieberman, AN; Neophytides, A; Pasternack, P | 1 |
| Carvey, PM; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Bankiewicz, KS; Chiueh, CC; Doppman, JL; Jacobowitz, DM; Kopin, IJ; Oldfield, EH | 1 |
| Harris, M; Nora, L; Tanner, CM | 1 |
| Friedman, JH; Max, J; Swift, R | 1 |
| Janota, I; Marsden, CD; Parkes, D; Quinn, N | 1 |
| Duvoisin, RC; Sage, JI | 1 |
| Luque, FA; Petruska, P; Selhorst, JB | 1 |
| Agniel, A; Celsis, P; Demonet, JF; Doyon, B; Marc-Vergnes, JP; Montastruc, JL; Puel, M; Rascol, A | 1 |
| Bouchard, S; Gawel, M; Libman, I; Riopelle, R | 1 |
| Jankovic, J; Orman, J | 1 |
| Alberts, MJ; Olanow, CW | 1 |
| Wick, MM | 2 |
| Chase, TN; Fabbrini, G; Juncos, JL; Kask, AM; Mouradian, MM; Serrati, C | 1 |
| Clough, CG | 1 |
| Carroll, VS; Goetz, CG; Klawans, HL; Shannon, KM; Tanner, CM | 2 |
| D'Antona, N; De Leo, V; Genazzani, AR; Gioffrè, WR; Mazzullo, G; Petraglia, F; Sardelli, S | 1 |
| Cedarbaum, JM; Kutt, H; Williamson, R | 1 |
| Ermini, M; Finch, CE; Flurkey, K; Randall, PK; Sinha, YN | 1 |
| Artal, R; Barnes, RB; Lobo, RA | 1 |
| Sandyk, R | 3 |
| Corbin, DO; Williams, AC | 1 |
| Herbster, G; Koller, WC | 1 |
| Borghi, A; Bugiardini, R; Lenzi, S; Morgagni, G; Ottani, F; Pozzati, A; Puddu, P | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM; Serrati, C | 1 |
| Chase, TN; Fabbrini, G; Juncos, JL; Mouradian, MM | 1 |
| Bamford, CR; Bernick, C; Iacono, RP; Lee, SM; Sandyk, R; Stern, LZ | 1 |
| Breck, L; Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| Hoerning, E; Kaplan, PE; Sohn, DG | 1 |
| Lazarus, A | 1 |
| Golubev, VL; Orlova, OR | 1 |
| Bozek, CB; Calne, DB; Calne, S; Purves, S; Suchowersky, O | 1 |
| Muenter, MD | 2 |
| Patterson, JF | 1 |
| Klawans, HL; Paleologos, N | 1 |
| Wilson, JA | 1 |
| Carter, JH; Nutt, JG; Woodward, WR | 1 |
| Clarke, A; Kurlan, R; Miller, C; Rivera-Calimlim, L; Rubin, AJ; Shoulson, I | 1 |
| Adamkov, J; Fundárek, J; Sútorová, D | 1 |
| Langdon, N; Malcolm, PN; Parkes, JD | 1 |
| Calne, DB; Glover, R; Lau, E; Schulzer, M; Waterman, K | 1 |
| Flemenbaum, A; Rosen, H; Slater, VL | 1 |
| Boyce, S; De Ceballos, ML; Jenner, P; Marsden, CD | 1 |
| Flechter, S; Graff, E; Oberman, Z; Rabey, JM; Vardi, J | 1 |
| Doe, J | 1 |
| Metzner, J; Steup, A; Voll, A | 1 |
| Gershanik, OS; Leist, A | 1 |
| Hoehn, MM | 3 |
| van der Drift, JH | 1 |
| Glantz, RH; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Friedman, J | 1 |
| Ballard, PA; Langston, JW; Tetrud, JW | 1 |
| Blonder, J; Cohen, BE; Normand, M; Peled, I; Quint, J; Szeinberg, A | 1 |
| Caranasos, GJ; Cluff, LE; Stewart, RB | 1 |
| Bakker, K; Bruno, G; Chase, TN; Ruggieri, S; Tamminga, CA | 1 |
| Feldman, RG; Lannon, MC | 1 |
| Kapfhammer, HP; Kuss, HJ; Rüther, E | 1 |
| Chang, JP; Cook, AF; Marchant, TA; Nahorniak, CS; Peter, RE | 1 |
| Boiadzhieva, N; Ovcharov, R; Zakharieva, B | 1 |
| Caraceni, T; Giovannini, P; Grassi, MP; Piccolo, I; Scigliano, G; Soliveri, P | 1 |
| Barnes, RB; Lobo, RA | 1 |
| Reches, A | 1 |
| Amanova, ZN; Badalian, LO; Grinio, ZN; Sadovskaia, IuE; Temin, PA | 1 |
| Wirz, D | 1 |
| Artieda, J; Luquin, MR; Martínez Lage, JM; Obeso, JA; Tuñón, T | 1 |
| Fahn, S; Jackson-Lewis, V; Reches, A | 1 |
| Poddar, MK; Ray, SK | 1 |
| Huang, BY; Huang, CC; Huang, HS; Leu, ML | 1 |
| Bitton, V; Melamed, E; Zelig, O | 1 |
| Artieda, J; Lang, AE; Marsden, CD; Obeso, JA; Quinn, NP; Rothwell, JC | 1 |
| Di Battista, G; Di Meo, L; Figà-Talamanca, L; Gualandi, C; Lo Russo, F; Neri, G | 1 |
| Sjølin, SU; Trykker, H | 1 |
| Vertosick, FT | 1 |
| Berglund, B; Kaijser, L; Sachs, C | 1 |
| Davis, BM; Davis, KL; Horvath, TB; Johns, CA; Levy, MI; Mathé, AA; Mohs, RC; Rothpearl, AB | 1 |
| Askenasy, JJ; Yahr, MD | 1 |
| Calne, DB; Jaffe, M; Larsen, TA; LeWitt, PA; Newman, RP | 1 |
| Friedman, A | 1 |
| Rae-Grant, A; Spence, JD; Young, GB | 1 |
| Jankovic, J; Pettigrew, LC | 1 |
| Murray, TS; Wilson, JA | 1 |
| Bertelsmann, FW; Smit, LM | 1 |
| Barbieri, C; Borzio, M; Caldara, R; Masci, E; Piepoli, V | 1 |
| Admani, AK; Cordingley, GJ; Harris, RI; Verma, S | 1 |
| Olson, LG; Saunders, NA | 1 |
| Benvenuti, F; Bindi, A; Costantini, S; De Scisciolo, G; Pantaleo, T; Rossi, L; Zappoli, R | 1 |
| Anderson, JL; Nutt, JG; Woodward, WR | 1 |
| Nausieda, PA | 1 |
| Zhou, XD | 1 |
| Yu, HZ | 1 |
| Kaakkola, S; Männistö, PT; Mäntylä, R; Nissinen, E; Vuorela, A | 1 |
| Bermejo Pareja, F; de Yébenes, JG; Martinez-Martin, P; Muradas, V | 1 |
| Glasgow, GL; Henley, JW; Willoughby, EW | 1 |
| Chase, TN | 1 |
| Antonaccio, MJ; Robson, RD | 1 |
| Bagdon, WJ; Bokelman, DL; Brown, WR; Hite, M; Jensen, RD; Mattis, PA; Mendlowski, B; Peck, HM; Porter, CC; Zwickey, RE | 1 |
| Anagnoste, B; Battista, AF; Fuxe, K; Goldstein, M; Miyamoto, T | 1 |
| Rondot, P | 1 |
| Banzán, AM; Barcaglioni, JC; Donoso, AO | 1 |
| Antonaccio, MJ; Burrell, R; Robson, RD | 1 |
| Braham, J; Sarova-Pinhas, I | 1 |
| Cotzias, GC; Mena, I; Papavasiliou, PS | 1 |
| Markham, CH | 1 |
| Carreray, N; Del Amo, F; Delgado, G; Marti-Massó, JF; Martínez-Lage, JM | 1 |
| Fermaglich, J | 1 |
| Bianchine, JR; Sunyapridakul, L | 1 |
| Amanova, ZN; Badalian, LO; Temin, PA | 1 |
| Henning, M; Johansson, P | 2 |
| Ross, ED; Stewart, RM | 1 |
| Enna, SJ; Lake, CR; Teychenné, PF; Ziegler, MG | 1 |
| Marsden, CD; Parkes, JD; Quinn, N | 1 |
| Bodis-Wollner, I; Mylin, L; Thornton, J; Yahr, MD | 1 |
| Bergmann, KJ; Clough, CG; Yahr, MD | 1 |
| Johansson, P | 2 |
| Shoulson, I | 1 |
| Agnati, LF; Benefenati, F; Calza, L; Farabegoli, C; Fuxe, K; Goldstein, M; Zini, I | 1 |
| Carvey, P; Goetz, CG; Klawans, HL | 1 |
| Casey, DE; Gerlach, J | 1 |
| Bitton, V; Melamed, E | 1 |
| Hanley, WB; Kapatos, G; Kaufman, S; MacGregor, D; McInnes, RR; Milstien, S; Soldin, S; Van Loon, GR; Walsh, P; Warsh, JJ | 1 |
| Luther, JS; Stoudemire, A | 1 |
| Collinson, PO; Kind, PR; Sandler, M; Slavin, B; Weg, MW | 1 |
| Clavier, RM; Foulks, JG; Godin, DV; Ito, M; Perry, TL; Wall, RA; Yong, VW | 1 |
| Calne, DB; Ebert, MH; Eisler, T; Kopin, IJ; Krebs, H; Lake, CR; Murphy, DL; Nelson, R; Teräväinen, H; Weise, V; Whetzel, N | 1 |
| Boespflug, O; Demeocq, F; Guyon, A; Malpuech, G; Piton, A; Vanlieferinghen, P | 1 |
| Goetz, CG | 3 |
| Iadgarov, IS | 1 |
| Hadjikonstantinou, M; Markianos, M | 1 |
| Wilke, WL | 1 |
| Calne, DB; Newman, RP; Smallberg, SA; Weingartner, H | 1 |
| Bianchine, JR; Dippel, RL; Hutton, JT; Meyer, PG; Strahlendorf, HK | 1 |
| Coffey, CE; Massey, EW; Olanow, CW; Ross, DR | 1 |
| Cheal, M | 1 |
| Gerstenbrand, F; Poewe, W; Ransmayr, G | 1 |
| Alonso, RJ; Covington, TR; Mancall, EL | 1 |
| Lobo, RA; Shoupe, D | 1 |
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
| Armstrong, D; Courtney, CL; Palfai, T | 1 |
| Beers, MF; Hurtig, H; Melvin, G; Scarpa, A; Stern, M | 1 |
| Albizzati, MG; Bassi, S; Frattola, L; Spano, PF; Trabucchi, M | 1 |
| Esteban, A; Giménez-Roldán, S; Mateo, D | 1 |
| Dvorkin, MA; Medina, JH; Pazo, JH; Tumilasci, OR | 1 |
| Indo, T | 1 |
| Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Spencer, SE; Wooten, GF | 1 |
| Friedrich, FJ; Posner, MI; Rafal, RD; Walker, JA | 1 |
| Calne, DB; Kopin, IJ; Trombley, IK; Ward, CD | 1 |
| Goldstein, M; Gopinathan, G; Hiesiger, E; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 1 |
| Calne, DB; Larsen, TA; LeWitt, P; Newman, R | 1 |
| Agid, Y; Barroche, G; de Smet, Y; Lhermitte, F; Mear, JY; Weber, M | 1 |
| Berkovic, SF; Bladin, PF | 1 |
| Glover, V; Lees, AJ; Sandler, M; Stern, GM; Ward, C | 1 |
| Maier Hoehn, MM | 1 |
| Rondot, P; Ziegler, M | 1 |
| Ballard, P; Langston, JW | 1 |
| Lucas, TS; Quock, RM | 1 |
| D'Antona, N; Danero, S; De Leo, V; Franchi, F; Genazzani, AR; La Marca, S; Pieroni, ML; Ricci, MG; Urbani, TM | 1 |
| Diamond, SG; Markham, CH | 1 |
| Gerdes, U; Lehmann, K; Ulm, G | 1 |
| Callieco, R; Cosi, V; Romani, A; Zerbi, F | 1 |
| Bermejo Pareja, F; Martínez-Martín, P | 1 |
| Klawans, HL | 1 |
| Kamenetskiĭ, VK | 1 |
| Curtius, HC; Endres, W; Niederwieser, A; Ohrt, B; Schaub, J; Wang, M | 1 |
| Jacob, RG; Szekely, BC; Turner, SM | 1 |
| Aubert, ML; Ganong, WF; Grumbach, MM; Holland, FJ; Kaplan, SL; Richards, GE | 1 |
| Matsumoto, Y; Miyamoto, T; Nakamura, S; Ohmoto, T | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; Del Roscio, S; Falaschi, P; Frajese, G; Mearelli, S; Rocco, A; Ruggieri, S | 1 |
| Lawton, NF; MacDermot, J | 1 |
| Bridger, WF; Gardner, EL; Seeger, TF | 1 |
| Bolwig, TG; Friis, ML; Hertz, MM; Paulson, OB | 1 |
| Alaghband-Zadeh, J; Das, PK; Gawel, MJ; Lavin, PJ; Rose, FC | 1 |
| Leino, E | 1 |
| Ayalon, D; Rabey, JM; Ravid, R; Vardi, Y | 1 |
| Calne, DB; Chuang, LW; Eisler, T; Karoum, F; Klein, DF; Liebowitz, MR; Quitkin, FM; Wyatt, RJ | 1 |
| Vartanian, KZ | 1 |
| Caraceni, T; Cocchi, D; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A | 1 |
| Calne, DB; Eisler, T; Kaiser, DL; MacLeod, RM; Thorner, MO | 1 |
| Benco, R; Caldara, R; Crosignani, PG; Ferrari, C; Rampini, P; Scarduelli, C | 1 |
| Anile, C; Barbarino, A; De Marinis, L; Maira, G; Menini, E; Merlini, G | 1 |
| Kokkinidis, L; MacNeill, EP | 1 |
| Gopinathan, G; Hiesiger, E; Leibowitz, M; Lieberman, AN; Neophytides, A; Walker, R | 1 |
| Meadows, GG; Pierson, HF | 1 |
| Shapiro, MB; Yaar, I | 1 |
| Gelber, LR; Neumeyer, JL | 1 |
| Fahn, S | 2 |
| Lees, AJ; Stern, GM | 1 |
| Kemi, M; Kondo, M; Maki, E; Tanabe, K | 1 |
| Glantz, RH; Glatt, SL; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Goldstein, M; Gopinathan, G; Hiesiger, E; Leibowitz, M; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 1 |
| Carvey, P; Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ | 2 |
| Guttridge, D | 1 |
| Reimherr, F; Wender, PH; Wood, D | 1 |
| Mintz, M; Myslobodsky, MS; Radwan, H; Tomer, R | 1 |
| Hedner, T; Lundborg, P | 1 |
| Reimherr, FW; Wender, PH; Wood, DR | 1 |
| Bird, ED; Langlais, PJ; McEntee, WJ | 1 |
| Baker, H; Gauthier, S; Magnussen, I; Osterland, CK; Sternberg, EM; Van Woert, MH; Young, SN | 1 |
| Brown, GL; Bunney, WE; Ebert, MH; Langer, DH; Rapoport, JL | 2 |
| Boshes, B | 1 |
| Barbieri, C; Caldara, R; Crossignani, RM; Ferrari, C; Recchia, M | 1 |
| Calne, DB; Le Witt, PA | 1 |
| Lightman, SL | 1 |
| Goetz, CG; Nausieda, PA; Tanner, CM | 1 |
| Camanni, F; Cocchi, D; De Leo, V; Genazzani, AR; Müller, EE; Murru, S | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; De Giorgio, G; Falaschi, P; Rocco, A; Ruggieri, S | 1 |
| Keren, O; Korczyn, AD | 1 |
| Abdallah, RM; Desai, PR; Meadows, GG; Pierson, HF | 1 |
| Frohman, LA; Rao, R; Scommegna, A | 1 |
| Manyam, BV | 1 |
| Nausieda, PA; Weiner, WJ | 2 |
| Barbieri, C; Caldara, R; Ferrari, C; Larovere, MT; Mariotti, G | 1 |
| Nissinen, E; Taskinen, J | 1 |
| Biller, BJ; Feldman, ZT; Goodman, RH; King, LW; Molitch, ME; Moses, AC; Post, KD; Reichlin, S | 1 |
| Edwards, M | 1 |
| Kaplan, LR; Klawans, HL; Nausieda, PA; Weber, S; Weiner, WJ | 1 |
| Agnoli, A; Bruno, G; Denaro, A; Ruggieri, S | 1 |
| Bonnet, KA; Redford, HR | 1 |
| Brown, LL; Warner, C; Wolfson, LI | 1 |
| Casey, DE | 1 |
| Klawans, HL; Koller, WC; Nausieda, PA; Perlik, S; Weiner, WJ | 1 |
| Berger, JR; Kelley, RE | 1 |
| Dvorkin, MA; Medina, JH; O'Donnell, P; Pazo, JH | 1 |
| Glantz, R; Goetz, CG; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Gilden, ER; Hansch, EC; Hirsch, SB; Potvin, AR; Potvin, JH; Syndulko, K; Tourtellotte, WW | 1 |
| Castrogiovanni, P; Cavallacci, G; Fornaro, P; Perossini, M; Placidi, GF | 1 |
| Lieberman, AN; Plasse, HM | 1 |
| Barbieri, C; Benco, R; Caldara, R; Crossignani, RM; Ferrari, C; Rampini, P; Testori, GP; Trezzi, R | 1 |
| Grimes, JD; Hassan, MN | 1 |
| Faglia, G; Moriondo, P; Nissim, M; Travaglini, P | 1 |
| Stewart, RM | 1 |
| Bansal, S; Lee, LA; Woolf, PD | 1 |
| Agnoli, A; Baldassarre, M; Falaschi, P; Rocco, A; Ruggieri, S; Urso, RD | 1 |
| Barbieri, C; Borzio, F; Borzio, M; Caldara, R; Ferrari, C; Romussi, M | 1 |
| Agostini, L; Piccinin, GL; Piccirilli, M | 1 |
| Clough, CG; Mendoza, M; Yahr, MD | 1 |
| Hefti, F; Melamed, E | 1 |
| Goldstein, M; Gopinathan, G; Kupersmith, M; Leibowitz, M; Lieberman, A; Mehl, S; Neophytides, A | 1 |
| La Medica, A; Piccinin, GL; Piccirilli, M | 1 |
| Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Lewis, PR; Miller, JW; Schriefer, JA | 1 |
| Bellizzi, J; Hale, MS | 1 |
| Forsling, M; Lightman, SL | 1 |
| Barrett, RE; Côté, LJ; Fahn, S; Snider, SR | 1 |
| Lander, CM; Lees, AJ; Shaw, KM; Stern, GM | 1 |
| Duvoisin, RC; Mendoza, MM; Yahr, MD | 1 |
| James, WP; Jung, RT; Liddell, F; Shetty, PS | 1 |
| Barbieri, C; Caldara, R; Crosignani, PG; Ferrari, C; Malinverni, A; Mattei, AM; Rocchetti, M | 1 |
| Das Gupta, V; Gupta, A | 1 |
| Hirsch, SB; Potvin, AR; Potvin, JH; Syndulko, K; Tourtellotte, WW | 1 |
| Frohman, LA; Gonzalez-Villapando, C; Szabo, M | 1 |
| Crespi, R; Gattei, G; Zanoboni, A; Zanoboni-Muciaccia, W | 1 |
| Boomsma, F; Man in 't Veld, A; Schalekamp, M; van den Meiracker, A | 1 |
| Bushenbark, K; Esterlitz, J; Gauger, L; Hauser, RA; Hubble, J; Koller, W; Lilienfeld, D; Malapira, T; Olanow, CW | 1 |
| Ghosh, S; Poddar, MK | 1 |
| Kaakkola, S; Kask, A; Männistö, PT; Törnwall, M; Tuomainen, P | 1 |
| Lima, L; Urbina, M | 1 |
| Gleckman, AD; Wolf, AP | 1 |
| Gottlob, I; Reinecke, RD; Wizov, SS | 1 |
| Feigen, A | 1 |
| Lang, AE | 1 |
| Abe, T; Saheki, M; Takahashi, S; Tohgi, H; Tsukamoto, Y; Yamazaki, K | 1 |
| Fitzpatrick, AJ | 1 |
| Eriksson, T; Holmgren, B | 1 |
| Borgohain, R; Mohandas, S; Radhakrishna, H; Rao, VC; Singh, AK | 1 |
| Heerschap, A; Hinshaw, DB; Holshouser, BA; Kolem, H; Komu, M; Masur, H; Möller, HE; Sonninen, P; Vermathen, P; Zijlmans, J | 1 |
| Kuno, S; Mizuta, E; Nakatake, M; Yamasaki, S | 1 |
| Lunn, V; Northcott, C; Yatham, LN | 1 |
| Aceves, J; Flores, G; Ondarza, R; Velasco, F; Velasco, M | 1 |
| Winn, P | 1 |
| Jenner, P; Jolkkonen, J; Marsden, CD; Zeng, BY | 1 |
| D'Costa, DF; Moore-Smith, B; Phillips, PA; Sheehan, LJ | 1 |
| Carter, JH; Maricle, RA; Nutt, JG | 1 |
| Burns, RS; Davis, TL; Roznoski, M | 2 |
| Mowry, D; Ockey, RR; Varghese, G | 1 |
| Greene, P | 1 |
| Fukuuchi, Y; Kobari, M; Nogawa, S; Obara, K; Shinohara, T | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Olsson, M | 1 |
| Iacono, RP; Lonser, RR; Yamada, S | 1 |
| Lang, A; Männistö, PT; Rauhala, P; Vasar, E | 1 |
| Calne, DB; Doudet, D; Hewitt, KA; Nugent, R; Olanow, W; Pate, BD; Perl, DP; Shinotoh, H; Snow, BJ | 1 |
| López Lozano, JJ; Moreno Cano, R | 1 |
| Huszonek, JJ | 1 |
| O'Keeffe, ST | 1 |
| Camicioli, R; Joseph, CL; McWhorter, K; Siple, J | 1 |
| Kawai, H; Mitsui, T; Miyata, M; Saito, S; Sakoda, S | 1 |
| Carmichael, SW; Cook, JA; Merkel, GJ; Stoddard, SL; Zinsmeister, AR | 1 |
| Brannan, T; Yahr, MD | 1 |
| Asanuma, M; Kawai, M; Kohno, M; Masumizu, T; Mori, A; Ogawa, N; Tanaka, K | 1 |
| Marsh, CB; Mazzaferri, EL | 1 |
| Demaggio, AJ; Havaich, M; Juneau, PL; Lewitt, PA; Loeffler, DA | 1 |
| Korczyn, AD; Kuritzky, A; Nisipeanu, P | 1 |
| Linazasoro, G | 1 |
| Bour, LJ; Hilgevoord, AA; Koelman, JH; Ongerboer de Visser, BW; Speelman, JD | 1 |
| Haas, RH; Hill, LR; Nakano, K; Nasirian, F; Pay, M; Shults, CW; Ward, DM | 1 |
| Ahuja, GK; Behari, M; Padma, MV | 1 |
| Bennett, KM; Castiello, U | 1 |
| Chutorian, AM; Levine, RA; Naini, AB; Nygaard, TG; Waran, SP | 1 |
| Ball, MC; Sagar, HJ | 1 |
| Husain, S; Rao, RN; Sekar, R | 1 |
| Factor, SA; Schneider, AS | 1 |
| Caligiuri, MP | 1 |
| Larner, AJ | 1 |
| Bankiewicz, KS; de Jesus, S; Sheng, J; Takubo, H; Thomas, J; Wang, J | 1 |
| Mahler, ME; Scharre, DW | 1 |
| Bräutigam, K; Morgenstern, R; Sohr, R | 1 |
| Chase, TN; Hoff, J; Metman, LV; Mouradian, MM | 1 |
| Brin, IL; Drozdov, AZ; Filatova, TS; Kogan, BM; Kovaleva, IA | 1 |
| Achiron, A; Djaldetti, R; Melamed, E; Ziv, I | 1 |
| Friedman, JH | 1 |
| Moul, DE; Oren, DA; Rosenthal, NE; Schwartz, PJ; Wehr, TA | 1 |
| Brooks, DJ; Burn, DJ; Lammertsma, AA; Luthra, S; Morrish, PK; Osman, S; Sawle, GV; Snow, BJ | 1 |
| Fahn, S; Lew, MF; Moskowitz, CB; Shindo, M; Waters, CH; Wilhelmsen, KC | 1 |
| Paulson, GW | 1 |
| Broe, GA; Hely, MA; Margrie, S; Morris, JG; O'Sullivan, DJ; Rail, D; Reid, WG; Williamson, PM | 1 |
| Bredberg, E; Lennernäs, H; Paalzow, L | 1 |
| Dasouki, M; Hiari, M; Mubaidin, A; Najim al-Din, AS; Wriekat, A | 1 |
| Bédard, PJ; Blanchette, P; DiPaolo, T; Falardeau, P; Gagnon, C; Gomez-Mancilla, B | 1 |
| Cetel, M; Guilleminault, C; Philip, P | 1 |
| Abe, T; Kikuchi, T; Nozaki, Y; Takahashi, J; Takahashi, S; Tohgi, H; Ueno, M | 1 |
| Abraham, OC; Archana, S; Cherian, AM; Kurien, T; Rajeev, KK | 1 |
| Lammers, GJ; Roos, RA | 1 |
| Ahlskog, JE; Imke, S; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, M; Schoenfelder, J; Wheeler, K; Wright, KF | 1 |
| Illi, A; Keränen, T; Myllylä, VV; Sotaniemi, KA; Suominen, K | 1 |
| Calne, DB; Duvoisin, RC; Koller, WC | 1 |
| Fahn, S; Grimes, JD; Hurtig, H; Jankovic, J; Klawans, H; Kurlan, R; Muenter, M; Olanow, CW; Shoulson, I; Stern, M | 1 |
| Allen, RP; Buchholz, DW; Kaplan, PW; Walters, JK | 1 |
| Lang, AE; Mark, MH; Sage, JI; Zimmerman, TR | 1 |
| George, A; Gray, P; Grimes, JD; Mendis, T; Mohr, E; Rusk, IN | 1 |
| Eller, RV; Gash, DM; Greenamyre, JT; Kurlan, R; Ovadia, A; Zhang, Z | 1 |
| Lauterbach, EC | 1 |
| Aquilonius, SM; Bredberg, E; Johansson, K; Johnels, B; Nilsson, D; Nyström, C; Paalzow, L | 1 |
| Comella, CL; Ristanovic, RK; Tanner, CM | 1 |
| Breimer, DD; Roos, RA; Tijssen, MA; van der Velde, EA | 1 |
| Amantea, MA; Bravi, D; Chase, TN; Cora-Locatelli, G; Mouradian, MM; Roberts, JW | 1 |
| Hossain, MA; Weiner, N | 1 |
| Bergen, M; Fowler, SB | 1 |
| Blau, N; Dhondt, JL | 1 |
| Fullerton, T | 1 |
| Atchison, PR; Frackowiak, RS; Marsden, CD; Thompson, PD | 1 |
| Bennett, JP; Schuh, LA | 1 |
| Golbe, LI; Nieforth, KA | 1 |
| Chase, TN; Davis, TL; Giuffra, ME; Mouradian, MM; Sethy, VH | 1 |
| Angrist, B; Sanfilipo, M; Wolfsohn, R | 1 |
| Bremer, DL; Leguire, LE; McGregor, ML; Rogers, GL; Walson, PD | 2 |
| Ahlskog, JE; Atkinson, EJ; Cha, RH; Maraganore, DM; Muenter, MD; O'Brien, PC; Uitti, RJ | 1 |
| Bravi, D; Chase, TN; Davis, TL; Mouradian, MM; Roberts, JW | 1 |
| Kajii, N; Kohsaka, S; Mizukami, S; Narita, M; Saitoh, S; Togashi, T; Wada, T | 1 |
| Goetz, CG; Irwin, I; Kurth, MC; Langston, JW; Stebbins, GT; Tanner, CM; Tetrud, JW | 1 |
| Imai, H; Kondo, T; Nakamura, T; Narabayashi, H | 1 |
| Da Prada, M; Dingemanse, J; Zürcher, G | 1 |
| Graff, E; Harsat, A; Korczyn, AD; Rabey, JM; Shabtai, H; Vered, Y | 1 |
| Chase, TN; Dambrosia, JM; Peppe, A | 1 |
| Cote, L; Fahn, S; Greene, P | 1 |
| Durso, R; Feldman, RG; Isaac, K; Perry, L; Saint-Hilaire, M | 1 |
| Gash, DM; Kurlan, R; McDermott, M; Smith, RD; Zhang, Z | 1 |
| Date, ES; Schwartz, M; Seibel, MO; Zeiner, H | 1 |
| Abe, T; Takahashi, S; Tohgi, H | 1 |
| Goldhammer, Y; Sadeh, M | 1 |
| Baraldo, M; Benetello, P; Furlanut, M; Hassan, E; Zara, G | 1 |
| Busenbark, K; Hubble, JP; Huber, SJ; Koller, WC; Michalek, D; Pahwa, R | 1 |
| Carter, JH; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, W | 1 |
| Factor, SA | 1 |
| Caraceni, T; Fetoni, V; Geminiani, GC; Genitrini, S; Giovannini, P; Girotti, F; Parati, EA; Soliveri, P; Testa, D | 1 |
| Gordin, A; Harjola, VP; Karlsson, M; Keränen, T; Korpela, K; Pentikäinen, PJ; Rita, H; Seppälä, L; Wikberg, T | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Nicholson, PW; O'Neill, CJ; Purkiss, A; Weller, C | 1 |
| Cashaw, JL | 1 |
| Irwin, I; Kurth, MC; Langston, JW; Lyness, WH; Tetrud, JW | 1 |
| Campistol, J; Garaizar, C; Prats, JM | 1 |
| Caligiuri, MP; Lohr, JB | 1 |
| Amiel, C; Comoy, E; Couette, S; Friedlander, G; Garcia-Ocaña, A; Perrichot, R | 1 |
| Avery, W; Belenky, G; Hall, M; McCann, UD; Popp, K; Sing, H; Thomas, M; Thorne, D | 1 |
| Cohen, G; DiRocco, A; Merchant, CA; Molinari, S; Moros, D; Mytilineou, C; Yahr, MD | 1 |
| Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ | 1 |
| Gould, TJ; Johnson, LN; Krohel, GB | 1 |
| Artem'ev, DV; Damulin, IV; Iakhno, NN | 1 |
| Bakhteev, KK; Brin, IL | 1 |
| Olanow, CW | 1 |
| Kulkantrakorn, K; Petruska, PJ; Selhorst, JB | 1 |
| Beal, MF; Calne, DB; Good, PF; Hewitt, KA; Olanow, CW; Perl, DP; Shinotoh, H; Snow, BJ; Vingerhoets, F | 1 |
| Koller, WC; Pahwa, R | 1 |
| Durso, R; Folkerth, RD | 1 |
| Childs, NL; Mercer, WN | 1 |
| Colosimo, C; Hughes, AJ; Lees, AJ; Merello, M; Sieradzan, K | 1 |
| Ahtila, S; Gordin, A; Heinävaara, S; Kaakkola, S; Karlsson, M; Korpela, K; Männistö, PT; Tuomainen, P; Wikberg, T | 1 |
| Chen, RS; Huang, CC; Lu, CS | 1 |
| Cabello López, J; Galvañ Berenguer, B; Gómez García, J; Leiva Santana, C | 1 |
| Blanchet, PJ; Chase, TN; de Jong, D; Metman, LV; Mouradian, MM | 1 |
| Carreras, MC; Fernandez Pardal, MM; Gatto, EM; Llesuy, S; Pargament, GA; Poderoso, JJ; Reides, C; Repetto, M; Riobo, NA | 1 |
| Arnold, G; Eichhorn, TE; Gasser, T; Mai, N; Marquardt, C; Oertel, WH; Schwarz, J | 1 |
| Facca, A; Sanchez-Ramos, J | 1 |
| Allen, RP; Earley, CJ | 2 |
| Ahlskog, JE; Dewey, RB; Maraganore, DM; Matsumoto, JY | 1 |
| Jackson, M; Jenner, P; Marsden, CD; Pearce, RK; Smith, L | 1 |
| Arutiunian, NA; Iakimovskiĭ, AF | 1 |
| Buhrfiend, C; Carvey, PM; Goetz, CG; Lipton, JW; Pappert, EJ; Stebbins, GT | 1 |
| Dethy, S; Goldman, S; Hildebrand, J; Laute, MA; Naini, AB; Przedborski, S; Raftopoulos, C | 1 |
| Pfeiffer, RF | 1 |
| Revell, SP; Shulman, LM; von Graevenitz, KS | 1 |
| Kamal, TJ; Kelley, SR; Molitch, ME | 1 |
| Dubinsky, R; Hubble, JP; Koller, WC; Lyons, K; McGuire, D; Pahwa, R | 1 |
| Hasegawa, T; Mizutani, Y; Nabeshima, T; Ogawa, M; Okada, Y | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Hunt, WB; Kirollos, C; Kosik, R; Mozol, K; Nicholson, PW; O'Neill, CJ; Purkiss, AG; Weller, C | 1 |
| Koller, WC; Lyons, K; Marjama, J; McGuire, D; Pahwa, R; Silverstein, P; Ward, R; Zwiebel, F | 1 |
| Arai, R; Karasawa, N; Nagatsu, I | 1 |
| Bulygina, VV; Markel', AL; Maslova, LN; Naumenko, EV; Shishkina, GT | 2 |
| Ichikawa, M; Matsuyama, K; Nakashima, M; Nakashima, MN; Sakurai, M; Sasaki, H; Zhao, MF | 1 |
| Andersen, AH; Avison, MJ; Chen, Q; Gash, DM; Ovadia, A; Zhang, Z | 1 |
| Muilenburg, ND | 1 |
| Andre, MH; Bruguerolle, B; Grignon, S | 1 |
| Simpson, JS | 1 |
| Currier, RD; Subramony, SH | 1 |
| Tesselaar, HJ; Wolters, EC | 1 |
| Moses, J; Siddiqui, A; Silverman, PB | 1 |
| Carvey, PM; Goetz, CG; Ling, ZD; Niederman, F; Pappert, EJ; Stebbins, GT | 1 |
| Cernek, PK; Shoop, SA | 1 |
| Obata, T; Yamanaka, Y | 1 |
| Block, G; Irr, J; Liss, C; Nibbelink, D; Reines, S | 1 |
| Dike, GL | 1 |
| Lanska, DJ | 1 |
| Aoki, K; Ikeda, K; Kinoshita, M; Tomatsuri, A | 1 |
| Fukuda, T; Iwata, S; Kaseda, S; Nomoto, M; Osame, M | 1 |
| Amyot, D; Demong, C; Duff, J; Gray, P; Murphy, D; Watson, J; Wilson, W | 1 |
| Blaney, TJ; Emerich, DF; Francis, JM; Lindner, MD; Plone, MA; Salamone, JD | 1 |
| Briner, V; Niedermaier, G | 1 |
| Emerich, DF; Francis, JM; Lindner, MD; Plone, MA | 1 |
| Agid, Y; Dziewczapolski, G; Gershanik, O; Murer, G; Raisman-Vozari, R | 1 |
| Calne, DB; Lee, CS; Schulzer, M; Shinotoh, H; Tsui, J; Uitti, RJ; Vingerhoets, FJ | 1 |
| Carter, JH; Lea, ES; Nutt, JG; Woodward, WR | 1 |
| Chang, HC; Chen, RS; Liao, KK; Lu, CS; Tsai, CH | 1 |
| Damhaut, P; Dethy, S; Goldman, S; Hildebrand, J; Laute, MA; Van Blercom, N | 1 |
| Kraus, MF; Maki, P | 1 |
| da Cruz Vieira, I; Fatibello-Filho, O | 1 |
| Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
| Dockray, GJ; Henry, J; Vaillant, C; Varro, A; Voronina, S | 1 |
| Chacón, J; Cordero, M; García de Yébenes, J; Giménez Roldán, S; Mateo, D; Mena, MA; Morales, B; Pastor, M; Pino, MA; Sánchez, V | 1 |
| Carvey, PM; Goetz, CG; Ling, ZD; Lipton, JW; Pappert, EJ; Stebbins, GT | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Tedroff, J | 1 |
| Collins, F; Gash, DM; Hilt, D; Kryscio, R; Lapchak, PA; Lebel, C; Miyoshi, Y; Ovadia, A; Zhang, Z | 1 |
| Brin, IL; Mashilov, KV | 1 |
| Bonuccelli, U; Napolitano, A; Rossi, B | 1 |
| Hajak, G; Rüther, E; Staedt, J; Stoppe, G; Wassmuth, F; Ziemann, U | 1 |
| Block, GA; Cyhan, G; Gancher, ST; Hammerstad, JP; Nutt, JG; Woodward, WR | 1 |
| Davila, V; Mena, MA; Sulzer, D | 1 |
| Dadmarz, M; Diederich, C; Hare, TA; Hofford, JM; Milakofsky, L; Vogel, WH | 1 |
| Aggarwal, S; Childers, MK; Jimenez, D | 1 |
| Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F | 1 |
| Balogh-Nemes, K; Horvai, G; Klebovich, I; Tolokán, A | 1 |
| Koller, WC; Lyons, K; McGuire, D; Pahwa, R; Robischon, M; Silverstein, P; Zwiebel, F | 1 |
| Sakajiri, K; Takamori, M | 1 |
| Gordin, A; Jenner, P; Marsden, CD; Smith, LA | 1 |
| McCallum, RW; Sarosiek, I; Shifflett, J; Soykan, I; Wooten, GF | 1 |
| Burns, RS; Jorga, K; Leese, P; Schmitt, M; Sêdek, G | 1 |
| Kumar, R; Lang, AE | 1 |
| Araki, T; Itoyama, Y; Kobayashi, T; Ohta, T; Oshima, Y; Takeshita, M | 1 |
| De Meirleir, K; Keizer, H; Magnus, L; Meeusen, R; Roeykens, J | 1 |
| Gerritsen, JJ; Lammers, GJ; Meinders, AE; Roos, RA; van Laar, T | 1 |
| Aquilonius, SM; Hansson, LE; Johansson, K; Nilsson, D; Nyström, C; Paalzow, L | 1 |
| Chase, TN; Lenz, FA; van den Munckhof, P | 1 |
| Bieglmayer, C; Birnbacher, R; Blau, N; Frisch, H; Scheibenreiter, S; Waldhauser, F | 1 |
| Budygin, EA; Gaĭnetdinov, RR; Mannisto, PT; Raevskiĭ, KS | 1 |
| Alberts, JL; Stelmach, GE; Tresilian, JR | 1 |
| Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Sedek, G | 1 |
| Golubev, VL; Shtul'man, DR; Shvareva, IS; Veĭn, AM; Zhuchenko, TD | 1 |
| Lapchak, PA | 1 |
| Koller, WC; Wasielewski, PG | 1 |
| Grandas, F; Linazasoro, G; Martínez-Martín, P | 1 |
| Capildeo, R | 1 |
| Ruggieri, S; Silver, DE | 1 |
| Carter, JH; Nutt, JG; Thulin, PC; Woodward, WR | 1 |
| Ellis, KL; Speed, J | 1 |
| Chokroverty, S; Masdeu, JC; Sander, HW; Tavoulareas, G; Walters, A; Zimmerman, T | 1 |
| Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R | 1 |
| Adler, CH; Deptula, D; Dorflinger, E; Hauser, RA; Lew, MF; Marek, KL; O'Brien, C; Pedder, S; Singer, C; Yoo, K | 1 |
| Amano, K; Takakura, K | 1 |
| Ahier, RG; Ashworth, S; Hume, SP; Opacka-Juffry, J | 1 |
| Dajani, EZ; Dajani, NE; Dayton, MT; Larsen, KR; Moore, JG | 1 |
| Bräutigam, C; de Rijk-van Andel, JF; Gabreëls, FJ; Hoffmann, GF; Jansen, RJ; Smeitink, JA; Wevers, RA | 1 |
| Goetz, CG; Stebbins, GT; Tanner, CM; Vogel, C | 1 |
| Black, KJ; Carl, JL; Hershey, T; McGee-Minnich, LA; Perlmutter, JS; Stambuk, MK | 1 |
| Egi, N; Harada, T; Kumagai, R; Kurokawa, K; Nakamura, S; Okazaki, M; Shimote, K | 1 |
| Hempel, AG; Maaty, MA; Sage, JI; Wagner, ML | 1 |
| Cailleux, N; Courtois, H; Lévesque, H; Marie, I; Moore, ND; Noblet, C; Verdure, L | 1 |
| Onofrj, M; Paci, C; Thomas, A | 1 |
| Beerahee, A; Burns, E; Citerone, DR; Cyronak, MJ; Fitzpatrick, KL; Leigh, TJ; Lennox, G; Lopez-Gil, A; Taylor, AC; Vakil, SD | 1 |
| McAuley, J; Shahmanesh, M; Swash, M | 1 |
| Avraham, M; Dabby, R; Djaldetti, R; Melamed, E; Ziv, I; Zoldan, J | 1 |
| Chaudhary, N; Mani, J; Mulye, R; Rawat, S; Shah, P | 1 |
| Boronat, A; Herreros, R; Serrat, I | 1 |
| de Ceballos, ML; Fontenla, JA; Nieto, O; Rivas, E | 1 |
| Castronuovo, J; Feigin, A; Innis, RB; Marek, KL; Seibyl, JP; Sheff, K; Zoghbi, S | 1 |
| Adair, JC; Davis, LE | 1 |
| Lalonde, R; Lestienne, F; Thullier, F | 1 |
| Andersen, AH; Avison, MJ; Gash, DM | 1 |
| Deguchi, K; Kamoda, M; Nishioka, M; Sasaki, I; Takeuchi, H; Touge, T; Tsukaguchi, M | 1 |
| Schoser, BG; Stuerenburg, HJ | 1 |
| Illarioshkin, SN; Ivanova-Smolenskaya, IA; Limborska, SA; Markova, ED; Miklina, NI; Popova, SN; Slominsky, PA | 1 |
| Arnold, G; Kupsch, A | 1 |
| Gordin, A; Huhtala, S; Huupponen, R; Korpela, K; Reinikainen, K; Rouru, J; Savontaus, E; Scheinin, M | 1 |
| Capilldeo, R; Hutton, JT; Koller, WC; Tolosa, E | 1 |
| Jorga, KM; Nicholl, DJ | 1 |
| Alaynick, WA; Kim, DS; Marck, BT; Matsumoto, AM; Palmiter, RD; Rainey, MA; Szczypka, MS | 1 |
| Bremer, DL; Jende, DL; Leguire, LE; McGregor, ML; Nairus, TM; Rogers, GL; Walson, PD | 1 |
| Stacy, M | 1 |
| Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM | 1 |
| DeLong, MR; Rye, DB | 1 |
| Scheife, RT | 1 |
| Ahlskog, JE; Burnett, OL; Maraganore, DM; Matsumoto, JY; O'Connor, MK; Stark, KF; Turk, MF; Uitti, RJ | 1 |
| Kimber, J; Mathias, CJ; Watson, L | 1 |
| Brousolle, E; Dentresangle, C; Froment, JC; Guerin, J; Lavenne, F; Le Bars, D; Pierre, C; Pollak, P; Veyre, L | 1 |
| Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL | 1 |
| Gainetdinov, R; Huotari, M; Männistö, PT | 1 |
| Fuchs, FD; Procianoy, E; Procianoy, F; Procianoy, L | 1 |
| Bennett, KM; Bonfiglioli, C; Castiello, U; Peppard, RF | 1 |
| Minagar, A; Shulman, LM; Weiner, WJ | 2 |
| Mandel, RJ | 1 |
| Guy, ME; Johnson, LN; Krohel, GB; Madsen, RW | 1 |
| Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA | 1 |
| Sagar, KA; Smyth, MR | 2 |
| Brooks, DJ; Gordin, A; Karlsson, M; Korpela, K; Pavese, N; Piccini, P | 1 |
| Bosco, D; Branca, D; Caracciolo, M; Gambardella, A; Napoli, ID; Nicoletti, G; Oliveri, RL; Quattrone, A; Zappia, M | 1 |
| Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
| Chernik, D; Dorflinger, E; Waters, C; Welsh, MD | 1 |
| Bressman, SB; Ford, B; Greene, PE; Hyland, K | 1 |
| Grimm, W; Koffler, T; Philippi, H; Pohlenz, J; Schönberger, W | 1 |
| Bonoma, RA; Iwuagwu, CU; Riley, D | 1 |
| Bankiewicz, KS; Bringas, J; Budinger, TF; Cunningham, J; Eberling, JL; Harvey-White, J; Jagust, W; Kohutnicka, M; Pivirotto, P | 1 |
| Schiess, MC; Van Horn, G | 1 |
| Mark, LP; Mueller, WR; Prieto, TE; Reynolds, NC; Terry, LC | 1 |
| Browne, TR; Durso, R; Evans, B; Evans, JE; Fernandez, HH; Josephs, E; Szabo, G | 1 |
| Brusa, L; Gasparini, M; Meco, G; Vanacore, N | 1 |
| Fanali, S; Pucci, V; Raggi, MA; Sabbioni, C | 1 |
| Kesler, S; Niehaus, DJ; Seedat, S; Stein, DJ | 1 |
| Milkov, V; Miteva, K; Pironcheva, G; Russev, G; Zlatarev, S | 1 |
| Calmes, J; Hendersen, N; Jankovic, J; Olson, S; Ondo, W; Overby, A; Warrior, D | 1 |
| Ahlskog, JE; Croghan, GA; Croghan, IT; Hurt, RD; Moyer, TP; Offord, KP; Wolter, TD | 1 |
| Black, KJ; Carl, JL; Hershey, T; Perlmutter, JS | 1 |
| Black, KJ; Mink, JW | 1 |
| Conner, D; Jackson, A; Miller, R | 1 |
| Hara, A; Matsushita, S; Mita, S; Murakami, T; Nakajima, M; Nakamura, T; Uchino, M; Uyama, E | 1 |
| Cooper, SD; Frank, C; Ismail, HA | 1 |
| Iwata, S; Kaseda, S; Nomoto, M | 1 |
| Gerlach, M; Kuhn, W; Lehnfeld, R; Riederer, P; Sontag, KH; Waldmeier, P; Xiao, AY | 1 |
| Haapaniemi, TH; Korpelainen, JT; Myllylä, VV; Sotaniemi, KA; Suominen, K; Tolonen, U | 1 |
| Boryczka, AT; Ganong, WF; Grumbach, M; Holland, J; Kaplan, S; Lovinger, R; Reid, IA; Salmon, J; Shackelford, R | 1 |
| Blau, N; Dudesek, A; Leupold, D; Muntau, AC; Röschinger, W; Seidel, J; Thöny, B | 1 |
| Ebinger, G; Jonkers, N; Michotte, Y; Sarre, S | 1 |
| Canals, S; Casarejos, MJ; de Bernardo, S; Handler, A; Mena, MA; Rodríguez-Martín, E | 1 |
| Susman, VL | 1 |
| Allen, DG; Brown, LK; Brown, SL; Guilmette, TJ; Mukand, JA; Tober, KL; Vandyck, WR | 1 |
| Ko, CH; Kong, CK; Lam, CW; Tong, SF | 1 |
| Ahangar, B; Burke, DT; Chae, H; Frates, EP | 1 |
| Ferger, B; Schmidt, N; Schulz, JB; Teismann, P; Xia, XG | 1 |
| Abe, K; Miyatake, T; Ren, J; Sano, T; Shinohara, T; Taguchi, K; Utsunomiya, I; Wasai, T | 1 |
| Borri-Voltattorni, C; Burkhard, P; Dominici, P; Jansonius, JN; Malashkevich, VN | 1 |
| Anderson, VC; Burchiel, KJ; Carter, JH; Hammerstad, JP; Nutt, JG; Pahwa, R; Rufener, SL | 1 |
| Halliwell, B; Jenner, P; Lyras, L; McKenzie, G; Pearce, RK; Zeng, BY | 1 |
| Dhanuka, AK; Singh, G | 1 |
| Alexander, MP | 1 |
| Campos, V; García De Yébenes, J; Mena, MA; Meseguer, E; Sánchez, V; Taboada, R | 1 |
| Cutler, NR; Dockens, RC; Frackiewicz, EJ; Jhee, SS; Salazar, DE; Shiovitz, TM; Topham, C; Webster, J; Whigan, D | 1 |
| Forsberg, M; Gogos, JA; Huotari, M; Hyttinen, J; Karayiorgou, M; Koponen, O; Männistö, PT; Raasmaja, A | 1 |
| Acerbi, D; Bettini, R; Caponetti, G; Catellani, PL; Cocconi, D; Colombo, P; Magi, N; Musa, R; Santi, P; Ventura, P | 1 |
| Hironishi, M; Kondo, T; Miwa, H | 1 |
| Danisi, F | 1 |
| Aquilonius, SM; Nilsson, D; Nyholm, D | 1 |
| Badarny, S; Djaldetti, R; Giladi, N; Herishano, Y; Honigman, S; Inzelberg, R; Korczyn, AD; Melamed, E; Peretz-Aharon, Y; Rabey, MJ | 1 |
| Sharif, AA | 1 |
| Ahuja, M; Srivastava, M; Srivastava, T; Trivedi, A | 1 |
| Brenninkmeijer, JH; Freijzer, PL | 1 |
| Kaku, DA; Sarasombath, P; Sumida, K | 1 |
| Gupta, BS; Tiwary, AK | 1 |
| Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N | 1 |
| Adler, CH; Blasucci, L; Carvey, P; Caviness, JN; Chase, WM; Ferry, JJ; Goetz, CG; Kompoliti, K; Leibowitz, MT; Leurgans, S; Pincus, JH; Raman, R; Tan, E; Yones, LC | 1 |
| Steur, EN | 1 |
| Ghika, J; Solida, A; Vingerhoets, F | 1 |
| Kapustina, MT; Karaban', IN; Karasevich, NV; Lukhanina, EP | 1 |
| Montgomery, EB | 1 |
| Cosentino, C; Torres, L; Vélez, M | 1 |
| Bar-Gad, I; Bergman, H; Goldberg, JA; Heimer, G | 1 |
| Schölzel-Dorenbos, CJ | 1 |
| Gupta, N; Malhotra, P | 1 |
| Hauser, RA; Holford, NH | 1 |
| Fekete, MI; Fülöp, F; Homicskó, KG; Kertész, I; Nagy, GM; Radnai, B; Tóth, BE; Tóth, G | 1 |
| Duarte, CA; González, S; Vázquez-Blomquist, D | 1 |
| Hirsch, EC; Muriel, MP; Orieux, G | 1 |
| Borra, S; Hauser, RA; Zesiewicz, TA | 1 |
| Reingardiene, D | 1 |
| Bhartiya, P; Biswas, NR; Khokhar, SK; Sharma, P; Tandon, R | 1 |
| Eng, JJ; Inkster, LM; MacIntyre, DL; Stoessl, AJ | 1 |
| Angelini, L; Blau, N; Fernandez Alvarez, E; Garavaglia, B; Invernizzi, F; Nardocci, N; Pannacci, M; Sesta, M; Zorzi, G | 1 |
| Huang, P; Liu, S; Ming, X; Tan, X; Wu, X; Xu, H | 1 |
| Kulkarni, SK; Singh, A | 1 |
| Bhattacharya, KF; Kaufmann, H; Nouri, S; Olanow, CW; Yahr, MD | 1 |
| Hillis, RE; Lee, DA | 1 |
| Blomgren, M; Goberman, AM | 1 |
| Hansard, MJ; Jackson, MJ; Jenner, P; Maratos, E; Smith, LA | 1 |
| Bakay, RA; Barnhart, H; Chockkan, V; DeLong, MR; Evatt, M; Freeman, A; Green, J; Haber, M; McDonald, W; Mewes, K; Triche, S; Vitek, JL; Wahlay, N; Zhang, JY | 1 |
| Black, KJ; Carl, JL; Hartlein, JM; Hershey, T; Perlmutter, JS; Warren, SL | 1 |
| Apetauerova, D; Norregaard, T; Ryan, P; Tarsy, D | 1 |
| Decker, PA; Dousa, MK; Muenter, MD; Offord, KP; Tyce, GM; Weinshilboum, RM | 1 |
| Gilgun-Sherki, Y; Mechoulam, R; Melamed, E; Offen, D | 1 |
| Bara-Jimenez, W; Bibbiani, F; Chase, TN; Dimitrova, T; Favit, A; Gillespie, M; Morris, MJ; Mouradian, MM; Sherzai, A | 1 |
| Karaban', IM; Kolesnikova, IeE; Serebrovs'ka, TV | 1 |
| Chaná, P; Fierro, A; Reyes-Parada, M; Sáez-Briones, P | 1 |
| Hanger, D; Joyce, JN; Reploge, M; Yarkov, AV | 1 |
| Bojko, A; Chutorian, AM; Edelberg, D; Frucht, S; Heier, L; Nygaard, T | 1 |
| Hauser, RA | 3 |
| Cheetham, SC; Hansard, MJ; Jackson, MJ; Jenner, P; Smith, LA | 1 |
| Krahn, M; Lang, A; Marras, C; Naglie, G; Tomlinson, G | 1 |
| Gadkary, CA; Mummaneni, PV; Quinones-Hinojosa, A; Rosenberg, WS | 1 |
| Barbato, L; Bolner, A; Caraceni, T; Nordera, G; Stocchi, F | 1 |
| Bruno, MK; Considine, E; Garraux, G; Gwinn-Hardy, K; Hallett, M; Hanson, M; Johnson, J; Ptacek, L; Ravina, B; Singleton, A | 1 |
| Bedell, JA; Bräutigam, C; Chang, YT; Hoffmann, GF; Hyland, K; Knust, A; Marsh, JL; McPherson, JD; Sharma, R | 1 |
| Finley, R; Lee, KC; Miller, B | 1 |
| Hurka, MR; Leopold, NA; Polansky, M | 1 |
| Gluck, MR; Granson, H; Santana, LA; Yahr, MD | 1 |
| Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H | 1 |
| Bassi, A; Brusa, L; Fedele, E; Giacomini, P; Lunardi, G; Pierantozzi, M; Stanzione, P | 1 |
| Chen, CM; Lee-Chen, GJ; Tang, LM; Wang, CK; Wang, SC; Wu, YR | 1 |
| Fisher, JS; Ju, JS; Racette, BA; Saha, BM; Smith, JL | 1 |
| Barch, DM; Black, KJ; Braver, TS; Carl, JL; Hartlein, J; Hershey, T; Perlmutter, JS | 1 |
| Berezetskaia, NM; Burenok, IuA; Karaban', IN; Lukhanina, EP; Mel'nik, NA | 1 |
| Chartoff, EH; Dorsa, DM; Palmiter, RD; Szczypka, MS | 1 |
| Bassi, A; Brusa, L; Fedele, E; Lunardi, G; Pasqualetti, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Bara-Jimenez, W; Chase, TN; Dimitrova, T; Favit, A; Mouradian, MM; Sherzai, A | 1 |
| de Freitas, RM; dos Santos Souza, MP; Fricke, D; Rieder, CR | 1 |
| Antenor, J; Black, KJ; Burkey, A; Esper, GJ; Kotagal, V; Moerlein, SM; Ojemann, JG; Perlmutter, JS; Racette, BA; Videen, TO | 1 |
| Al-Barghouthy, G; Jackson, MJ; Jenner, P; Kuoppamaki, M; Olanow, W; Rose, S; Smith, LA | 1 |
| Cullen, EI; Hahne, WA; Kirby, L; Kumar, D; Okereke, CS; Pratt, RD | 1 |
| Guarnieri, M; Hubble, J; Koller, W; Rabinowicz, AL; Silver, D | 1 |
| Jung, SK | 1 |
| Groswasser, Z; Keren, O; Krimchansky, BZ; Sazbon, L | 1 |
| Delville, Y; Fleming, SM; Schallert, T | 1 |
| Fahn, S; Kieburtz, K; Lang, A; Marek, K; Oakes, D; Olanow, CW; Rudolph, A; Shoulson, I; Tanner, C | 1 |
| Ogawa, N; Tanaka, K | 1 |
| Antenor, JA; Kotagal, V; McGee-Minnich, L; Moerlein, SM; Perlmutter, JS; Racette, BA; Videen, TO | 1 |
| Aquilonius, SM; Askmark, H; Constantinescu, R; Dizdar, N; Holmberg, B; Jansson, R; Nilsson Remahl, AI; Nyholm, D | 1 |
| Akalan, N; Arica, B; Hincal, AA; Kaş, HS; Moghdam, A | 1 |
| Ling, W; Majewska, MD; Montgomery, MA; Rawson, RA; Reiber, C; Shoptaw, S; Watson, DW | 1 |
| Goberman, AM | 1 |
| DeRoche, C; Kastenholz, KV; Nausieda, PA; Pfeiffer, RF; Slevin, JT; Tagliati, M | 1 |
| Artemova, IIu; Batysheva, TT; Boĭko, AN; Chikina, ES; Ganzhula, PA; Ismailov, AM; Khozova, AA; Lisenker, LN; Obydenova, NA; Rotor, LD; Vdovichenko, TV; Vinetskiĭ, IaIa | 1 |
| Bronstein, J; Guarnieri, M; Hubble, J; Kang, GA; Ostrem, JL; Rabinowicz, AL; Subramanian, I | 1 |
| Silver, DE | 2 |
| Acaroglu, G; Eryilmaz, T; Simsek, T | 1 |
| Chang, CY; Chang, ML; Chien, HF; Jiang-Shieh, YF; Wei, IH; Wu, CH; Yeh, KY | 1 |
| Alvarez, L; Castro, A; Gimenez-Roldan, S; Grandas, F; Hernandez, B; Jenner, P; Linazasoro, G; Luquin, MR; Macias, R; Marin, C; Obeso, JA; Pavon, N; Rodriguez, M; Rodriguez-Oroz, MC; Stochi, F; Tolosa, E; Vaamonde, J; Valldeoriola, F | 1 |
| Agid, Y; Brooks, DJ; Eggert, K; Holopainen, A; Ostergaard, K; Widner, H | 1 |
| Blau, N; Connolly, MB; Demos, MK; Hyland, K; Lillquist, Y; Makhseed, N; Vallance, HD; Waters, PJ | 1 |
| Apajasalo, M; Findley, LJ; Lees, A; Pitkänen, A; Turunen, H | 1 |
| Oberpichler-Schwenk, H | 1 |
| Bakay, RA; Corcos, DM; Metman, LV; Prodoehl, J; Sturman, MM; Vaillancourt, DE | 1 |
| Arthur, K; Foley, SR; Kelly, BD | 1 |
| Calle, A; Carriedo, D; Diez, MJ; Fernandez, N; Garcia, JJ; Gonzalez, A; Sahagun, A; Sierra, M | 1 |
| Bremen, D; Erdmann, C; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Beiske, AG; Grotli, R; Lundqvist, C; Nystedt, T; Reiertsen, O | 1 |
| Obara, K; Ohta, K | 1 |
| Gille, G; Radad, K; Rausch, WD; Reichmann, H | 1 |
| Cercy, SP; Walker, RH; Warwick, R | 1 |
| Iyer, SS; Morgan, JC; Sethi, KD | 1 |
| Chan, PL; Holford, NH; Nutt, JG | 1 |
| Brown, LA; Doan, J; Pellis, SM; Suchowersky, O; Whishaw, IQ | 1 |
| Asmus, F; Bhatia, KP; Davis, M; Gasser, T; Mohire, MD; Schneider, SA; Sweeney, M; Trender-Gerhard, I; Wood, NW | 1 |
| Carl, JL; Karimi, M; Loftin, S; Perlmutter, JS | 1 |
| Bremen, D; Erdmann, C; Goetze, O; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Haginoya, K; Higano, S; Iinuma, K; Ishitobi, M; Kitamura, T; Nara, T; Onuma, A; Togashi, N; Wakusawa, K; Yokoyama, H | 1 |
| Brodsky, MA; Hogarth, P; Nutt, JG | 1 |
| Imamura, A; Uitti, RJ; Wszolek, ZK | 1 |
| Dougherty, MS; Groth, T; Nyholm, D; Palhagen, SE; Westin, J; Yerramsetty, PK | 1 |
| Berry-Kravis, E; Hagerman, PJ; Hagerman, RJ; Hall, DA; Leehey, MA; Rice, CD | 1 |
| Stocchi, F | 1 |
| Chigir', IP; Fedorova, NV | 1 |
| Bain, PG; Hensman, DJ | 1 |
| Costa, ER; Dahners, LE; Hooker, JA; Tayrose, GA; Weinhold, P | 1 |
| Haapaniemi, T; Hartikainen, P; Heikkinen, H; Jolma, T; Kaakkola, S; Kinnunen, E; Kuopio, AM; Myllylä, V; Nuutinen, J; Rissanen, A; Satomaa, O | 1 |
| Herkes, GK; McKay, D; Meagher, LJ; Needham, M | 1 |
| Black, KJ; Gordon, M; Hartlein, JM; Koller, JM; Loftin, S; Markham, J | 1 |
| Kanzato, N; Murao, H; Nishihira, T; Takara, H | 1 |
| Konno, R; Wang, YX; Wu, M; Zhou, XJ | 1 |
| Weiner, WJ | 1 |
| Fedorova, NV; Kulua, TK; Levin, OS; Smolentseva, IG | 1 |
| Assmann, B; Blau, N; Echenne, B; Hoffmann, GF; Lutz, T; Penzien, JM; Roubertie, A; Thöny, B | 1 |
| Nyholm, D | 2 |
| Grabowski, J; Moeller, FG; Mooney, ME; Schmitz, JM | 1 |
| Eskey, CJ; Gardner, TB; Lewis, LD; Nierenberg, DW; Osterling, W; Reddy, NJ | 1 |
| Mercimek-Mahmutoglu, S; Stockler-Ipsiroglu, S | 1 |
| Drago, V; Fitzgerald, DB; Heilman, KM; Sutherland, D | 1 |
| Ludin, HP; Surber, Ch | 1 |
| aan het Rot, M; Baker, GB; Benkelfat, C; Booij, L; Leyton, M; Young, SN | 1 |
| Garske, U; Orlefors, H; Sundin, A | 1 |
| Chou, KL; Stacy, MA | 1 |
| Safavi, A; Tohidi, M | 1 |
| Alonso-Navarro, H; Jiménez-Jiménez, FJ | 1 |
| Brusa, L; Finazzi-Agrò, E; Iani, C; Miano, R; Moschella, V; Petta, F; Pisani, A; Stanzione, P | 1 |
| Bliwise, DL; Rye, DB; Trotti, LM | 1 |
| Madrakian, T; Mohammadnejad, M | 1 |
| Young, DK | 1 |
| Ander, L; Kolf, K; Muhlack, S; Müller, T; Woitalla, D | 1 |
| Aimi, Y; Arai, R; Kudo, M; Nagatsu, I; Taki, K; Yamada, H | 1 |
| Antonini, A; Canesi, M; Dal Fante, M; Isaias, IU; Lopiano, L; Mancini, F; Manfredi, L; Pezzoli, G; Zibetti, M | 1 |
| Mosekilde, L; Rejnmark, L; Vestergaard, P | 1 |
| Hauser, RA; Schapira, AH; Simonson, W | 1 |
| Adeva-Bartolomé, T; Alonso-Navarro, H; Jiménez-Jiménez, FJ; Ruiz-Ezquerro, JJ | 1 |
| Chamsaz, M; Fadaee, J; Safavi, A | 1 |
| Duggal, HS; Singh, I | 1 |
| Garmarudi, AB; Kargosha, K; Khanmohammadi, M; Mobedi, E; Mobedi, H | 1 |
| Hernández, B; Kulisevsky, J; Linazasoro, G | 1 |
| Delmas, G; Flesch, F; Rothmann, C | 1 |
| Cheyette, BN; Cheyette, SN; Cusmano-Ozog, K; Enns, GM | 1 |
| Kaufmann, H | 1 |
| Klivényi, P; Vécsei, L | 3 |
| Crucian, GP; Drago, V; Foster, PS; Heilman, KM; Skidmore, F; Skoblar, BM | 1 |
| Concolino, D; Moricca, MT; Muzzi, G; Pascale, MG; Rapsomaniki, M; Strisciuglio, P | 1 |
| Babina, LA; Batysheva, TT; Boĭko, AN; Khozova, AA; Kostenko, EV; Malykhina, EA; Minaeva, NG; Shikhkerimov, RK; Vdovichenko, TV; Zaĭtsev, KA; Zhuravleva, EIu | 1 |
| Diez, MJ; Fernandez, N; Garcia, JJ; Prieto, C; Sahagun, A; Sierra, M | 1 |
| Karim, MM; Kim, WH; Lee, SH | 1 |
| Erdmann, C; Goetze, O; Müller, T; Woitalla, D | 1 |
| Malmlöf, T; Schilström, B; Svensson, TH | 1 |
| Almeida, LF; Centurión, ME; de Araújo, MC; Fernández Band, BS; Fragoso, WD; Grünhut, M | 1 |
| Hsu, A; Khor, SP | 1 |
| Doan, JB; Melvin, KG; Suchowersky, O; Whishaw, IQ | 1 |
| Delgado, MR; Donovan, MA; Jou, RL; Kang, PB; Kim, SY; Neilan, EG; Wu, BL | 1 |
| Comella, CL; Fahn, S; Friedman, JH; Marek, K; Oakes, D; Schifitto, G; Shulman, L | 1 |
| Breitenstein, C; Flöel, A; Heuschmann, P; Knecht, S; Rösser, N; Wersching, H | 1 |
| Amighi, K; Blocklet, D; Deleuze, P; Goldman, S; Goole, J; Pandolfo, M; Pilcer, G; Van Gansbeke, B; Vanderbist, F | 1 |
| Aste, R; Cannas, A; Congia, S; Floris, G; Marrosu, MG; Solla, P; Tacconi, P | 1 |
| Chigir', IP; Dokadina, LV; Fedorova, NV; Levin, OS; Makhnev, SO; Smolentseva, IG | 1 |
| Fung, VS; Herawati, L; Wan, Y | 1 |
| Babina, LA; Batysheva, TT; Boiko, AN; Khozova, AA; Kostenko, EV; Malykhina, EA; Minaeva, NG; Shikhkerimov, RK; Vdovichenko, TV; Zaitsev, KA; Zhuravleva, EY | 1 |
| Almeida, L; Costa, R; Falcão, A; Lopes, C; Loureiro, AI; Machado, R; Nunes, T; Rocha, J; Soares-da-Silva, P; Torrão, L; Vaz-da-Silva, M; Wright, L | 1 |
| Abbruzzese, G; Dronamraju, N; Hauser, RA; Kakarieka, A; Mancione, L; Panisset, M | 1 |
| Arai, H; Hatta, K; Hattori, N; Ishikawa, K; Kamigaichi, R; Kubo, S; Mochizuki, H; Ogaki, K; Usui, C; Yokoyama, K | 1 |
| Litvinenko, IV; Mogil'naia, VI; Odinak, MM; Sakharovskaia, AA; Sologub, OS | 1 |
| Bono, G; Garavaglia, P; Guidotti, M; Leva, S; Pianezzola, C; Raudino, F; Riboldazzi, G | 1 |
| Frei, K; Truong, DD; Wolters, E | 1 |
| Lundgren, D; Nyholm, D; Nyman, R | 1 |
| Ellmén, J; Hänninen, J; Hartikainen, P; Kaakkola, S; Kaasinen, V; Kailajärvi, M; Korpela, K; Kuoppamäki, M; Löyttyniemi, E; Lyytinen, J; Marttila, R; Ruokoniemi, P | 1 |
| Cannas, A; Floris, G; Marrosu, F; Marrosu, MG; Piga, M; Serra, A; Solla, P; Tacconi, P | 1 |
| Ahlskog, JE; Bostwick, JM; Bower, JH; Hecksel, KA; Stevens, SR | 1 |
| Lima, MA; Maradei, S; Maranhao Filho, P | 1 |
| Calle, AP; Diez, MJ; Fernández, N; García, JJ; Sahagún, A; Sierra, M | 1 |
| Guarnieri, M; Hubble, JP; Jennings, D; LeWitt, PA; Lyons, KE; Murck, H; Pahwa, R; Rabinowicz, AL; Wang, J | 1 |
| Couvadelli, BV; England, SJ; Hening, W; Lewin, DS; Picchietti, DL; Picchietti, MA; Walters, AS | 1 |
| Cabezón, MA; Ibáñez, GA; Pagani, AP | 1 |
| Killick, R; Wong, K; Yee, B | 1 |
| Addy, C; Assaid, C; Ellenbogen, A; Gottesdiener, K; Herring, WJ; Hreniuk, D; Jinnah, HA; Kirby, L; Leibowitz, MT; Stewart, RM; Stoch, SA; Stroh, M; Tarsy, D; Tetrud, J; Wagner, J; Xu, Y | 1 |
| Bloem, BR; Gerschlager, W | 1 |
| Hauser, RA; Seeberger, LC | 2 |
| Andreas, JO; Boekens, H; Braun, M; Cawello, W; Horstmann, R | 1 |
| Muhlack, S; Müller, T | 4 |
| Kroenke, K; Murck, H; Stacy, MA | 1 |
| Alp, R; Alp, SI; Ure, H | 1 |
| Abdel Wahab, Z; El-Moursy, SA; Rashed, L; Shawky, HM | 1 |
| Garcia-Horsman, JA; Gogos, JA; Käenmäki, M; Karayiorgou, M; Männistö, PT; Myöhänen, T; Schendzielorz, N; Tammimäki, A | 1 |
| Hsu, FL; Hsu, KY; Lin, SJ; Uang, YS; Wang, LH; Yang, LM | 1 |
| Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O | 1 |
| Jurjevic, A; Kovacevic, M; Ljubicic, D; Mrsic-Pelcic, J; Perkovic, O; Rudez, J; Vitezic, D; Vitezic, M | 1 |
| Jackson, MJ; Jenner, P; Olanow, CW; Rose, S; Tayarani-Binazir, KA | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Butler, IJ; Clement-Cormier, YC; Seifert, WE; Wilner, KD | 1 |
| Fu, HY; Li, SF; Li, YN; Nie, JF; Wu, HL; Yu, RQ; Yu, YJ | 1 |
| Fisher, R; Jackson, MJ; Jenner, P; Rose, S; Tayarani-Binazir, KA; Zoubiane, G | 1 |
| Guertin, PA; Rouleau, P; Ung, RV | 1 |
| Agrawal, AK; Choudhary, H; Jaliwala, YA; Malviya, R; Patil, UK; Yadav, SK | 1 |
| Marconi, S; Stocchi, F | 1 |
| Delea, TE; Hagiwara, M; Mancione, L; Thomas, SK | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
| Green, CE; Lindsay, JA; Moeller, FG; Schmitz, JM; Stotts, AL | 1 |
| Cámara, A; Valldeoriola, F | 1 |
| Müller, T | 1 |
| Nowak, DA; Reiner, B; Seidel, B | 1 |
| Barone, P; Jankovic, J; Kieburtz, K; Lang, AE; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Cetas, JS; Fields, JD | 1 |
| de Vries, MH; Knecht, S; Szymanski, B; Ulte, C; Zwitserlood, P | 1 |
| García-Horsman, JA; Käenmäki, M; Kambur, O; Karvonen, E; Keisala, T; Kulesskaya, N; Männistö, PT; Rauvala, H; Tammimäki, A | 1 |
| Bonnici, A; Hornstein, D; Ruiner, CE; St-Laurent, L | 1 |
| Centurión, ME; Fernández Band, BS; Garrido, M; Grünhut, M | 1 |
| Bagheri, M; Rahat, F; Razeghinejad, MR | 1 |
| Almeida, L; Ferreira, JJ; Nunes, T; Poewe, W; Rascol, O; Rocha, JF; Sampaio, C; Soares-da-Silva, P | 1 |
| Dall'Armi, V; Kulisevsky, J; Lamberti, P; Obeso, JA; Stocchi, F; Zappia, M | 1 |
| Alvarez-Lueje, A; Bravo, M; Olivieri, AC; Pérez-Ortiz, M; Zapata-Urzúa, C | 1 |
| Barrero, FJ; Duran, R; Luna, JD; Morales, B; Ramirez, M; Vives, F | 1 |
| Bokor, M; Szentesi, A | 1 |
| Hinz, AB; Hoffmann, G; Hörster, F; Klein, C; Neidhardt, K; Opladen, T; Wolf, N | 1 |
| Khadem, NR; Nirenberg, MJ | 1 |
| Armand, C; Groenendaal, H; Tarrants, ML | 1 |
| Deuschl, G; Herzog, J; Volkmann, J; Wailke, S; Witt, K | 1 |
| Bugalho, P; Lampreia, T; Santos, L; Soares, P | 1 |
| Moore, S; Ondo, WG; Shinawi, L | 1 |
| Drent, M; Leenders, KL; Meppelink, AM; Nyman, R; Prins, T; van Laar, T | 1 |
| Ellmén, J; Kailajärvi, M; Korpela, K; Kuoppamäki, M; Lehtinen, T; Sauramo, A; Vahteristo, M | 1 |
| MARKOWITZ, J | 1 |
| Barba, E; Bugamelli, F; Marcheselli, C; Raggi, MA | 1 |
| Gradl, B; Persson, U; Willis, M; Zoellner, Y | 1 |
| Ferreira, JJ; Sampaio, C | 1 |
| Hamann, M; Lange, N; Richter, A; Shashidharan, P | 1 |
| Delea, TE; Hagiwara, M; Thomas, SK | 1 |
| Bogdanov, RR; Kotov, SV; Kunitsyna, AN; Turbina, LG | 1 |
| Auclair-Ouellet, N; Cantin, L; Chantal, S; Langlois, M; Macoir, J; Prud'homme, M | 1 |
| Hawley, JS; Robottom, BJ; Weiner, WJ | 1 |
| Ivanov, AK; Levin, OS; Shindriaeva, NN | 1 |
| Fernandez, HH; Odin, P | 1 |
| Bengel, G; Ebersbach, G; Ehret, R; Jugel, C; Klostermann, F; Muhlack, S; Müller, T | 1 |
| Arami, MA; Ayromlou, H; Najmi, S | 1 |
| Arai, M | 3 |
| Dotchin, C; Jusabani, A; Walker, R | 1 |
| Armstrong, J; Artuch, R; Barredo-Valderrama, E; Campistol, J; Castro de Castro, P; Cormand, B; Garcia-Cazorla, A; Ormazabal, A; Serrano, M; Toma, C | 1 |
| Angrisano, S; Lanotte, M; Lopiano, L; Merola, A; Rizzi, L; Zibetti, M | 1 |
| Muhlack, S; Müller, T; Woitalla, D | 1 |
| Abbs, JH; Bendlin, BB; Brooks, BR; Brown, WD; Chung, MK; Dejesus, OT; Dogan, S; Gallagher, CL; Holden, JE; Johnson, SC; Konopacki, RA; Nickles, RJ; Oakes, TR; Pyzalski, RW; Xu, G | 1 |
| Fonseca-Ornelas, L; Hernández-Vargas, R; López-González, I; Reynaud, E; Riesgo-Escovar, J; Zurita, M | 1 |
| Bonifácio, MJ; Falcão, A; Lobo, JS; Machado, R; Soares-da-Silva, P; Sousa e Silva, JP | 1 |
| Hazan, D; Siegert, S; Szyper-Kravitz, M | 1 |
| Chen, C; Cowles, VE; Illarioshkin, SN; Stolyarov, ID; Sweeney, M | 1 |
| Carpintero, P; de la Fuente-Fernández, R; Llaneza, M; Macías, M; Sanjurjo, LF; Santos-García, D | 1 |
| Belcastro, V; Calabresi, P; Castrioto, A; Gallina, A; Rossi, A; Tambasco, N | 1 |
| Agarwal, P; Alcalay, R; Black, KJ; Chou, KL; Cote, L; Dayalu, P; Frank, S; Friedman, JH; Hartlein, J; Hauser, RA; Lang, AE; Marsh, L; Marshall, F; Moskowitz, C; Ravina, B; Riley, D; Sanchez-Ramos, J; Simon, DK; Simuni, T; Sutton, J; Tuite, P; Weintraub, D; Zesiewicz, T | 1 |
| Bel'gusheva, ME; Fedorova, NV; Iablonskaia, AIu | 1 |
| Adam, JJ; Duits, A; Scholtissen, B; van Houdt, H; Visser-Vandewalle, V; Winogrodzka, A | 1 |
| Kishi, M; Ogawa, E; Sakakibara, R; Takahashi, O; Tateno, F; Uchiyama, T; Yamamoto, T; Yamanishi, T; Yokoi, Y | 1 |
| Bergman, A; Chaudhuri, KR; Findley, LJ; Lowin, J; Morris, S; Roeder, C; Schifflers, M; Wood, E | 1 |
| Ellenbogen, AL; Gupta, SK; Hauser, RA; Hsu, A; Kell, SH; Metman, LV; Modi, NB; O'Connell, MJ; Yao, HM | 1 |
| Jugel, C; Klostermann, F; Marzinzik, F; Müller, T | 1 |
| Lew, MF; McCague, K; Somogyi, M; Welsh, M | 1 |
| Ahlskog, JE; Josephs, KA; Kumar, N; Matsumoto, JY; McKeon, A; Savica, R | 1 |
| Bonfim, RR; Byrro, RM; César, IC; Gomes, SA; Mundim, IM; Pianetti, GA; Santana E Silva Cardoso, FF; Souza Teixeira, L | 1 |
| Ellmén, J; Ingman, K; Korpela, I; Kuoppamäki, M; Naukkarinen, T; Vahteristo, M | 1 |
| Almer, Z; Gerstenhaber, M; Klein, KS; Marsh, L; Repka, MX | 1 |
| Babiuc, RD; Bajenaru, OA; Ene, A; Negreanu, L; Popescu, BO; Smarandache, GC | 1 |
| Buttarelli, FR; Campanelli, D; Fanciulli, A; Misasi, R; Pontieri, FR | 1 |
| Fedorova, NV; Kulua, TK; Popovkina, OA | 1 |
| Becker, N; Munhoz, RP; Teive, HA | 1 |
| Ishihara, A; Kihira, K; Kimura, Y; Matsumoto, M; Miyachi, T; Nakamura, T; Ohtsuki, T; Yamawaki, T | 1 |
| Aguilar-Venegas, LC; Espinola-Nadurille, M; Fricchione, GL; Merida-Puga, J; Ramirez-Bermudez, J | 1 |
| Okun, MS | 1 |
| Grice, T; Stagg, P | 1 |
| Boskovic, R; Clark, M; Houle, S; Kish, SJ; Meyer, JH; Rabiner, EA; Rusjan, P; Sacher, J; Soliman, A; Wilson, AA | 1 |
| Askmark, H; Munro Neville, A; Nyholm, D; Parsons, RW | 1 |
| Añón, MJ; de la Fuente-Fernández, R; Fuster-Sanjurjo, L; Santos-García, D | 1 |
| Ehret, R; Haas, T; Lütge, S; Marg, M; Müller, T | 1 |
| Emre, M; Reichmann, H | 1 |
| Benko, R; Jain, L; Safranek, S | 1 |
| Coon, EA; Laughlin, RS | 1 |
| Danoudis, M; Iansek, R | 1 |
| Johansson, A; Klangemo, K; Nyholm, D | 1 |
| Abdollahi-Alibeik, M; Benvidi, A; Mazloum-Ardakani, M; Sheikh-Mohseni, MA | 1 |
| Beitollahi, H; Dehghani, H; Khoshroo, A; Mazloum-Ardakani, M; Taleat, Z | 1 |
| Aldred, JL; Brod, LS; Nutt, JG | 1 |
| Bhatia, KP; Dayan, P; Dolan, RJ; Hill, C; Seymour, B; Shiner, T; Wunderlich, K | 1 |
| Boukherroub, R; Das, MR; Li, M; Szunerits, S; Wang, Q | 1 |
| Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P | 1 |
| Bartalini, S; Bianco, G; Chieca, R; Rossi, A; Rossi, S; Ulivelli, M; Vuolo, G | 1 |
| Busk, K; Nyholm, D | 1 |
| Nishijima, K; Saito, S; Shioda, K | 1 |
| Birthi, P; McDowell, S; Perry, D; Salles, S | 1 |
| George, S; Jones, HB | 1 |
| Dizdar, N; Hauge, T; Holmberg, B; Jansson, R; Johansson, A; Linder, J; Nyholm, D; Pålhagen, SE; Sydow, O; Wainwright, M; Widner, H | 1 |
| Tarsy, D | 1 |
| Belavic, J | 1 |
| Derkinderen, P; Lebouvier, T; Pouclet, H | 1 |
| Aquilonius, SM; Bäckström, T; Ehrnebo, M; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G; Spira, J; Trolin, CG | 1 |
| Artusi, CA; De Angelis, C; Lopiano, L; Marchisio, A; Merola, A; Montanaro, E; Reggio, D; Ricchi, V; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Müller, T; Skodda, S | 1 |
| Camargos, S; Cardoso, F; Lees, AJ; Singleton, A | 1 |
| Fedotova, EIu; Illarioshkin, SN; Ivanova-Smolenskaia, IA; Karabanov, AV; Mirkasimov, AF; Poleshchuk, VV; Polevaia, EV; Zagorovskaia, TB | 1 |
| Foote, KD; Hassan, A; Iyer, S; McFarland, NR; Okun, MS; Rodriguez, RL; Sriram, A; Ward, HE | 1 |
| Colamartino, M; Cornetta, T; Cozzi, R; Leone, S; Meneghini, C; Padua, L; Testa, A | 1 |
| Puig-Junoy, J; Puig-Peiró, R; Valldeoriola, F | 1 |
| Fortuna, G; Pollio, A | 1 |
| Ahmad, M; Gupta, A; Rizvi, I; Zaidi, N | 1 |
| Agarwala, R; Bennett, SF; Berry, MW; Bick, DP; Chen, B; Chin, EL; Compton, JG; Das, S; Dimmock, DP; Farkas, DH; Ferber, MJ; Funke, BH; Furtado, MR; Ganova-Raeva, LM; Gargis, AS; Geigenmüller, U; Gunselman, SJ; Hambuch, T; Hegde, MR; Johnson, PL; Kalman, L; Kasarskis, A; Kulkarni, S; Lenk, T; Liu, CS; Lu, F; Lubin, IM; Lyon, E; Manion, M; Manolio, TA; Mardis, ER; Merker, JD; Rajeevan, MS; Reese, MG; Rehm, HL; Simen, BB; Voelkerding, KV; Yeakley, JM; Zehnbauer, BA; Zook, JM | 1 |
| Burguera, JA; Martínez-Castrillo, JC | 1 |
| Grandas, FJ; Sesar-Ignacio, Á | 1 |
| Lalla, R; Patil, TB; Verma, R | 1 |
| Bömelburg, M; Ebersbach, G; Jugel, C; Klostermann, F; Marzinzik, F; Müller, T | 1 |
| Fukui, M; Kang, KS; Wen, Y; Yamabe, N; Zhu, BT | 1 |
| Chari, V; Ennis, JD; Graham, A; Harvey, D; Ho, E; Nesathurai, S | 1 |
| Chatamra, K; Dutta, S; Johansson, A; Locke, C; Nyholm, D; Odin, P; Othman, AA | 1 |
| Anderson, LC; Fagerlund, K; Gurvich, O | 1 |
| Datieva, VK; Levin, OS; Makotrova, TA | 1 |
| Benesh, J; Chatamra, K; Espay, AJ; Fernandez, HH; Hass, SL; Hauser, RA; Lenz, RA; Odin, P; Pritchett, Y; Standaert, DG; Vanagunas, A | 1 |
| Albanese, A; Antonini, A; Chaudhuri, KR; Clarke, CE; de Bie, RM; Deuschl, G; Eggert, K; Houeto, JL; Kulisevsky, J; Nyholm, D; Odin, P; Oertel, W; Poewe, W; Pollak, P; Rabey, JM; Rascol, O; Ruzicka, E; Samuel, M; Speelman, H; Sydow, O; Valldeoriola, F; van der Linden, C; Volkmann, J; Østergaard, K | 1 |
| Angrisano, S; Cicolin, A; Lopiano, L; Merola, A; Montanaro, E; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Jančić Stojanović, B; Malenović, A; Stamenković, I; Vemić, A | 1 |
| Joo, HS; Kim, ES; Kim, YH; Kwon, OK; Lee, J; Moon, DE; Park, HJ | 1 |
| Holiga, Š; Jech, R; Möller, HE; Mueller, K; Růžička, E; Schroeter, ML; Sieger, T; Vymazal, J | 1 |
| Gupta, S; Hsu, A; Mao, Z; Modi, NB | 1 |
| de Jong, MH; Van Gool, AR; Zemel, D | 1 |
| Hernández, B; Martínez-Martín, P; Ricart, J | 1 |
| Sheehan, J; Thorpe, M; Wilson, L | 1 |
| Ossig, C; Reichmann, H | 1 |
| Rascol, O | 2 |
| Espay, AJ; Gupta, S; Hauser, RA; Hsu, A; Kell, S; O'Connell, M; Ondo, W; Sethi, K; Stacy, M | 1 |
| Worth, PF | 1 |
| Agarwal, P; Burdick, DJ; Griffith, A | 1 |
| Junnotula, V; Licea-Perez, H | 1 |
| Durso, R; Josephs, E; Modak, A; Rosen, D | 1 |
| Álvarez-Sabin, J; Boronat-Guerrero, S; Hernández-Vara, J; Salvado, M | 1 |
| Best, CM; Ifedi, BO; Reichel, LM | 2 |
| Ehlen, F; Jugel, C; Klostermann, F; Marzinzik, F; Müller, T; Taskin, B | 1 |
| Angrisano, S; Artusi, CA; Cocito, D; Lopiano, L; Merola, A; Rizzone, MG; Troiano, M; Zibetti, M | 1 |
| Aschermann, Z; Komoly, S; Kovács, N | 1 |
| Jackson, MJ; Jenner, P; Pearce, RK; Swart, T | 1 |
| Namazi, H | 1 |
| Levin, OS; Liashchenko, EA; Skripkina, NA | 1 |
| Hernández-Vara, J; Salvado, M | 1 |
| Filipek, B; Pytka, K; Zygmunt, M | 1 |
| Galazky, I; Heinze, HJ; Kluge, C; Kupsch, A; Schoof, J; Stallforth, S | 1 |
| Fahn, S; Gupta, S; Hauser, RA; Hsu, A; Jankovic, J; Kell, S; Lyons, KE; O'Connell, M; Pahwa, R; Pourcher, E | 1 |
| Heidenreich, WF | 1 |
| Khoshroo, A; Mazloum-Ardakani, M | 1 |
| Snider, S | 1 |
| Hernández, B; Kulisevsky, J; Linazasoro, G; López-Lozano, JJ; Marey, J; Mir, P; Tolosa, E | 1 |
| Corona-Morales, AA; Hernández, VS; Jáuregui-Huerta, F; Luquín, S; Medina, MP; Ruíz-Velasco, S; Zhang, L | 1 |
| Angrisano, S; Artusi, CA; De Angelis, C; Lopiano, L; Merola, A; Reggio, D; Rizzi, L; Rizzone, M; Zibetti, M | 1 |
| Baumann, CR; Waldvogel, D | 1 |
| Fülöp, F; Hara, S; Hashizume, T; Jin, J; Nagy, GM; Sawai, K | 1 |
| Gelfius, CD; Mortimer, D; Potts, MA | 1 |
| Chen, D; Cundy, KC; Hauser, RA; Huff, FJ; LeWitt, PA; Lissin, D; Zomorodi, K | 1 |
| Antonini, A; Benesh, J; Chatamra, K; Espay, AJ; Fernandez, HH; Kieburtz, K; Lenz, RA; Odin, P; Olanow, CW; Othman, AA; Pritchett, Y; Robieson, WZ; Standaert, DG; Vanagunas, A; Widnell, KL | 1 |
| de Beyl, DZ; Dethy, S; Pickut, BA; Van De Maele, H; van der Linden, C | 1 |
| Bhidayasiri, R; Boonrod, N; Jitkritsadakul, O; Rerknimitr, R | 1 |
| Capone, JG; Contini, E; Golfre-Andreasi, N; Gragnaniello, D; Preda, F; Quatrale, R; Sensi, M; Sette, E; Tola, MR; Trevisani, L; Tugnoli, V | 1 |
| Farag, NE; Hammad, LN; Zaitone, SA | 1 |
| Charde, SY; Raut, PP | 1 |
| Grabowski, J; Green, CE; Lindsay, JA; Moeller, FG; Rathnayaka, NS; Schmitz, JM; Stotts, AL | 1 |
| Fedorova, NV; Kulua, TK | 1 |
| Dutta, S; Othman, AA | 1 |
| Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Huertas-Fernández, I; Lama, MJ; Mir, P; Vargas-González, L | 1 |
| Berg, J; Crooks, K; Evans, J; Fan, Z; Felix, AC; Greenwood, R; Roche, M; Shiloh-Malawsky, Y; Tennison, M; Weck, K; Wilhelmsen, K | 1 |
| Katzenschlager, R; Poewe, W | 1 |
| Nagy, H; Radics, P; Takáts, A; Tamás, G; Tóth, A | 1 |
| Aglan, H; Ahmed, H; Atta, H; Ghazy, M; Salem, A | 1 |
| Chowdhury, JH; Chowdhury, TI; Rahman, MM; Uddin, MJ | 1 |
| Jost, WH | 2 |
| Hattori, T; Karasawa, H; Mogami, S; Taché, Y; Wang, L; Yakabi, K; Yakabi, S; Yamada, C | 1 |
| Ceballos-Baumann, AO; Fietzek, UM; Lehnerer, SM; Messner, M | 1 |
| Chen, CH; Chen, NF; Chen, WF; Feng, CW; Hsiao, CD; Huang, SY; Hung, HC; Wang, HM; Wen, ZH; Yang, SN | 1 |
| Kimber, TE; Schoeman, M | 1 |
| Herrmann, L; Muhlack, S; Müller, T; Salmen, S | 1 |
| Green, CE; Kosten, TR; Lane, SD; Liu, S; Moeller, FG; Nielsen, DA; Schmitz, JM | 1 |
| Carpintero, P; de Deus, T; de la Fuente-Fernandez, R; Echarri-Piudo, A; Llaneza-Gonzalez, MA; Lopez-Pazos, E; Macias-Arribi, M; Santos-Garcia, D | 1 |
| Fregly, BJ; Hass, CJ; Roemmich, RT | 1 |
| Argyris, P; Barla, G; Maltezou, M; Stathis, P; Tzias, V | 1 |
| Alizadeh, R; Beitollahi, H; Molaakbari, E; Mostafavi, A | 1 |
| Cardoso, MA; de Carvalho, KA; Marson, BM; Pontarolo, R; Pontes, FL; Ribeiro, RP; Vilhena, Rde O | 1 |
| Epstein, J; Hayes, MT; Lai, L; Madiedo, CJ | 1 |
| Ondo, W | 1 |
| Eleopra, R; Onofrj, M; Uncini, A | 1 |
| Giladi, N; Goldstein, S; Gurevich, T; Hilel, A; Shapira, Y; Zlotnik, Y | 1 |
| Guthikonda, LN; Lyons, KE; Pahwa, R | 1 |
| Dillmann, U; Ellenbogen, A; Gupta, S; Hsu, A; Kell, S; Khanna, S; Liang, G; Mahler, A; Rubens, R; Stocchi, F | 1 |
| Odin, P; Walter, E | 1 |
| Ceci, R; Colamartino, M; Cozzi, R; Duranti, G; Padua, L; Sabatini, S; Santoro, M; Testa, A | 1 |
| Merello, M; Rossi, M | 1 |
| Alexiou, A; Psiha, M; Vlamos, P | 1 |
| Hashizume, T; Jin, J | 1 |
| Katunina, EA; Titova, NV | 2 |
| Antonini, A; Poewe, W | 1 |
| Chang, MC; Jang, SH; Kwon, YM | 1 |
| Aparicio-Martinez, MJ; Fernández-López, M; Moya-Jiménez, MC; Perea-Rodriguez, A; Perea-Rodriguez, C; Rubí-Callejón, J | 1 |
| Ács, P; Aschermann, Z; Bosnyák, E; Deli, G; Janszky, J; Komoly, S; Kovács, N | 1 |
| Arolt, V; Deckert, J; Dlugos, A; Domschke, K; Gajewska, A; Gieselmann, A; Herrmann, MJ; Jacob, C; Markulin, F; Mühlberger, A; Nienhaus, K; Notzon, S; Pauli, P; Reif, A; Unterecker, S; Warrings, B; Winter, B; Zwanzger, P | 1 |
| Chang, MC; Chun, MH; Kang, CG; Kong, EJ | 1 |
| Benesh, JA; Chatamra, K; Chouinard, S; Dubow, J; Espay, AJ; Fernandez, HH; Fung, VS; Hall, CM; Hauser, RA; Klostermann, F; Lang, AE; Lew, MF; Odin, P; Robieson, WZ; Standaert, DG; Steiger, M; Suchowersky, O; Yakupov, EZ | 1 |
| Chang, FC; Drury, M; Fung, VS; Griffith, JM; Ha, AD; Kim, SD; Mahant, N; Tsui, DS; Wolfe, N | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Preda, C; Yegin, A | 1 |
| Cardoso, MA; de Carvalho, KA; de Francisco, TM; de Oliveira Vilhena, R; Gasparetto, JC; Guimarães de Francisco, TM; Martins, CA; Pontarolo, R; Ribeiro, RP | 1 |
| Benesh, J; Chatamra, K; Dubow, J; Eaton, S; Fernandez, HH; Hall, C; Slevin, JT; Zadikoff, C | 1 |
| Kretova, AS; Lyubimov, AV | 1 |
| di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G; Scrascia, F | 1 |
| Rudakova, AV; Yakupov, EZ | 1 |
| Andersen, LM; Gross, J; Joensson, M; Lou, HC; Mouridsen, K; Sandberg, K; Thomsen, KR; Østergaard, L | 1 |
| Timofeeva, AA | 1 |
| Limón, ID; Palafox-Sánchez, V; Ramírez-García, G | 1 |
| Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Fahn, S; Kestenbaum, M | 1 |
| Aschermann, Z; Bereczki, D; Dézsi, L; Dibó, G; Klivényi, P; Komoly, S; Kovács, N; Nagy, H; Takáts, A; Tóth, A; Valikovics, A; Varannai, L; Vécsei, L; Zemlényi, G | 1 |
| Nutt, JG | 1 |
| Afshari, D; Azimi, H; Ghadami, MR; Heidarnejadian, J; Razazian, N | 1 |
| Fasano, A; Lang, AE; Liu, LW; Poon, YY | 1 |
| Fung, VS | 1 |
| Chen, C; Cowles, VE; Stover, N; Sweeney, M; Verhagen Metman, L | 1 |
| Gupta, S; Hsu, A; Modi, NB; Yao, HM | 1 |
| Bankiewicz, K; Beyer, J; Ciesielska, A; Forsayeth, J; Sharma, N | 1 |
| Benesh, J; Chatamra, K; Dutta, S; Mohamed, ME; Nagai, M; Othman, AA; Yanagawa, M | 1 |
| Gambini, O; Islam, L; Piacentini, S; Scarone, S; Soliveri, P | 1 |
| Dzyak, L; Gupta, S; Hsu, A; Kell, S; Khanna, S; Nausieda, P; Rudzinska, M; Silver, DE; Spiegel, J; Tsurkalenko, ES; Waters, CH | 1 |
| Antonini, A; Cossu, G; Mancini, F; Melis, M; Mereu, A; Murgia, D; Pilleri, M; Ricchi, V; Ricchieri, G | 1 |
| Barrios-Barrios, A; Bustamante-Balén, M; del-Hoyo-Francisco, J; Martínez-Torres, I; Pons-Beltrán, V; Satorres-Paniagua, C | 1 |
| Benesh, JA; Chatamra, K; Dubow, JS; Fung, VS; Krüger, R; Lew, MF; Martínez Castrillo, JC; Robieson, WZ; Slevin, JT | 1 |
| Cansev, M; Celikler Kasimogullari, S; Orenlili Yaylagul, E | 1 |
| Johnson, KE | 1 |
| Antonelli, F; Buongiorno, M; Calopa, M; Cámara, A; Campolongo, A; de Fabregues-Nebot, O; Hernandez-Vara, J; Kulisevsky, J; Martí, MJ; Pascual-Sedano, B; Puente, V; Tolosa, E; Valldeoriola, F | 1 |
| Benedetti, A; Gros, P; Kaminska, M; Kimoff, RJ; Lafontaine, AL; Mery, VP; Robinson, A | 1 |
| Cannas, A; Fasano, A; Lang, AE; Marrosu, F; Marrosu, MG; Mulas, CS; Solla, P | 1 |
| Dam-Larsen, S; Darkahi, B; Glad, A; Gleditsch, D; Gustavsson, L; Halttunen, J; Johansson, KE; Pischel, A; Reiertsen, O; Törnqvist, B; Zebski, H | 1 |
| Bellante, F; Dethy, S; Zegers de Beyl, D | 1 |
| Bruno, E; Cicero, CE; Contrafatto, D; Dibilio, V; Giuliano, L; Luca, A; Mostile, G; Nicoletti, A; Pappalardo, I; Raciti, L; Sciacca, G; Sofia, V; Zappia, M | 1 |
| Bonuccelli, U; Ceravolo, R; Frosini, D; Mazzucchi, S | 1 |
| Andersen, JK; Kim, YH; Lazzara, CA; Rane, A; Riley, RR | 1 |
| Benesh, JA; Chatamra, K; Fernandez, HH; Standaert, DG | 1 |
| Flisar, D; Kojovic, M; Kramberger, MG; Pirtosek, Z; Zorko, N | 1 |
| Garg, A; Jha, S; Khanna, A | 1 |
| Nyholm, D; Nyman, R; van Laar, T | 1 |
| di Biase, L; Di Lazzaro, V; Marano, M; Melgari, JM; Salomone, G | 2 |
| Kuoppamäki, M; Leinonen, M; Poewe, W | 1 |
| Dar, SA; Orge, FH | 1 |
| Antonini, A; Chaudhuri, KR; Fox, K; Fox, T; Honig, H; Martinez-Martin, P; Odin, P; Timpka, J | 1 |
| Hattori, N; Ishiguro, Y; Kawajiri, S; Noda, K; Okuma, Y; Tomizawa, Y; Tosaka, Y | 1 |
| Mick, D; Resan, B; Segec, I; Skelac, D; Soldo, SB; Tomic, S | 1 |
| Elmer, L; Gil, RA; Gupta, S; Hsu, A; Kell, S; Khanna, S; Modi, NB; Nausieda, PA; Rubens, R; Singer, C; Spiegel, J | 1 |
| Cannas, A; Fasano, A; Marrosu, F; Solla, P | 1 |
| Cannas, A; Marrosu, F; Marrosu, MG; Solla, P | 1 |
| Cordery, P; James, LJ; Maughan, RJ; Peirce, N; Watson, P | 1 |
| Burgess, T; Cunningham, V; Glamuzina, E; Hill, R; Jacobsen, JC; Lehnert, K; Love, DR; Prosser, DO; Robertson, SP; Snell, RG; Swan, B; Taylor, J; Wilson, C | 1 |
| Bernardini, A; Cocito, D; Lopiano, L; Merola, A; Romagnolo, A; Zibetti, M | 1 |
| Elroby, SA; Hilal, R; Sukker, GM | 1 |
| Harada, N; Kakiuchi, T; Kanazawa, M; Muramatsu, S; Ohba, H; Tsukada, H | 1 |
| Bloem, BR; de Bie, RM; de Haan, RJ; Deuschl, G; Dijkgraaf, M; Lang, AE; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CV | 1 |
| Abou Al-Shaar, H; Al-Ajlan, F; Alkahtani, K; Alkhairallah, T; Bohlega, S; Hasan, N | 1 |
| Mao, ZL; Modi, NB | 1 |
| Greig, SL; McKeage, K | 1 |
| Benesh, JA; Boyd, JT; Chatamra, K; Chouinard, S; Draganov, PV; Dubow, J; Eaton, S; Espay, AJ; Fasano, A; Fernandez, HH; Fung, VS; Klostermann, F; Lang, AE; Lew, MF; Odin, P; Robieson, WZ; Rodriguez, RL; Schmulewitz, N; Slevin, JT; Stein, DA; Zadikoff, C | 1 |
| Băjenaru, O; Buraga, I; Constantinescu, A; Ene, A; Mureşan, DF; Perju-Dumbrava, L; Popescu, BO; Popescu, CD; Sabău, M; Simu, M; Szász, JA | 1 |
| Hattori, N | 1 |
| Dagher, A; Fellows, LK; Simioni, AC | 1 |
| Bereczki, D; Nagy, H; Takáts, A; Toth, A; Wacha, J | 1 |
| Chang, FC; Fung, VS; Griffith, JM; Ha, AD; Kim, SD; Kwan, V; Mahant, N; Tsui, D; van der Poorten, D; Wolfe, N | 1 |
| Ito, H; Koh, J; Kondo, T; Nagashima, Y; Sakata, M | 1 |
| Alonso, V; Anyanwu, EC; Benoit, JL; Ebara, L; Pettit, NN; Wojcik, E | 1 |
| Antonini, A; Benesh, JA; Boyd, JT; Chatamra, K; Eaton, S; Fung, VS; Hall, C; Slevin, JT | 1 |
| Jankovic, J; Lotia, M | 1 |
| Atlas, D | 1 |
| Mueller, BK; Muhlack, S; Müller, T; Trommer, I | 1 |
| Bishnoi, P; Charde, SY; Raut, PP | 1 |
| Bedi, G; Bisaga, A; Foltin, RW; Nunes, EV; Shiffrin, L; Vadhan, NP | 1 |
| Cicero, CE; Mostile, G; Nicoletti, A; Zappia, M | 1 |
| Bove, F; Espay, AJ; Espay, KJ; Fasano, A; Krikorian, R; Lena, F; Modugno, N; Poon, YY; Ricciardi, L | 1 |
| Gore, C; Wu, C | 1 |
| Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
| Algom, AA; Dickson, DW; Fujioka, S; Murray, ME; Rademakers, R; Ross, OA; Sanchez-Contreras, MY; Tacik, P; Tsuboi, Y; Uitti, RJ; Van Gerpen, JA; Wszolek, ZK | 1 |
| Dhall, R; Kreitzman, DL | 1 |
| Silver, DE; Trosch, RM | 1 |
| Benita León, V; Campolongo Perillo, A; Fernández Díez, S; Mariscal Pérez, N; Martínez Castrillo, JC; Puente Périz, V; Santos García, D; Seoane Urgorri, A; Udaeta Baldivieso, B | 1 |
| Friedman, JR | 1 |
| Nyholm, D; Odin, P; Wirdefeldt, K | 2 |
| Almeida, L; Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Shubhakaran, K | 1 |
| Bernardini, A; Espay, AJ; Espay, KJ; Lanotte, M; Lopiano, L; Merola, A; Rizzi, L; Romagnolo, A; Rosso, M; Zibetti, M | 1 |
| Jog, MS; Kumar, N; Rizek, P | 1 |
| Lyons, KE; Pahwa, R | 1 |
| Abreu, L; Bernardo, C; López Gómez, M; Magaz Martínez, M; Martínez Porras, JL; Santiago, J | 1 |
| Baek, JS; Choo, CC; Loo, SC; Qian, C; Shen, Z; Tan, NS | 1 |
| Mundt-Petersen, U; Odin, P; Timpka, J | 1 |
| Bergmann, L; Dizdar, N; Hauge, T; Holmberg, B; Jansson, R; Johansson, A; Kjellander, S; Linder, J; Marshall, TS; Nyholm, D; Pålhagen, SE; Sydow, O; Widner, H | 1 |
| Amato, MR; De Micco, R; Del Prete, A; Esposito, P; Ferraro, F; Sica, M; Tessitore, A; Zulli, C | 1 |
| Durso, R; McNamara, P; Morgan, J; Smart, K | 1 |
| Cubo, E; Giuffrida, JP; Heldman, DA | 1 |
| Antonini, A; Cannas, A; Costanzo, AM; di Luzio Paparatti, U; Gualberti, G; Gusmaroli, G; Lopiano, L; Mancini, F; Marano, P; Meco, G; Melzi, G; Modugno, N; Quatrale, R; Sensi, M; Tamma, F | 1 |
| Cannas, A; Marrosu, F; Meloni, M; Solla, P | 1 |
| Carpenter, MG; Inglis, JT; McKeown, MD; McKeown, MJ; Pasman, EP; Peters, RM | 1 |
| Arbelo, JM; Catalán, MJ; Grandas, F; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Ebersbach, G; Holtmann, M; Jost, W; Odin, P; Schrader, C; Südmeyer, M; Winkler, C | 1 |
| Bloem, BR; Faber, MJ; Nijhuis, FA; Post, B; van Heek, J | 1 |
| Devigili, G; Eleopra, R; Lettieri, C; Rinaldo, S | 1 |
| Lambarth, AT | 1 |
| Abdel-Ghany, MF; Ayad, MF; Hussein, LA; Youssef, MM | 1 |
| Avolio, C; De Francesco, V; Lalla, A; Martino, T; Melchionda, D; Specchio, LM; Tonti, P | 1 |
| Bilic, B; Markos, P; Miletic, V; Rustemovic, N | 1 |
| Pidaparthi, K; Suares, D | 1 |
| Khatoon, H; Mirza, T; Najam, R; Sikandar, B | 1 |
| Fox, SH; Freitas, ME; Ruiz-Lopez, M | 1 |
| MacDonald, PA; Seergobin, KN; Vo, A | 2 |
| Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P | 1 |
| Cataldo, BO; Cury, RG; de Campos Duprat, A; Fonoff, E; Noffs, G; Zarzur, AP | 1 |
| Bojarski, C; Ehlen, F; Klostermann, F; Maier, A; Marzinzik, F; Schindlbeck, KA | 1 |
| Guertin, PA | 1 |
| Abreu, L; Magaz Martínez, M; Martínez Porras, JL; Oliva, B | 1 |
| Nielsen, EI; Nyholm, D; Senek, M | 3 |
| Borgemeester, R; van Laar, T | 1 |
| Altamura, C; Basile, S; Calcagno, M; Garibaldi, S; Pinelli, S; Salerno, MG | 1 |
| Dyck, S; Guertin, PA; Kia, M; Matte, G; Mongeon, D; Prince, F; Radhakrishna, M; Roberts, M; Steuer, I; Vaillancourt, M | 1 |
| Cannas, A; Marrosu, F; Mascia, MM; Meloni, M; Solla, P | 1 |
| Jog, M; Kumar, N | 1 |
| Aquilonius, SM; Askmark, H; Bergquist, F; Constantinescu, R; Ericsson, A; Lycke, S; Medvedev, A; Memedi, M; Nyholm, D; Ohlsson, F; Senek, M; Spira, J; Westin, J | 1 |
| Alonso-Frech, F; Catalán, MJ; Escribano, PM | 1 |
| Modi, NB | 1 |
| Duker, AP; Ellenbogen, A; Farbman, ES; Gupta, S; Hauser, RA; Hsu, A; Kell, S; Khanna, S; Kreitzman, D; Liang, GS; Nausieda, P; Nieves, A; Rubens, R; Tetrud, J | 1 |
| Dietrichs, E; Odin, P | 1 |
| Ács, P; Annus, Á; Aschermann, Z; Dézsi, L; Dibó, G; Harmat, M; Janszky, J; Juhász, A; Karádi, K; Klivényi, P; Komoly, S; Kovács, M; Kovács, N; Makkos, A; Nagy, H; Takáts, A; Tényi, D; Tóth, A; Varannai, L; Vécsei, L; Zádori, D | 1 |
| Debelius, JW; Factor, SA; Hill-Burns, EM; Knight, R; Lewis, MR; Molho, E; Morton, JT; Payami, H; Peddada, SD; Wallen, ZD; Wissemann, WT; Zabetian, CP | 1 |
| Evans, AH; Fung, VSC; Hayes, M; Iansek, R; Kimber, T; O'Sullivan, JD; Sue, CM; Williams, DR | 1 |
| Chatamra, K; Dutta, S; Locke, C; Othman, AA; Rosebraugh, M | 1 |
| Buhmann, C; Hilker, R; Lingor, P; Reichmann, H; Schrader, C; Schwarz, J; Wolz, M | 1 |
| Gupta, S; Mittur, A; Modi, NB | 1 |
| Antonini, A; Cossu, G; Mancini, F; Modugno, N; Pilleri, M; Quatrale, R; Sensi, M; Tamma, F; Zibetti, M | 1 |
| Artusi, CA; Comi, C; Duker, AP; Espay, AJ; Lanotte, M; Lopiano, L; Maule, S; Merola, A; Romagnolo, A; Rosso, M; Zibetti, M | 1 |
| Aquilonius, SM; Nyholm, D | 1 |
| Albo, J; Hellström, M; Nyholm, D; Senek, M; Svenningsson, P | 1 |
| Aonurm-Helm, A; Männistö, PT; Tammimäki, A | 1 |
| de la Casa, B; Díaz Gómez, A; Díaz Ruiz, R; Fernández Alvárez, C; González Asanza, C; Nogales, Ó | 1 |
| Fasano, A; Naranian, T; Poon, YY; Rohani, M | 1 |
| Greenberg, I; Levy, HV; Sintov, AC | 1 |
| Chi, J; Jenkins, R; Li, F; Ling, Y | 1 |
| Angrisano, S; Cicolin, A; Lopiano, L; Merola, A; Montanaro, E; Priano, L; Romagnolo, A; Tribolo, A; Zibetti, M | 1 |
| Aasly, J; Dietrichs, E; Egge, A; Ezat, B; Pihlstrøm, L; Tysnes, OB | 1 |
| Ehm, G; Jeon, B; Kim, A; Kim, HJ; Kim, YE; Lee, WW; Yang, HJ; Yun, JY | 1 |
| Chorbadzhieva, E; Dressler, D; Kleimann, A; Loens, S; Schrader, C | 1 |
| Fülöp, F; Hashizume, T; Inaba, Y; Nagy, GM; Sawai, K; Watanabe, R | 1 |
| Capone, JG; Golfrè Andreasi, N; Preda, F; Rispoli, V; Sensi, M; Sette, E; Simioni, V; Tugnoli, V | 1 |
| Antonini, A; Danielsen, EH; de Fabregues, O; Doskas, T; Henselmans, JML; Krüger, R; Lingor, P; Onuk, K; Parra, JC; Sensken, SC; Stefani, A; Yegin, A | 1 |
| Belagaje, SR; Buetefisch, CM; Haut, MW; Hobbs, G; Kesar, TM; Pergami, P | 1 |
| Bove, F; Di Iorio, R; Fasano, A; Gallicchio, L; Luigetti, M; Petruzzellis, A; Recchia, V; Tamma, F | 1 |
| Durando, M; Kim, JS; Tiu, H | 1 |
| Bentivoglio, AR; Bove, F; Fasano, A; Naranian, T | 1 |
| Eerola-Rautio, J; Kenttämies, A; Kylänpää, L; Lindström, O; Lyytinen, J; Pekkonen, E; Udd, M | 1 |
| Ando, R; Miyaue, N; Nagai, M; Nishikawa, N; Nomoto, M; Tada, S; Yabe, H | 1 |
| Mundt-Petersen, U; Odin, P | 1 |
| Klein, S; Wollmer, E | 1 |
| Elsea, SH; Hanchard, NA; Kennedy, AD; Magoulas, PL; Pappan, KL; Sun, Q | 1 |
| Abu-Suboh, M; Alvarez-Sabín, J; Armengol, JR; De Fabregues, O; Dot, J; Ferré, A; Gómez, MR; Hernández-Vara, J; Ibarria, M; Puiggros, C; Quintana, M; Raguer, N; Romero, O; Seoane, JL | 1 |
| D'Elia, A; Imbriani, P; Pisani, A; Schirinzi, T | 1 |
| Manno, RA; Maronpot, RR; Nyska, A; Ramot, Y; Sacco, G; Shaltiel-Karyo, R; Tsarfati, Y; Yacoby-Zeevi, O | 1 |
| Baj, R; Chaudhuri, KR; Jalundhwala, YJ; Konwea, H; Lowin, J; Marshall, TS; Sail, K | 1 |
| Dizdar, N; Grenholm, P; Groth, K; Kjellander, S; Larsson, J; Nyholm, D; Permert, J; Schmiauke, U; Urbom, A; Widner, H; Willows, T | 1 |
| Antonini, A; Barch, D; Bergmann, L; Chaudhuri, KR; Jech, R; Odin, P; Onuk, K; Pickut, B; Pirtošek, Z; Poewe, W; Szasz, J; Valldeoriola, F; Winkler, C; Yegin, A | 1 |
| Baastrup, C; Benedetti, F; Grosen, K; Hall, KT; Jensen, TS; Kaptchuk, TJ; Moslemi, K; Petersen, GL; Price, DD; Skyt, I; Svensson, P; Vase, L | 1 |
| Fasano, A; Jog, M; Kumar, N; Murgai, A; Naranian, T | 1 |
| Hoon, M; Petzer, A; Petzer, JP; Viljoen, F | 1 |
| Bopeththa, BVKM; Ralapanawa, U | 1 |
| Compta, Y; Martí, MJ; Muñoz, JE; Ríos, J; Rumià, J; Santacruz, P; Tolosa, E; Valldeoriola, F | 1 |
| Cestari, DM; Eichler, FS; Hunt, AL; Rapalino, O; Swoboda, KJ | 1 |
| Fairchild, A; Hass, S; Marshall, T; Pugh, A | 1 |
| Bartel, T; Blydt-Hansen, I; Connolly, MB; Horvath, GA; Race, S; Ross, CJ; Tarailo-Graovac, M; Van Allen, MI; van Karnebeek, CDM; Wasserman, WW | 1 |
| Challa, JA; Harewood Smith, AN; Silver, MA | 1 |
| Catalán, MJ; Grandas, F; Matías-Arbelo, J; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Ding, H; Fengsi, -; Liu, H; Sun, C; Zhang, D | 1 |
| Barichella, M; Cassani, E; Cereda, E; Cilia, R; Laguna, J; Pezzoli, G; Raspini, B | 1 |
| Angrisano, S; Artusi, CA; Dematteis, F; Lopiano, L; Merola, A; Romagnolo, A; Zibetti, M | 1 |
| Esqueda-Liquidano, M; García-Gomar, MG; Velasco, AL; Velasco, F | 1 |
| Alhadhrami, A; Alharthi, SS; Alrobaian, MM; Kabel, AM; Omar, MS | 1 |
| Albero Roselló, I; Argente Navarro, P; Gimenez Jimenez, I; Romero García, E | 1 |
| Bendi, VS; Joy, S; Shou, J; Torres-Russotto, D | 1 |
| Bakis, G; Nutt, J; Staisch, J | 1 |
| Ascaso Puyuelo, J; Jiménez Benito, J | 1 |
| Antonini, A; Canesi, M; Costanzo, AM; Defazio, G; di Luzio Paparatti, U; Gualberti, G; Latorre, A; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pontieri, FE; Quatrale, R; Sensi, M; Solla, P; Tambasco, N; Tessitore, A | 1 |
| Kundt, FS; Lex, KM; Lorenzl, S | 1 |
| Arbelo, JM; Catalan, MJ; Cubo, E; Martinez-Martin, P; Mir, P; Molina-Arjona, JA | 1 |
| Eklund, M; Henriksen, T; Nyholm, D; Odin, P; Sahlström, T; Timpka, J | 1 |
| Benesh, J; Boyd, JT; Chatamra, K; Eaton, S; Espay, AJ; Facheris, MF; Fernandez, HH; Fung, VSC; Hall, C; Lew, MF; Robieson, WZ; Rodriguez, RL; Slevin, JT; Standaert, DG; Vanagunas, AD; Zadikoff, C | 1 |
| Andrisani, G; di Biase, L; Di Lazzaro, V; Di Matteo, FM; Di Santo, A; Marano, M; Martino, M; Pandolfi, M; Pizzicannella, M; Rea, R | 1 |
| Ikram, R; Riaz, B; Sikandar, B | 1 |
| Bertram, KL; Hewer, S; Lee, W; Ligtermoet, M; Paul, E; Varley, S; Vijiaratnam, N; Williams, DR | 1 |
| Sue, CM; Vijiaratnam, N | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Robieson, WZ; Yegin, A | 1 |
| Bergquist, F; Ericsson, A; Johansson, A; Johansson, D; Medvedev, A; Nyholm, D; Ohlsson, F; Senek, M; Spira, J; Thomas, I; Westin, J | 1 |
| Fujioka, S; Fukae, J; Hasegawa, S; Hayashi, Y; Mishima, T; Nose, K; Shiwaku, H; Tsuboi, Y; Umemoto, G; Yamashita, K | 1 |
| Baek, JS; Ho, HK; Lim, KL; Loo, SCJ; Pang, YY; Tan, EY; Tee, JK | 1 |
| Culican, SM; Kraus, CL | 1 |
| Alaa, H; Belal, F; Ibrahim, F; Sheribah, ZA | 1 |
| Aiyappan, V; Tashkent, Y | 1 |
| Ares-Pensado, B; Castro, A; Fernandez-Pajarin, G; Iglesias-Canle, J; Masa-Vazquez, L; Sesar, A | 1 |
| Bingel, U; Gerardi, M; Zunhammer, M | 1 |
| Allone, C; Bonanno, L; Bramanti, P; Ciurleo, R; Corallo, F; Di Lorenzo, G; Lo Buono, V; Marino, S; Palmeri, R; Versaci, R | 1 |
| Cerrone, P; Marchese, M; Marini, C; Pistoia, MA | 1 |
| Antonini, A; Kleinman, LS; Marshall, TS; Odin, PLA; Onuk, K; Sail, KR; Skalicky, AM; Stoessl, AJ | 1 |
| Anang, JBM | 1 |
| Alicart, H; Antonijoan, RM; Ferreri, L; Gómez-Andrés, A; Marco-Pallares, J; Mas-Herrero, E; Noesselt, T; Riba, J; Ripollés, P; Rodriguez-Fornells, A; Valle, M | 1 |
| Hirozawa, D; Ikenaka, K; Mochizuki, H; Nakano, T; Sasaki, T; Shimamura, M | 1 |
| Memedi, M; Nyholm, D; Thomas, I; Westin, J | 1 |
| Cowie, F; Grosset, DG; Watson-Fargie, T; White, J | 1 |
| den Heijer, T; Groen, J; van der Steen, W | 1 |
| Dinh, P | 1 |
| Goldstein, DS; Holmes, C; Lamotte, G; Sullivan, P | 1 |
| Brandão, AH; Davanço, MG; de Campos, DR; Ferreira, MS; Gabbai, JJ; Júnior, PS; Martho, AC; Meulman, J; Noboli, AC; Pepi, GT; Previde, N; Riccio, MF | 1 |
| Fabbri, M; Ferreira, JJ; Rosa, MM | 1 |
| Beccaria, L; Fabbri, M; Ferreira, JJ; Lopiano, L; Merola, A; Montanaro, E; Palermo, S; Romagnolo, A; Zibetti, M | 1 |
| Antonini, A; Bergmann, L; Poewe, W; Ray Chaudhuri, K; Robieson, WZ; Sanchez-Soliño, O | 1 |
| Hirata, Y; Ishikawa, H; Kato, N; Matsuura, K; Matsuyama, H; Narita, Y; Niwa, A; Tomimoto, H | 1 |
| Baik, JS; Cho, J; Jeon, B; Kim, HT; Kim, JM; Kim, JW; Koh, SB; Kwon, OD; Lee, HW; Lee, JY; Ma, HI; Yoon, WT | 1 |
| Hamed, M; Lazarescu, A; Shetty, A; Suchowersky, O; Tremain, G | 1 |
| Hirakawa, M; Hirota, T; Ieiri, I; Irie, S; Kashihara, Y; Kimura, M; Kubota, T; Matsuki, S; Terao, Y; Yoda, K | 1 |
| Christie, M; Coss, P; Ondo, W; Pascual, B | 1 |
| Duvvuri, S; Gray, DL; Liu, W; Papapetropoulos, S; Thayer, K | 1 |
| Belsey, J; Kalabina, S; Mohamed, B; Paterson, B; Pivonka, D; Thomas, C | 1 |
| Antonini, A; Bergmann, L; Chaudhuri, KR; Poewe, W | 1 |
| Arbelo, JM; Catalán, MIJ; Grandas, F; Mir, P; Parra, JC; Puente, V; Regidor, I; Santos-García, D; Valldeoriola, F | 1 |
| Cramer, SC; Finklestein, SP; Lin, DJ | 1 |
| Grassini, P; Heller, A; Heller, E; Kieburtz, K; Leinonen, M; Stocchi, F; Torti, M; Vacca, L; Warren Olanow, C | 1 |
| Alam, M; Bergquist, F; Johansson, D; Memedi, M; Nyholm, D; Thomas, I; Westin, J | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Deuschl, G; Dijkgraaf, MGW; Lang, AE; Munts, AG; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Abd El Fattah, MA; Badawi, GA; El Sayed, MI; Zaki, HF | 1 |
| Sablaban, IM; Sivananthan, M | 1 |
| Lees, AJ; Moro, A; Munhoz, RP; Pessoa, RR; Teive, HAG | 1 |
| Aschermann, Z; Harmat, M; Janszky, J; Juhász, A; Kovács, N; Pintér, D | 1 |
| Hideshima, M; Hirozawa, D; Ikenaka, K; Ishikura, T; Kitano, T; Konaka, K; Mochizuki, H; Nakano, T; Shimamura, M; Shinzaki, S; Takehara, T | 1 |
| Metzer, WS; Rodrigues, FB | 1 |
| Basson, MD; Chaturvedi, LS; More, SK; Vomhof-DeKrey, EE; Wang, Q | 1 |
| Cabreira, V; Massano, J; Soares-da-Silva, P | 1 |
| Mukai, Y; Murata, M; Nishikawa, N; Takahashi, Y | 1 |
| Barbagallo, G; Quattrone, A | 1 |
| Benesh, J; Han, JH; Kalluri, HV; Liu, W; Locke, C; Rosebraugh, M; Sidhu, D | 1 |
| Ellenbogen, A; Hauser, RA; Isaacson, SH; Kegler-Ebo, DM; Komjathy, SF; Oh, C; Safirstein, BE; Truong, DD; Zhao, P | 1 |
| Artusi, CA; Fabbri, M; Lopiano, L; Pongmala, C; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Chen, YC; Ho, PL; Huang, P; Teng, CH; Wu, CC | 1 |
| Khan, SS; Mirza, T; Naeem, S; Najam, R; Sikandar, B | 1 |
| Di Vico, IA; Novelli, A; Ramat, S; Sorbi, S; Terenzi, F | 1 |
| Januário, C; Morgadinho, A; Reis Carneiro, D; Sousa, M | 1 |
| Centonze, D; Fasano, A; Femiano, C; Lena, F; Modugno, N; Olivola, E; Santilli, M; Varanese, S | 1 |
| Bhakta, BB; Cozens, A; Farrin, AJ; Ford, GA; Hartley, S; Holloway, I; Meads, D; Pearn, J; Ruddock, S; Sackley, CM; Saloniki, EC; Santorelli, G; Walker, MF | 1 |
| Egawa, H; Fukunaga, T; Hatano, T; Hattori, N; Ishibashi, Y; Kaji, S; Kanda, S; Kohira, Y; Oka, S; Oyama, G; Shimo, Y; Yube, Y | 1 |
| Antonini, A; Bentivoglio, A; Eleopra, R; Gualberti, G; Gusmaroli, G; Lopiano, L; Mancini, F; Marano, P; Meco, G; Melzi, G; Modugno, N; Quatrale, R; Sensi, M; Solla, P; Tamma, F; Zangaglia, R | 1 |
| Dhanalakshmi, N; Karthikeyan, V; Priya, T; Thinakaran, N | 1 |
| Giladi, N; LeWitt, PA; Navon, N | 1 |
| Abi-Dargham, A; Bailey, V; Brown, PJ; Chen, C; Roose, SP; Rutherford, BR; Slifstein, M; Stern, Y; Valente, E; Vanegas-Arroyave, N; Wall, MW | 1 |
| Navon, N | 1 |
| Duma, S; Fung, VS; Griffith, J; Mahant, N; Martin, A; Morales-Briceño, H; Tsui, D | 1 |
| Bartig, D; Gold, R; Jörges, C; Jost, W; Krogias, C; Richter, D; Stumpe, B; Tönges, L | 1 |
| Amjad, F; Bhatti, D; Davis, TL; Kukreja, P; Metman, LV; Oguh, O; Pahwa, R; Zamudio, J | 1 |
| Antonini, A; Bergmann, L; Kukreja, P; Poewe, W; Robieson, WZ | 1 |
| Zesiewicz, TA | 1 |
| Jinnah, HA | 1 |
| Bancila, I; Ciocîrlan, M; Cotruta, B; Dobru, D; Drug, V; Dumitru, E; Gheorghe, C; Goldis, A; Jinga, M; Manuc, M; Mercea, VA; Pitigoi, D; Saftoiu, A; Seicean, A; Tanțău, M | 1 |
| Almeida, L; Barabas, M; Eisinger, RS; Elkouzi, A; Malaty, IA; Okun, MS; Ramirez-Zamora, A; Zeilman, P | 1 |
| Hoy, SM | 1 |
| Ares-Pensado, B; Castro, A; Fernandez-Pajarin, G; Rivero-de-Aguilar, A; Sesar, A | 1 |
| Fernández García, J; García Hernández, M; Garrido Durán, C; Khorrami Minaei, S; Legarda Ramírez, I; Sendra Rumbeu, P | 1 |
| Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD | 1 |
| Alam, M; Rönnegård, L; Saqlain, M; Westin, J | 1 |
| Chang, FCF; Fung, VSC; Galea, D; Griffith, J; Ha, AD; Kim, SD; Mahant, N; Morales-Briceño, H; Tsui, D | 1 |
| Artusi, CA; Balestrino, R; Bortolani, S; Fabbri, M; Imbalzano, G; Lopiano, L; Montanaro, E; Tuttobene, S; Zibetti, M | 1 |
| Baille, G; Blaise, AS; Carrière, N; Defebvre, L; Devos, D; Dujardin, K; Grolez, G; Kreisler, A; Kyheng, M; Moreau, C; Mutez, E; Seguy, D | 1 |
| Akbostanci, MC; Bilgiç, B; Bora Tokçaer, A; Çakmur, R; Doğu, O; Elibol, B; Erer Özbek, ÇS; Gültekin, M; Hanağasi, H; İnce Günal, D; Kenangil, G; Mirza, M; Tezcan, S; Ulukan, Ç; Yilmaz Küsbeci, Ö | 1 |
| Arca, R; Cossu, G; di Biase, L; Di Lazzaro, V; Di Santo, A; Fasano, A; Marano, M; Marano, P; Naranian, T; Poon, YY | 1 |
| Ahsan, SA; Briggs, RG; Chendeb, K; Conner, AK; Jacobs, CC; Jones, RG; Nix, CE; Palejwala, AH; Sheets, JR; Sughrue, ME | 1 |
| Jalundhwala, YJ; Lakdawalla, DN; Marshall, TS; Sail, KR; Shih, TM; Sullivan, J; van Eijndhoven, E; Zadikoff, C | 1 |
| Ayala, A; Forjaz, MJ; Harmat, M; Janszky, J; Juhász, A; Kovács, N; Martinez-Martin, P; Pintér, D; Rodriguez-Blazquez, C | 1 |
| McFarthing, K; Prakash, N; Simuni, T | 1 |
| Honsberger, S; Husnain, MG; Su, JS | 1 |
| Belcaro, G; Cesarone, MR; Cotellese, R; Feragalli, B; Hosoi, M; Hu, S; Ledda, A; Maione, C; Scipione, C; Scipione, V | 1 |
| Stocchi, F; Vacca, L | 1 |
| Balogun, CI; Fatoki, AM; Oladimeji, S; Olofinnade, AT; Onaolapo, AY; Onaolapo, OJ; Onaolapo, TM | 1 |
| Gallentine, WB; Mikati, MA; Trau, SP | 1 |
| Armstrong, MJ; Okun, MS | 1 |
| Allen, RS; Bales, KL; Chesler, KC; Feola, AJ; Hendrick, AM; Iuvone, PM; Maa, AY; Mees, LM; Motz, CT; Olson, DE; Pardue, MT; Thule, PM | 1 |
| Chen, HJ; He, JC; Jiang, ZY; Wu, K; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Li, K; Li, S; Liao, X; Liu, D; Shuai, B; Wu, N | 1 |
| Fung, VSC; Griffith, J; Mahant, N; Martin, AJ; Morales-Briceño, H; Tsui, D | 1 |
| Burmaoğlu, RE; Sağlık Aslan, S | 1 |
| Artusi, CA; Fabbri, M; Imbalzano, G; Lopiano, L; Pongmala, C; Romagnolo, A; Zibetti, M | 1 |
| Abbruzzese, G; Antonini, A; Bentivoglio, AR; Berardelli, A; Comi, C; Cossu, G; Fabbrini, G; Lopiano, L; Mancini, F; Martino, T; Melchionda, D; Minafra, B; Modugno, N; Pontieri, FE; Riboldazzi, G; Sensi, M; Solla, P; Stefani, A; Stroppa, I; Tambasco, N; Tamma, F; Tessitore, A | 1 |
| Cerroni, R; Imbriani, P; Liguori, C; Mercuri, NB; Pierantozzi, M; Pisani, A; Scalise, S; Stefani, A | 1 |
| Paik, J | 1 |
| Antonini, A; Bergmann, L; Gusmaroli, G; Lopiano, L; Marano, P; Melzi, G; Modugno, N; Pacchetti, C; Sensi, M; Zibetti, M | 1 |
| Baumann, CR; Oertel, MF; Stieglitz, LH | 1 |
| Antonini, A; Chaudhuri, KR; Leta, V; Teo, J | 1 |
| Bolia, R; Panda, PK; Sharawat, IK; Shrivastava, Y | 1 |
| Ehlers, C; Honig, H; Odin, P; Timpka, J | 1 |
| Bloem, BR; Nonnekes, J | 1 |
| Ebersbach, G; Jost, WH; Kassubek, J; Klebe, S; Tönges, L | 1 |
| Bonno, D; Lizarraga, KJ; Modica, JS | 1 |
| Barone, P; Canoro, V; Cicarelli, G; Erro, R; Picillo, M | 1 |
| D'Souza, R; Fisher, S; Hauser, RA; Zeitlin, L | 2 |
| Chaudhuri, KR; Jones, S; Leta, V; Parry, M; Rizos, A; Sauerbier, A; van Wamelen, DJ | 1 |
| Aracil-Bolaños, I; Bejr-Kasem, H; Calopa, M; Campolongo, A; Crespo-Cuevas, A; de Fàbregues, O; Horta-Barba, A; Izquierdo-Barrionuevo, C; Kulisevsky, J; Marín-Lahoz, J; Martinez-Horta, S; Pagonabarraga, J; Pascual-Sedano, B; Pérez-Pérez, J; Puente, V | 1 |
| Boettcher, L; Edinger, G; Erickson, LO; Gardner, J; Kitzmann, R; Nance, MA; Wichmann, R; Wielinski, CL | 1 |
| Boyd, BM; Christensen, CA; Fagan, TC; Figueroa, AG; Javid, CG; McKay, BS; Snyder, RW | 1 |
| de Bie, RMA; Dijk, JM; Espay, AJ; Katzenschlager, R | 1 |
| Adnan, M; Nyholm, D; Senek, M | 1 |
| Borovič, M; Dugonik, J; Flisar, D; Novak, D; Verber, D | 1 |
| Drent, M; Groenendal-Laurensse, JWMJ; Moes, HR; Tissingh, G; van Laar, T | 1 |
| Al-Hashel, JY; Kamel, WA | 1 |
| Ahmed-Farid, OA; Lashin, FM; Re, L; Rizk, HA; Saber, SM; Shehata, AM | 1 |
| Altiparmak, E; Erdoğan Küçükdağli, F; Köseoğlu, HT; Öztürk, Ö; Saltoğlu, T; Sücüllü Karadağ, Y | 1 |
| Aradi, SD; Hauser, RA | 1 |
| Arnold, AC; De Jesus, S; Delnomdedieu, M; Duvvuri, S; Eslinger, PJ; Fernandez-Mendoza, J; Gray, DL; Harrington, W; Huang, X; Kong, L; Lewis, MM; Mahoney, SE; Mailman, RB; Miller, AJ; Snyder, B; Sun, D; Van Scoy, LJ; Wang, X | 1 |
| Farbman, ES; Hauser, RA; Klingler, M; Lee, A; LeWitt, PA; Oh, C; Qian, J; Rudzińska, M; Waters, CH | 1 |
| Adar, L; Case, RJ; Ellenbogen, AL; Espay, AJ; Leinonen, M; Olanow, CW; Oren, S; Orenbach, SF; Poewe, W; Stocchi, F; Yardeni, T | 1 |
| Leucuta, DC; Perju-Dumbrava, L; Popa, LC; Popa, SL; Tohanean, N | 1 |
| Atzori, L; Contu, P; Cossu, G; Cusano, R; Fabbri, M; Lopiano, L; Madau, V; Manzin, A; Melis, M; Mereu, A; Morelli, M; Murgia, D; Oppo, V; Palmas, V; Perra, D; Pisanu, S; Santoru, ML; Sarchioto, M; Serra, A; Uva, P; Vascellari, S; Zibetti, M | 1 |
| Barrajón Masa, AJ; Colmenares Bulgheroni, M; Moralejo Lozano, Ó | 1 |
| Carroll, DG; Halli-Tierney, AD; Luker, J | 1 |
| Bonvegna, S; Cilia, R; Colucci, F; Cossu, G; De Micco, R; Eleopra, R; Elia, AE; Fabbri, M; Ielo, GC; Lopiano, L; Modugno, N; Morgante, F; Novelli, A; Olivola, E; Oppo, V; Pilleri, M; Ricciardi, L; Sensi, M; Sorbera, C; Tessitore, A; Zibetti, M | 1 |
| Gillespie, A; Jones, E; Pappert, E; Pike, J; Thach, A; Wright, J | 1 |
| Bologna, M; Colosimo, C; Marsili, L; Miyasaki, JM | 1 |
| Guillén Climent, S; Monteagudo, C; Pinazo Canales, MI; Porcar Saura, S | 1 |
| Azandeh, SS; Farbood, Y; Ghasemi Dehcheshmeh, M; Jalali, MS; Mansouri, E; Saki, G; Sarkaki, A | 1 |
| Adamski, P; Buszko, K; Gasior, M; Gorący, J; Kleinrok, A; Kosobucka, A; Kubica, A; Kubica, J; Lesiak, M; Nadolny, K; Navarese, E; Niezgoda, P; Wojakowski, W | 1 |
| Awad, N; Roy, D; Song, J; Zamudio, P | 1 |
| Athanasakis, E; Avgoustaki, A; Boura, I; Chlouverakis, G; Giakoumakis, E; Giannopoulou, IA; Koulentaki, M; Orfanoudaki, E; Spanaki, C | 1 |
| Barcellos, LJG; de Alcantara Barcellos, HH; de Oliveira, CM; Fagundes, M; Idalencio, R; Kalichak, F; Lopes, TM; Pompermaier, A; Soares, SM | 1 |
| Carr, RA; Enright, BP; Facheris, MF; Jameel, F; Kym, PR; Liu, W; Lou, X; Mayer, PT; Moussa, EM; Rosebraugh, M; Stolarik, D; Voight, EA; Zhang, GGZ | 1 |
| Bloem, BR; de Bie, RMA; Esselink, R; Groenewoud, H; Meinders, MJ; Nijhuis, FAP; Post, B | 1 |
| Akiyama, T; Hanaoka, Y; Kaji, R; Kawarai, T; Kobayashi, K; Miyamoto, R; Yoshinaga, H | 1 |
| Arai, A; Hanabata, N; Katagai, A; Okudera, R; Tomiyama, M; Ueno, T | 1 |
| Fasano, A; Kulasingam, V; Merola, A; Mestre, T; Naranian, T; Poon, YY; Suchowersky, O; Taher, J | 1 |
| Ashby, R; Karouta, C; Kelly, T; Morgan, I; Thomson, K | 1 |
| Babu, S; Chang, FC; Dal, S; Fletcher, N; Fung, VSC; Mahant, N; Martin, AJ; Morales-Briceno, H; Nankervis, J; Ong, TL; Robbie, M; Williams, LJ | 1 |
| Fukae, J; Hatano, T; Hattori, N; Oyama, G; Saiki, S; Shimo, Y; Tsunemi, T | 1 |
| Khurana, N; Muthuraman, A; Sharma, N; Utreja, P | 1 |
| Bergmann, L; Fasano, A; Gurevich, T; Jech, R; Johnson, A; Kovács, N; Parra, JC; Sanchez-Soliño, O; Svenningsson, P; Szász, J; Tang, Z; Vela-Desojo, L | 1 |
| Benner, J; Jalundhwala, YJ; Lakdawalla, DN; Marshall, TS; Sail, KR; Shih, TM; Sullivan, J; van Eijndhoven, E; Zadikoff, C | 1 |
| Fujioka, S; Komorita, S; Mishima, T; Nishida, A; Okajima, M; Tsuboi, Y | 1 |
| Aldred, J; Alobaidi, A; Antonini, A; Bao, Y; Bergmann, L; Chaudhuri, KR; Inguva, S; Jalundhwala, YJ; Kukreja, P; Odin, P; Pahwa, R | 1 |
| Du, YS; Guo, HM; Hu, KR; Hu, YZ; Li, CJ; Liang, Y; Sun, H; Wang, GJ; Wang, H; Xie, L; Xu, WS; Yu, TJ | 1 |
| Altomare, C; Andresciani, F; Beomonte Zobel, B; Bernetti, C; Castiello, G; Faiella, E; Grasso, RF; Pacella, G | 1 |
| Comella, CL; Hauser, RA; LeWitt, PA | 1 |
| Davis, RL; Holmes, AJ; Lubomski, M; Sue, CM; Xu, X; Yang, JYH | 1 |
| Barange, K; Barthélémy, C; Brefel-Courbon, C; Dupouy, J; Fabre-Delcros, MH; Fernández-Rodríguez, B; Harroch, E; Loubière, P; Ory-Magne, F; Rascol, O | 1 |
| Fujioka, S; Fukuchi, T; Furukawa, K; Furune, S; Ikeda, Y; Jin, X; Kato, M; Koike, T; Kubota, E; Murakami, H; Sato, Y; Suzuki, T; Tsuboi, Y; Uehara, T; Yamashita, K; Yamazaki, Y; Yube, Y | 1 |
| Avramovic, V; Blydt-Hansen, I; Drogemoller, B; Friedman, JM; Ghani, A; Horvath, GA; Lee, J; Lehman, A; Matthews, AM; Mwenifumbo, J; Price, M; Ross, CJ; Shyr, C; Stockler, S; Tarailo-Graovac, M; van Karnebeek, CD; Wasserman, WW | 1 |
| Baig, F; Boca, M; Cheminais, L; Collin, N; Mooney, L; Rolinski, M; Selikhova, M; Szewczyk-Krolikowski, K; Whone, A | 1 |
| Barbato, LM; Freire-Alvarez, E; Kurča, E; Liu, Y; Lopez Manzanares, L; Pekkonen, E; Sánchez-Soliño, O; Spanaki, C; Vanni, P | 1 |
| Ashok, A; Balaraman, S; Bellettini, JR; Cardinal-David, B; Chan, VS; Ghosh, S; Hill, DR; Huters, AD; Ji, J; Klix, RC; Kotecki, BJ; Matulenko, MA; Reddy, RE; Shou, M; Simanis, J; Stambuli, J; Towne, TB; Voight, EA | 1 |
| Ruiz Pardo, J; Sánchez Fuentes, PA; Vidaña Márquez, E | 1 |
| Ammendolia, A; de Sire, A; Demeco, A; Marinaro, C; Moggio, L; Petraroli, A; Pino, I | 1 |
| Corti, EJ; Egan, SJ; Gasson, N; Loftus, AM; Nielsen, C; Starkstein, S | 1 |
| Facheris, MF; Liu, W; Neenan, M; Rosebraugh, M | 1 |
| Ho, Y; Hsu, KY; Huang, YJ; Lin, SJ; Tai, L; Uang, YS; Wang, LH | 1 |
| Adar, L; Arkadir, D; Case, R; Ebersbach, G; Ellenbogen, AL; Espay, AJ; Fuchs Orenbach, S; Giladi, N; Isaacson, SH; Kieburtz, K; LeWitt, P; Olanow, CW; Oren, S; Poewe, W; Rosenfeld, O; Sasson, N; Simuni, T; Stocchi, F; Thomas, A; Yardeni, T; Zlotogorski, A | 1 |
| Ando, R; Hosokawa, Y; Miyaue, N; Nagai, M; Tada, S; Yabe, H; Yamanishi, Y; Yoshida, A | 1 |
| Adar, L; Caraco, Y; Case, R; Djaldetti, R; Giladi, N; Gurevich, T; Leibman-Barak, S; Sasson, N | 1 |
| Adamski, P; Alexopoulos, D; Badarienė, J; Budaj, A; Buszko, K; Dąbrowski, P; Di Somma, S; Dudek, D; Gąsior, M; Giannitsis, E; Gil, R; Gorog, DA; Gruchała, M; Gurbel, PA; Horszczaruk, G; Jaguszewski, MJ; James, S; Jeong, YH; Jilma, B; Kasprzak, J; Kleinrok, A; Kryjak, M; Kubica, A; Kubica, J; Legutko, J; Lesiak, M; Navarese, EP; Niezgoda, P; Ostrowska, M; Patti, G; Romanek, J; Siller-Matula, JM; Specchia, G; Tantry, U; Tycińska, A; Wojakowski, W | 1 |
| Adamski, P; Barańska, M; Gorog, D; Jilma, B; Kubica, A; Kubica, J; Kuliczkowski, W; Marszałł, MP; Nadolny, K; Navarese, EP; Niezgoda, P; Pietrzykowski, Ł; Wojakowski, W | 1 |
| Eerola-Rautio, J; Koivu, M; Pauls, KAM; Pekkonen, E; Toppila, J; Udd, M | 1 |
| Adamski, P; Anielska-Michalak, E; Bartuś, S; Brycht, O; Budaj, A; Curzytek, A; Drożdż, J; Dudek, A; Gąsior, M; Gromadziński, L; Gruchała, M; Grzelakowska, K; Grzelakowski, P; Jaguszewski, M; Jankowski, P; Kamiński, L; Kasprzak, M; Kaźmierczak, J; Kleinrok, A; Kostkiewicz, M; Koziński, M; Król, P; Kryś, J; Kubica, A; Kubica, J; Kulawik, T; Legutko, J; Lesiak, M; Leszek, P; Minczew, G; Mindykowski, M; Mitkowski, P; Navarese, EP; Nessler, J; Ostrowska, M; Pawlak, A; Podhajski, P; Prokopczuk, J; Skonieczny, G; Sobkowicz, B; Sowiński, S; Stankala, S; Stolarek, W; Szymański, P; Tomaszuk-Kazberuk, A; Tycińska, A; Wester, A; Wilczewski, P; Zdrojewski, T | 1 |
| Emanuele, R; Lettieri, M; Minunni, M; Palladino, P; Scarano, S | 1 |
| Bergman, H; Deffains, M; Eitan, R; Fonar, G; Iskhakova, L; Israel, Z; Marmor, O; Paz, R; Rappel, P | 1 |
| Aldred, J; Anca-Herschkovitsch, M; Bergmann, L; Bourgeois, P; Chaudhuri, KR; Cubo, E; Davis, TL; Gao, T; Iansek, R; Kovács, N; Kukreja, P; Pontieri, FE; Siddiqui, MS; Simu, M; Standaert, DG | 1 |
| Bullock, A; El Aidy, S; van Dijk, G; van Kessel, SP | 1 |
| Berger, SI; Miller, I; Tochen, L | 1 |
| Cubo, E; Miranda, J | 1 |
| Baviera-Muñoz, R; Campins-Romeu, M; Losada-López, M; Martínez-Torres, I; Morata-Martínez, C; Pérez-García, J; Pons-Beltrán, V; Sastre-Bataller, I | 1 |
| Habet, S | 1 |
| Alobaidi, A; Bao, Y; Chaudhuri, KR; Jalundhwala, YJ; Jones, G; Kandukuri, PL; Madin-Warburton, M; Najle-Rahim, S; Oddsdottir, J; Pickard, AS; Ridley, C; Schrag, A; Sus, J; Xu, W | 1 |
| Facheris, MF; Liu, W; Rosebraugh, M; Stodtmann, S | 1 |
| Ichikawa, T; Inamasu, J; Kimata, M; Oshima, T; Tomiyasu, K; Yoshii, M | 1 |
| Buskens, E; Moes, HR; van Laar, T | 1 |
| Bianchini, E; Ceriello, F; De Carolis, L; Pontieri, FE; Rinaldi, D | 1 |
| Flisar, D; Kojović, M; Kolmančič, K; Kramberger, MG; Pirtošek, Z; Trošt, M; Zupančič, NK | 1 |
| Baba, Y; Futamura, A; Kinno, R; Nabeshima, Y; Nomoto, S; Osakabe, Y; Shoji, D; Takahashi, S; Yasumoto, T | 1 |
| García-Cano Lizcano, J; Gil Rojas, S; González Martínez, F; López Moreno, MB; Martínez Blanco, P; Olcina Domínguez, P | 1 |
| Baviera-Muñoz, R; Buigues-Lafuente, A; Campins-Romeu, M; Garcés-Sánchez, M; Martinez-Torres, I | 1 |
| Müller, T; Schlegel, E; Thiede, HM; Zingler, S | 1 |
| Ando, M; Hatano, T; Hattori, N; Honda, T; Komatsu, N; Tsutsui, M; Yasuda, H | 1 |
| Alobaidi, A; Bergmann, L; Elibol, B; Fasano, A; Fung, VSC; Onuk, K; Parra, JC; Pirtosek, Z; Seppi, K; Takáts, A | 1 |
| Fernandez, HH; Liao, J; Mata, IF; Salles, PA; Shuaib, U | 1 |
| Artusi, CA; Imbalzano, G; Ledda, C; Lopiano, L; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M | 1 |
| Bahroo, L; Di Maria, G; Jankovic, J; Lamotte, G; Lenka, A | 1 |
| Kubo, M; Miyaue, N; Nagai, M | 1 |
| Jiang, R; Mei, S; Yang, J; Zhao, Z | 1 |
| Blaise, AS; Carrière, N; Cuvelier, E; Defebvre, L; Devos, D; Moreau, F; Mutez, E | 1 |
| Gažová, A; Košutzká, Z; Minár, M; Stanková, S; Straka, I | 1 |
| Lezzi, P; Lezzi, T; Lupo, R; Vitale, E | 1 |
| Antonini, A; Biundo, R; Calandrella, D; Carecchio, M; Carrer, T; Del Sorbo, F; Farinati, F; Garrì, F; Mainardi, M; Pezzoli, G; Pistonesi, F; Russo, FP; Sandre, M; Savarino, E; Soliveri, P; Weis, L; Zecchinelli, AL | 1 |
| Baróti, B; Constantin, V; Forró, T; Frigy, A; Kelemen, K; Metz, J; Mihály, I; Orbán-Kis, K; Szász, JA; Szász, RM; Szatmári, S; Török, Á | 1 |
| Kramberger, MG; Križnar, NZ; Ocepek, L; Pirtošek, Z; Premzl, M; Rajnar, R; Rus, T; Trošt, M | 1 |
| Andreotti, F; Brouwer, MA; Bukowski, P; Conte, M; Gajda, J; Gajda, R; Jasiewicz, M; Kubica, A; Kubica, J; La Torre, G; Lackowski, P; Michalski, P; Navarese, EP; Nowicka, M; Omyła, M; Orsini, N; Piasecki, M; Pietrzykowski, Ł; Pinkas, J; Podhajski, P; Radziwanowski, A; Szymański, P; Urbanowicz, I | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Dijkgraaf, MGW; Munts, A; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Boleková, V; Gmitterová, K; Košutzká, Z; Matejička, P; Minár, M; Valkovič, P | 1 |
| Alobaidi, A; Antonini, A; Bergmann, L; Chaudhuri, KR; Hegde, S; Odin, P; Pahwa, R; Parra, JC; Snedecor, SJ; Standaert, DG; Thakkar, S; Titova, N; Zadikoff, C | 1 |
| Mortazavinik, S; Reza Sohrabi, M; Salimian, M | 1 |
| Bergmann, L; Fasano, A; Femia, S; Gurevich, T; Kovács, N; Parra, JC; Sanchez-Soliño, O; Svenningsson, P; Szász, J; Vela-Desojo, L | 1 |
| Antonini, A; Ferreira, JJ; Guimarães, B; Moreira, J; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P; Stocchi, F | 1 |
| Arlt, C; Ebersbach, G; Eggert, K; Fritz, B; Möller, JC; Schwarz, J; Sensken, SC; Weiss, D | 1 |
| Amato, F; Artusi, CA; Calandra-Buonaura, G; Contin, M; Cortelli, P; Giannini, G; Imbalzano, G; Ledda, C; Lopiano, L; Olmo, G; Rinaldi, D; Romagnolo, A; Sambati, L; Zibetti, M | 1 |
| Liu, X; Ming, D; Moussian, B; Pang, M; Peng, R; Su, Y; Wang, P; Wang, Y; Zhu, Y | 1 |
| Adekunle, AO; Alananzeh, WA; Amali, MO; Ayipo, YO; Badeggi, UM; Lawal, BA; Mordi, MN | 1 |
| Aballéa, S; Bebrysz, M; Fujimura, K; Fujioka, S; Migita, H; Mishima, T; Nomoto, M; Tsuboi, Y; Yamaguchi, J; Yamazaki, T | 1 |
| Anstice, N; Ashby, R; Game, J; Jong, T; Karouta, C; Leung, M; Maddess, T; Morgan, IG; Sabeti, F; Thomson, K | 1 |
| Boura, I; Chaudhuri, KR; Espay, AJ; Jenner, P; Leta, V; Odin, P; Rota, S; Urso, D; van Wamelen, DJ | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Deuschl, G; Dijk, JM; Dijkgraaf, MGW; Frequin, HL; Lang, A; Munts, AG; Post, B; Schouten, J; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Ellmén, J; Kuoppamäki, M; Rouru, J; Sjöstedt, N; Tuunainen, J; Vahteristo, M; Yliperttula, M | 1 |
| Belotti, LMB; Calandra-Buonaura, G; Contin, M; Cortelli, P; Galletti, M; Lopane, G | 1 |
| Langer, K; Rose, O; Weitzel, J; Wünsch, A | 1 |
| Fox, SH | 1 |
| Aldred, J; Budur, K; Facheris, MF; Fisseha, N; Fung, VS; Hauser, RA; Jeong, A; Kimber, TE; Klos, K; Litvan, I; O'Neill, D; Robieson, WZ; Soileau, MJ; Spindler, MA; Standaert, DG; Talapala, S; Vaou, EO; Zheng, H | 1 |
| Alobaidi, A; Antonini, A; Bao, Y; Bergmann, L; Chaudhuri, KR; Isaacson, SH; Kandukuri, PL; Merola, A; Odin, P; Pahwa, R; Parra, JC; Wang, L; Yan, CH; Zadikoff, C | 1 |
| Antonoglou, A; Bougea, A; Efthymiopoulou, E; Loupo, B | 1 |
| Baló, B; Botz, K; Györfi, B; Jost, WH | 1 |
| Dulski, J; Piekarski, R; Roszmann, A; Sławek, J | 2 |
| Ando, R; Ito, YH; Miyaue, N; Nagai, M; Ochi, C; Tada, S; Yamanishi, Y | 1 |
| Belozertseva, IV; Dorotenko, A; Efimova, EV; Fesenko, Z; Gainetdinov, RR; Mor, MS; Savchenko, A; Sotnikova, TD; Sukhanov, I | 1 |
| Bergmann, L; Fasano, A; García-Ramos, R; Gurevich, T; Jech, R; Parra, JC; Sanchez-Soliño, O; Simu, M | 1 |
| Duckworth-Mothes, B; Grund, KE; Jost, WH; Zipfel, A | 1 |
| Disilvestro, I; Donzuso, G; Mostile, G; Nicoletti, A; Sciacca, G; Zappia, M | 1 |
| Artusi, CA; Bianchini, E; De Carolis, L; Galli, S; Imbalzano, G; Ledda, C; Lopiano, L; Pontieri, FE; Rinaldi, D; Zibetti, M | 1 |
| Cawley, A; Fu, S; Keen, B; Loy, J; Noble, G; Reedy, B | 1 |
| De Simone, LM; Henry, J; Lynch, E; Reyes, ZMD; Sobotka, SA | 1 |
| Contreras Chicote, A; Grandas Perez, F; Mas Serrano, M; Velilla Alonso, G | 1 |
| Fanciulli, A; Galli, S; Pontieri, FE; Rinaldi, D | 1 |
| Danoudis, M; Iansek, R; Paul, E; Sung, CB | 1 |
| Bauer, MP; Chernova, VO; Contarino, MF; Keller, JJ; Kuijper, EJ; Terveer, EM; van der Meulen-de Jong, AE; van Hilten, JJ; van Prehn, J | 1 |
| Bonno, D; Bouchard, M; Canissario, R; Déry, C; Dupré, N; Lang, AE; Lizarraga, KJ; Logigian, E; McDermott, MP; Modica, JS; Stanton, M | 1 |
| Capelli, C; Charlier, B; Cilia, R; Coglianese, A; Conti, V; D'Urso, A; de Grazia, U; Eleopra, R; Izzo, V; Molteni, L | 1 |
| Aldred, J; Anca-Herschkovitsch, M; Ballina, M; Bergmann, L; Bourgeois, P; Chaudhuri, KR; Cubo, E; Davis, TL; Iansek, R; Jia, J; Kovács, N; Kukreja, P; Ladhani, O; Pontieri, FE; Siddiqui, MS; Simu, M; Standaert, DG | 1 |
| Antonini, A; Chaudhuri, KR; Henriksen, T; Trošt, M; van Laar, T | 1 |
| Finsterer, J | 1 |
| Baehr, M; Dadkhah, A; Eggert, J; Gottfried, K; Gundler, C; Gutowski, T; Langebrake, C; Nürnberg, S; Rosch, M | 1 |
| Buskens, E; Henriksen, T; Moes, HR; Phokaewvarangkul, O; Sławek, J; van Laar, T | 1 |
| Bar, MR; Borovečki, F; Katzenschlager, R; Kovacs, N; LeWitt, PA; Perković, R | 1 |
| Iwaki, H; Mukai, Y; Nishikawa, N; Takahashi, Y | 1 |
| Furihata, M; Hagiwara, H; Ishino, H; Kitamura, T; Nakatsu, Y; Nishi, S; Noda, K; Nomoto, Y; Ogiwara, S; Okawa, H; Osada, T; Yano, S | 1 |
| Antonini, A; D'Onofrio, V; Guerra, A | 1 |
| Bachoud-Lévi, AC; Blasco-Amaro, JA; Capuano, A; Isabel-Gómez, R; Martín-Gómez, C; Nou-Fontanet, L; Ortigoza-Escobar, JD; Zorzi, G | 1 |
| Horiba, M; Imamura, A; Kuroyanagi, G; Matsukawa, N; Murakami, H; Sakai, H; Sato, T; Takahashi, A; Ueki, Y; Usami, T | 1 |
| Griffiths, H; Keeling, E; Lee, H; Lotery, AJ; Lynn, SA; Macdonald, SL; Newall, T; Ratnayaka, JA; Sanchez-Bretano, A; Scott, JA; Self, JE; Soundara-Pandi, SP | 1 |
| Ce, Z; Jiren, Z; Pinyuan, Z; Tian, W; Ting, L; Wenbo, Z; Zhigang, M | 1 |
| Amouzandeh, A; Barbe, MT; Basheer, AA; Bornmann, S; Csoti, I; Ebersbach, G; Falkenburger, B; Flöel, A; Gruber, D; Gülke, E; Gutsmiedl, PK; Haller, B; Haslinger, B; Herting, B; Hormozi, M; Ip, CW; Jergas, H; Jochim, AM; Jost, WH; Klingelhöfer, L; Kohl, Z; Koschel, J; Krause, P; Kühn, AA; Lingor, P; Liszka, R; Maetzler, W; Paschen, S; Pérez-González, P; Pötter-Nerger, M; Prell, T; Pürner, D; Rijntjes, M; Rozanski, V; Scheller, U; Schröter, N; Schwarz, J; Südmeyer, M; Torka, E; van de Loo, S; van Riesen, C; Weiß, D; Wesbuer, S; Wolff, A; Wolz, M | 1 |
| Jenner, P; Leta, V; Pirtošek, Z; Vérin, M | 1 |
| Lettieri, M; Minunni, M; Palladino, P; Pieraccini, G; Rainetti, A; Scarano, S | 1 |
166 review(s) available for levodopa and carbidopa
| Article | Year |
|---|---|
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarboxylase; Dopamine; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Levodopa; Norepinephrine; Parkinson Disease; Selegiline; Serotonin; Substance P; Tyrosine 3-Monooxygenase | 1978 |
Two types of dopamine receptors in behavioral regulation.
Topics: Animals; Behavior; Behavior, Animal; Benserazide; Brain; Carbidopa; Cats; Dopamine; Haloperidol; Humans; Levodopa; Psychomotor Agitation; Rats; Receptors, Dopamine; Reserpine; Snails; Tranquilizing Agents | 1978 |
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Topics: Benserazide; Binding Sites; Carbidopa; Carboxy-Lyases; Drug Interactions; Humans; Hydrazines; Kinetics; Levodopa; Liver Function Tests; Parkinson Disease | 1976 |
Effect of selected drugs on arterial pressure response to upright posture.
Topics: Blood Pressure; Carbidopa; Dihydroergotamine; Drug Evaluation; Drug Interactions; Ergotamines; Humans; Hypotension, Orthostatic; Levodopa; Posture; Sympathomimetics; Vasoconstrictor Agents | 1976 |
Recent advances in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Depression, Chemical; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Postoperative Complications; Pyridoxine; Stereotaxic Techniques | 1975 |
[Dopa-sensitive dystonia].
Topics: Carbidopa; Child; Child, Preschool; Dystonia; Female; Follow-Up Studies; Homovanillic Acid; Humans; Infant; Levodopa; Male | 1992 |
An integrated approach to patient management in Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Selegiline | 1992 |
Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa | 1992 |
Optimization of levodopa therapy.
Topics: Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Interactions; Gastrointestinal Diseases; Humans; Hypotension, Orthostatic; Levodopa; Mental Disorders; Sleep Wake Disorders | 1992 |
Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Disability Evaluation; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Time Factors | 1992 |
Newly-diagnosed Parkinson's disease: a therapeutic update.
Topics: Antiparkinson Agents; Brain; Carbidopa; Humans; Levodopa; Parkinson Disease | 1992 |
Neuroleptic malignant syndrome. When levodopa withdrawal is the cause.
Topics: Aged; Carbidopa; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome | 1991 |
Medical treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1989 |
The promise and limitations of controlled-release oral levodopa administration.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
Pharmaceutical design and development of a Sinemet controlled-release formulation.
Topics: Antiparkinson Agents; Carbidopa; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Tablets | 1989 |
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
Parkinson's disease: recent advances in therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Antiparkinson Agents; Carbidopa; Dopamine; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1988 |
Clinically desirable drug interactions.
Topics: Aminoglycosides; Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Carbidopa; Diuretics; Drug Combinations; Drug Interactions; Drug Synergism; Humans; Hydroxamic Acids; Hypokalemia; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Penicillins; Probenecid; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1985 |
Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
Topics: Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Carbidopa; Dopamine; Droxidopa; Levodopa; Locus Coeruleus; Myocardium; Norepinephrine; Pargyline; Parkinson Disease; Serine; Stereoisomerism; Tyrosine | 1985 |
Update on the treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Synergism; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline; Time Factors | 1985 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extrapyramidal Tracts; Fenclonine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Imipramine; Levodopa; Muscular Diseases; Paralysis; Parkinson Disease; Parkinson Disease, Secondary; Probenecid; Reserpine; Serotonin; Spinal Cord Diseases; Tetrabenazine; Time Factors | 1974 |
Individualization of levodopa therapy.
Topics: Amantadine; Amphetamine; Anesthetics; Animals; Antihypertensive Agents; Apomorphine; Arrhythmias, Cardiac; Carbidopa; Depression, Chemical; Diet; Disulfiram; Drug Interactions; Drug Therapy, Combination; Endocrine Glands; Glaucoma; Humans; Hydrogen-Ion Concentration; Levodopa; Mice; Parasympatholytics; Parkinson Disease; Stomach | 1974 |
Comparative aspects of central cardiovascular control with special reference to adrenergic mechanisms.
Topics: Amphibians; Animals; Birds; Blood Pressure; Brain; Carbidopa; Cardiovascular Physiological Phenomena; Cardiovascular System; Central Nervous System; Clonidine; Electric Stimulation; Fishes; Levodopa; Reptiles; Sympathomimetics; Vertebrates | 1983 |
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior | 1983 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
Sinemet and the treatment of Parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Chemical Phenomena; Chemistry; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Prognosis | 1981 |
Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome.
Topics: Antiparkinson Agents; Blood Glucose; Carbidopa; Contrast Media; Deoxyglucose; Dihydroxyphenylalanine; Dominance, Cerebral; Drug Combinations; Female; Fluorodeoxyglucose F18; Functional Laterality; Hemiplegia; Humans; Levodopa; Middle Aged; Muscle Hypotonia; Muscular Atrophy; Neurologic Examination; Parkinson Disease, Secondary; Physical Exertion; Substantia Nigra; Tomography, Emission-Computed | 1995 |
Dopa-responsive dystonia.
Topics: Adult; Carbidopa; Drug Therapy, Combination; Dystonia; Female; Humans; Levodopa; Tablets | 1994 |
Treatment of Parkinson's disease. From theory to practice.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Dopamine; Drug Combinations; Free Radicals; Humans; Levodopa; Oxygen; Parkinson Disease; Selegiline | 1994 |
The syndrome of gait ignition failure: a report of six cases.
Topics: Aged; Benserazide; Brain; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Neurologic Examination; Parkinson Disease; Syndrome; Tomography, X-Ray Computed | 1993 |
Treatment of Parkinson's disease.
Topics: Alzheimer Disease; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Neurons; Parkinson Disease; Receptors, Dopamine; Selegiline | 1993 |
Treatment of early Parkinson's disease: are complicated strategies justified?
Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide; Selegiline | 1996 |
Pharmacokinetics of continuous-release carbidopa/levodopa.
Topics: Aging; Antiparkinson Agents; Area Under Curve; Blood-Brain Barrier; Carbidopa; Delayed-Action Preparations; Drug Combinations; Gastric Emptying; Humans; Levodopa; Solubility | 1994 |
A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Nerve Growth Factors; Nerve Regeneration; Nerve Tissue Proteins; Neuroglia; Neuronal Plasticity; Parkinson Disease, Secondary; Substantia Nigra; Tyrosine 3-Monooxygenase | 1998 |
Initiating therapy for Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Selegiline | 1998 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Too many treatments for Parkinson's disease: how should they be used?
Topics: Antiparkinson Agents; Carbidopa; Decision Making; Drug Combinations; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques | 2000 |
Parkinsonian symptoms as an initial manifestation in a Japanese patient with acquired immunodeficiency syndrome and Toxoplasma infection.
Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Carbidopa; Corpus Striatum; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parietal Lobe; Parkinsonian Disorders; Pyrimethamine; Syphilis; Toxoplasmosis, Cerebral | 2000 |
[Pharmacological treatments of Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Tolcapone | 2001 |
Clinical management of neuroleptic malignant syndrome.
Topics: Bromocriptine; Carbidopa; Dopamine Agonists; Drug Combinations; Electroconvulsive Therapy; Guidelines as Topic; Humans; Levodopa; Neuroleptic Malignant Syndrome; Physical Therapy Specialty | 2001 |
Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life | 2002 |
[Serotonin syndrome: report of a fatal case and review of the literature].
Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism; Fatal Outcome; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome | 2002 |
Two advances in the management of Parkinson disease.
Topics: Age Factors; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dyskinesias; Electric Stimulation Therapy; Forecasting; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Risk Factors; Stereotaxic Techniques; Thiazoles | 2002 |
[Neuroleptic malignant syndrome].
Topics: Acute Kidney Injury; Adult; Amantadine; Bromocriptine; Carbidopa; Contraindications; Dantrolene; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Female; Humans; Intensive Care Units; Levodopa; Male; Muscle Relaxants, Central; Neuroleptic Malignant Syndrome; Prognosis; Rhabdomyolysis | 2002 |
Entacapone/levodopa/carbidopa combination tablet: Stalevo.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Movement Disorders; Nitriles; Parkinson Disease; Tablets | 2003 |
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2004 |
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Topics: Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine; Drug Therapy, Combination; Humans; Hyperhomocysteinemia; Levodopa; MPTP Poisoning; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Rats; Treatment Outcome | 2005 |
Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Topics: Antiparkinson Agents; Brain; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Delayed-Action Preparations; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2006 |
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Nitriles; Parkinson Disease | 2006 |
Motor fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neurosurgical Procedures; Parkinson Disease; Tremor | 2006 |
Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
Topics: Carbidopa; Dyskinesias; Gels; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Parkinson Disease | 2006 |
[Prevention and treatment of fluctuations in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Infusion Pumps, Implantable; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2006 |
Nuclear imaging of neuroendocrine tumours.
Topics: 3-Iodobenzylguanidine; 5-Hydroxytryptophan; Carbidopa; Glucose-6-Phosphate; Humans; Levodopa; Neuroendocrine Tumors; Positron-Emission Tomography; Receptors, Somatostatin; Somatostatin | 2007 |
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Parkinson Disease; Patient Education as Topic; Pharmacists; Professional Role; Severity of Illness Index | 2007 |
L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
Topics: Autonomic Nervous System Diseases; Blood Pressure; Carbidopa; Central Nervous System Diseases; Controlled Clinical Trials as Topic; Droxidopa; Humans; Hypotension, Orthostatic; Levodopa; Multiple System Atrophy; Norepinephrine; United States | 2008 |
The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Carbidopa; Drug Interactions; Humans; Levodopa; Parkinson Disease; Tissue Distribution | 2007 |
Pharmacologic management of Parkinson's disease in long-term care residents: maintaining functionality to improve quality of life.
Topics: Accidental Falls; Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Disease Progression; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Patient Care Planning; Practice Guidelines as Topic; Quality of Life; Safety Management | 2007 |
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Hyperkinesis; Levodopa; Male; Parkinson Disease; Solubility; Time Factors | 2010 |
[Intraduodenal infusion of levodopa].
Topics: Carbidopa; Deep Brain Stimulation; Dopamine Agents; Drug Administration Routes; Duodenum; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2010 |
Entacapone.
Topics: Animals; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Parkinson Disease | 2010 |
Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; MEDLINE; Parkinson Disease; Randomized Controlled Trials as Topic | 2011 |
Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Outcome Assessment, Health Care; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index | 2012 |
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2012 |
IPX066: a novel carbidopa-levodopa extended-release formulation.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2012 |
Clinical inquiry. Which drugs work best for early Parkinson's disease?
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Family Practice; Humans; Indoles; Levodopa; Motor Skills; Neurologic Examination; Parkinson Disease | 2012 |
Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety.
Topics: Animals; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2012 |
[Proposed alternative to standard apomorphine challenge test].
Topics: Antidotes; Antiparkinson Agents; Apomorphine; Carbidopa; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Levodopa; Motor Activity; Parkinson Disease; Severity of Illness Index; Time Factors | 2012 |
[Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Topics: Aftercare; Ambulatory Care; Antiparkinson Agents; Apomorphine; Benserazide; Carbidopa; Caregivers; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Patient Education as Topic; Patient Selection; Retrospective Studies | 2012 |
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Administration Routes; Evidence-Based Practice; Humans; Levodopa; Parkinson Disease | 2013 |
Treatment of Parkinson's disease in the advanced stage.
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2013 |
When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease; Patient Selection | 2013 |
[Chorea due to TITF1/NKX2-1 mutation: phenotypical description and therapeutic response in a family].
Topics: Adolescent; Adult; Age of Onset; Brain; Carbidopa; Chorea; Congenital Hypothyroidism; Drug Therapy, Combination; Exons; Female; Humans; Infant, Newborn; Intellectual Disability; Levodopa; Magnetic Resonance Imaging; Nuclear Proteins; Pedigree; Phenotype; Pregnancy; Sequence Deletion; Thyroid Nuclear Factor 1; Transcription Factors; Young Adult | 2013 |
[Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2013 |
[Pharmacotherapy of Parkinson's disease: progress or regress?].
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Dopamine Antagonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Substantia Nigra | 2013 |
The impact of restless legs syndrome: a familial case study.
Topics: Adult; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Benzothiazoles; Carbidopa; Dopamine Agonists; Drug Combinations; Family Health; Humans; Incidence; Indoles; Levodopa; Male; Middle Aged; Pramipexole; Prevalence; Restless Legs Syndrome | 2013 |
[The treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Combined Modality Therapy; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Physical Therapy Modalities | 2013 |
[Treatment possibilities in advanced Parkinson's disease].
Topics: Administration, Oral; Age Factors; Antiparkinson Agents; Apomorphine; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Dopamine Agents; Drug Tolerance; Duodenum; Dyskinesia, Drug-Induced; Gels; Humans; Infusion Pumps, Implantable; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index | 2013 |
Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Humans; Jejunum; Levodopa; Parkinson Disease | 2014 |
[Clinical studies with levodopa/carbidopa intestinal gel].
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Cognition; Confounding Factors, Epidemiologic; Dopamine Agents; Drug Delivery Systems; Gels; Humans; Intestines; Levodopa; Parkinson Disease; Peripheral Nervous System Diseases; Quality of Life; Research Design; Sample Size; Sleep | 2014 |
[Management of complications related to intraduodenal infusion of levodopa/carbidopa in patients with Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Duodenum; Gastrointestinal Diseases; Gastrostomy; Granuloma; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Multicenter Studies as Topic; Observational Studies as Topic; Pain; Parkinson Disease; Peritonitis; Postoperative Complications; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Surgical Stomas | 2014 |
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Schedule; Drug Combinations; Hospitalization; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Nursing Care; Parkinson Disease | 2014 |
IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease; Time Factors | 2014 |
Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management.
Topics: Administration, Oral; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Parkinson Disease; Polyneuropathies; Vitamin B 12 | 2015 |
[Levodopa: the story continues].
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Novel formulations and modes of delivery of levodopa.
Topics: Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease | 2015 |
[Pharmacoeconomic aspects of using levodopa/carbidopa intestinal gel in Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Europe; Humans; Levodopa; Parkinson Disease | 2014 |
[Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2014 |
Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Half-Life; Humans; Levodopa; Parkinson Disease | 2015 |
Carbidopa/levodopa extended-release capsules (Rytary).
Topics: Animals; Antiparkinson Agents; Capsules; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2015 |
Approach to the patient with Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Diagnosis, Differential; Drug Combinations; Humans; Levodopa; Parkinson Disease; Primary Health Care; Risk Factors | 2015 |
Best practice in placement of percutaneous endoscopic gastrostomy with jejunal extension tube for continuous infusion of levodopa carbidopa intestinal gel in the treatment of selected patients with Parkinson's disease in the Nordic region.
Topics: Antiparkinson Agents; Carbidopa; Gastrostomy; Gels; Humans; Levodopa; Parkinson Disease; Patient Selection; Postoperative Complications; Quality of Life; Scandinavian and Nordic Countries | 2015 |
Current treatment and future prospects of dopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Treatment Outcome | 2015 |
[Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2015 |
Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Chemistry, Pharmaceutical; Drug Administration Routes; Drug Combinations; Drug Costs; Humans; Levodopa; Motor Activity; Parkinson Disease; Treatment Outcome | 2015 |
Carbidopa levodopa enteral suspension.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Suspensions | 2015 |
Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Interactions; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Movement disorders: advances in 2015.
Topics: Animals; Antiparkinson Agents; Carbidopa; DNA-Binding Proteins; Drug Combinations; Humans; Levodopa; Mitochondrial Proteins; Movement Disorders; Parkinson Disease; Transcription Factors | 2016 |
[Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agents; Dyskinesias; Gastrostomy; Gels; Humans; Intestines; Jejunostomy; Levodopa; Parkinson Disease; Quality of Life | 2015 |
New and emerging medical therapies in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Routes; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Quality of Life | 2016 |
Medical Therapies of Amblyopia: Translational Research to Expand Our Treatment Armamentarium.
Topics: Amblyopia; Carbidopa; Cholinesterase Inhibitors; Donepezil; Dopamine Agonists; Drug Combinations; Fluoxetine; Humans; Indans; Levodopa; Neuronal Plasticity; Piperidines; Selective Serotonin Reuptake Inhibitors; Translational Research, Biomedical; Visual Cortex | 2016 |
Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2016 |
Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life | 2016 |
An update on the diagnosis and treatment of Parkinson disease.
Topics: Age of Onset; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Dyskinesias; Humans; Levodopa; Life Expectancy; Parkinson Disease; Practice Guidelines as Topic; Risk Assessment | 2016 |
Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances.
Topics: Administration, Cutaneous; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2016 |
[Practical Use of the Levodopa Pump].
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Duodenum; Equipment Design; Gastrostomy; Humans; Infusion Pumps, Implantable; Jejunum; Levodopa; Neurologic Examination; Parkinson Disease | 2016 |
Comment on: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Intestines; Levodopa; Parkinson Disease | 2016 |
Novel Levodopa Formulations for Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Chemistry, Pharmaceutical; Drug Combinations; Humans; Levodopa; Nitriles; Parkinson Disease | 2016 |
Rationale for Assessing Safety and Efficacy of Drug Candidates Alone and in Combination with Medical Devices: The Case Study of SpinalonTM.
Topics: Animals; Buspirone; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Humans; Levodopa; Locomotion; Motor Neurons; Randomized Controlled Trials as Topic; Spinal Cord Injuries | 2017 |
The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Administration Routes; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2016 |
Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug and Narcotic Control; Drug Combinations; Drug Repositioning; Levodopa; Pharmacokinetics | 2017 |
Algorithms for the treatment of motor problems in Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Consensus; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2017 |
Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
Topics: Antiparkinson Agents; Apomorphine; Australia; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2017 |
Pharmacokinetics of Rytary
Topics: Animals; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Drug Compounding; Humans; Levodopa; Parkinson Disease | 2017 |
Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside.
Topics: Animals; Carbidopa; Central Nervous System; Drug Approval; Drug Combinations; Drug Delivery Systems; Drug Design; European Union; Gels; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Tablets | 2017 |
Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2017 |
Using tube feeding and levodopa-carbidopa intestinal gel application in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease; Quality of Life | 2018 |
Levodopa-carbidopa intestinal gel: 'dismantling the road blocks of a journey'.
Topics: Administration, Intranasal; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrostomy; Humans; Jejunostomy; Jejunum; Levodopa; Parkinson Disease; Patient Compliance | 2018 |
New advances in amblyopia therapy I: binocular therapies and pharmacologic augmentation.
Topics: Amblyopia; Carbidopa; Child; Cytidine Diphosphate Choline; Dopamine Agonists; Drug Combinations; Eyeglasses; Humans; Levodopa; Nootropic Agents; Sensory Deprivation; Vision, Binocular | 2018 |
Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
New Directions in Treatments Targeting Stroke Recovery.
Topics: Brain-Computer Interfaces; Carbidopa; Cell- and Tissue-Based Therapy; Chorionic Gonadotropin; Dopamine Agonists; Drug Combinations; Epoetin Alfa; Humans; Levodopa; Occupational Therapy; Physical Therapy Modalities; Recovery of Function; Robotics; Selective Serotonin Reuptake Inhibitors; Speech Therapy; Stroke; Stroke Rehabilitation; Telerehabilitation; Transcranial Direct Current Stimulation; Transcranial Magnetic Stimulation; Vagus Nerve Stimulation; Virtual Reality | 2018 |
Apomorphine in the treatment of Parkinson's disease: a review.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2018 |
[Selection of the optimal device-aided therapy in Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Hungary; Levodopa; Parkinson Disease; Quality of Life | 2019 |
Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
Topics: Antiparkinson Agents; Basal Ganglia; Carbidopa; Dopamine Agonists; Drug Carriers; Drug Combinations; Drug Compounding; Drug Liberation; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Signal Transduction | 2019 |
The Accordion Pill
Topics: Administration, Oral; Carbidopa; Delayed-Action Preparations; Gastrointestinal Tract; Half-Life; Humans; Levodopa; Parkinson Disease; Solubility | 2019 |
Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Observational Studies as Topic; Parkinson Disease; Precision Medicine; Prospective Studies; United States | 2019 |
Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Exercise; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Therapies, Investigational | 2019 |
The Dystonias.
Topics: Acetylcholine Release Inhibitors; Adult; Botulinum Toxins; Carbidopa; Dopamine Agonists; Drug Combinations; Dystonia; Dystonic Disorders; Female; Humans; Levodopa; Middle Aged; Physical Therapy Modalities | 2019 |
Percutaneous Endoscopic Gastrostomy with Jejunal Extension Tube for the Delivery of Levodopa Carbidopa Intestinal Gel: Clinical Practice Guidelines of the Romanian Society of Digestive Endoscopy.
Topics: Antiparkinson Agents; Carbidopa; Consensus; Drug Administration Routes; Drug Combinations; Drug Compounding; Endoscopy, Gastrointestinal; Equipment Design; Gastrostomy; Gels; Humans; Infusion Pumps; Jejunum; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2019 |
A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2019 |
Diagnosis and Treatment of Parkinson Disease: A Review.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Diagnosis, Differential; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Prognosis | 2020 |
The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Humans; Levodopa; Nitriles; Parkinson Disease | 2020 |
Levodopa Inhalation Powder: A Review in Parkinson's Disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Powders | 2020 |
The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Clinical Decision-Making; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease | 2020 |
LCIG in treatment of non-motor symptoms in advanced Parkinson's disease: Review of literature.
Topics: Antiparkinson Agents; Carbidopa; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2020 |
Medical Management and Prevention of Motor Complications in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Disease Management; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2020 |
Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Dopaminergic Neurons; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2021 |
Comparison chart: Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Dopamine Agonists; Humans; Kidney Diseases; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2020 |
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
Topics: Activities of Daily Living; Antiparkinson Agents; Apomorphine; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Phytobezoar Associated with Levodopa-carbidopa Intestinal Gel Infusion in Patients with Parkinson's Disease: A Case Report and Literature Review.
Topics: Antiparkinson Agents; Bezoars; Carbidopa; Humans; Levodopa; Parkinson Disease | 2021 |
Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Quality of Life; Vitamins | 2022 |
Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Observational Studies as Topic; Parkinson Disease; Quality of Life; Retrospective Studies | 2021 |
On demand therapy for Parkinson's disease patients: Opportunities and choices.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine Agonists; Drug Administration Routes; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
Effects of rehabilitation on reducing dyskinesias in a Parkinson's disease patient abusing therapy with levodopa-carbidopa intestinal gel: a paradigmatic case report and literature review.
Topics: Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2021 |
A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Humans; Levodopa; Parkinson Disease | 2022 |
SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review.
Topics: Carbidopa; COVID-19; COVID-19 Vaccines; Deep Brain Stimulation; Drug Combinations; Humans; Immunization, Secondary; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome; Vaccination | 2022 |
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease | 2022 |
Determination of levodopa by chromatography-based methods in biological samples: a review.
Topics: Carbidopa; Catecholamines; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 2022 |
The Prephase Nursing in Levodopa Carbidopa Intestinal Gel Therapy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Quality of Life | 2022 |
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Follow-Up Studies; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Sleep | 2022 |
Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson's disease.
Topics: Aged; Biological Products; Carbidopa; Cholinergic Antagonists; Dopamine; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase; Neurodegenerative Diseases; Parkinson Disease | 2022 |
Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Humans; Levodopa; Parkinson Disease | 2022 |
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Aged; Apomorphine; Carbidopa; Humans; Levodopa; Middle Aged; Network Meta-Analysis; Parkinson Disease; Quality of Life | 2022 |
[Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Observational Studies as Topic; Parkinson Disease | 2022 |
Acute/subacutae demyelinating polyneuropathy in Parkinson's Disease patients on levodopa-carbidopa intestinal gel therapy: systematic review with new case report.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Polyneuropathies; Prospective Studies | 2023 |
The Use of Liquid Sinemet in Routine Clinical Practice of Advanced Parkinson's Disease: A Comparison of Available Options.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Postural Balance; Time and Motion Studies | 2023 |
A systematic review of the potential consequences of abnormal serum levels of vitamin B6 in people living with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Epilepsy; Humans; Levodopa; Parkinson Disease; Polyneuropathies; Vitamin B 12; Vitamin B 6; Vitamins | 2023 |
Infusion Therapies in the Treatment of Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Tools and criteria to select patients with advanced Parkinson's disease for device-aided therapies: a narrative review.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Current and novel infusion therapies for patients with Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2023 |
Systematic review of drug therapy for chorea in NXK2-1-related disorders: Efficacy and safety evidence from case studies and series.
Topics: Carbidopa; Chorea; Clonazepam; Humans; Levodopa; Methylphenidate; Tetrabenazine | 2023 |
Levodopa-Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review.
Topics: Antiparkinson Agents; Arthroplasty, Replacement, Hip; Carbidopa; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease | 2023 |
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson's disease?
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Parkinson Disease; Quality of Life; Standard of Care | 2023 |
379 trial(s) available for levodopa and carbidopa
| Article | Year |
|---|---|
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with parkinson's disease.
Topics: Adult; Aged; Arrhythmias, Cardiac; Carbidopa; Cardiac Complexes, Premature; Cardiovascular System; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Tachycardia | 1975 |
Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.
Topics: Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Ergolines; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Time Factors | 1976 |
Deprenyl in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Phenethylamines | 1977 |
Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Topics: Aged; Benserazide; Carbidopa; Consumer Behavior; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Neuroendocrine function in Huntington's disease: dopaminergic regulation of prolactin release.
Topics: Adult; Bromocriptine; Carbidopa; Chlorpromazine; Dopamine; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Placebos; Prolactin; Time Factors | 1978 |
Experimental and clinical studies on bromocriptine in the Parkinsonian syndrome.
Topics: Animals; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Ergot Alkaloids; Haplorhini; Humans; Levodopa; Parkinson Disease, Secondary; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine | 1978 |
Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Nomifensine in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Placebos; Trihexyphenidyl | 1977 |
Treatment of Parkinson's disease with lergotrile mesylate.
Topics: Acetonitriles; Antiparkinson Agents; Bromocriptine; Carbidopa; Carboxy-Lyases; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Parkinson Disease | 1977 |
Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1978 |
A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
Topics: Adult; Benserazide; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1978 |
Effects of apomorphine and apomorphine-L-dopa-carbidopa on alcohol post-intoxication symptoms.
Topics: Adult; Aged; Alcoholic Intoxication; Alcoholism; Apomorphine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged | 1978 |
Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).
Topics: Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
A comparative clinical investigation of the therapeutic effect of levodopa alone and in combination with a decarboxylase inhibitor (carbidopa) in cases of Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Electrocardiography; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1978 |
Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor.
Topics: Adult; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Catecholaminergic drugs in chronic schizophrenia.
Topics: Adult; Apomorphine; Carbidopa; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Follicle Stimulating Hormone; Growth Hormone; Humans; Hydrazines; Imipramine; Levodopa; Luteinizing Hormone; Male; Middle Aged; Placebos; Schizophrenia, Disorganized; Testosterone | 1979 |
Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid | 1979 |
[Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) (author's transl)].
Topics: Adult; Benserazide; Brain; Carbidopa; Clinical Trials as Topic; Confusion; Electrocardiography; Electroencephalography; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Stomach Diseases; Tomography, X-Ray Computed | 1979 |
Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Tablets, Enteric-Coated | 1979 |
[The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Levodopa with benserazide or carbidopa in Parkinson disease.
Topics: Benserazide; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Cyproheptadine in levodopa-induced dyskinesia in parkinsonism.
Topics: Aged; Carbidopa; Cyproheptadine; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1978 |
Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Clonidine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Piribedil; Placebos | 1976 |
[The clinical experience with the decarboxylase-blocked levodopa (Nacom) in the Parkinsonism patients].
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interview, Psychological; Levodopa; Male; Mental Status Schedule; Methyldopa; Middle Aged; Parkinson Disease; Placebos; Recurrence; Trihexyphenidyl | 1976 |
[Sinomet and Madopar, a comparative study on the treatment of Parkinson's disease].
Topics: Benserazide; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1976 |
Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
Topics: Aged; Amantadine; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Parkinson Disease; Pyridoxine | 1976 |
Combined anti-prolactin and anti-oestrogen therapy for breast carcinoma.
Topics: Aged; Breast Neoplasms; Bromocriptine; Carbidopa; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Levodopa; Middle Aged; Nausea; Prolactin; Remission, Spontaneous; Stilbenes; Tamoxifen; Time Factors; Vomiting | 1977 |
Madopar versus sinemet. A clinical study on their effectiveness.
Topics: Adult; Aged; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Serine | 1975 |
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Parkinson Disease, Secondary; Pimozide; Placebos; Promethazine | 1975 |
Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Time Factors | 1975 |
Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
The effects of combining carbidopa with levodopa for Parkinson's disease.
Topics: Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydrazines; Hypotension, Orthostatic; Levodopa; Male; Nausea; Parkinson Disease; Vomiting | 1975 |
L-dopa and carbidopa (sinemet) in the management of parkinsonism.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis | 1975 |
Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.
Topics: Administration, Oral; Aged; Apomorphine; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Growth Hormone; Humans; Kidney; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Secretory Rate | 1976 |
Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
The evolution of dementia in idiopathic Parkinson's disease: neuropsychological and clinical evidence in support of subtypes.
Topics: Age Factors; Aged; Bromocriptine; Carbidopa; Dementia; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinson Disease | 1992 |
Hereditary motor and sensory neuropathy with treatable extrapyramidal features.
Topics: Adult; Aged; Basal Ganglia Diseases; Carbidopa; Drug Combinations; Female; Hereditary Sensory and Motor Neuropathy; Humans; Levodopa; Male; Middle Aged; Peripheral Nervous System Diseases; Placebos | 1992 |
Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group.
Topics: Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Patient Satisfaction; Sleep Stages | 1992 |
Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa.
Topics: 5-Hydroxytryptophan; Adult; Alcoholism; Analysis of Variance; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Educational Status; Female; Humans; Intelligence Tests; Levodopa; Male; Memory; Middle Aged; Neuropsychological Tests; Time Factors | 1992 |
Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Tablets | 1992 |
Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Topics: Adult; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Methyldopa; Neurologic Examination; Parkinson Disease | 1992 |
Trial of Sinemet CR4 in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1992 |
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
Topics: Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1992 |
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxazines; Parkinson Disease | 1991 |
A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
Topics: Aged; Benserazide; Carbidopa; Chlormethiazole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Sleep Initiation and Maintenance Disorders; Sleep Stages; Temazepam | 1991 |
Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Movement; Parkinson Disease; Time Factors | 1991 |
L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Selegiline; Time Factors | 1991 |
Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR).
Topics: Adult; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Food; Gastrointestinal Transit; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Levodopa; Male; Reference Values; Stomach | 1991 |
Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Sinemet CR in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos | 1991 |
Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dietary Proteins; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Parkinson Disease | 1991 |
Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Blood Pressure; Carbidopa; Gait; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance; Random Allocation | 1991 |
Depression treatment in Parkinson's disease.
Topics: Antidepressive Agents, Tricyclic; Carbidopa; Depression; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Nortriptyline; Parkinson Disease | 1991 |
An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1991 |
L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.
Topics: Aged; Carbidopa; Follow-Up Studies; Humans; Levodopa; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline | 1990 |
The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Lisuride; Long-Term Care; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy.
Topics: Aged; Aged, 80 and over; Blood Pressure; Carbidopa; Double-Blind Method; Female; Gait; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Randomized Controlled Trials as Topic | 1990 |
A long-term study of Parkinson's patients subjected to autoimplants of perfused adrenal medulla into the caudate nucleus. CPH Neural Transplantation Group.
Topics: Adrenal Medulla; Carbidopa; Caudate Nucleus; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perfusion; Tissue Transplantation; Transplantation, Autologous; Transplantation, Heterotopic | 1990 |
Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Statistics as Topic; Time Factors | 1990 |
Diurnal differences in response to oral levodopa.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Circadian Rhythm; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Decreased efficacy of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants.
Topics: Adrenal Medulla; Adult; Carbidopa; Corpus Striatum; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Random Allocation | 1990 |
Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
The effect of dietary protein on the efficacy of L-dopa: a double-blind study.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Selegiline | 1989 |
Stable remission of tardive dyskinesia by L-dopa.
Topics: Adult; Aged; Antipsychotic Agents; Carbidopa; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Schizophrenia | 1989 |
CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
Topics: Adult; Aged; Aminoquinolines; Antiparkinson Agents; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease.
Topics: Aged; Amino Acids; Carbidopa; Clinical Trials as Topic; Dietary Proteins; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
Topics: Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Random Allocation | 1989 |
Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Multicenter Studies as Topic; Parkinson Disease; Random Allocation; Time Factors | 1989 |
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Fasting; Half-Life; Humans; Intestinal Absorption; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Reference Values; Tablets; Tyrosine | 1989 |
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Tyrosine | 1989 |
Gastrointestinal transit of Sinemet CR in healthy volunteers.
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Eating; Gastric Emptying; Gastrointestinal Transit; Humans; Levodopa; Male; Random Allocation; Tablets | 1989 |
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Movement Disorders; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1989 |
[Clinical results of using Nakom in diseases of the nervous system].
Topics: Adolescent; Adult; Age Factors; Carbidopa; Catecholamines; Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; Drug Combinations; Dystonia Musculorum Deformans; Humans; Levodopa; Muscle Rigidity; Myasthenia Gravis | 1989 |
The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.
Topics: Administration, Oral; Adult; Aged; Aging; Carbidopa; Drug Interactions; Female; Humans; Injections, Intravenous; Levodopa; Male | 1989 |
Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia.
Topics: Adult; Aged; Antipsychotic Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Psychiatric Status Rating Scales; Random Allocation | 1988 |
Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Consumer Behavior; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation; Time Factors | 1988 |
Treatment of Parkinson's disease with pergolide: a double-blind study.
Topics: Activities of Daily Living; Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Random Allocation | 1988 |
Pergolide: long-term use in Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Placebos; Retrospective Studies | 1988 |
Long term bromocriptine treatment in de novo parkinsonian patients.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1988 |
Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline; Self Concept | 1987 |
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Random Allocation; Selegiline | 1988 |
Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Motor Activity; Parkinson Disease | 1988 |
A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Neurologic Examination; Parkinson Disease | 1987 |
Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa.
Topics: Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Levodopa; Parkinson Disease; Random Allocation; Sleep | 1987 |
A double-blind evaluation of ciladopa in Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Piperazines; Random Allocation | 1987 |
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Topics: Animals; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1988 |
Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
Topics: Aged; Carbidopa; Chronic Disease; Delayed-Action Preparations; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Topics: Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
Parallel double-blind study of pergolide in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Pergolide; Random Allocation | 1987 |
Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Random Allocation | 1987 |
The Sydney multicentre study of Parkinson's disease. The first 18 months.
Topics: Australia; Bromocriptine; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1987 |
Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women.
Topics: Amphetamine; Carbidopa; Dopamine; Dopamine Antagonists; Female; Humans; Levodopa; Nomifensine; Postpartum Period; Pregnancy; Prolactin; Receptors, Dopamine | 1987 |
Adjuvant therapy of parkinsonian tremor.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clonazepam; Double-Blind Method; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Primidone; Propranolol; Random Allocation; Tremor; Trihexyphenidyl | 1987 |
Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 1987 |
Double-blind trial of pergolide for Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1985 |
Caerulein treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Ceruletide; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1985 |
Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
Topics: Acute Disease; Adult; Age Factors; Apomorphine; Carbidopa; Depression, Chemical; Dopamine; Humans; Levodopa; Male; Prolactin; Research Design; Schizophrenia; Schizophrenic Psychology; Sodium Chloride | 1985 |
Motor function in the normal aging population: treatment with levodopa.
Topics: Aged; Aging; Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Middle Aged; Movement; Movement Disorders; Parkinson Disease | 1985 |
Effect of L-dopa with and without inhibition of extra cerebral dopa decarboxylase on gastric acid secretion and gastrin release in man.
Topics: Adult; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Female; Gastric Acid; Gastrins; Humans; Levodopa; Male; Middle Aged; Pentagastrin | 1985 |
Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
Topics: Activities of Daily Living; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Carbidopa; Dopamine; Drug Interactions; Female; Humans; Kinetics; Levodopa; Male; Random Allocation | 1985 |
L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease.
Topics: Aged; Blood Pressure; Carbidopa; Clinical Trials as Topic; Depression, Chemical; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Placebos; Posture; Vomiting | 1974 |
Sinemet.
Topics: Carbidopa; Clinical Trials as Topic; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1974 |
Deprenyl in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Dopamine; Double-Blind Method; Drug Combinations; Epinephrine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1981 |
Effortful and automatic memory: effects of dopamine.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Cognition; Double-Blind Method; Drug Combinations; Humans; Levodopa; Memory; Middle Aged | 1984 |
Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
Dyskinesias associated with lithium therapy in parkinsonism.
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Lithium; Male; Middle Aged; Parkinson Disease; Random Allocation | 1984 |
Atypical phenylketonuria due to biopterin deficiency. Early treatment with tetrahydrobiopterin and neurotransmitter precursors, trials of monotherapy.
Topics: 5-Hydroxytryptophan; Biopterins; Carbidopa; Clinical Trials as Topic; Humans; Infant; Levodopa; Male; Phenylketonurias; Pteridines | 1982 |
Open trial with levodopa-carbidopa combination to patients with long-standing progressive myoclonus epilepsy.
Topics: Adult; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Epilepsies, Myoclonic; Female; Humans; Levodopa; Male; Middle Aged | 1981 |
Prolactin secretion in Parkinson disease.
Topics: Adult; Aged; Blood-Brain Barrier; Bromocriptine; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Hypothalamus, Anterior; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary Gland; Placebos; Prolactin; Receptors, Dopamine; Thyrotropin-Releasing Hormone | 1981 |
An open clinical trial of L-dopa and carbidopa in adults with minimal brain dysfunction.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Drug Synergism; Female; Humans; Levodopa; Male; Methylphenidate | 1980 |
Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Kynurenine; Levodopa; Male; Middle Aged; Myoclonus; Parkinson Disease; Scleroderma, Systemic; Serotonin | 1980 |
Questioning a dopaminergic hypothesis.
Topics: Attention Deficit Disorder with Hyperactivity; Carbidopa; Clinical Trials as Topic; Dopamine; Humans; Levodopa | 1981 |
Inhibition of the renin-angiotensin-aldosterone system by L-dopa with and without inhibition of extracerebral dopa decarboxylase in man.
Topics: Adult; Aldosterone; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Pressure; Carbidopa; Female; Humans; Levodopa; Male; Renin | 1981 |
Recent advances in the treatment of Parkinson's disease: the role of bromocriptine.
Topics: Bromocriptine; Carbidopa; Clinical Trials as Topic; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1981 |
Weekly drug holiday in Parkinson disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Behavioral effects of carbidopa/levodopa in hyperactive boys.
Topics: Attention Deficit Disorder with Hyperactivity; Carbidopa; Child; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male | 1982 |
Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system.
Topics: Administration, Oral; Adult; Carbidopa; Central Nervous System; Ethanolamines; Female; Humans; Hypertension; Injections, Intravenous; Labetalol; Levodopa; Male; Middle Aged; Prolactin | 1982 |
Parkinson's disease: Cogentin with Sinemet, a better response.
Topics: Aged; Antiparkinson Agents; Benztropine; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Tropanes | 1982 |
Central nervous system and pituitary mechanisms in dopaminergic stimulation of growth hormone release in women.
Topics: Adolescent; Adult; Carbidopa; Central Nervous System; Dopamine; Female; Growth Hormone; Humans; Levodopa; Nomifensine; Pituitary Gland; Receptors, Dopamine | 1981 |
Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease.
Topics: Aged; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Bromocriptine; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Levodopa; Male; Parkinson Disease; Prospective Studies; Selegiline; Statistics, Nonparametric; Treatment Outcome | 1995 |
Visual acuities and scotomas after 3 weeks' levodopa administration in adult amblyopia.
Topics: Administration, Oral; Adolescent; Adult; Amblyopia; Carbidopa; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Female; Fixation, Ocular; Humans; Levodopa; Male; Middle Aged; Scotoma; Visual Acuity; Visual Fields | 1995 |
Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Aspartic Acid; Carbidopa; Choline; Corpus Striatum; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Magnetic Resonance Spectroscopy; Male; Middle Aged; Parkinson Disease; Pilot Projects; Protons | 1995 |
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Treatment Outcome | 1995 |
Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism.
Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Carbidopa; Citrate (si)-Synthase; Electron Transport; Electron Transport Complex II; Electron Transport Complex III; Female; Humans; Levodopa; Male; Middle Aged; Mitochondria; Multienzyme Complexes; NAD(P)H Dehydrogenase (Quinone); Oxidoreductases; Parkinson Disease; Plateletpheresis; Selegiline; Succinate Dehydrogenase | 1995 |
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Solutions; Tablets; Therapeutic Equivalency | 1994 |
A controlled trial of levodopa plus carbidopa in the treatment of winter seasonal affective disorder: a test of the dopamine hypothesis.
Topics: Adult; Carbidopa; Dopamine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Psychological Tests; Seasonal Affective Disorder | 1994 |
The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
Topics: Aged; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dihydroxyphenylalanine; Drug Synergism; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Nitriles; Occipital Lobe; Parkinson Disease; Tomography, Emission-Computed | 1994 |
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prevalence; Prospective Studies; Severity of Illness Index; Survival Analysis; Treatment Failure | 1994 |
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agents; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1993 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
Topics: Aged; Blood Pressure; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Hemodynamics; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Pulse; Respiration | 1993 |
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Electrocardiography; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease; Pergolide | 1994 |
A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene.
Topics: Adult; Aged; Carbidopa; Dextropropoxyphene; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Polysomnography; Reaction Time; Restless Legs Syndrome; Sleep Wake Disorders; Time Factors | 1993 |
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Topics: Adolescent; Adult; Aged; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Synergism; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease, Secondary; Placebos; Tolcapone | 1993 |
Milacemide therapy for Parkinson's disease.
Topics: Acetamides; Aged; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Muscle Rigidity; Neurologic Examination; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Single-Blind Method; Synaptic Transmission | 1993 |
A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence.
Topics: Adult; Breath Tests; Carbidopa; Cocaine; Drug Combinations; Electrocardiography; Humans; Levodopa; Substance Withdrawal Syndrome | 1993 |
Levodopa/carbidopa for childhood amblyopia.
Topics: Adolescent; Amblyopia; Carbidopa; Child; Child, Preschool; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Levodopa; Male; Sensory Deprivation; Visual Acuity | 1993 |
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Double-Blind Method; Drug Combinations; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Tablets | 1993 |
Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Movement Disorders; Muscle Rigidity; Neurologic Examination; Parkinson Disease | 1993 |
Broad bean (Vicia faba) consumption and Parkinson's disease.
Topics: Carbidopa; Fabaceae; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Plants, Medicinal | 1993 |
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.
Topics: Activity Cycles; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Solutions; Tablets | 1993 |
The effects of L-dihydroxyphenylalanine on alertness and mood in alpha-methyl-para-tyrosine-treated healthy humans. Further evidence for the role of catecholamines in arousal and anxiety.
Topics: Adult; Affect; alpha-Methyltyrosine; Anxiety; Carbidopa; Catecholamines; Enzyme Inhibitors; Humans; Levodopa; Male; Methyltyrosines; Psychiatric Status Rating Scales; Surveys and Questionnaires; Time Factors; Volunteers | 1995 |
Human transplacental transfer of carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Female; Fetus; Homovanillic Acid; Humans; Levodopa; Maternal-Fetal Exchange; Parkinson Disease; Pregnancy; Tyrosine | 1995 |
Effect of levodopa and carbidopa on recovery of visual function in patients with nonarteritic anterior ischemic optic neuropathy of longer than six months' duration.
Topics: Aged; Aged, 80 and over; Arteritis; Carbidopa; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Optic Neuropathy, Ischemic; Pilot Projects; Prospective Studies; Vision Disorders; Visual Acuity | 1996 |
[The use of the Sinemet-CR preparation in treating Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Higher Nervous Activity; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1995 |
Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1996 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
Topics: Adult; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Male; Nitriles; Reference Values | 1995 |
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Treatment Outcome | 1996 |
Intranasal apomorphine rescue therapy for parkinsonian "off" periods.
Topics: Administration, Intranasal; Antiemetics; Antiparkinson Agents; Apomorphine; Benzamides; Carbidopa; Dopamine Agonists; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Vomiting | 1996 |
Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.
Topics: Aged; Carbidopa; Circadian Rhythm; Cross-Over Studies; Delayed-Action Preparations; Dihydroxyphenylalanine; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Hand Strength; Humans; Isometric Contraction; Levodopa; Male; Muscle Rigidity; Parkinson Disease; Physical Exertion; Reproducibility of Results; Sensitivity and Specificity; Torque; Trihexyphenidyl | 1996 |
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Motor Skills; Neurologic Examination; Parkinson Disease; Therapeutic Equivalency | 1996 |
International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; International Cooperation; Levodopa; Middle Aged; Parkinson Disease | 1996 |
Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation.
Topics: Adult; Aged; Carbidopa; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders | 1996 |
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1997 |
Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study.
Topics: Adult; Anticonvulsants; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Lamotrigine; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Treatment Outcome; Triazines | 1997 |
[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
Topics: Age of Onset; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Plasma | 1997 |
Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.
Topics: Aged; Carbidopa; Circadian Rhythm; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Myoclonus; Pergolide; Restless Legs Syndrome; Sleep; Syndrome; Treatment Outcome | 1997 |
Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
Topics: Absorption; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1994 |
Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Topics: Activities of Daily Living; Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Carbidopa; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Matched-Pair Analysis; Motor Skills; Parkinson Disease; Quality of Life; Sickness Impact Profile | 1997 |
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Emptying; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Severity of Illness Index | 1997 |
Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers.
Topics: Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Benzophenones; Biotransformation; Carbidopa; Cross-Over Studies; Drug Combinations; Half-Life; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Single-Blind Method; Tolcapone | 1997 |
Endurance performance in humans: the effect of a dopamine precursor or a specific serotonin (5-HT2A/2C) antagonist.
Topics: Adult; Analysis of Variance; Blood Chemical Analysis; Carbidopa; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Combinations; Energy Metabolism; Exercise Test; Humans; Levodopa; Male; Physical Endurance; Ritanserin; Serotonin Antagonists; Statistics, Nonparametric | 1997 |
Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease.
Topics: Activities of Daily Living; Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Disease Progression; Duodenum; Female; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Time and Motion Studies; Time Factors; Treatment Outcome; Videotape Recording | 1998 |
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Benzophenones; Biological Availability; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome | 1998 |
Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International Response Fluctuation Study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1998 |
Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.
Topics: Aged; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Eating; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1998 |
Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist?
Topics: Aged; Aged, 80 and over; Bromocriptine; Carbidopa; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Stereotaxic Techniques; Treatment Outcome | 1997 |
Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies | 1998 |
Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
Topics: Aged; Antiparkinson Agents; Biological Transport; Carbidopa; Cocaine; Corpus Striatum; Dopamine; Drug Therapy, Combination; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Monoamine Oxidase; Occipital Lobe; Parkinson Disease; Selegiline; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1999 |
Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Topics: Adult; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Interactions; Enzyme Inhibitors; Erythrocytes; Humans; Levodopa; Male; Nitriles | 1999 |
Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.
Topics: Activities of Daily Living; Aged; Carbidopa; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1999 |
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
Levodopa-carbidopa and childhood retinal disease.
Topics: Adolescent; Carbidopa; Child; Child, Preschool; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Longitudinal Studies; Retinal Diseases; Visual Acuity | 1998 |
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
Topics: Aged; Brain; Brain Mapping; Carbidopa; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Motor Skills; Nerve Tissue Proteins; Parkinson Disease; Pergolide; Putamen; Tomography, Emission-Computed, Single-Photon | 1999 |
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Models, Statistical; Nitrophenols; Parkinson Disease; Population; Risk Factors; Single-Blind Method; Tolcapone | 2000 |
The effect of increasing doses of levodopa on children with strabismic amblyopia.
Topics: Administration, Oral; Adolescent; Amblyopia; Carbidopa; Child; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Sensory Deprivation; Strabismus; Treatment Outcome; Visual Acuity | 1999 |
Occlusion and levodopa-carbidopa treatment for childhood amblyopia.
Topics: Administration, Oral; Amblyopia; Carbidopa; Child; Contrast Sensitivity; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Patient Compliance; Sensory Deprivation; Treatment Outcome; Vision Tests; Visual Acuity | 1998 |
Levodopa may improve vision loss in recent-onset, nonarteritic anterior ischemic optic neuropathy.
Topics: Aged; Arteritis; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Optic Neuropathy, Ischemic; Time Factors; Vision Disorders; Visual Acuity; Visual Fields | 2000 |
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2000 |
The long-duration response to L-dopa in the treatment of early PD.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Treatment Outcome | 2000 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
Topics: Adaptation, Psychological; Adult; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Quality of Life; Sick Role; Sickness Impact Profile; Tolcapone; Treatment Outcome | 2000 |
Carbidopa/levodopa for smoking cessation: a pilot study with negative results.
Topics: Adult; Carbidopa; Carbon Monoxide; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Patient Compliance; Pilot Projects; Smoking Cessation | 2000 |
Suppressed sympathetic skin response in Parkinson disease.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Electric Stimulation; Evoked Potentials; Evoked Potentials, Auditory; Female; Foot; Hand; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reaction Time; Reference Values; Selegiline; Skin; Sympathetic Nervous System | 2000 |
Dopaminergic therapy with carbidopa L-dopa for left neglect after stroke: a case series.
Topics: Activities of Daily Living; Aged; Carbidopa; Dopamine Agents; Female; Geriatric Assessment; Humans; Levodopa; Perceptual Disorders; Severity of Illness Index; Stroke; Treatment Outcome | 2001 |
Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Heterocyclic Compounds, 2-Ring; Humans; Levodopa; Male; Middle Aged; Oximes; Parkinson Disease; Treatment Outcome | 2002 |
Influence of layer position on in vitro and in vivo release of levodopa methyl ester and carbidopa from three-layer matrix tablets.
Topics: Administration, Oral; Antiparkinson Agents; Biological Availability; Carbidopa; Chemistry, Pharmaceutical; Cross-Over Studies; Drug Delivery Systems; Humans; Levodopa; Pilot Projects; Tablets, Enteric-Coated | 2002 |
Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Treatment Outcome | 2002 |
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzothiazoles; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Parkinson Disease; Postmenopause; Pramipexole; Sex Factors; Thiazoles | 2002 |
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
Topics: Activities of Daily Living; Aged; Bromocriptine; Carbidopa; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Withholding Treatment | 2002 |
Levodopa-carbidopa with occlusion in older children with amblyopia.
Topics: Adolescent; Amblyopia; Carbidopa; Child; Contrast Sensitivity; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Patient Compliance; Sensory Deprivation; Treatment Outcome; Visual Acuity | 2002 |
Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Blood Pressure; Carbidopa; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Supine Position | 2003 |
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
Topics: Antiparkinson Agents; Atrophy; Brain; Carbidopa; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Globus Pallidus; Humans; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Rigidity; Neurosurgical Procedures; Parkinson Disease; Severity of Illness Index; Treatment Outcome; Tremor | 2003 |
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Purines; Safety; Treatment Outcome | 2003 |
[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2003 |
Levodopa/carbidopa/entacapone (Stalevo).
Topics: Aged; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechols; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Evaluation; Female; Headache; Humans; Levodopa; Male; Middle Aged; Nausea; Nitriles; Reference Values; Therapeutic Equivalency | 2004 |
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Pain Measurement; Parkinson Disease; Pramipexole; Quality of Life; Thiazoles | 2004 |
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.
Topics: Aged; Area Under Curve; Carbidopa; Catechols; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Single-Blind Method | 2004 |
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Single-Blind Method; Treatment Outcome | 2004 |
Dopaminergic modulation of response inhibition: an fMRI study.
Topics: Adult; Carbidopa; Cerebellum; Cognition; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Inhibition; Parietal Lobe; Psychomotor Performance; Tourette Syndrome | 2004 |
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Drug Resistance; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2004 |
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Indoles; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Pilot Projects; Pramipexole; Thiazoles | 2004 |
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Cross-Over Studies; Donepezil; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperidines | 2004 |
An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
Topics: Adult; Aged; Carbidopa; Catechols; Drug Combinations; Drug Tolerance; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease | 2005 |
Levodopa and the progression of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2004 |
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Therapy, Combination; Duodenum; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intubation; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Quality of Life; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Suspensions; Videotape Recording | 2005 |
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST).
Topics: Adult; Cabergoline; Carbidopa; Cocaine-Related Disorders; Dopamine Agents; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Pilot Projects | 2005 |
A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Parkinson Disease; Patient Satisfaction; Surveys and Questionnaires; Tablets | 2005 |
The effect of entacapone on homocysteine levels in Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Treatment Outcome | 2005 |
Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Optic Neuropathy, Ischemic; Prospective Studies; Treatment Outcome; Vision Disorders; Visual Acuity | 2005 |
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Disability Evaluation; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome | 2005 |
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Arm; Benzothiazoles; Biomechanical Phenomena; Carbidopa; Catechols; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 2006 |
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Tyrosine | 2006 |
Dopamine agonist therapy for Parkinson disease and pathological gambling.
Topics: Carbidopa; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Male; MEDLINE; Middle Aged; Parkinson Disease; Retrospective Studies | 2006 |
Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 2006 |
Intravenous levodopa administration in humans based on a two-compartment kinetic model.
Topics: Administration, Oral; Adult; Algorithms; Antiparkinson Agents; Body Fluid Compartments; Carbidopa; Dopamine; Female; Human Growth Hormone; Humans; Infusions, Intravenous; Levodopa; Male; Models, Biological; Pain Measurement; Prolactin | 2007 |
[Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2006 |
Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials.
Topics: Adult; Alcoholism; Carbidopa; Cocaine-Related Disorders; Dopamine; Double-Blind Method; Female; Humans; Levodopa; Male; Marijuana Abuse; Patient Compliance; Placebos; Safety; Socioeconomic Factors | 2007 |
Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion.
Topics: Adult; Affect; Attention; Carbidopa; Central Nervous System Stimulants; Dextroamphetamine; Dopamine; Double-Blind Method; Drug Combinations; Humans; Levodopa; Male; Motivation; Neuropsychological Tests; Pain Measurement; Phenylalanine; Reaction Time; Tyrosine | 2007 |
Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
Topics: Acute Disease; Carbidopa; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypogastric Plexus; Levodopa; Male; Middle Aged; Parasympathetic Fibers, Postganglionic; Parkinson Disease; Synaptic Transmission; Treatment Outcome; Urinary Bladder; Urinary Bladder, Neurogenic; Urination Disorders | 2007 |
Comment on Shpirer et al. ("Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnographic study").
Topics: Aged; Antiparkinson Agents; Carbidopa; Disorders of Excessive Somnolence; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Polysomnography; Reaction Time; Statistics, Nonparametric | 2007 |
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechols; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2007 |
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Duodenum; Dyskinesias; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2007 |
Should levodopa dose be reduced when switched to stalevo?
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2008 |
Greater motor improvement in right hemibody Parkinson's patients after dopaminergic medications.
Topics: Aged; Analysis of Variance; Carbidopa; Dopamine Agents; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 2009 |
[The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
Topics: Activities of Daily Living; Aged; Ambulatory Care Facilities; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Outpatients; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2007 |
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Breath Tests; Caprylates; Carbidopa; Carbon Isotopes; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastric Emptying; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Solubility | 2008 |
Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disability Evaluation; Double-Blind Method; Drug Combinations; Feeding Behavior; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Prospective Studies; Severity of Illness Index | 2008 |
Fatigue in levodopa-naive subjects with Parkinson disease.
Topics: Aged; Antiparkinson Agents; Brain; Carbidopa; Double-Blind Method; Fatigue; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2008 |
Levodopa improves procedural motor learning in chronic stroke patients.
Topics: Aged; Carbidopa; Chronic Disease; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Female; Germany; Humans; Levodopa; Male; Middle Aged; Motor Skills; Placebos; Reaction Time; Statistics, Nonparametric; Stroke; Stroke Rehabilitation; Treatment Outcome | 2008 |
Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa.
Topics: Adult; Antiparkinson Agents; Area Under Curve; Carbidopa; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Half-Life; Humans; Indium Radioisotopes; Isotope Labeling; Levodopa; Male; Powders; Radionuclide Imaging; Tablets; Tissue Distribution; Young Adult | 2008 |
[The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost-Benefit Analysis; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Disorders; Severity of Illness Index | 2008 |
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2009 |
Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Outpatients; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2008 |
Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Topics: Acetophenones; Adult; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Time Factors; Tyrosine; Young Adult | 2008 |
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index | 2009 |
[Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2009 |
Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenum; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Time; Time Factors; Treatment Outcome | 2009 |
Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Connective Tissue; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2009 |
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
Topics: Administration, Oral; Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Carbidopa; Case-Control Studies; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Nitriles; Young Adult | 2009 |
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2009 |
Children show individual night-to-night variability of periodic limb movements in sleep.
Topics: Analysis of Variance; Carbidopa; Child; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Nocturnal Myoclonus Syndrome; Polysomnography; Reference Values | 2009 |
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hypertension; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Piperidines; Pyrimidines; Receptors, N-Methyl-D-Aspartate | 2009 |
Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Area Under Curve; Carbidopa; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2009 |
Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy.
Topics: Activities of Daily Living; Behavioral Symptoms; Carbidopa; Disability Evaluation; Dopamine Agents; Female; Humans; Levodopa; Male; Motor Activity; Outcome Assessment, Health Care; Parkinson Disease; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires | 2010 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse Reactions; Dyskinesias; Feasibility Studies; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2010 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets.
Topics: Adult; Behavior Therapy; Carbidopa; Cocaine; Cocaine-Related Disorders; Dopamine Agents; Female; Humans; Levodopa; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Reinforcement, Psychology; Treatment Outcome | 2010 |
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Risk; Time Factors; Treatment Outcome | 2010 |
Increasing dopamine levels in the brain improves feedback-based procedural learning in healthy participants: an artificial-grammar-learning experiment.
Topics: Brain Chemistry; Carbidopa; Dopamine; Dopamine Agents; Double-Blind Method; Feedback, Psychological; Female; Humans; Language; Learning; Levodopa; Male; Neuropsychological Tests; Young Adult | 2010 |
Levodopa-carbidopa may improve vision loss in indirect traumatic optic neuropathy.
Topics: Adolescent; Adult; Blindness; Carbidopa; Chi-Square Distribution; Child; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Methylprednisolone; Middle Aged; Optic Nerve Injuries; Treatment Outcome; Visual Acuity | 2010 |
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
Topics: Acetophenones; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome | 2010 |
Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Intention to Treat Analysis; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2010 |
Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep; Sleep Wake Disorders | 2011 |
Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease; Treatment Outcome | 2010 |
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
Topics: Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechols; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Half-Life; Humans; Levodopa; Male; Nitriles; Time Factors; Young Adult | 2010 |
[Pharmacotherapy of motor manifestations in late stages of Parkinson's disease].
Topics: Aged; Carbidopa; Catechols; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2010 |
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Gels; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 2011 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2011 |
Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Tablets; Time Factors | 2012 |
Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Emotions; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Time | 2012 |
[Levodopa medications in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drugs, Generic; Female; Humans; Levodopa; Male; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2011 |
Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Constipation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Time Factors | 2011 |
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies; Quality of Life; Single-Blind Method | 2011 |
The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.
Topics: Adult; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechols; Cross-Over Studies; Dopamine Agents; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Nitriles; Young Adult | 2012 |
Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Female; Flow Cytometry; Gene Expression Regulation; Humans; Indoles; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Pramipexole | 2011 |
[Nocturnal motor symptoms of Parkinson's disease and their treatment with the three-component drug levodopa/carbidopa/entacapone].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep Disorders, Intrinsic | 2011 |
Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study.
Topics: Carbidopa; Carbon Radioisotopes; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Combinations; Harmine; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Positron-Emission Tomography; Prefrontal Cortex; Protein Binding; Serotonin; Substrate Specificity; Time Factors; Tryptophan | 2012 |
Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Carbidopa; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Association Learning; Carbidopa; Choice Behavior; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Female; Generalization, Psychological; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Nucleus Accumbens; Oxygen; Parkinson Disease; Photic Stimulation; Prefrontal Cortex; Psychomotor Performance; Reinforcement, Psychology | 2012 |
Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Treatment Outcome | 2012 |
Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
Topics: Adult; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Levodopa; Male; Nitriles; Tablets; Young Adult | 2013 |
Levodopa/carbidopa to improve motor function subsequent to brain tumor excision.
Topics: Adult; Brain Neoplasms; Carbidopa; Combined Modality Therapy; Dopamine Agonists; Drug Combinations; Exercise Therapy; Female; Humans; Levodopa; Magnetic Resonance Imaging; Motor Skills; Paresis; Postoperative Complications | 2013 |
[The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2013 |
Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disorders of Excessive Somnolence; Drug Administration Routes; Drug Combinations; Duodenum; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Jejunum; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Parkinson Disease; Prospective Studies; Severity of Illness Index; Sleep Disorders, Intrinsic; Treatment Outcome | 2013 |
Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Topics: Aged; Arginine Vasopressin; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Inappropriate ADH Syndrome; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2012 |
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Models, Biological; Parkinson Disease | 2013 |
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
Topics: Aged; Carbidopa; Chemistry, Pharmaceutical; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Treatment Outcome | 2013 |
A rapid non invasive L-DOPA-¹³C breath test for optimally suppressing extracerebral AADC enzyme activity - toward individualizing carbidopa therapy in Parkinson’s disease.
Topics: Brain; Carbidopa; Dopa Decarboxylase; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients.
Topics: Action Potentials; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Neural Conduction; Parkinsonian Disorders; Peripheral Nervous System Diseases; Prospective Studies; Reaction Time; Vitamin B 12; Vitamin B 12 Deficiency | 2014 |
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires | 2014 |
Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prodrugs; Treatment Outcome | 2014 |
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
Topics: Aged; Carbidopa; Double-Blind Method; Female; Gels; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Treatment Outcome | 2014 |
Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Compassionate Use Trials; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Supranuclear Palsy, Progressive; Treatment Outcome | 2014 |
A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.
Topics: Adolescent; Adult; Benzhydryl Compounds; Carbidopa; Central Nervous System Stimulants; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Data Interpretation, Statistical; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Modafinil; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Patient Compliance; Secondary Prevention; Treatment Outcome; Young Adult | 2014 |
[Nocturnal symptoms of Parkinson's disease and approaches to their correction].
Topics: Carbidopa; Catechols; Drug Combinations; Dyskinesias; Humans; Levodopa; Muscle Cramp; Nocturia; Parkinson Disease; Restless Legs Syndrome | 2013 |
Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Biological Availability; Carbidopa; Double-Blind Method; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Tablets | 2014 |
The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study.
Topics: Adult; Carbidopa; Cocaine-Related Disorders; Dopamine beta-Hydroxylase; Double-Blind Method; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Odds Ratio; Pharmacogenetics; Polymorphism, Genetic; Treatment Outcome | 2014 |
Neuromuscular complexity during gait is not responsive to medication in persons with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Electromyography; Female; Gait; Humans; Leg; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Walking | 2014 |
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome; Walking | 2014 |
[The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Gels; Health Status; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2014 |
Multilevel impact of the dopamine system on the emotion-potentiated startle reflex.
Topics: Adult; Alleles; Anxiety; Arousal; Carbidopa; Catechol O-Methyltransferase; Dopamine; Double-Blind Method; Drug Combinations; Emotions; Female; Genotype; Humans; Levodopa; Male; Polymorphism, Genetic; Reflex, Startle | 2015 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2015 |
Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
Topics: Aged; Antiparkinson Agents; Carbidopa; Europe; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2015 |
Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Topics: Age Factors; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Delivery Systems; Female; Gels; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2015 |
[The use of stalevo in the treatment of patients with Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2015 |
Gabapentin versus levodopa-c for the treatment of restless legs syndrome in hemodialysis patients: a randomized clinical trial.
Topics: Adult; Aged; Amines; Carbidopa; Cyclohexanecarboxylic Acids; Drug Combinations; Gabapentin; gamma-Aminobutyric Acid; Humans; Iran; Levodopa; Male; Middle Aged; Motor Activity; Renal Dialysis; Restless Legs Syndrome; Sleep; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2015 |
Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Gastrointestinal Tract; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapo
Topics: Adolescent; Adult; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Young Adult | 2015 |
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Precision Medicine; Tablets | 2015 |
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2015 |
Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials.
Topics: Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Female; Gels; Humans; Internationality; Intestinal Absorption; Intubation, Gastrointestinal; Jejunum; Levodopa; Male | 2015 |
Obstructive sleep apnea in Parkinson's disease patients: effect of Sinemet CR taken at bedtime.
Topics: Aged; Arousal; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep Apnea, Obstructive; Wakefulness | 2016 |
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2015 |
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Treatment Outcome | 2015 |
A Catecholamine Precursor Does Not Influence Exercise Performance in Warm Conditions.
Topics: Adult; Athletic Performance; Bicycling; Body Temperature; Carbidopa; Cross-Over Studies; Drug Combinations; Exercise Test; Heart Rate; Hot Temperature; Humans; Levodopa; Male; Prolactin; Single-Blind Method; Skin Temperature; Young Adult | 2016 |
Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Netherlands; Parkinson Disease; Quality of Life; Time-to-Treatment | 2015 |
Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Capsules; Carbidopa; Cohort Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Australia; Carbidopa; Dopamine Agents; Duodenum; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prospective Studies; Psychomotor Performance; Quality of Life | 2016 |
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Drug Combinations; Female; GPI-Linked Proteins; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Pilot Projects | 2016 |
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease | 2016 |
Effects of levodopa on stimulus-response learning versus response selection in healthy young adults.
Topics: Association Learning; Carbidopa; Choice Behavior; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Photic Stimulation; Psychomotor Performance; Young Adult | 2017 |
Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Topics: Adult; Antiparkinson Agents; Benserazide; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles | 2017 |
Effect of Levodopa + Carbidopa on the Laryngeal Electromyographic Pattern in Parkinson Disease.
Topics: Aged; Antiparkinson Agents; Brazil; Carbidopa; Drug Administration Schedule; Drug Combinations; Electromyography; Female; Humans; Laryngeal Muscles; Levodopa; Male; Middle Aged; Parkinson Disease; Phonation; Predictive Value of Tests; Prospective Studies; Time Factors; Treatment Outcome; Voice Quality | 2017 |
Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Male; Nitriles; Parkinson Disease; Treatment Outcome | 2017 |
Double-Blind, Placebo-Controlled, Randomized Phase I/IIa Study (Safety and Efficacy) with Buspirone/Levodopa/Carbidopa (SpinalonTM) in Subjects with Complete AIS A or Motor-Complete AIS B Spinal Cord Injury.
Topics: Administration, Oral; Adult; Buspirone; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Spinal Cord Injuries; Young Adult | 2017 |
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Gels; Humans; Levodopa; Parkinson Disease | 2017 |
Effects of monoaminergic drugs on training-induced motor cortex plasticity in older adults.
Topics: Aged; Biogenic Monoamines; Biomechanical Phenomena; Carbidopa; Cross-Over Studies; Dextroamphetamine; Double-Blind Method; Drug Combinations; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Male; Methylphenidate; Middle Aged; Motor Cortex; Motor Skills; Movement; Muscle, Skeletal; Neuronal Plasticity; Transcranial Magnetic Stimulation; Wrist | 2017 |
Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mucuna; Outcome Assessment, Health Care; Parkinson Disease; Phytotherapy; Pilot Projects; Plant Preparations; Seeds | 2018 |
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Double-Blind Method; Drug Combinations; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Polyneuropathies; Weight Loss | 2018 |
The effect of dopamine on conditioned placebo analgesia in healthy individuals: a double-blind randomized trial.
Topics: Adult; Analgesia; Carbidopa; Conditioning, Psychological; Dopamine; Double-Blind Method; Drug Combinations; Female; Humans; Learning; Levodopa; Male; Pain; Pain Measurement; Placebo Effect; Reward | 2018 |
Intrinsically regulated learning is modulated by synaptic dopamine signaling.
Topics: Adult; Carbidopa; Dopamine; Dopamine Agents; Dopamine Antagonists; Double-Blind Method; Female; Humans; Learning; Levodopa; Male; Memory, Long-Term; Reward; Risperidone; Signal Transduction; Synaptic Transmission; Young Adult | 2018 |
A Transitional Probability Model for Parkinson's Disease Motor States With Applications to Missing Data.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Double-Blind Method; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Models, Statistical; Movement; Parkinson Disease | 2019 |
Sensitive LC-MS/MS method for quantitation of levodopa and carbidopa in plasma: application to a pharmacokinetic study.
Topics: Adolescent; Adult; Analytic Sample Preparation Methods; Blood Chemical Analysis; Carbidopa; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Limit of Detection; Male; Middle Aged; Reproducibility of Results; Tandem Mass Spectrometry; Young Adult | 2018 |
Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug Combinations; Drug Substitution; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole | 2019 |
Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation.
Topics: Administration, Oral; Adult; Animals; Antiparkinson Agents; Carbidopa; Computer Simulation; Drug Combinations; Drug Interactions; Drug Stability; Female; Healthy Volunteers; Humans; Injections, Intravenous; Levodopa; Magnesium Oxide; Male; Models, Biological; Rats, Wistar; Young Adult | 2019 |
Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time-to-Treatment | 2019 |
Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation.
Topics: Adult; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Drug Combinations; Drug Liberation; Female; Gels; Humans; Levodopa; Male; Middle Aged; Therapeutic Equivalency | 2019 |
Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.
Topics: Administration, Inhalation; Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2019 |
Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Carbidopa; Dopamine Agents; Double-Blind Method; Drug Combinations; Female; Humans; Intracranial Hemorrhages; Levodopa; Male; Middle Aged; Mobility Limitation; Occupational Therapy; Physical Therapy Modalities; Prospective Studies; Stroke; Stroke Rehabilitation; Treatment Outcome | 2019 |
Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
Topics: Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Cross-Over Studies; Drug Combinations; Drug Compounding; Drug Delivery Systems; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Proof of Concept Study; Treatment Outcome | 2019 |
Effects of L-DOPA Monotherapy on Psychomotor Speed and [
Topics: Aged; Aged, 80 and over; Carbidopa; Corpus Striatum; Depressive Disorder, Major; Dopamine; Dopamine Antagonists; Drug Combinations; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; New York; Positron-Emission Tomography; Raclopride; Receptors, Dopamine D2; Walking Speed | 2019 |
The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Female; Gels; Homes for the Aged; Humans; Levodopa; Male; Medicare; Monte Carlo Method; Nursing Homes; Parkinson Disease; Physical Functional Performance; Severity of Illness Index; United States | 2020 |
Novel Detection and Restorative Levodopa Treatment for Preclinical Diabetic Retinopathy.
Topics: Adult; Aged; Carbidopa; Diabetic Retinopathy; Drug Combinations; Electroretinography; Female; Humans; Levodopa; Male; Middle Aged | 2020 |
Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa.
Topics: Antiparkinson Agents; Carbidopa; Cognition; Cross-Over Studies; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
Topics: Aged; Carbidopa; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Combinations; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D5; Severity of Illness Index | 2020 |
Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Topics: Carbidopa; Catechol O-Methyltransferase; Catechols; Cross-Over Studies; Dopa Decarboxylase; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Female; Gels; Genotype; Humans; Levodopa; Male; Models, Biological; Nitriles; Parkinson Disease; Polymorphism, Genetic | 2020 |
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease.
Topics: Administration, Inhalation; Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Powders; Single-Blind Method; Spirometry | 2020 |
Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Feasibility Studies; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Single-Blind Method | 2021 |
Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®).
Topics: Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Time Factors | 2021 |
ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial.
Topics: Acute Coronary Syndrome; Analgesics; Carbidopa; Drug Combinations; Humans; Levodopa; Methoxyflurane; Morphine; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome | 2021 |
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion.
Topics: Adult; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Parkinson Disease; Single-Blind Method | 2021 |
Fasting state is one of the factors associated with plasma levodopa fluctuations during levodopa‒carbidopa intestinal gel treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Eating; Fasting; Female; Gels; Humans; Intestines; Levodopa; Lunch; Male; Motor Activity; Parkinson Disease | 2021 |
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Proof of Concept Study; Treatment Outcome | 2021 |
Influence of METHoxyflurane on ANtiplatelet Effect of ticagrelor in patients with unstable angina pectoris: Rationale and a protocol of a randomized clinical METHANE-SIRIO 4 study.
Topics: Angina, Unstable; Carbidopa; Drug Combinations; Humans; Levodopa; Methane; Methoxyflurane; Randomized Controlled Trials as Topic; Ticagrelor | 2022 |
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusions, Subcutaneous; Jejunum; Levodopa; Male; Parkinson Disease | 2022 |
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial.
Topics: Amiodarone; C-Reactive Protein; Carbidopa; COVID-19; Drug Combinations; Humans; Ion Channels; Levodopa; SARS-CoV-2; Verapamil | 2022 |
Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Humans; Levodopa; Parkinson Disease | 2022 |
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Humans; Levodopa; Parkinson Disease | 2022 |
Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Gels; Germany; Humans; Levodopa; Parkinson Disease; Quality of Life; Switzerland | 2022 |
The safety and tolerability of levodopa eye drops for the treatment of ocular disorders: A randomized first-in-human study.
Topics: Adult; Carbidopa; Double-Blind Method; Humans; Levodopa; Male; Myopia; Ophthalmic Solutions; Visual Acuity; Young Adult | 2022 |
Levodopa Response in Patients With Early Parkinson Disease: Further Observations of the LEAP Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor | 2023 |
Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Healthy Volunteers; Humans; Levodopa; Parkinson Disease | 2023 |
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Topics: Antiparkinson Agents; Carbidopa; Cellulitis; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2022 |
1426 other study(ies) available for levodopa and carbidopa
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Drug therapy for Parkinsonism.
Topics: Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1976 |
How to achieve maximum benefit for the patient with Parkinson's disease.
Topics: Aged; Amantadine; Carbidopa; Diagnosis, Differential; Histamine H1 Antagonists; Humans; Levodopa; Nervous System Diseases; Occupational Therapy; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Psychotherapy; Trihexyphenidyl | 1976 |
Central dopaminergic and serotoninergic systems in the regulation of adrenal tyrosine hydroxylase.
Topics: 5-Hydroxytryptophan; 5,6-Dihydroxytryptamine; Adrenal Glands; Animals; Apomorphine; Bromocriptine; Carbidopa; Clonidine; Dopamine; Drug Interactions; Haloperidol; Hydroxydopamines; Injections, Intraventricular; Kinetics; Levodopa; Male; Piribedil; Pituitary Gland; Rats; Serotonin; Serotonin Antagonists; Splanchnic Nerves; Tyrosine 3-Monooxygenase | 1977 |
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Piribedil; Pizotyline; Propranolol | 1976 |
Parkinson's disease.
Topics: Amantadine; Antidepressive Agents; Carbidopa; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities | 1977 |
Update on drug treatment of Parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Histamine H1 Antagonists; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1977 |
Biogenic amine synthesis defect in dihydropteridine reductase deficiency.
Topics: 5-Hydroxytryptophan; Biogenic Amines; Carbidopa; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Infant; Intellectual Disability; Levodopa; Male; NADH, NADPH Oxidoreductases; Neurotransmitter Agents; Phenylketonurias; Probenecid; Seizures; Serotonin; Tyrosine | 1977 |
Transmitter histochemistry of the rat olfactory bulb. II. Fluorescence histochemical, autoradiographic and electron microscopic localization of monoamines.
Topics: Animals; Autoradiography; Brain Mapping; Carbidopa; Denervation; Hydroxydopamines; Levodopa; Male; Nerve Fibers; Neurotransmitter Agents; Norepinephrine; Olfactory Bulb; Rats; Reserpine; Serotonin | 1978 |
Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Circadian Rhythm; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Sleep | 1978 |
Letter: L-dopa and 5-hydroxytryptophan therapy in phenylketonuria with normal phenylalanine-hydroxylase activity.
Topics: 5-Hydroxytryptophan; Carbidopa; Drug Therapy, Combination; Humans; Infant; Levodopa; Phenylalanine Hydroxylase; Phenylketonurias | 1975 |
Letter: Psychosis in patient on bromocriptine and levodopa with carbidopa.
Topics: Bromocriptine; Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Schizophrenia, Paranoid | 1976 |
Levodopa in subacute sclerosing panencephalitis.
Topics: Carbidopa; Child; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Subacute Sclerosing Panencephalitis | 1977 |
The effect of biogenic monomines on rapid axonal transport in the rabbit optic nerve.
Topics: 5-Hydroxytryptophan; Animals; Axonal Transport; Biogenic Amines; Carbidopa; Female; Levodopa; Male; Optic Nerve; Pargyline; Rabbits; Time Factors | 1978 |
Dream phenomena induced by chronic levodopa therapy.
Topics: Adult; Aged; Carbidopa; Delusions; Dreams; Female; Hallucinations; Humans; Illusions; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1978 |
Effects of levodopa and dopamine of plasma glucose concentration in mice.
Topics: Animals; Apomorphine; Benserazide; Blood Glucose; Carbidopa; Cyproheptadine; Dopamine; Fatty Acids, Nonesterified; Fenclonine; Haloperidol; Insulin; Levodopa; Liver Glycogen; Male; Methysergide; Mice; Nialamide; Pargyline; Pimozide; Time Factors | 1977 |
Therapeutics of disordered movement.
Topics: Carbidopa; Chorea; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Movement Disorders; Parasympatholytics; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Tremor | 1977 |
The effects of L-dopa on in vitro and in vivo calcitonin release from medullary thyroid carcinoma.
Topics: Calcitonin; Calcium; Carbidopa; Cyclic AMP; Humans; Levodopa; Pentagastrin; Thyroid Neoplasms | 1979 |
Cerebrospinal fluid cyclic AMP in parkinsonism [proceedings].
Topics: Adult; Carbidopa; Cyclic AMP; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1979 |
Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats.
Topics: Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Hydroxydopamines; Levodopa; Male; Movement; Nerve Degeneration; Neurons; Neurotransmitter Agents; Oxotremorine; Parkinson Disease, Secondary; Rats; Rotation; Stereotaxic Techniques; Substantia Nigra; Synaptic Transmission; Time Factors | 1975 |
Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients.
Topics: Acromegaly; Adult; Carbidopa; Dopamine; Female; Growth Hormone; Humans; Kinetics; Levodopa; Male; Middle Aged; Prolactin; Thyrotropin | 1978 |
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.
Topics: Adult; Bromocriptine; Carbidopa; Chronic Disease; Humans; Levodopa; Locus Coeruleus; Male; Meperidine; Opioid-Related Disorders; Parkinson Disease, Secondary; Substantia Nigra | 1979 |
Aminergic and thermoregulatory mechanims in hypothalamic regulation of growth hormone in cats.
Topics: 18-Hydroxycorticosterone; 5-Hydroxytryptophan; Animals; Apomorphine; Biogenic Amines; Blood Glucose; Body Temperature Regulation; Carbidopa; Cats; Growth Hormone; Hypothalamus; Levodopa; Male; Mesencephalon; Norepinephrine; Phenoxybenzamine; Pimozide; Serotonin; Temperature | 1977 |
Evidence for a central monoaminergic influence on urinary bladder control mechanism.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Brain; Carbidopa; Catecholamines; Dopamine; Levodopa; Male; Norepinephrine; Parasympathetic Nervous System; Pressure; Rats; Spiperone; Urinary Bladder; Urodynamics | 1979 |
Effects of CNS dopamine augmentation on stimulated prolactin secretion.
Topics: Adult; Carbidopa; Humans; Hydrazines; Insulin; Levodopa; Male; Prolactin; Thyrotropin-Releasing Hormone | 1977 |
Effect of metoclopramide, a dopaminergic inhibitor, on renin and aldosterone in idiopathic edema: possible therapeutic approach with levodopa and carbidopa.
Topics: Adult; Aldosterone; Body Weight; Carbidopa; Edema; Female; Humans; Hydrazines; Levodopa; Metoclopramide; Renin; Sodium | 1979 |
Inhibition of human and rat hepatic aminotransferase activity with L-3,4-dihydroxyphenylalanine by inhibitors of peripheral aromatic amino acid decarboxylase.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Female; In Vitro Techniques; Kinetics; Levodopa; Liver; Male; Rats; Transaminases | 1979 |
Hemiparkinsonism. A human model for studying dopaminergic supersensitivity.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Dextroamphetamine; Disease Models, Animal; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease, Secondary; Receptors, Dopamine | 1979 |
Electroencephalographic change in Parkinsonian patients treated with levodopa-carbidopa.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Electroencephalography; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1979 |
Studies on the enzymatic blood-brain barrier: quantitative measurements of DOPA decarboxylase in the wall of microvessels as related to the parenchyma in various CNS regions.
Topics: Animals; Blood-Brain Barrier; Brain; Capillaries; Carbidopa; Caudate Nucleus; Cerebellum; Dopa Decarboxylase; Dopamine; Female; Levodopa; Microcirculation; Microscopy, Fluorescence; Norepinephrine; Rats; Spinal Cord; Venules | 1979 |
Causes of pseudotumor cerebri and papilledema.
Topics: Aged; Carbidopa; Dose-Response Relationship, Drug; Female; Humans; Hydrazines; Levodopa; Papilledema; Parkinson Disease; Pseudotumor Cerebri | 1979 |
[Therapy of rigidity and hypokinesis in old age using Sinemet].
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Movement Disorders; Muscle Rigidity; Parkinson Disease, Postencephalitic; Trihexyphenidyl | 1979 |
Reversible haemolytic anaemia after levodopa-carbidopa.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1979 |
Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.
Topics: Animals; Apomorphine; Bromocriptine; Carbidopa; Corpus Striatum; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Radioligand Assay; Rats; Receptors, Dopamine; Receptors, Drug; Spiperone | 1979 |
Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
Topics: Adolescent; Adult; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Hydrazines; Levodopa; Male; Micrococcus; Middle Aged; Nicotinamidase; Nicotinic Acids; Parkinson Disease; Tryptophan | 1979 |
Role of peripheral adrenoreceptors and vasopressin in the suppression of plasma renin activity by L-dopa in carbidopa-treated dogs.
Topics: Animals; Carbidopa; Dogs; Drug Interactions; Female; Levodopa; Male; Phenoxybenzamine; Propranolol; Receptors, Adrenergic; Renin; Vasopressins | 1979 |
[Stimulation of growth hormone (STH) in the outpatient clinic using L-Dopa plus carbidopa and physical loading].
Topics: Adolescent; Carbidopa; Child; Child, Preschool; Dwarfism; Dwarfism, Pituitary; Growth Hormone; Humans; Levodopa; Physical Exertion | 1979 |
Depletion of 5-HT by L-DOPA in spinal cord and brainstem of rat.
Topics: Animals; Brain Stem; Carbidopa; Carboxy-Lyases; Levodopa; Male; Rats; Serotonin; Spinal Cord | 1979 |
Conditioning of the H reflex by stimulation of the posterior tibial nerve in Parkinson's disease.
Topics: Aged; Carbidopa; Conditioning, Psychological; Drug Therapy, Combination; Electric Stimulation; Evoked Potentials; Female; H-Reflex; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease; Reflex, Monosynaptic; Tibial Nerve | 1979 |
[Sleep: biochemical correlations and pharmacological considerations].
Topics: Acetylcholine; Animals; Apomorphine; Brain Chemistry; Carbidopa; Catecholamines; gamma-Aminobutyric Acid; Humans; Levodopa; Peptides; Serotonin; Serotonin Antagonists; Sleep; Vasopressins | 1979 |
L-Dopa inhibits prolactin secretion in proestrous rats.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Female; Levodopa; Pregnancy; Proestrus; Prolactin; Rats; Time Factors | 1977 |
Western equine encephalitis with rapid onset of parkinsonism.
Topics: Adult; Carbidopa; Encephalitis Virus, Western Equine; Encephalomyelitis, Equine; Female; Humans; Levodopa; Parkinson Disease; Trihexyphenidyl | 1977 |
L-DOPA reversal of hyperdopaminergic behaviour.
Topics: Animals; Apomorphine; Behavior; Carbidopa; Dopamine; Humans; Levodopa; Male; Rats; Reserpine; Stereotyped Behavior | 1978 |
Influence of dopaminergic agonists upon body temperature and behavior of spontaneously hypertensive and normotensive rats.
Topics: Animals; Apomorphine; Behavior, Animal; Body Temperature; Carbidopa; Dopamine; Haloperidol; Humans; Hypertension; Levodopa; Male; Motor Activity; Rats; Stereotyped Behavior | 1978 |
Normal pressure hydrocephalus, parkinsonism, and primary empty sella--coincidence or cause-effect?
Topics: Aged; Carbidopa; Cerebrospinal Fluid Shunts; Drug Therapy, Combination; Empty Sella Syndrome; Female; Humans; Hydrocephalus; Hydrocephalus, Normal Pressure; Jugular Veins; Levodopa; Parkinson Disease | 1978 |
Need for uncombined carbidopa to treat parkinsonism.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease | 1978 |
Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.
Topics: Aged; Carbidopa; Dihydroxyphenylalanine; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Bromocriptine in Parkinson disease: further studies.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1979 |
Sinemet and thyroid function in Parkinson disease.
Topics: Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Thyroid Function Tests; Thyroid Gland; Thyrotropin | 1979 |
Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
Topics: Animals; Brain; Bromocriptine; Carbidopa; Dopamine; Drug Interactions; Ergolines; gamma-Aminobutyric Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Parkinson Disease; Rats; Serotonin | 1977 |
CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
Topics: Aged; Athetosis; Carbidopa; Chorea; Dihydroxyphenylalanine; Dopamine; Dystonia Musculorum Deformans; Hepatolenticular Degeneration; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Middle Aged; Movement Disorders; Parkinson Disease; Parkinson Disease, Postencephalitic; Serotonin; Tetrabenazine; Torticollis | 1977 |
Effect of the dopa decarboxylase inhibitor MK-486 on L-dopa-induced inhibition of prolactin secretion: evidence for CNS participation in the L-dopa effects.
Topics: Adrenal Medulla; Animals; Brain; Carbidopa; Cerebral Cortex; Depression, Chemical; Hydrazines; Hypothalamus; Levodopa; Male; Pituitary Gland, Anterior; Prolactin; Rats | 1977 |
Action of phenytoin, ethosuximide and of the carbidopa-L-dopa association in semi-chronic cobalt-induced epilepsy in the rat.
Topics: Animals; Carbidopa; Cobalt; Dose-Response Relationship, Drug; Drug Interactions; Electroencephalography; Ethosuximide; Hydrazines; Levodopa; Male; Phenytoin; Rats; Seizures | 1977 |
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
Topics: Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
A method for mechanographical recording of muscle tone in the rat: the effect of some antiparkinsonian drugs on rigidity induced by reserpine.
Topics: Animals; Antiparkinson Agents; Apomorphine; Bromocriptine; Carbidopa; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Male; Muscle Rigidity; Muscle Tonus; Myography; Rats; Reserpine | 1978 |
Application of paired-ion high-pressure liquid column chromatography to the analysis of L-3,4-dihydroxyphenylalanine metabolites.
Topics: Carbidopa; Chromatography, High Pressure Liquid; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1978 |
The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours.
Topics: Adult; Aged; Breast Neoplasms; Carbidopa; Dihydroxyphenylalanine; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Middle Aged; Prolactin; Thyroxine; Time Factors | 1978 |
Effect of l-dopa on sympathetic nerve activity and blood pressure in the spontaneously hypertensive rat.
Topics: Animals; Blood Pressure; Carbidopa; Heart Rate; Hypertension; Levodopa; Male; Rats; Sympathetic Nervous System | 1978 |
Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
Topics: Adult; Carbidopa; Dopamine; Female; Homovanillic Acid; Humans; Hypothalamo-Hypophyseal System; Levodopa; Male; Middle Aged; Pituitary Neoplasms; Prolactin | 1978 |
Effect of pyridoxine on the depletion of tissue pyridoxal phosphate by carbidopa.
Topics: Animals; Brain; Carbidopa; Dopa Decarboxylase; Dopamine; Hydrazines; Hypothalamus; Levodopa; Liver; Male; Muscles; Pyridoxal Phosphate; Pyridoxine; Rats | 1978 |
Comparison between lergotrile and bromocriptine in parkinsonism.
Topics: Acetonitriles; Adult; Aged; Bromocriptine; Carbidopa; Chemical Phenomena; Chemistry; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1978 |
Paradoxial response to dopaminergic agents in parkinsonism.
Topics: Acetonitriles; Aged; Carbidopa; Ergolines; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Receptors, Dopamine | 1978 |
Bromocriptine in parkinsonism. A long-term study.
Topics: Anorexia; Bromocriptine; Carbidopa; Hallucinations; Humans; Levodopa; Middle Aged; Nausea; Parkinson Disease; Time Factors; Urinary Incontinence; Vasomotor System | 1978 |
Simultaneous determination by GC-MS-SIM of o-, m-, p-hydroxyphenylacetic acid, 3:4-dihydroxyphenylacetic acid and homovanillic acid in biological samples using a common selected ion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Carbidopa; Chromatography, Gas; Homovanillic Acid; Humans; Levodopa; Mass Spectrometry; Methods; Phenylacetates | 1978 |
Photic EEG-driving responses in thalamotomized and medicated cases of Parkinson's disease.
Topics: Adult; Aged; Alpha Rhythm; Beta Rhythm; Carbidopa; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Spectrum Analysis; Thalamus; Theta Rhythm | 1978 |
[Pathogenesis and treatment of torsion dystonia].
Topics: Carbidopa; Dihydroxyphenylalanine; Dopamine; Dystonia Musculorum Deformans; Epinephrine; Homovanillic Acid; Humans; Hydrazines; Jews; Levodopa; Norepinephrine; Vanilmandelic Acid | 1978 |
On the mechanism of hyperglycemia and stimulation of growth hormone secretion by L-dopa.
Topics: Animals; Blood Glucose; Carbidopa; Dogs; Glucose; Growth Hormone; Hydrocortisone; Levodopa; Liver; Phentolamine; Pimozide; Propranolol; Stress, Physiological; Time Factors | 1978 |
Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
Topics: Animals; Carbidopa; Disease Models, Animal; Drug Combinations; Dyskinesia, Drug-Induced; Hydrazines; Levodopa; Rats; Receptors, Dopamine | 1978 |
Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Therapy, Combination; Furosemide; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Parkinson Disease; Posture; Renin | 1978 |
Regional cerebral blood flow in parkinsonism. Measurement before and after levodopa.
Topics: Adult; Aged; Carbidopa; Cerebrovascular Circulation; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Regional Blood Flow; Xenon Radioisotopes | 1978 |
[Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dopa Decarboxylase; Hydrazines; Levodopa; Male; Pyridoxine; Rats | 1978 |
Measurements of visual evoked potentials in Parkinson's disease.
Topics: Age Factors; Aged; Carbidopa; Dominance, Cerebral; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Photic Stimulation; Reaction Time; Visual Cortex; Visual Pathways; Visual Perception | 1978 |
L-3,4-dihydroxyphenylalanine (L-dopa) as an inhibitor of prolactin release.
Topics: Animals; Carbidopa; Castration; Dopamine; Dose-Response Relationship, Drug; Female; Hypothalamo-Hypophyseal System; Levodopa; Luteinizing Hormone; Norepinephrine; Prolactin; Rats; Submandibular Gland | 1978 |
The role of biogenic amines in the regulation of growth hormone and corticotropin secretion in the trained conscious dog.
Topics: Adrenal Cortex Hormones; Animals; Apomorphine; Biogenic Amines; Blood Glucose; Carbidopa; Clonidine; Dogs; Growth Hormone; Levodopa; Male; Pimozide | 1978 |
Parkinson's disease improvement after the addition of levodopa-carbidopa to anticholinergic treatment. An open controlled study.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease, Secondary; Tremor; Trihexyphenidyl | 1978 |
Electrical properties of motor units in Parkinsonism and a possible relationship with bradykinesia.
Topics: Action Potentials; Adult; Aged; Carbidopa; Electromyography; Forearm; Gait; Hand; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement Disorders; Muscle Contraction; Muscles; Neuromuscular Junction; Parkinson Disease; Recruitment, Neurophysiological | 1979 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Benserazide; Carbidopa; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physical Therapy Modalities; Reserpine; Stereotaxic Techniques | 1976 |
Effect of carbidopa on the metabolism of L-dopa in the pigtail monkey.
Topics: Animals; Carbidopa; Dopa Decarboxylase; Female; Haplorhini; Homovanillic Acid; Hydrazines; Lactates; Levodopa; Time Factors | 1976 |
Alteration of basal ganglia evoked responses by reserpine and L-dopa.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia; Carbidopa; Cats; Caudate Nucleus; Evoked Potentials; Globus Pallidus; Levodopa; Reserpine; Substantia Nigra | 1976 |
[Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
Topics: Animals; Carbidopa; Carboxy-Lyases; Dogs; Drug Therapy, Combination; Female; Haplorhini; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pyridoxine; Rats; Tremor | 1976 |
The long-term effects of combining carbidopa with levodopa for Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Parkinson Disease | 1976 |
The effect of L-dopa with and without decarboxylase inhibitor on growth hormone secretion in children with short stature.
Topics: Administration, Oral; Adolescent; Body Height; Carbidopa; Child; Child, Preschool; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Pituitary Gland; Pituitary Gland, Anterior; Secretory Rate | 1977 |
Drug therapy of Parkinsonism dopaminergic drugs.
Topics: Carbidopa; Humans; Hydrazines; Levodopa; Parkinson Disease | 1977 |
The shaking patient. Diagnosis and management of tremor.
Topics: Amantadine; Carbidopa; Cerebellar Diseases; Humans; Levodopa; Parkinson Disease; Propranolol; Tremor | 1977 |
The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor.
Topics: Adult; Carbidopa; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
[Variations of the therapeutic action (on-off phenomenon) in patients with Parkin].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Humans; Levodopa; Parkinson Disease, Secondary | 1977 |
[Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].
Topics: Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Movement Disorders; Parkinson Disease; Psychoses, Substance-Induced | 1977 |
Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients.
Topics: Aged; Aphasia; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Speech; Thalamus; Vital Capacity | 1977 |
Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Pressure; Carbidopa; Denervation; Dogs; Drug Interactions; Female; Kidney; Levodopa; Male; Renin; Time Factors | 1977 |
[Stimulation of the secretion of somatotropin by administration of Nacom (L-dopa and L-carbidopa) in ambulatory patients with retarded growth].
Topics: Adolescent; Ambulatory Care; Carbidopa; Child; Drug Combinations; Growth Disorders; Growth Hormone; Humans; Hydrazines; Levodopa | 1977 |
Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
Topics: Adult; Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1977 |
Dopaminergic drugs and ovulation: studies on PMS-induced ovulation and changes in median eminence DA and NE turnover in immature female rats.
Topics: Animals; Apomorphine; Carbidopa; Dopamine; Ergot Alkaloids; Female; Gonadotropins, Equine; Hypothalamo-Hypophyseal System; Levodopa; Lysergic Acid Diethylamide; Median Eminence; Norepinephrine; Ovulation; Piribedil; Pregnancy; Rats; Receptors, Adrenergic; Receptors, Dopamine | 1977 |
Analgesic effects of 3-carboxysalsolinol alone and in combination with morphine.
Topics: Analgesia; Animals; Carbidopa; Dose-Response Relationship, Drug; Drug Synergism; Isoquinolines; Levodopa; Mice; Morphine; Naloxone; Salsoline Alkaloids | 1977 |
Ethanol, levodopa and inhibitors of extracerebral aromatic L-amino acid decarboxylase: a drug-drug interaction study.
Topics: Alcohol Drinking; Amino Acids; Animals; Benserazide; Carbidopa; Carboxy-Lyases; Choice Behavior; Drug Interactions; Levodopa; Male; Rats; Time Factors | 1977 |
Hypertensive crisis in a patient given sinemet, metoclopramide, and amitriptyline.
Topics: Acute Disease; Amitriptyline; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Hypertension; Levodopa; Metoclopramide; Middle Aged; Parkinson Disease | 1977 |
[Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Occurrence of a new class of tetrahydroisoquinoline alkaloids in L-dopa-treated parkinsonian patients.
Topics: Animals; Biotransformation; Brain; Carbidopa; Catechols; Humans; Levodopa; Mice; Papaverine; Parkinson Disease; Rats; Tetrahydropapaveroline | 1977 |
Problems in the treatment of Parkinsonism.
Topics: Antiparkinson Agents; Arteriosclerosis; Carbidopa; Diagnosis, Differential; Drug Combinations; Eye Manifestations; Humans; Levodopa; Mental Disorders; Movement Disorders; Parasympatholytics; Paresthesia; Parkinson Disease; Vision Disorders | 1977 |
Treatment of parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Carbidopa; Dopamine; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1977 |
Psychiatric symptoms with initiation of carbidopa-levodopa treatment.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1976 |
In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dopamine; Drug Interactions; Humans; Hydrazines; Levodopa; Parkinson Disease; Pyridoxine; Rats | 1976 |
A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Benserazide; Brain; Brocresine; Carbidopa; Dopamine; Hydrazines; Levodopa; Male; Methyldopa; Rats; Time Factors | 1976 |
[Carbidopa-levodopa, growth hormone and parkinsonism].
Topics: Aged; Carbidopa; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary Gland; Stimulation, Chemical | 1976 |
14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
Topics: Aged; Brain; Carbidopa; Carboxy-Lyases; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Probenecid; Sensory Receptor Cells | 1976 |
[Hormonal effects of carbidopa-levodopa in normal patients].
Topics: Adult; Blood Glucose; Carbidopa; Evaluation Studies as Topic; Female; Growth Hormone; Humans; Hydrazines; Hydrocortisone; Hypothalamus; Insulin; Levodopa; Male; Stimulation, Chemical | 1976 |
[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Topics: Adult; Aged; Benserazide; Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Reinstatement of vaginal cycles in aged female rats.
Topics: Aging; Animals; Benserazide; Carbidopa; Dose-Response Relationship, Drug; Drug Interactions; Estrus; Female; Fusaric Acid; Hypophysectomy; Levodopa; Phenoxybenzamine; Pimozide; Pregnancy; Propranolol; Rats; Tyrosine; Vagina | 1976 |
New drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Interactions; Drug Therapy, Combination; Food; Humans; Levodopa; Parkinson Disease | 1976 |
[Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
Topics: Adult; Aged; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets | 1976 |
[Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease | 1976 |
Beneficial effects of serotonin precursors in postanoxic action myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Carbidopa; Female; Humans; Hydroxyindoleacetic Acid; Hypoxia; Levodopa; Male; Methysergide; Middle Aged; Myoclonus; Serotonin; Syndrome; Tryptophan | 1976 |
Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Evaluation; Humans; Levodopa; Parkinson Disease; Parkinson Disease, Postencephalitic | 1975 |
Rotatory behavior induced in nigra-lesioned rats by N-propylnoraporphine, apomorphine, and levodopa.
Topics: Animals; Apomorphine; Aporphines; Atropine; Behavior, Animal; Brain Injuries; Carbidopa; Dose-Response Relationship, Drug; Drug Synergism; Hydroxydopamines; Levodopa; Male; Rats; Rotation; Substantia Nigra; Time Factors | 1975 |
Differences between (+)- and (-)-amphetamine in effects on locomotor activity and L-dopa potentiating action in mice.
Topics: Amphetamine; Animals; Carbidopa; Carboxy-Lyases; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Synergism; Female; Levodopa; Motor Activity; Stereoisomerism; Time Factors | 1975 |
Experimental studies on the pathogenesis and prophylaxis of stroke in stroke-prone spontaneously hypertensive rats (SHR). (2) Prophylactic effect of moderate control of blood pressure on stroke.
Topics: Animals; Carbidopa; Carboxy-Lyases; Cerebrovascular Disorders; Heart Rate; Hydralazine; Hypertension; Levodopa; Male; Methyldopa; Rats | 1975 |
Effect of L-DOPA on endogenous histamine metabolism.
Topics: Acetates; Adult; Aged; Animals; Carbidopa; Depression, Chemical; Female; Guinea Pigs; Histamine; Humans; Imidazoles; Levodopa; Male; Methylation; Middle Aged; Parkinson Disease; Rats; Species Specificity | 1975 |
L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
Topics: Adult; Aged; Animals; Carbidopa; Carboxy-Lyases; Cats; Dopamine; Drug Therapy, Combination; Female; Humans; Hydrazines; Injections, Intraperitoneal; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1975 |
Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase.
Topics: Adult; Amino Acids; Blood Pressure; Carbidopa; Carboxy-Lyases; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Stimulation, Chemical; Time Factors; Tranylcypromine | 1975 |
Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.
Topics: Adult; Aged; Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1975 |
Patterns of clinical response and plasma dopa levels in Parkinson's disease.
Topics: Adult; Aged; Brain; Carbidopa; Dihydroxyphenylalanine; Disability Evaluation; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1975 |
Supersensitivity to dopamine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice.
Topics: Animals; Apomorphine; Brain Chemistry; Carbidopa; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hydroxydopamines; Levodopa; Male; Mice; Motor Activity; Nerve Endings; Stereotyped Behavior; Time Factors | 1975 |
Drug therapy for Parkinson's disease.
Topics: Carbidopa; Circadian Rhythm; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1975 |
The evaluation of anti-parkinson drugs on reserpine-induced rigidity in rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Apomorphine; Benztropine; Carbidopa; Hindlimb; Levodopa; Male; Methamphetamine; Muscle Rigidity; Rats; Reserpine; Scopolamine; Time Factors; Trihexyphenidyl | 1975 |
[Treatment of Parkinson's syndromes by a combination of levodopa with decarboxylase inhibitors].
Topics: Adult; Aged; Carbidopa; Carboxy-Lyases; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1975 |
Proceedings: The importance of intracerebral decarboxylation of L-DOPA in the suppression of prolactin secretion.
Topics: Brain; Carbidopa; Humans; Levodopa; Prolactin | 1975 |
The action of L-dopa in rats with the raphe nuclei lesions.
Topics: Animals; Benserazide; Body Temperature; Brain; Carbidopa; Electric Stimulation; Hydroxyindoleacetic Acid; Levodopa; Rats; Serotonin; Thalamic Nuclei; Time Factors | 1975 |
Treatment of Sydenham's chorea with a combination of L-dopa and a peripheral dopa decarboxylase inhibitor.
Topics: Acute Disease; Adolescent; Carbidopa; Chorea; Drug Therapy, Combination; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Recurrence | 1975 |
[Effect of carbidopa and L-dopa combination on the secretion of growth hormone in normal subjects and in patients with Parkinsonism].
Topics: Carbidopa; Growth Hormone; Humans; Hydrazines; Levodopa; Parkinson Disease; Pituitary Gland; Stimulation, Chemical | 1975 |
L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Centrally mediated increased reflex vagal bradycardia after L-dopa in monoamine oxidase-inhibited anesthetized dogs.
Topics: Animals; Atropine; Benserazide; Blood Pressure; Carbidopa; Dogs; Dopamine; Drug Interactions; Female; Levodopa; Male; Monoamine Oxidase Inhibitors; Norepinephrine; Phentolamine; Pressoreceptors; Propranolol; Vagus Nerve | 1976 |
Potentiation of ethanol narcosis by dopamine- and l-DOPA-based isoquinolines.
Topics: Alkaloids; Animals; Carbidopa; Dopamine; Drug Synergism; Ethanol; Isoquinolines; Levodopa; Male; Mice; Salsoline Alkaloids; Sleep | 1976 |
Gout induced by L-dopa and decarboxylase inhibitors.
Topics: Aged; Carbidopa; Carboxy-Lyases; Gout; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1976 |
Letter: Alternatives to levodopa.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease | 1976 |
[HGH secretion after oral application of L-dopa and L-carbidopa (author's transl)].
Topics: Administration, Oral; Adolescent; Carbidopa; Child; Growth Hormone; Humans; Hydrazines; Levodopa; Time Factors | 1976 |
Effects of pharmacological manipulation of dopaminergic and cholinergic neurotransmission in genetically dystonic hamsters.
Topics: Acetylcholine; Animals; Apomorphine; Behavior, Animal; Carbidopa; Cricetinae; Dopamine; Drug Interactions; Dystonia; Haloperidol; Levodopa; Mesocricetus; Motor Activity; Mutation; Pilocarpine; Synaptic Transmission; Trihexyphenidyl | 1992 |
[Modulation of the immune response of HSIAH strain rats with the preparations Nakom and L-dopa. Hereditary stress-induced arterial hypertension].
Topics: Adjuvants, Immunologic; Animals; Carbidopa; Drug Combinations; Female; Hypertension; Iliac Artery; Levodopa; Lymph Nodes; Male; Rats; Rats, Inbred Strains; Stress, Physiological | 1992 |
Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced hemiparkinsonism on the kinematics of a two-dimensional,multijoint arm movement in the rhesus monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arm; Behavior, Animal; Carbidopa; Female; Levodopa; Macaca mulatta; Male; Movement; Parkinson Disease, Secondary; Reaction Time; Substantia Nigra; Tyrosine 3-Monooxygenase | 1992 |
Dopaminergic responsivity during cocaine abstinence: a pilot study.
Topics: Adult; Carbidopa; Cocaine; Dopamine Agents; Drug Combinations; Growth Hormone; Homovanillic Acid; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Prolactin; Receptors, Dopamine; Substance Withdrawal Syndrome; Substance-Related Disorders | 1992 |
Actions of levodopa on rat substantia nigra zona compacta neurons.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Cocaine; Female; Levodopa; Male; Neurons; Nomifensine; Rats; Rats, Wistar; Substantia Nigra; Sulpiride | 1992 |
Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
Topics: Animals; Carbidopa; Cholecystokinin; Chromatography, High Pressure Liquid; Corpus Striatum; Enkephalin, Leucine; Enkephalin, Methionine; Levodopa; Male; Neuropeptides; Neurotensin; Oxidopamine; Prosencephalon; Rats; Rats, Wistar; Substance P; Substantia Nigra | 1992 |
Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa.
Topics: Animals; Apomorphine; Autoradiography; Brain Tissue Transplantation; Carbidopa; Corpus Striatum; Dextroamphetamine; Female; Fetal Tissue Transplantation; In Vitro Techniques; Levodopa; Mesencephalon; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Time Factors | 1992 |
Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers.
Topics: Adult; Carbidopa; Humans; Levodopa; Male; Spiramycin | 1992 |
Upper airway dysfunction in olivopontocerebellar atrophy.
Topics: Adult; Carbidopa; Drug Combinations; Humans; Laryngeal Diseases; Levodopa; Male; Olivopontocerebellar Atrophies; Respiration Disorders; Respiratory Mechanics; Respiratory Sounds | 1992 |
Effect of nitecapone and clorgyline, given intracerebro-ventricularly on L-dopa metabolism in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Carbidopa; Catechols; Cerebral Ventricles; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; Hypothalamus; Injections, Intraventricular; Levodopa; Male; Pentanones; Prolactin; Rats; Rats, Wistar; Thyrotropin | 1992 |
Phenelzine treatment of depression in Parkinson's disease.
Topics: Aged; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Phenelzine | 1992 |
ECT and delirium in Parkinson's disease.
Topics: Carbidopa; Combined Modality Therapy; Delirium; Depressive Disorder; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parkinson Disease | 1992 |
The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
Topics: Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Paranoid Disorders; Parkinson Disease; Psychoses, Substance-Induced | 1992 |
Juvenile parkinsonism: ventricular CSF biopterin levels and clinical features.
Topics: Adult; Age Factors; Benserazide; Biomarkers; Biopterins; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Parkinson Disease | 1992 |
Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption.
Topics: Aged; Bromocriptine; Carbidopa; Combined Modality Therapy; Fabaceae; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Plants, Medicinal | 1992 |
5-HT2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis.
Topics: Action Potentials; Amphetamines; Animals; Apomorphine; Carbidopa; Dopamine; Dopamine Antagonists; Fenclonine; Levodopa; Male; Neurons; Piperidines; Rats; Rats, Inbred Strains; Ritanserin | 1992 |
Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopa.
Topics: Aged; Carbidopa; Cerebral Ventricles; Drug Combinations; Female; Homovanillic Acid; Humans; Hydrocephalus, Normal Pressure; Levodopa; Male; Middle Aged; Parkinson Disease | 1992 |
Sensorimotor disinhibition in Parkinson's disease: effects of levodopa.
Topics: Carbidopa; Drug Combinations; Hand; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Psychomotor Performance; Reaction Time | 1992 |
Controlled-release carbidopa-levodopa: old drug--new drug. Introduction.
Topics: Carbidopa; Circadian Rhythm; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Evaluation Studies as Topic; Humans; Levodopa; Parkinson Disease | 1992 |
The use of Sinemet CR in the management of mild to moderate Parkinson's disease.
Topics: Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement; Parkinson Disease; Patient Compliance; Patient Education as Topic; Tissue Distribution | 1992 |
Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration.
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Carbidopa; Central Nervous System Diseases; Chorea; Diagnosis, Differential; Drug Combinations; Female; Humans; Levodopa; Movement Disorders; Nerve Degeneration; Parkinson Disease; Spinal Cord | 1992 |
Effects of systemic carbidopa on dopamine synthesis in rat hypothalamus and striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Corpus Striatum; Depression, Chemical; Dialysis; Dopamine; Homovanillic Acid; Hypothalamus; Injections, Intraperitoneal; Levodopa; Male; Perfusion; Rats; Rats, Inbred Strains; Tyrosine | 1992 |
Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Carbidopa; Domperidone; Humans; Levodopa; Middle Aged; Parkinson Disease; Psychomotor Performance | 1992 |
Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Female; Fetal Tissue Transplantation; Gliosis; Graft Survival; Immunohistochemistry; Levodopa; Mesencephalon; Neuroglia; Oxidopamine; Psychomotor Performance; Rats; Rats, Inbred Strains; Stereotaxic Techniques; Stereotyped Behavior; Sympathectomy, Chemical | 1992 |
Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Lactose; Levodopa; Male; Methylcellulose; Middle Aged; Oxazines; Parkinson Disease; Pergolide | 1992 |
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Topics: Age Factors; Blood Glucose; Blood Platelets; Carbidopa; Drug Therapy, Combination; Energy Metabolism; Female; Humans; Lactates; Lactic Acid; Levodopa; Lisuride; Male; Middle Aged; Mitochondria; Oxygen Consumption; Parkinson Disease; Receptors, Dopamine; Selegiline | 1992 |
Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
Topics: Adult; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Reaction Time | 1992 |
Unforeseen beneficial effects of controlled-release levodopa-carbidopa (Sinemet CR)
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Depressive Disorder; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease | 1992 |
Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Topics: Amidines; Animals; Benzophenones; Biogenic Monoamines; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Homovanillic Acid; Hypothalamus; Levodopa; Male; Methyldopa; Nitriles; Nitrophenols; Pyridones; Rats; Rats, Inbred Strains; Tolcapone | 1992 |
L-dopa potentiates the neurotoxicity of some amphetamine analogues.
Topics: Amphetamines; Animals; Brain; Carbidopa; Dopamine; Drug Synergism; Levodopa; Neurotoxins; Organ Specificity; Serotonin | 1992 |
Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Topics: Amphetamine; Animals; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catecholamines; Catechols; Clorgyline; Convulsants; Desipramine; Drug Interactions; Lethal Dose 50; Levodopa; Male; Mice; Motor Activity; Nitriles; Nomifensine; Pentanones; Selegiline; Synaptic Transmission; Yohimbine | 1991 |
Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Aorta, Thoracic; Carbidopa; Chromatography, High Pressure Liquid; Homovanillic Acid; Injections, Intravenous; Levodopa; Male; Rats; Rats, Inbred Strains; Tyrosine | 1991 |
The effect of L-dopa and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography.
Topics: Animals; Autoradiography; Brain Tissue Transplantation; Carbidopa; Dopamine; Female; Fetal Tissue Transplantation; Graft Survival; Immunohistochemistry; Levodopa; Mazindol; Rats; Rats, Inbred Strains; Tyrosine 3-Monooxygenase | 1991 |
Prostaglandin E2 production in rat IMCD cells. II. Possible role for locally formed dopamine.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Cells, Cultured; Dinoprostone; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Hydrazines; Kidney Medulla; Kidney Tubules, Collecting; Levodopa; Rats; Tyrosine 3-Monooxygenase | 1991 |
Effects of dopamine prodrugs and fenoldopam on glomerular hyperfiltration in streptozotocin-induced diabetes in rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Carbidopa; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dopamine Agents; Fenoldopam; Glomerular Filtration Rate; Hemodynamics; Levodopa; Male; Prodrugs; Rats; Rats, Inbred Strains; Streptozocin | 1991 |
Consideration on two cases of dystonia-parkinsonism.
Topics: Carbidopa; Child; Dystonia; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methoxyhydroxyphenylglycol; Parkinson Disease, Secondary | 1991 |
Protein redistribution diet remains effective in patients with fluctuating parkinsonism.
Topics: Adult; Aged; Amino Acids; Antiparkinson Agents; Brain; Carbidopa; Dietary Proteins; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
Levodopa-associated hemifacial dystonia.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dystonia; Facial Muscles; Female; Humans; Levodopa; Parkinson Disease; Putamen | 1991 |
Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.
Topics: Administration, Oral; Aged; Carbidopa; Drug Therapy, Combination; Duodenum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease.
Topics: Age Factors; Aged; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1991 |
Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
Topics: Animals; Behavior, Animal; Brain Chemistry; Carbidopa; Catechol O-Methyltransferase Inhibitors; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Hypothalamus; Levodopa; Male; Monoamine Oxidase Inhibitors; Norepinephrine; Pituitary Hormones, Anterior; Radioimmunoassay; Rats; Rats, Inbred Strains | 1991 |
Association of a thyrotropin-secreting pituitary adenoma and a thyroid follicular carcinoma.
Topics: Adenocarcinoma; Adenoma; Brain; Carbidopa; Drug Therapy, Combination; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hydrocortisone; Insulin; Levodopa; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Radioimmunoassay; Thyroid Neoplasms; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Tomography, X-Ray Computed; Triiodothyronine | 1991 |
The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
Topics: Biogenic Monoamines; Biomarkers; Carbidopa; Humans; Levodopa; Middle Aged; Parkinson Disease; Tyrosine | 1991 |
In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle. A microdialysis study.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Dialysis; Dogs; Injections, Intravenous; Levodopa; Male; Muscles; Tyrosine | 1991 |
Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Carbidopa; Corpus Striatum; Denervation; Drug Tolerance; Functional Laterality; Homovanillic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome | 1991 |
Effect of dopamine, L-dopa, carbidopa and L-dopa/carbidopa on arthus and delayed hypersensitivity skin reactions in the rat.
Topics: Animals; Arthus Reaction; Carbidopa; Dopamine; Hypersensitivity, Delayed; Levodopa; Male; Rats; Rats, Inbred Strains; Skin Tests | 1991 |
Autologous adrenal medullary transplants in advanced Parkinson's disease with particular attention to the selective improvement in symptoms.
Topics: Adrenal Medulla; Adult; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Combined Modality Therapy; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Time Factors; Tomography, X-Ray Computed; Transplantation, Heterotopic | 1991 |
Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1991 |
Sinemet (CR4): an open-label study in moderately severe Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices.
Topics: Animals; Binding, Competitive; Carbidopa; Cocaine; Hydrazines; Hypothalamus; In Vitro Techniques; Levodopa; Norepinephrine; Propranolol; Rats; Structure-Activity Relationship; Sulpiride | 1991 |
Continuous intravenous monitoring of levodopa and 3-O-methyldopa by microdialysis and high-performance liquid chromatography with electrochemical detection.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Dialysis; Dogs; Electrochemistry; Levodopa; Male; Microchemistry; Reference Standards; Regression Analysis; Tyrosine | 1991 |
Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography.
Topics: 3,4-Dihydroxyphenylacetic Acid; Carbidopa; Chromatography, High Pressure Liquid; Chromatography, Liquid; Freeze Drying; Homovanillic Acid; Humans; Hydrogen-Ion Concentration; Levodopa; Solutions; Tyrosine | 1991 |
Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Cerebral Cortex; Cognition Disorders; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 1991 |
Sinemet CR for Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1991 |
Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Male; Mesencephalon; Naloxone; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Time Factors | 1991 |
The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Topics: Animals; Apomorphine; Body Weight; Carbidopa; Corpus Striatum; Drinking; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Nervous System; Oxidopamine; Parkinson Disease; Rats; Rotation; Stereotyped Behavior; Time Factors | 1991 |
Treating the progressive stages of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Electroconvulsive Therapy; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Pergolide; Selegiline | 1991 |
Decrease in blood histamine in drug-treated parkinsonian patients.
Topics: Adult; Aged; Amine Oxidase (Copper-Containing); Antiparkinson Agents; Carbidopa; Female; Histamine; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1991 |
Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures.
Topics: Animals; Axons; Behavior, Animal; Carbidopa; Cell Survival; Cells, Cultured; Corpus Striatum; Growth Substances; Levodopa; Oxidopamine; Regression Analysis; Rotation; Tegmentum Mesencephali; Tissue Extracts | 1991 |
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Topics: Carbidopa; Cerebral Ventricles; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease; Sulfates | 1991 |
Clinical and genetic analysis of progressive dystonia with diurnal variation.
Topics: Adolescent; Adult; Carbidopa; Child; Child, Preschool; Circadian Rhythm; Drug Combinations; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Pedigree | 1991 |
New concepts in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Diet; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Intestinal Absorption; Levodopa; Parkinson Disease; Selegiline | 1990 |
Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Autoradiography; Brain; Bromocriptine; Carbidopa; Catecholamines; Dopamine Agents; Female; Levodopa; Macaca fascicularis; Receptors, Dopamine; Spiperone | 1990 |
Modulatory role for CCK-B antagonists in Parkinson's disease.
Topics: Animals; Benzodiazepinones; Carbidopa; Cholecystokinin; Devazepide; Dopamine Agents; Levodopa; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenylurea Compounds; Receptors, Cholecystokinin; Saimiri | 1990 |
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Topics: Activities of Daily Living; Antiparkinson Agents; Brain; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Oxazines; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2 | 1990 |
Carbidopa-levodopa overdose.
Topics: Acetaminophen; Carbidopa; Carisoprodol; Female; Humans; Hydrocodone; Ibuprofen; Levodopa; Middle Aged; Poisoning | 1991 |
The use of L-dopa and carbidopa in metastatic malignant melanoma.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms | 1991 |
Off-period screaming accompanying motor fluctuations in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Crying; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1991 |
Effects of high salt intake on dopamine production in rat kidney.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Blood Pressure; Body Weight; Carbidopa; Denervation; Dopamine; Inulin; Kidney; Levodopa; Male; Rats; Rats, Inbred Strains; Reference Values; Sodium, Dietary | 1991 |
A 73-year-old woman with confusion, rigidity, and fever.
Topics: Aged; Carbidopa; Confusion; Drug Therapy, Combination; Female; Fever; Humans; Levodopa; Muscle Rigidity; Neuroleptic Malignant Syndrome; Parkinson Disease | 1991 |
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Neurologic Examination; Parkinson Disease, Secondary; Stereotyped Behavior | 1991 |
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates.
Topics: Acetylcarnitine; Animals; Carbidopa; Caudate Nucleus; Electroretinography; Female; Homovanillic Acid; Immunohistochemistry; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary; Substantia Nigra | 1991 |
Simultaneous high-performance liquid chromatographic analysis of carbidopa, levodopa and 3-O-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection.
Topics: Carbidopa; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Humans; Levodopa; Reproducibility of Results; Sensitivity and Specificity; Tyrosine | 1990 |
Short- and long-term effects of L-dopa administration on striatal acetylcholinesterase activity.
Topics: Acetylcholinesterase; Animals; Carbidopa; Corpus Striatum; Levodopa; Male; Rats; Rats, Inbred Strains | 1990 |
Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.
Topics: Animals; Brain; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Fluorine Radioisotopes; Injections, Intravenous; Kinetics; Levodopa; Male; Rats; Rats, Inbred Strains; Tritium | 1990 |
Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.
Topics: Animals; Carbidopa; Catechol O-Methyltransferase; Catecholamines; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Hydroxydopamines; Hypothalamus; Levodopa; Male; Monoamine Oxidase; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains | 1990 |
The in vivo antimelanoma effect of 4-S-cysteaminylphenol and its n-acetyl derivative.
Topics: Animals; Antineoplastic Agents; Carbidopa; Cell Division; Cysteamine; Cysteine; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Kinetics; Levodopa; Melanoma, Experimental; Mice; Mice, Inbred Strains; Monophenol Monooxygenase; Neoplasm Transplantation; Phenols; Substrate Specificity | 1990 |
Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson's disease.
Topics: Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Duodenum; Dystonia; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Long-Term Care; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Carbidopa; Corpus Striatum; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1990 |
L-dopa and streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Benzazepines; Carbidopa; Diabetic Nephropathies; Dopamine Antagonists; Glomerular Filtration Rate; Levodopa; Male; Rats; Rats, Inbred Strains; Streptozocin | 1990 |
New drugs for Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Quality of Life; Selegiline | 1990 |
Levodopa-responsive parkinsonism in a patient with Down's syndrome.
Topics: Activities of Daily Living; Carbidopa; Dose-Response Relationship, Drug; Down Syndrome; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
[Studies on the abnormal response of pituitary somatotropin to dopaminergic drugs in patients with acromegaly].
Topics: Acromegaly; Adenoma; Adult; Carbidopa; Dopamine; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prospective Studies | 1990 |
Responses of rat substantia nigra compacta neurones to L-DOPA.
Topics: Animals; Calcium Channel Blockers; Carbidopa; Cobalt; Dopamine; Female; In Vitro Techniques; Levodopa; Male; Membrane Potentials; Neurons; Rats; Rats, Inbred Strains; Sodium Channels; Substantia Nigra; Sulpiride; Tetrodotoxin | 1990 |
In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Corpus Striatum; Dopamine; Homovanillic Acid; Hydroxydopamines; Levodopa; Male; Neural Pathways; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Substantia Nigra; Synaptic Transmission | 1990 |
Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans: rationale, techniques, and observations.
Topics: Adrenal Medulla; Adult; Aged; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurosurgery; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques; Tomography, X-Ray Computed | 1990 |
A view from inside.
Topics: Accidental Falls; Antiparkinson Agents; Bromocriptine; Carbidopa; Dentists; Drug Combinations; Humans; Levodopa; Male; Northern Ireland; Parkinson Disease | 1990 |
Parkinsonism with neuroacanthocytosis.
Topics: Acanthocytes; Adult; Carbidopa; Erythrocytes; Humans; Levodopa; Lipids; Male; Middle Aged; Parkinson Disease; Tomography, Emission-Computed | 1990 |
Hypotensive effect of long-term levodopa in patients with Parkinson's disease.
Topics: Aged; Biogenic Monoamines; Blood Pressure; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1990 |
[A study on the relationship between natriuresis and renally formed dopamine in the rat].
Topics: Animals; Carbidopa; Cricetinae; Dopamine; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Kidney; Levodopa; Male; Natriuresis; Rats; Rats, Inbred Strains; Renal Circulation | 1990 |
Simultaneous measurement of L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients by improved sample pretreatment and high-performance liquid chromatographic determination.
Topics: Carbidopa; Catecholamines; Catechols; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Hydrogen-Ion Concentration; Indicators and Reagents; Levodopa; Parkinson Disease | 1990 |
Does GABA act through dopaminergic/cholinergic interaction in the regulation of higher environmental temperature-induced change in body temperature?
Topics: Animals; Body Temperature; Carbidopa; Choline; Cold Temperature; Dopamine; Environment; gamma-Aminobutyric Acid; Levodopa; Male; Muscimol; Neurons; Rats; Temperature | 1990 |
Recovery from vegetative state of six months' duration associated with Sinemet (levodopa/carbidopa).
Topics: Activities of Daily Living; Adult; Antiparkinson Agents; Brain Injuries; Carbidopa; Cognition; Coma; Drug Combinations; Humans; Levodopa; Male | 1990 |
Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
Topics: Carbidopa; Droxidopa; Humans; Levodopa; Middle Aged; Norepinephrine; Parkinson Disease | 1990 |
Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.
Topics: Aged; Carbidopa; Epilepsy; Female; Humans; Kidney Failure, Chronic; Levodopa; Middle Aged; Renal Dialysis | 1990 |
Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
Topics: Adult; Blood Pressure; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catecholamines; Catechols; Electrocardiography; Erythrocytes; Heart Rate; Humans; Intestinal Absorption; Levodopa; Male; Pentanones | 1990 |
Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.
Topics: Animals; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Levodopa; Macaca fascicularis; Male; Pentanones; Tyrosine | 1990 |
Coulometric determination of levodopa, methyldopa and carbidopa.
Topics: Azo Compounds; Carbidopa; Electrochemistry; Levodopa; Methyldopa | 1990 |
Modulating role of dopamine on anesthetic requirements.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Anesthesia; Animals; Benzamides; Benzazepines; Carbidopa; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Halothane; Kinetics; Levodopa; Mice; Mice, Inbred C57BL; Receptors, Dopamine | 1990 |
Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Carbidopa; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Neuroleptic malignant syndrome without neuroleptics.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdrawal Syndrome; Tranylcypromine; Tryptophan | 1990 |
A pilot trial of levodopa/carbidopa in early cocaine abstinence.
Topics: Adult; Arousal; Carbidopa; Cocaine; Drug Therapy, Combination; Humans; Levodopa; Pilot Projects; Substance Withdrawal Syndrome; Substance-Related Disorders | 1990 |
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Striatum; Deoxyglucose; Flunitrazepam; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Macaca fascicularis; Neurons; Organ Specificity; Parkinson Disease; Parkinson Disease, Secondary; Tritium | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Animal; Carbidopa; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease; Sural Nerve; Transplantation, Heterotopic | 1990 |
A year follow-up of autoimplants of perfused adrenal medulla into parkinsonian patients. CPH Neural Transplantation Group.
Topics: Adrenal Medulla; Carbidopa; Caudate Nucleus; Combined Modality Therapy; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Perfusion; Severity of Illness Index; Transplantation, Autologous; Transplantation, Heterotopic | 1990 |
Sinemet-ferrous sulphate interaction in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Drug Combinations; Drug Interactions; Female; Ferrous Compounds; Humans; Levodopa; Male; Middle Aged; Oxygen; Parkinson Disease | 1990 |
Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Models, Biological; Parkinson Disease | 1990 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease | 1990 |
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Steady plasma levodopa concentrations required for good clinical response to CR-4 in patients with 'on-off'.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Marijuana for parkinsonian tremor.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Diazepam; Drug Combinations; Humans; Levodopa; Marijuana Smoking; Parkinson Disease; Tremor | 1990 |
MAO and L-dopa treatment of Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease | 1990 |
Respiratory dysfunction due to L-dopa therapy for parkinsonism: diagnosis using serial pulmonary function tests and respiratory inductive plethysmography.
Topics: Aged; Carbidopa; Dyspnea; Humans; Levodopa; Lung Volume Measurements; Male; Middle Aged; Parkinson Disease; Plethysmography; Pulmonary Ventilation; Respiration Disorders | 1990 |
Influence of L-DOPA/carbidopa on pattern reversal VEP: behavioural difference in primary and secondary parkinsonism.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Electroencephalography; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pattern Recognition, Visual | 1985 |
Pathological findings in a case of hypoxic myoclonus treated with 5-hydroxytryptophan and a decarboxylase inhibitor.
Topics: 5-Hydroxytryptophan; Aged; Brain; Carbidopa; Diazepam; Electroencephalography; Female; Fenclonine; Humans; Hydroxyindoleacetic Acid; Hypoxia; Levodopa; Methysergide; Myoclonus | 1986 |
Central and peripheral motor effects of morphine on the rat urinary bladder.
Topics: Acetylcholine; Animals; Carbidopa; Dose-Response Relationship, Drug; Electric Stimulation; Injections, Intra-Arterial; Injections, Intraventricular; Levodopa; Male; Morphine; Muscle Contraction; Muscle, Smooth; Naloxone; Pelvis; Rats; Rats, Inbred Strains; Substance P; Urinary Bladder | 1986 |
Neurotransmitter therapy and diet in malignant phenylketonuria.
Topics: 5-Hydroxytryptophan; Carbidopa; Combined Modality Therapy; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Infant; Infant, Newborn; Levodopa; Phenylalanine; Phenylketonurias | 1987 |
Dystonia with marked diurnal variation associated with biopterin deficiency.
Topics: Adolescent; Adult; Biopterins; Carbidopa; Child; Child, Preschool; Circadian Rhythm; Drug Combinations; Dystonia; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Neopterin; Sibling Relations | 1988 |
Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters.
Topics: Carbidopa; Catecholamines; Child; Child, Preschool; Fluphenazine; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Lesch-Nyhan Syndrome; Levodopa; Male; Methoxyhydroxyphenylglycol; Movement Disorders; Self Mutilation; Tetrabenazine | 1988 |
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Long-Term Care; Male; Metabolic Clearance Rate; Middle Aged; Motor Skills; Parkinson Disease; Reaction Time | 1989 |
Computerized rotometer apparatus for recording circling behavior.
Topics: Animals; Apomorphine; Carbidopa; Computers; Dextroamphetamine; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Psychology, Experimental; Rats; Rats, Inbred Strains; Software; Stereotyped Behavior | 1989 |
Selegiline in the treatment of Parkinson's disease--long term experience.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Dopamine and memory function in Parkinson's disease.
Topics: Aged; Attention; Brain; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Mental Recall; Middle Aged; Motor Skills; Neuropsychological Tests; Parkinson Disease; Pattern Recognition, Visual; Receptors, Dopamine; Synaptic Transmission; Verbal Learning | 1989 |
Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
Hyperprolactinemia in hepatic encephalopathy may result from impaired central dopaminergic neurotransmission.
Topics: Adult; Carbidopa; Dopamine; Female; Hepatic Encephalopathy; Humans; Hyperprolactinemia; Levodopa; Liver Cirrhosis; Male; Middle Aged; Synaptic Transmission | 1989 |
[Dopamine deficiency syndrome in children with specific reaction to the treatment with levodopa preparations].
Topics: Adolescent; Aphasia; Carbidopa; Child; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Dystonia Musculorum Deformans; Enzyme Activation; Female; Humans; Levodopa; Male; Tyrosine 3-Monooxygenase | 1989 |
Quantification of L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (NB-355) by high-performance liquid chromatography using o-phthalaldehyde/N-acetyl-L-cysteine derivatization.
Topics: Acetylcysteine; Animals; Biological Availability; Carbidopa; Chromatography, High Pressure Liquid; Dogs; Levodopa; Male; o-Phthalaldehyde; Prodrugs | 1989 |
New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1989 |
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease; Psychomotor Performance | 1989 |
Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Tablets | 1989 |
Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1989 |
Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Experiences with Sinemet CR in the Paracelsus-Elena-Klinik.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1989 |
Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Middle Aged; Movement Disorders; Parkinson Disease | 1989 |
Darkening of white hair in Parkinson's disease.
Topics: Carbidopa; Hair Color; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Evaluation of hypothalamic dopaminergic function in patients with pituitary prolactinoma.
Topics: Adult; Carbidopa; Female; Humans; Levodopa; Luteinizing Hormone; Metoclopramide; Pituitary Neoplasms; Prolactin; Prolactinoma; Thyrotropin | 1989 |
Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolites.
Topics: Aged; Carbidopa; Drug Combinations; Homovanillic Acid; Humans; Levodopa; Male; Methyldopa; Middle Aged; Parkinson Disease | 1989 |
On-off phenomenon in a child with tetrahydrobiopterin deficiency due to 6-pyruvoyl tetrahydropterin synthase deficiency (BH4 deficiency).
Topics: Administration, Oral; Alcohol Oxidoreductases; Biopterins; Carbidopa; Child; Female; Humans; Levodopa; Phosphorus-Oxygen Lyases; Psychomotor Performance | 1989 |
Adrenal medullary autograft transplantation into the striatum of patients with Parkinson's disease.
Topics: Adrenal Medulla; Adult; Carbidopa; Caudate Nucleus; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Stereotaxic Techniques | 1989 |
Correlates of memory in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Memory; Memory Disorders; Middle Aged; Movement Disorders; Neuropsychological Tests; Parkinson Disease | 1989 |
Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
Topics: Adult; Aged; Carbidopa; Disability Evaluation; Dominance, Cerebral; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Nerve Degeneration; Parkinson Disease; Substantia Nigra | 1989 |
Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Biological Availability; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1989 |
Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response.
Topics: Aged; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
Topics: Aged; Aged, 80 and over; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Disability profiles and objective quantitative assessment in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Locomotion; Male; Middle Aged; Parkinson Disease; Posture; Psychomotor Performance; Reaction Time | 1989 |
Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Mathematics; Middle Aged; Models, Theoretical; Parkinson Disease | 1989 |
Spectrophotometric determination of microquantities of Carbidopa, Levodopa and alpha-methyldopa using molybdatophosphoric acid.
Topics: Carbidopa; Levodopa; Methyldopa; Molybdenum; Phosphoric Acids; Spectrophotometry, Ultraviolet | 1989 |
[The problems of L-dopa therapy in the course of Parkinson syndrome].
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1989 |
Motor abnormalities during sleep in patients with childhood hereditary progressive dystonia, and their unaffected family members.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Basal Ganglia; Carbidopa; Child; Child, Preschool; Drug Combinations; Dystonia; Female; Genetic Carrier Screening; Humans; Levodopa; Male; Middle Aged; Motor Activity; Sleep Stages; Sleep Wake Disorders; Sleep, REM | 1989 |
An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease.
Topics: Aged; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease | 1989 |
Acute postoperative confusion and hallucinations in Parkinson disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Cognition Disorders; Confusion; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Retrospective Studies; Risk | 1989 |
Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease.
Topics: Acetaminophen; Carbidopa; Cytochrome P-450 Enzyme System; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
A new potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine.
Topics: Animals; Biological Availability; Carbidopa; Chromatography, High Pressure Liquid; Dogs; Levodopa; Male; Prodrugs; Rats; Rats, Inbred Strains; Tyrosine | 1989 |
Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
Topics: Aged; Apomorphine; Carbidopa; Drug Resistance; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine | 1989 |
Tremors in early Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Tremor | 1989 |
ECT and Parkinson's disease revisited: a "naturalistic" study.
Topics: Aged; Carbidopa; Confusion; Depressive Disorder; Electroconvulsive Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1989 |
Locally formed dopamine inhibits Na+-K+-ATPase activity in rat renal cortical tubule cells.
Topics: Animals; Carbidopa; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Dopamine; Enzyme Inhibitors; In Vitro Techniques; Kidney Cortex; Kidney Tubules, Proximal; Kinetics; Levodopa; Male; Nystatin; Ouabain; Oxygen Consumption; Rats; Rats, Inbred Strains; Rubidium; Sodium-Potassium-Exchanging ATPase | 1988 |
Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Carbidopa; Dipeptides; Drug Synergism; Drug Therapy, Combination; Levodopa; Motor Activity; MSH Release-Inhibiting Hormone; Neuropeptides; Parkinson Disease; Peptides, Cyclic; Rats; Structure-Activity Relationship | 1985 |
Dopamine and L-dopa: inhibition of thyrotropin-stimulated thyroidal thyroxine release.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Atropine; Bucladesine; Carbidopa; Cyclic AMP; Dopamine; Dopamine beta-Hydroxylase; Female; Levodopa; Mice; Receptors, Adrenergic, alpha; Receptors, Dopamine; Sulpiride; Thyroid Gland; Thyrotropin; Thyroxine | 1986 |
Black cartilage associated with levodopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cartilage Diseases; Drug Combinations; Female; Humans; Levodopa; Pigmentation Disorders; Ribs | 1986 |
(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
Topics: Animals; Callithrix; Carbidopa; Domperidone; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Oxazines; Parkinson Disease; Time Factors | 1986 |
Painful Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain; Parkinson Disease; Time Factors | 1986 |
Role of dopamine in the inhibition of vasopressin secretion by L-dopa in carbidopa-treated dogs.
Topics: Adrenergic alpha-Antagonists; Adrenocorticotropic Hormone; Animals; Blood Pressure; Carbidopa; Dogs; Dopamine; Female; Levodopa; Male; Norepinephrine; Vasopressins | 1986 |
Folinic acid therapy in treatment of dihydropteridine reductase deficiency.
Topics: 5-Hydroxytryptophan; Brain; Carbidopa; Drug Therapy, Combination; Female; Folic Acid; Humans; Infant; Infant, Newborn; Leucovorin; Levodopa; Male; NADH, NADPH Oxidoreductases; Neurotransmitter Agents; Phenylketonurias | 1987 |
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Humans; Hypromellose Derivatives; Lactose; Levodopa; Lisuride; Methylcellulose; Middle Aged; Nausea; Oxazines; Parkinson Disease; Pergolide; Psychomotor Performance; Receptors, Dopamine | 1988 |
Antiparkinsonian activity of a single oral dose of PHNO.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time | 1987 |
Parkinson's disease, depression, and the on-off phenomenon.
Topics: Bromocriptine; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1989 |
Intracerebral dialysis monitoring of striatal dopamine release and metabolism in response to L-dopa.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Levodopa; Male; Rats; Rats, Inbred Strains | 1989 |
Dose-dependent memory impairment in Parkinson's disease.
Topics: Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Memory Disorders; Parkinson Disease | 1989 |
Comprehensive care of the patient with Parkinson's disease.
Topics: Aged; Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Muscle Rigidity; Parasympatholytics; Parkinson Disease; Patient Care Planning; Patient Care Team; Tremor | 1986 |
Dopamine receptor changes in response to prolonged treatment with L-dopa.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Benzazepines; Carbidopa; Corpus Striatum; Dopamine; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Spiperone; Stereotyped Behavior; Substantia Nigra; Sulpiride | 1986 |
Pharmacokinetics of L-dopa in patients with Parkinson's disease.
Topics: Biotransformation; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Kinetics; Levodopa; Methyldopa; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2; Tiapamil Hydrochloride | 1987 |
Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans.
Topics: Adult; Aged; Brain; Carbidopa; Dopamine; Evoked Potentials, Visual; Female; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Synaptic Transmission; Visual Pathways | 1986 |
Effect of supplemental carbidopa on bioavailability of L-dopa.
Topics: Aged; Biological Availability; Carbidopa; Dihydroxyphenylalanine; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease | 1986 |
Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation.
Topics: Adult; Brain; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Pituitary Gland, Anterior; Prolactin; Thyrotropin-Releasing Hormone | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
Effects of 5-hydroxytryptamine, dopamine, and aromatic L-amino acids on growth hormone (GH)-releasing factor-stimulated GH release in rat anterior pituitaries.
Topics: Animals; Benserazide; Carbidopa; Dopamine; Growth Hormone; Growth Hormone-Releasing Hormone; In Vitro Techniques; Kinetics; Levodopa; Male; Pituitary Gland, Anterior; Rats; Rats, Inbred Strains; Serotonin; Tyrosine | 1987 |
The visual system in Parkinson's disease.
Topics: Animals; Carbidopa; Drug Therapy, Combination; Evoked Potentials, Visual; Haplorhini; Humans; Levodopa; Parkinson Disease; Rats; Reaction Time; Vision Disorders; Vision Tests; Visual Acuity | 1987 |
Current and future approaches to therapy.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Parkinson Disease; Selegiline | 1987 |
Effects of dopaminergic agonists on plasma luteinizing hormone-releasing hormone (LRH) and gonadotropins in man.
Topics: Administration, Oral; Adolescent; Adult; Aged; Carbidopa; Dopamine; Female; Follicle Stimulating Hormone; Follicular Phase; Gonadotropin-Releasing Hormone; Humans; Infusions, Intravenous; Kinetics; Levodopa; Luteinizing Hormone; Male; Menopause; Middle Aged | 1987 |
L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.
Topics: Animals; Apomorphine; Carbidopa; Corpus Striatum; Denervation; Levodopa; Male; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1987 |
Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Topics: Administration, Oral; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Carbidopa; Delayed-Action Preparations; Dihydroxyphenylalanine; Dogs; Dopa Decarboxylase; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrazines; Kidney; Levodopa; Liver; Male; Mice; Rats; Time Factors; Tyrosine | 1987 |
Successful long term therapy of biopterin deficiency.
Topics: 5-Hydroxytryptophan; Biopterins; Carbidopa; Dihydropteridine Reductase; Female; Humans; Infant, Newborn; Levodopa; Liver; Neopterin; Phenylalanine; Phenylalanine Hydroxylase | 1987 |
Reversal of the increase in apomorphine-induced stereotypy and aggression in REM sleep deprived rats by dopamine agonist pretreatments.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Bromocriptine; Carbidopa; Dopamine; Imipramine; Levodopa; Male; Nomifensine; Rats; Rats, Inbred Strains; Sleep Deprivation; Sleep, REM; Stereotyped Behavior | 1988 |
D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Carbidopa; Cerebral Ventricles; Dihydroxyphenylalanine; Dopamine; Homovanillic Acid; Levodopa; Male; Rats; Rats, Inbred Strains; Stereotyped Behavior; Structure-Activity Relationship | 1988 |
Drugs for parkinsonism.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1988 |
Acute exacerbation of Parkinson's disease with sulindac.
Topics: Back Pain; Carbidopa; Drug Combinations; Humans; Indenes; Levodopa; Male; Middle Aged; Parkinson Disease; Sulindac | 1985 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, Animal; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Movement Disorders; Parkinson Disease, Secondary; Pyridines | 1985 |
Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
Topics: Animals; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Ketones; Levodopa; Male; Mice; Motor Activity; Parkinson Disease; Pentanones; Rats; Rats, Inbred Strains; Rotation | 1988 |
Treatment of Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pergolide | 1988 |
A new syndrome of axial muscle rigidity associated with etretinate therapy.
Topics: Adult; Antiparkinson Agents; Back; Carbidopa; Drug Combinations; Etretinate; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Neck Muscles; Psoriasis; Syndrome | 1988 |
Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat.
Topics: Animals; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Interactions; Duodenum; Erythrocytes; In Vitro Techniques; Ketones; Levodopa; Liver; Male; Pentanones; Rats; Rats, Inbred Strains; Tyrosine | 1988 |
Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brocresine; Carbidopa; Catalase; Chromatography, High Pressure Liquid; Glutathione; Glutathione Disulfide; Hydrogen Peroxide; Levodopa; Male; Peroxides; Rats; Rats, Inbred Strains; Reserpine; Synaptosomes; tert-Butylhydroperoxide | 1988 |
The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Chromatography, High Pressure Liquid; Dopamine; Drug Synergism; Homovanillic Acid; Levodopa; Muscles; Rats; Tyrosine | 1988 |
Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy.
Topics: Carbidopa; Catecholamines; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Levodopa; Parkinson Disease; Spectrometry, Fluorescence | 1988 |
Restless legs syndrome. An update and case report.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Male; Restless Legs Syndrome | 1988 |
The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Half-Life; Injections, Intravenous; Intubation, Gastrointestinal; Levodopa; Male; Rats; Rats, Inbred Strains | 1988 |
[Effect of carbidopa-levodopa on growth hormone secretion and absolute eosinophil count in healthy persons and those with allergic diseases].
Topics: Adult; Asthma; Carbidopa; Eosinophils; Female; Growth Hormone; Humans; Leukocyte Count; Levodopa; Male; Middle Aged; Rhinitis, Allergic, Seasonal | 1987 |
Cerebrospinal fluid amino compounds in Parkinson's disease. Alterations due to carbidopa/levodopa.
Topics: Adult; Aged; Amino Acids; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
International symposium on early dopamine agonist therapy of Parkinson's disease.
Topics: Animals; Bromocriptine; Carbidopa; Dopamine; Humans; Levodopa; Parkinson Disease; Pergolide; Time Factors | 1988 |
Drug-induced alzheimerism.
Topics: Aged; Alzheimer Disease; Biperiden; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Piperidines | 1988 |
Lack of pharmacokinetic influence on levodopa by bromocriptine.
Topics: Bromocriptine; Carbidopa; Chromatography, High Pressure Liquid; Drug Interactions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1988 |
[HPLC determination of L-dopa and carbidopa in Isicom tablets].
Topics: Carbidopa; Chromatography, High Pressure Liquid; Drug Combinations; Levodopa; Tablets | 1988 |
Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Humans; Levodopa; Parkinson Disease | 1988 |
Treatable dystonia presenting as spastic cerebral palsy.
Topics: Adolescent; Adult; Carbidopa; Cerebral Palsy; Child; Child, Preschool; Diagnosis, Differential; Dystonia; Humans; Levodopa; Muscle Spasticity | 1988 |
The effect of L-dopa on in vivo dopamine release from nigrostriatal bundle neurons.
Topics: Animals; Carbidopa; Corpus Striatum; Dopamine; Electric Stimulation; Kinetics; Levodopa; Male; Neurons; Rats; Reference Values; Substantia Nigra | 1988 |
Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients.
Topics: Age Factors; Aged; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
False positive diagnosis of phaeochromocytoma in a patient with Parkinson's disease receiving levodopa.
Topics: Adrenal Gland Neoplasms; Aged; Carbidopa; Diagnostic Errors; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Pheochromocytoma; Vanilmandelic Acid | 1988 |
Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism.
Topics: Adult; Carbidopa; Drug Therapy, Combination; Duodenum; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
[Cholestasis caused by Nakom].
Topics: Antiparkinson Agents; Carbidopa; Cholestasis; Diagnosis, Differential; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients.
Topics: Adrenal Medulla; Adult; Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurosurgery; Parkinson Disease; Postoperative Complications | 1988 |
Mood swings associated with the 'on-off' phenomenon in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Mood Disorders; Parkinson Disease; Parkinson Disease, Secondary | 1987 |
Amine sulfate formation in the central nervous system.
Topics: Animals; Arylsulfotransferase; Brain; Carbidopa; Chlorocebus aethiops; Contraceptives, Oral, Combined; Dopamine; Homovanillic Acid; Humans; Levodopa; Norepinephrine; Serotonin; Sulfurtransferases | 1986 |
Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Domperidone; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1986 |
Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
Topics: Aged; Carbidopa; Drug Antagonism; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
Drug-induced myoclonus.
Topics: 5-Hydroxytryptophan; Anesthetics; Animals; Anti-Bacterial Agents; Antidepressive Agents; Bismuth; Carbidopa; Electroencephalography; Gasoline; Guinea Pigs; Humans; Hydrocarbons, Brominated; Imipramine; Levodopa; Methysergide; Models, Biological; Myoclonus; Parkinson Disease; Sleep | 1986 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Rats | 1986 |
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Carotid Artery, Internal; Disease Models, Animal; Dominance, Cerebral; Dopamine; Homovanillic Acid; Injections, Intra-Arterial; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Pyridines | 1986 |
Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Parkinson Disease, Secondary; Pyridines | 1986 |
Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis.
Topics: Adult; Carbidopa; Drug Combinations; Haloperidol; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome; Psychotic Disorders | 1987 |
Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa.
Topics: Adult; Carbidopa; Clozapine; Dibenzazepines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Schizophrenia | 1987 |
Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period.
Topics: Aged; Carbidopa; Drug Combinations; Humans; Levodopa; Locus Coeruleus; Male; Parkinson Disease; Substantia Nigra | 1986 |
Sudden onset of confusion with severe exacerbation of parkinsonism during levodopa therapy.
Topics: Aged; Carbidopa; Cognition Disorders; Confusion; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease, Secondary | 1986 |
Parkinsonism induced by high-dose cytosine arabinoside.
Topics: Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1987 |
Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements.
Topics: Administration, Oral; Aged; Bromocriptine; Carbidopa; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Regional Blood Flow; Tomography, Emission-Computed | 1987 |
Inhibition of transformation by levodopa-carbidopa in lymphocytes derived from patients with melanoma.
Topics: Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Lymphocyte Activation; Melanoma; Osmolar Concentration; Phytohemagglutinins | 1987 |
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1987 |
A case of normal pressure hydrocephalus presenting as levodopa responsive parkinsonism.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hydrocephalus; Hydrocephalus, Normal Pressure; Levodopa; Middle Aged; Parkinson Disease | 1987 |
Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
Topics: Adult; Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease | 1987 |
Simultaneous determination of levodopa, its metabolites and carbidopa in clinical samples.
Topics: Carbidopa; Chromatography, Liquid; Humans; Levodopa; Spectrophotometry, Infrared | 1987 |
Transient shortening of estrous cycles in aging C57BL/6J mice: effects of spontaneous pseudopregnancy, progesterone, L-dihydroxyphenylalanine, and hydergine.
Topics: Aging; Animals; Carbidopa; Dihydroergotoxine; Estrus; Female; Levodopa; Mice; Mice, Inbred C57BL; Ovulation; Progesterone; Pseudopregnancy; Silicone Elastomers; Time Factors | 1987 |
Peripheral dopamine metabolism in polycystic ovary syndrome.
Topics: Adult; Carbidopa; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Methoxyhydroxyphenylglycol; Norepinephrine; Polycystic Ovary Syndrome | 1987 |
Excessive yawning and progressive supranuclear palsy.
Topics: Aged; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Supranuclear Palsy, Progressive; Yawning | 1987 |
Stridor during dystonic phases of Parkinson's disease.
Topics: Adult; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Respiratory Sounds | 1987 |
Fluctuations in plasma dopamine level impair memory in Parkinson's disease.
Topics: Carbidopa; Dopamine; Humans; Levodopa; Memory; Parkinson Disease | 1987 |
Controlled-release Sinemet.
Topics: Carbidopa; Delayed-Action Preparations; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1987 |
Effect of oral levodopa and carbidopa on coronary spasm in variant angina pectoris.
Topics: Administration, Oral; Angina Pectoris, Variant; Carbidopa; Cardiac Catheterization; Coronary Angiography; Coronary Vasospasm; Dopamine; Humans; Levodopa; Time Factors | 1987 |
Dietary influences on the antiparkinsonian response to levodopa.
Topics: Amino Acids; Carbidopa; Dietary Proteins; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
L-dopa in uremic patients with the restless legs syndrome.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Uremia | 1987 |
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Topics: Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Paranoid Disorders; Parkinson Disease; Patient Acceptance of Health Care; Time Factors | 1987 |
Carbidopa-levodopa therapy for movement disorders.
Topics: Basal Ganglia Diseases; Carbidopa; Craniocerebral Trauma; Drug Therapy, Combination; Humans; Levodopa; Movement Disorders | 1987 |
Therapy of neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Carbidopa; Combined Modality Therapy; Dantrolene; Diazepam; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Levodopa; Neuroleptic Malignant Syndrome; Receptors, Dopamine | 1986 |
[Phenomenon of inverted rotation in spastic torticollis].
Topics: Adult; Brain; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Muscle Spasticity; Receptors, Dopamine; Rotation; Substance Withdrawal Syndrome; Torticollis | 1986 |
Sinemet in Parkinson's disease: efficacy with and without food.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Diet; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Pharmacotherapy: problems and practices.
Topics: Amantadine; Bromocriptine; Carbidopa; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine.
Topics: Aged; Bromocriptine; Carbidopa; Drug Combinations; Drug Interactions; Humans; Levodopa; Male; Myoclonus; Parkinson Disease; Serotonin | 1986 |
Drugs for parkinsonism.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1986 |
Akinetic parkinsonism and the catatonic syndrome: an overview.
Topics: Adult; Akinetic Mutism; Benztropine; Carbidopa; Catatonia; Humans; Levodopa; Male; Parasympatholytics; Parkinson Disease; Syndrome | 1986 |
Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
Topics: Adult; Bromocriptine; Carbidopa; Dystonia; Ergolines; Humans; Levodopa; Meige Syndrome; Middle Aged; Parkinson Disease; Pergolide; Torticollis | 1986 |
Management of Parkinson's disease in general practice.
Topics: Aged; Benserazide; Bromocriptine; Carbidopa; Drug Combinations; Family Practice; Humans; Levodopa; Medical Audit; Parkinson Disease | 1986 |
Clinical and biochemical studies with controlled-release levodopa/carbidopa.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.
Topics: Adult; Aged; Carbidopa; Drug Combinations; Duodenum; Female; Gastric Emptying; Humans; Intubation, Gastrointestinal; Levodopa; Male; Parkinson Disease | 1986 |
[Neurologic and electromyographic findings in chronic manganese encephalopathy].
Topics: Adult; Brain Diseases; Carbidopa; Chronic Disease; Drug Combinations; Electromyography; Humans; Levodopa; Male; Manganese Poisoning; Metallurgy; Middle Aged; Occupational Diseases | 1986 |
Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Domperidone; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1986 |
Effect of antacid on levodopa therapy.
Topics: Aluminum Hydroxide; Bromocriptine; Carbidopa; Double-Blind Method; Drug Combinations; Drug Interactions; Humans; Levodopa; Magnesium; Magnesium Hydroxide; Parkinson Disease | 1986 |
Clinical trial of carbidopa-L-dopa combination for cocaine abuse.
Topics: Carbidopa; Cocaine; Drug Therapy, Combination; Humans; Levodopa; Substance-Related Disorders | 1986 |
Alterations in [Met5]- and [Leu5]enkephalin and neurotensin content in basal ganglia induced by the long-term administration of dopamine agonist and antagonist drugs to rats.
Topics: Animals; Basal Ganglia; Bromocriptine; Carbidopa; Dopamine; Dopamine Antagonists; Enkephalin, Leucine; Enkephalin, Methionine; Levodopa; Male; Neurotensin; Pergolide; Rats; Rats, Inbred Strains; Trifluoperazine | 1986 |
Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nervous System Diseases; Parkinson Disease | 1987 |
Selective regional effect of various neuroactive drugs on bromocriptine concentration in the brain of rats.
Topics: Amantadine; Animals; Biperiden; Brain Chemistry; Bromocriptine; Carbidopa; Diazepam; Haloperidol; Levodopa; Methysergide; Naloxone; Rats | 1986 |
Alleviation of severe emotional symptoms by carbidopa-levodopa, MSD, in a Parkinson's patient: a personal report.
Topics: Affective Symptoms; Aged; Carbidopa; Dopamine; Drug Combinations; Emotions; Humans; Levodopa; Male; Parkinson Disease | 1987 |
[Simple photometric method for the determination of L-dopa and carbidopa in drug preparations].
Topics: Carbidopa; Levodopa; Photometry | 1986 |
Juvenile onset Parkinson's disease.
Topics: Adolescent; Adult; Carbidopa; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1987 |
Parkinson's disease: progression and mortality.
Topics: Carbidopa; Disability Evaluation; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Middle Aged; Parkinson Disease | 1987 |
Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
Topics: Aged; Bromocriptine; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Orphenadrine; Parkinson Disease | 1987 |
Pergolide mesylate: four years experience in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1987 |
Controversies in the treatment of Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1985 |
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Adult; Carbidopa; Chronic Disease; Drug Combinations; Female; Humans; Levodopa; Male; Parkinson Disease; Pyridines; Substance-Related Disorders; Substantia Nigra | 1985 |
Malignant phenylketonuria due to defective synthesis of dihydrobiopterin.
Topics: 5-Hydroxytryptophan; Biopterins; Carbidopa; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Male; Nervous System Diseases; Phenylalanine; Phenylketonurias; Pteridines; Tyrosine | 1985 |
Parkinson disease. Individualizing therapy.
Topics: Aged; Bromocriptine; Carbidopa; Central Nervous System Diseases; Diagnosis, Differential; Gait; Humans; Levodopa; Male; Motor Activity; Parkinson Disease; Psychoses, Substance-Induced; Tremor | 1985 |
[L-dopa therapy of parkinson syndrome].
Topics: Benserazide; Biotransformation; Carbidopa; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Parkinson Disease; Receptors, Dopamine | 1985 |
Influences of catecholamines on growth hormone release in female goldfish, Carassius auratus.
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Carbidopa; Catecholamines; Cyprinidae; Dopamine; Female; Goldfish; Growth Hormone; Hydroxydopamines; Levodopa; Methyltyrosines; Norepinephrine; Oxidopamine; Phentolamine; Preoptic Area | 1985 |
[Effect of dopaminergic pharmacological agents on thyrotropic hormone secretion by the hypophysis when stimulated with thyrotropin-releasing hormone].
Topics: Animals; Apomorphine; Bromocriptine; Carbidopa; Dopamine; Dopamine Antagonists; Haloperidol; Levodopa; Male; Pituitary Gland; Rats; Thyrotropin; Thyrotropin-Releasing Hormone | 1985 |
Deprenyl in Parkinson disease: personal experience.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.
Topics: Adult; Brain Chemistry; Carbidopa; Dopamine; Endorphins; Estrogens; Female; Follicle Stimulating Hormone; Humans; Levodopa; Luteinizing Hormone; Naloxone; Polycystic Ovary Syndrome; Prolactin | 1985 |
[Effect of the test with the drug Nakom on the dynamics of excretion of catecholamines and DOPA in children with Duchenne's progressive muscular dystrophy].
Topics: Adolescent; Carbidopa; Catecholamines; Child; Child, Preschool; Circadian Rhythm; Dihydroxyphenylalanine; Drug Combinations; Humans; Levodopa; Muscular Dystrophies | 1985 |
Dopamine agonists suppress visual-cortical reflex myoclonus.
Topics: Aged; Apomorphine; Atrophy; Carbidopa; Cerebellum; Drug Therapy, Combination; Electromyography; Epilepsies, Myoclonic; Ergolines; Evoked Potentials, Somatosensory; Evoked Potentials, Visual; Female; Humans; Levodopa; Lisuride; Olivary Nucleus; Photic Stimulation; Pons; Reflex; Visual Cortex | 1985 |
DL-threo-DOPS as a precursor of noradrenaline.
Topics: alpha-Methyltyrosine; Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain Chemistry; Carbidopa; Dopamine; Droxidopa; Levodopa; Male; Methyltyrosines; Myocardium; Norepinephrine; Pargyline; Rats; Rats, Inbred Strains; Reserpine; Serine; Stereotyped Behavior | 1985 |
Central cholinergic-dopaminergic interaction in carbaryl-induced tremor.
Topics: Animals; Atropine; Carbaryl; Carbidopa; Dose-Response Relationship, Drug; Drug Synergism; Haloperidol; Levodopa; Male; Rats; Receptors, Cholinergic; Receptors, Dopamine; Tremor | 1985 |
Abnormalities in the regulation of prolactin in patients on maintenance hemodialysis.
Topics: Adult; Carbidopa; Female; Humans; Kidney Failure, Chronic; Levodopa; Male; Metoclopramide; Middle Aged; Prolactin; Renal Dialysis; Thyrotropin-Releasing Hormone | 1985 |
Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.
Topics: Aged; Carbidopa; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1986 |
Lisuride in the treatment of myoclonus.
Topics: Adolescent; Adult; Aged; Carbidopa; Dopamine Antagonists; Electric Stimulation; Electroencephalography; Electromyography; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Myoclonus; Serotonin Antagonists | 1986 |
Pharmacologic treatment of parkinsonian tremor.
Topics: Amantadine; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tremor; Trihexyphenidyl | 1986 |
Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
Topics: Body Temperature Regulation; Bromocriptine; Carbidopa; Drug Combinations; Female; Fever; Humans; Levodopa; Malignant Hyperthermia; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease; Receptors, Dopamine | 1985 |
Unsuccessful treatment of severe pain from bone metastases with Sinemet 25/100.
Topics: Analgesics; Bone Neoplasms; Carbidopa; Drug Combinations; Humans; Levodopa; Pain, Intractable; Pilot Projects | 1985 |
Role of defective dopaminergic inhibition of prolactin secretion in the pathogenesis of prolactinoma.
Topics: Autoantibodies; Carbidopa; Dopamine; Female; Humans; Hypothalamo-Hypophyseal System; Levodopa; Metoclopramide; Monoiodotyrosine; Neural Inhibition; Nomifensine; Pituitary Neoplasms; Prolactin; Radioligand Assay; Receptors, Dopamine | 1985 |
Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Autonomic Nervous System; Benserazide; Blood Pressure; Carbidopa; Drug Therapy, Combination; Female; Heart; Heart Rate; Humans; Hydrazines; Levodopa; Male; Middle Aged; Muscle Contraction; Parkinson Disease | 1985 |
Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.
Topics: Aged; Carbidopa; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Receptors, Dopamine; Sleep Wake Disorders; Sleep, REM | 1985 |
Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1985 |
Levodopa-induced dyskinesia: clinical observations.
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk | 1985 |
Monoamine oxidase inhibitors and Sinemet in Shy-Drager syndrome.
Topics: Autonomic Nervous System Diseases; Carbidopa; Drug Combinations; Female; Humans; Hypotension, Orthostatic; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Shy-Drager Syndrome | 1985 |
Hemidystonia: a report of 22 patients and a review of the literature.
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Brain Damage, Chronic; Brain Diseases; Brain Injuries; Carbidopa; Child; Child, Preschool; Dominance, Cerebral; Dystonia; Dystonia Musculorum Deformans; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Tomography, X-Ray Computed; Trihexyphenidyl | 1985 |
Audit of the drug treatment of Parkinson's disease in general practice.
Topics: Aged; Carbidopa; Family Practice; Humans; Levodopa; Medical Audit; Middle Aged; Parasympatholytics; Parkinson Disease | 1985 |
Progressive dystonia with marked diurnal fluctuation. Report of a case.
Topics: Carbidopa; Child; Circadian Rhythm; Conversion Disorder; Diagnosis, Differential; Drug Therapy, Combination; Dystonia; Female; Humans; Levodopa; Muscle Spasticity; Paraplegia | 1985 |
The effect of central and peripheral dopamine-agonists on ventilation in the mouse.
Topics: Animals; Blood-Brain Barrier; Brain; Carbidopa; Chemoreceptor Cells; Dopamine; Drug Interactions; Haloperidol; Hypercapnia; Hypoxia; Kinetics; Levodopa; Male; Mice; Peripheral Nerves; Respiration | 1985 |
Auditory and somatosensory evoked potentials (AEPs and SEPs) and ballistic movements in Parkinson disease.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Electromyography; Evoked Potentials, Auditory; Evoked Potentials, Somatosensory; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1985 |
The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Drug Therapy, Combination; Female; Half-Life; Humans; Infusions, Parenteral; Kinetics; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Parkinson Disease | 1985 |
Sinemet "abusers".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Self Administration; Substance-Related Disorders | 1985 |
[Drug therapy of Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Combined therapy of carbidopa and levodopa in Parkinson's disease].
Topics: Adult; Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Clinical significance of cramps of the lower extremities in patients with parkinsonism].
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Leg; Levodopa; Male; Middle Aged; Muscle Cramp; Parkinson Disease | 1985 |
Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Tryptophan; Tyrosine | 1985 |
L-dopa hypotension in dogs: evidence for mediation through 5-HT release.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Pressure; Brain Chemistry; Carbidopa; Chlorpromazine; Depression, Chemical; Dogs; Drug Interactions; Female; Fenclonine; Haloperidol; Heart Rate; Levodopa; Male; Methysergide; Monoamine Oxidase Inhibitors; Norepinephrine; Reserpine; Serotonin; Time Factors; Yohimbine | 1974 |
Preclinical toxicological studies of carbidopa and combinations of carbidopa and levodopa.
Topics: Animals; Carbidopa; Dogs; Drug Interactions; Female; Lethal Dose 50; Levodopa; Macaca mulatta; Male; Mice; Rabbits; Rats | 1974 |
Mechanisms involved in the control of extrapyramidal dysfunctions and in striatal dopamine synthesis.
Topics: Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Bucladesine; Carbidopa; Carbon Radioisotopes; Corpus Striatum; Depression, Chemical; Dopamine; Drug Therapy, Combination; Haloperidol; Haplorhini; Levodopa; Receptors, Drug; Stimulation, Chemical; Tremor | 1974 |
[Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzyl Compounds; Carbidopa; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenols | 1974 |
Further evidence on the direct action of L-Dopa on prolactin release.
Topics: Animals; Brain; Carbidopa; Depression, Chemical; Dopamine; Hypothalamus; Injections, Intraperitoneal; Injections, Intravenous; Levodopa; Male; Norepinephrine; Pituitary Gland, Anterior; Prolactin; Radioimmunoassay; Rats; Time Factors; Transplantation, Homologous | 1974 |
The effects of L-dopa and alpha-methyldopa on reflexes and sympathetic nerve function.
Topics: Animals; Atropine; Barbiturates; Benserazide; Blood Pressure; Carbidopa; Carotid Arteries; Dogs; Electric Stimulation; Heart Rate; Hindlimb; Levodopa; Methyldopa; Monoamine Oxidase Inhibitors; Neurons; Perfusion; Posture; Reflex; Regional Blood Flow; Sympathetic Nervous System; Vagotomy; Vagus Nerve | 1974 |
[Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1974 |
Short- and long-term approaches to the "on-off" phenomenon.
Topics: Apomorphine; Carbidopa; Dietary Proteins; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Time Factors | 1974 |
The "on-off" side effect of L-DOPA.
Topics: Age Factors; Amitriptyline; Aromatic Amino Acid Decarboxylase Inhibitors; Athetosis; Carbidopa; Catechol O-Methyltransferase Inhibitors; Chlordiazepoxide; Chorea; Desipramine; Diazepam; Dietary Proteins; Enzyme Inhibitors; Female; Humans; Imipramine; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Physical Exertion; Picolinic Acids; Prochlorperazine; Sex Factors; Stress, Psychological | 1974 |
[A year of treatment with carbidopa and levodopa in Parkinsonian patients].
Topics: Carbidopa; Drug Evaluation; Female; Humans; Levodopa; Male; Parkinson Disease; Tablets; Time Factors | 1974 |
Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
Topics: Aged; Carbidopa; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1974 |
[Value of the test with Nakom for assessing the state of the sympathoadrenal system in patients with different forms of progressive muscular dystrophy].
Topics: Adolescent; Adult; Carbidopa; Catecholamines; Child; Child, Preschool; Drug Combinations; Humans; Levodopa; Male; Muscular Atrophy; Muscular Dystrophies | 1984 |
Central action of L-DOPA in blood pressure regulation and effect on catecholamine content in the frog, Xenopus laevis.
Topics: Animals; Benserazide; Blood Pressure; Brain; Carbidopa; Catecholamines; Dopamine; Female; Levodopa; Myocardium; Xenopus laevis | 1981 |
The effect of L-DOPA on blood pressure and catecholamine content in the brain and peripheral organs in the Atlantic cod, Gadus morhua.
Topics: Animals; Benserazide; Blood Pressure; Brain Chemistry; Carbidopa; Catecholamines; Dopamine; Fishes; Levodopa; Time Factors | 1981 |
Akinetic mutism from hypothalamic damage: successful treatment with dopamine agonists.
Topics: Adult; Akinetic Mutism; Bromocriptine; Carbidopa; Ergolines; Humans; Hypothalamic Neoplasms; Hypothalamus; Levodopa; Male; Methylphenidate; Postoperative Complications | 1981 |
Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Ergolines; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Radioligand Assay | 1982 |
Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.
Topics: Administration, Oral; Carbidopa; Dopamine; Drug Combinations; Humans; Infusions, Parenteral; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Adrenergic; Time Factors | 1982 |
Dopaminergic deficiency and delayed visual evoked potentials in humans.
Topics: Adult; Antipsychotic Agents; Carbidopa; Dopamine; Drug Therapy, Combination; Evoked Potentials, Visual; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenothiazines; Schizophrenia | 1982 |
Cholinergic and dopaminergic mechanisms in Parkinson's disease after long term levodopa administration.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Receptors, Cholinergic; Receptors, Dopamine; Time Factors | 1982 |
Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Carbidopa; Drug Combinations; Drug Evaluation; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Parkinson Disease, Secondary | 1983 |
Chronic treatment with 1-dopa plus carbidopa in hemitransected rats: preferential effects at intact dopamine synapses leading to behavioural signs of dopamine receptor supersensitivity.
Topics: Animals; Behavior, Animal; Carbidopa; Corpus Striatum; Diencephalon; Fluorescent Antibody Technique; Levodopa; Male; Nerve Endings; Rats; Rats, Inbred Strains; Receptors, Dopamine; Rotation; Spiperone; Substantia Nigra; Synapses; Tyrosine 3-Monooxygenase | 1983 |
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission | 1983 |
Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
Topics: Aged; Antipsychotic Agents; Carbidopa; Corpus Striatum; Depressive Disorder; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Metoclopramide; Parkinson Disease, Secondary; Receptors, Dopamine | 1984 |
Biopterin synthesis defect. Treatment with L-dopa and 5-hydroxytryptophan compared with therapy with a tetrahydropterin.
Topics: 5-Hydroxytryptophan; Amino Acid Metabolism, Inborn Errors; Biopterins; Carbidopa; Catecholamines; Dose-Response Relationship, Drug; Female; Humans; Infant; Levodopa; Neopterin; Neurotransmitter Agents; Pteridines; Pterins | 1984 |
Neuroleptic malignant syndrome and neuroleptic-induced catatonia: differential diagnosis and treatment.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Carbidopa; Catatonia; Diagnosis, Differential; Female; Haloperidol; Humans; Levodopa; Syndrome; Trihexyphenidyl | 1984 |
False diagnosis of phaeochromocytoma in patients on Sinemet.
Topics: Adrenal Gland Neoplasms; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; False Positive Reactions; Female; Humans; Levodopa; Male; Middle Aged; Pheochromocytoma; Vanilmandelic Acid | 1984 |
Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically.
Topics: Animals; Buthionine Sulfoximine; Carbidopa; Corpus Striatum; Dopamine; Female; Glutathione; Levodopa; Methionine Sulfoximine; Neurons; Rats; Rats, Inbred Strains; Substantia Nigra; Tyrosine 3-Monooxygenase | 1984 |
[Malignant phenylketonuria caused by biopterin synthetase deficiency. Study of neuromediator catabolites in the cerebrospinal fluid during treatment].
Topics: Alcohol Oxidoreductases; Biopterins; Carbidopa; Follow-Up Studies; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Infant; Levodopa; Male; Neurotransmitter Agents; Phenylketonurias; Serotonin | 1984 |
Skin rash associated with Sinemet 25/100.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Eruptions; Humans; Levodopa | 1983 |
[Circadian rhythm of catecholamine excretion, effect of L-DOPA and Nacom in various diseases of the nervous system].
Topics: Adult; Aged; Carbidopa; Catecholamines; Drug Combinations; Dystonia Musculorum Deformans; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Muscular Dystrophies; Nervous System Diseases; Neurotic Disorders; Parkinson Disease | 1983 |
Sinemet skin rash.
Topics: Aged; Carbidopa; Coloring Agents; Drug Combinations; Drug Eruptions; Female; Humans; Levodopa | 1984 |
Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: effect of L-dopa treatment.
Topics: Aged; Carbidopa; Cyclic AMP; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates | 1981 |
Age-dependent depressor effect of L-dopa in dogs with inhibition of extracerebral dopa decarboxylase.
Topics: Aging; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Pressure; Brain; Carbidopa; Dogs; Drug Therapy, Combination; Heart Rate; Levodopa; Male; Renin; Renin-Angiotensin System; Time Factors | 1983 |
L-Dopa and piribedil alter different components of attentional behavior dependent on dose.
Topics: Animals; Attention; Behavior, Animal; Carbidopa; Dose-Response Relationship, Drug; Exploratory Behavior; Female; Gerbillinae; Levodopa; Male; Motor Activity; Piperazines; Piribedil; Time Factors | 1983 |
Deprenyl (selegiline) in combination treatment of Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Therapy of neurologic disorders in the elderly.
Topics: Aged; Amantadine; Anticoagulants; Brain Ischemia; Bromocriptine; Carbidopa; Dexamethasone; Drug Interactions; Heparin; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Trihexyphenidyl | 1984 |
Evidence for altered catecholamine metabolism in polycystic ovary syndrome.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adult; Carbidopa; Catecholamines; Drug Therapy, Combination; Female; Follicle Stimulating Hormone; Homovanillic Acid; Humans; Levodopa; Luteinizing Hormone; Methoxyhydroxyphenylglycol; Pituitary Hormone-Releasing Hormones; Polycystic Ovary Syndrome | 1984 |
Effect of l-dopa or bromocriptine on feeding and motor behavior of rats with lesions in the globus pallidus.
Topics: Animals; Body Weight; Brain Mapping; Bromocriptine; Carbidopa; Drinking; Eating; Globus Pallidus; Hydroxydopamines; Levodopa; Male; Motor Activity; Neural Pathways; Oxidopamine; Rats; Receptors, Dopamine; Sex Factors | 1984 |
Simultaneous determination of L-dopa and 3-O-methyldopa in human serum by high-performance liquid chromatography.
Topics: Adult; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Epinephrine; Humans; Levodopa; Male; Methyltyrosines; Norepinephrine; Parkinson Disease; Tyrosine | 1984 |
Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects.
Topics: Aged; Carbidopa; Dystonia; Ergolines; Female; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1980 |
Early detection of Huntington's disease. Blink reflex and levodopa load in presymptomatic and incipient subjects.
Topics: Adolescent; Adult; Blinking; Carbidopa; Child; Ethics, Medical; Female; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Time Factors | 1981 |
Salivary secretion induced by L-DOPA in haloperidol-treated rats.
Topics: Animals; Carbidopa; Denervation; Haloperidol; Levodopa; Male; Norepinephrine; Phentolamine; Rats; Rats, Inbred Strains; Saliva; Submandibular Gland | 1984 |
Study on the striatal dopamine availability in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Corpus Striatum; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Time Factors | 1984 |
The pharmacology of olivopontocerebellar atrophy.
Topics: Adult; Amantadine; Atrophy; Baclofen; Brain Diseases; Carbidopa; Cerebellar Ataxia; Female; Humans; Levodopa; Male; Middle Aged; Olivary Nucleus; Pons; Propranolol; Syndrome | 1984 |
Pharmacologic effects of L-dopa are not closely linked temporally to striatal dopamine concentration.
Topics: Animals; Behavior, Animal; Brain; Carbidopa; Corpus Striatum; Dopamine; Dopamine Antagonists; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Strains; Substantia Nigra | 1984 |
Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease.
Topics: Adult; Aged; Attention; Basal Ganglia; Carbidopa; Cognition Disorders; Female; Humans; Levodopa; Male; Memory; Middle Aged; Motor Activity; Movement; Parkinson Disease; Reaction Time | 1984 |
L-dopa decarboxylation in chronically treated patients.
Topics: Adult; Carbidopa; Chemistry, Organic; Decarboxylation; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Organic Chemistry Phenomena; Parkinson Disease; Time Factors | 1984 |
Combined use of benserazide and carbidopa in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease | 1984 |
Severity of Parkinson's disease and the dosage of bromocriptine.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1984 |
Pergolide in the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Rubral tremor: clinical features and treatment of three cases.
Topics: Aged; Benztropine; Carbidopa; Cerebellum; Cerebrovascular Disorders; Female; Humans; Levodopa; Male; Middle Aged; Red Nucleus; Tegmentum Mesencephali; Thalamus; Tremor | 1984 |
Platelet phenolsulphotransferase activity in Parkinson's disease.
Topics: Age Factors; Arylsulfotransferase; Blood Platelets; Carbidopa; Drug Combinations; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease; Sulfurtransferases; Time Factors | 1983 |
Parkinsonism treated with levodopa: progression and mortality.
Topics: Aged; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Disease | 1983 |
Dystonia--L-dopa responsive or juvenile parkinsonism?
Topics: Adolescent; Benserazide; Carbidopa; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dystonia; Follow-Up Studies; Growth Hormone; Humans; Infant; Levodopa; Male; Parkinson Disease; Prolactin | 1983 |
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Carbidopa; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Movement Disorders; Parkinson Disease; Parkinson Disease, Secondary; Pyridines | 1984 |
Potentiation by naloxone of the anti-oxotremorine effect of L-DOPA.
Topics: Animals; Carbidopa; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred ICR; Naloxone; Oxotremorine; Tremor | 1983 |
[Various aspects of dopaminergic function in patients with prolactin-secreting hypophyseal adenoma].
Topics: Adenoma; Adult; Amenorrhea; Carbidopa; Dopamine; Female; Humans; Levodopa; Nomifensine; Pituitary Neoplasms; Prolactin | 1983 |
One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
Topics: Athetosis; Carbidopa; Chorea; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Hypotension; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Response to Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Benserazide; Body Weight; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Sex Factors | 1984 |
Acute effects of levodopa plus carbidopa on evoked potentials in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Evoked Potentials, Visual; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Time Factors | 1984 |
[Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies | 1984 |
What to do when Sinemet fails: Part one.
Topics: Antiparkinson Agents; Carbidopa; Dementia; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Psychoses, Substance-Induced | 1984 |
[Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1984 |
"On-off" phenomenon in Parkinson's disease.
Topics: Animals; Carbidopa; Humans; Levodopa; Methyldopa; Parkinson Disease | 1984 |
Behavioral control of L-dopa induced dyskinesia in Parkinsonism.
Topics: Adult; Antiparkinson Agents; Biofeedback, Psychology; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Electromyography; Humans; Levodopa; Male; Relaxation Therapy | 1982 |
Regulation of prolactin and growth hormone secretion. Site and mechanism of action of thyrotropin-releasing hormone, L-dopa and L-5-hydroxytryptophan in unanesthetized dogs.
Topics: 5-Hydroxytryptophan; Animals; Carbidopa; Depression, Chemical; Dogs; Female; Growth Hormone; Hormones; Levodopa; Male; Metergoline; Prolactin; Radioimmunoassay; Serotonin; Sex Factors; Stimulation, Chemical; Thyrotropin-Releasing Hormone | 1980 |
[Experimental studies on L-dopa induced dyskinesia (author's transl)].
Topics: Animals; Carbidopa; Chlorocebus aethiops; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Motor Activity; Nystagmus, Pathologic | 1980 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Nomifensine; Parkinson Disease; Prolactin; Receptors, Dopamine; Selegiline; Tremor | 1980 |
Abnormal regulation of prolactin release in idiopathic Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin-Releasing Hormone | 1980 |
Increase in mesolimbic electrical self-stimulation after chronic haloperidol: reversal by L-DOPA or lithium.
Topics: Animals; Carbidopa; Drug Antagonism; Electric Stimulation; Haloperidol; Levodopa; Lithium; Lithium Carbonate; Male; Rats; Self Stimulation; Tegmentum Mesencephali | 1981 |
Blood-brain barrier permeability of L-dopa in man.
Topics: Adult; Aged; Blood-Brain Barrier; Capillary Permeability; Carbidopa; Carbon Radioisotopes; Cerebrovascular Circulation; Female; Humans; Levodopa; Male; Middle Aged; Radioisotope Dilution Technique | 1981 |
Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyroid Gland; Thyrotropin; Thyrotropin-Releasing Hormone | 1981 |
Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients.
Topics: Aged; Carbidopa; Drug Therapy, Combination; Humans; Kinetics; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone | 1981 |
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Combinations; Female; Humans; Levodopa; Male; Methamphetamine; Middle Aged; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Selegiline; Tyramine | 1982 |
[Biochemical evaluation of the effectiveness of antiparkinson preparations containing L-DOPA].
Topics: Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Combinations; Epinephrine; Humans; Levodopa; Norepinephrine; Parkinson Disease | 1981 |
Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine | 1982 |
Functional characterization of hypothalamic hyperprolactinemia.
Topics: Adult; Aged; Carbidopa; Child; Dopamine; Female; Humans; Hypothalamic Diseases; Levodopa; Male; Meningeal Neoplasms; Middle Aged; Nomifensine; Pituitary Neoplasms; Prolactin; Sulpiride; Thyrotropin-Releasing Hormone | 1982 |
Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery.
Topics: Adenoma; Adolescent; Adult; Carbidopa; Dopamine; Female; Follow-Up Studies; Humans; Levodopa; Metoclopramide; Pituitary Neoplasms; Prolactin; Sphenoid Bone; Thyrotropin-Releasing Hormone | 1982 |
Potentiation of d-amphetamine and L-dopa-induced acoustic startle activity after long-term exposure to amphetamine.
Topics: Acoustic Stimulation; Animals; Carbidopa; Dextroamphetamine; Humans; Levodopa; Male; Mice; Reflex, Startle; Stereotyped Behavior; Time Factors | 1982 |
Bromocriptine and lisuride in Parkinson disease.
Topics: Aged; Bromocriptine; Carbidopa; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1983 |
Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma.
Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Carbidopa; Cell Line; Diet; Drug Synergism; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Levodopa; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Phenylalanine; Tyrosine | 1983 |
A quantitative study of the electroencephalographic response to levodopa treatment in parkinsonian patients.
Topics: Aged; Carbidopa; Cerebral Cortex; Drug Therapy, Combination; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1983 |
Determination of the enantiomeric purity of levodopa, methyldopa, carbidopa and tryptophan by use of chiral mobile phase high-performance liquid chromatography.
Topics: Capsules; Carbidopa; Chromatography, High Pressure Liquid; Copper; Copper Sulfate; Drug Contamination; Levodopa; Methyldopa; Phenylalanine; Stereoisomerism; Tablets; Tryptophan | 1983 |
The chemotherapy of malignant melanoma.
Topics: Carbidopa; Cardiovascular Diseases; Dopamine; Drug Evaluation; Humans; Levodopa; Melanoma; Mitotic Index; Skin Neoplasms | 1983 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyltyrosines; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Reserpine; Synapses; Tetrabenazine | 1983 |
Sustained low-dose levodopa therapy in Parkinson's disease: a 3-year follow-up.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 1983 |
Influence of carbidopa, an aromatic amino acid decarboxylase inhibitor, on the development of autoimmune hemolytic anemia in NZB mice.
Topics: Anemia, Hemolytic, Autoimmune; Animals; Body Weight; Carbidopa; Coombs Test; Female; Hematocrit; Levodopa; Male; Methyldopa; Mice; Mice, Inbred NZB | 1983 |
Pergolide mesylate and idiopathic Parkinson disease.
Topics: Adolescent; Adult; Carbidopa; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 1982 |
Further studies with pergolide in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Confusion; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1982 |
Effect of chronic levodopa on haloperidol-induced behavioral supersensitivity in the guinea pig.
Topics: Animals; Apomorphine; Behavior, Animal; Carbidopa; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Stereotyped Behavior; Time Factors | 1982 |
Levodopa-carbidopa.
Topics: Adult; Carbidopa; Female; Humans; Levodopa; Parkinson Disease; Pregnancy | 1980 |
Effects of levodopa on attention deficit disorder, residual type.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male | 1982 |
A comparison of levodopa treatment and task demands on visual evoked potentials in hemi-parkinsonism.
Topics: Adult; Aged; Attention; Carbidopa; Dominance, Cerebral; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Survival of neonatal rats during hypoxia after monoamine stimulating agents.
Topics: 5-Hydroxytryptophan; Animals; Animals, Newborn; Apomorphine; Biogenic Amines; Carbidopa; Female; Hypoxia; Levodopa; Pregnancy; Rats; Rats, Inbred Strains; Time Factors | 1982 |
Rapid liquid-chromatographic measurement of 3-methoxy-4-hydroxyphenylglycol and other monoamine metabolites in human cerebrospinal fluid.
Topics: 3-Methoxy-4-hydroxyphenylethanol; 3,4-Dihydroxyphenylacetic Acid; Aged; Carbidopa; Chromatography, High Pressure Liquid; Glycols; Homovanillic Acid; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Vanilmandelic Acid | 1980 |
Studies on the responses of plasma renin activity and aldosterone and cortisol levels to dopaminergic and opiate stimuli in man.
Topics: Adult; Aldosterone; Carbidopa; Domperidone; Dopamine; Female; Humans; Hydrocortisone; Levodopa; Male; Naloxone; Posture; Renin | 1981 |
Dynamic tests of prolactin secretion in hyperprolactinemic states: carbidopa-L-dopa and indirectly acting dopamine agonists.
Topics: Adenoma; Adult; Carbidopa; Dopamine; Female; Humans; Kinetics; Levodopa; Methylphenidate; Nomifensine; Pituitary Neoplasms; Postpartum Period; Pregnancy; Prolactin | 1982 |
Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Topics: Aged; Animals; Benserazide; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Rats | 1982 |
The effect of L-dopa on pupillary diameter in mice.
Topics: Animals; Benserazide; Carbidopa; Fusaric Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Phentolamine; Pupil | 1982 |
Dietary influence of tyrosine and phenylalanine on the response of B16 melanoma to carbidopa-levodopa methyl ester chemotherapy.
Topics: Animals; Carbidopa; Diet; Drug Evaluation, Preclinical; Female; Levodopa; Melanoma; Mice; Neoplasms, Experimental; Phenylalanine; Tyrosine | 1982 |
Integrity of central dopaminergic system in women with postpartum hyperprolactinemia.
Topics: Carbidopa; Female; Humans; Levodopa; Pregnancy; Prolactin; Puerperal Disorders; Thyrotropin | 1982 |
Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.
Topics: Aged; Carbidopa; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Meige's syndrome during long-term dopaminergic therapy in Parkinson's disease.
Topics: Aged; Blepharospasm; Carbidopa; Dystonia; Facial Muscles; Female; Humans; Levodopa; Male; Mandibular Diseases; Middle Aged; Parkinson Disease; Syndrome; Time Factors | 1982 |
Parkinsonism in the elderly.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Humans; Levodopa; Parkinson Disease | 1982 |
Management of patients who fail to respond to levodopa therapy.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1982 |
Initial treatment of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Prognosis | 1982 |
Simultaneous determination of carbidopa, levodopa and 3,4-dihydroxyphenyl-acetic acid using high-performance liquid chromatography with electrochemical detection.
Topics: 3,4-Dihydroxyphenylacetic Acid; Carbidopa; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Humans; Levodopa; Phenylacetates | 1982 |
Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopa.
Topics: Adenoma; Carbidopa; Dopamine; Female; Humans; Hypothalamus; Levodopa; Pituitary Neoplasms; Prolactin; Radioimmunoassay | 1982 |
Adverse interaction of levodopa with tricyclic antidepressants.
Topics: Aged; Amitriptyline; Carbidopa; Drug Combinations; Drug Interactions; Female; Humans; Imipramine; Levodopa; Parkinson Disease | 1982 |
Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis.
Topics: Aged; Bromocriptine; Carbidopa; Dreams; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Sleep Initiation and Maintenance Disorders; Sleep Stages | 1982 |
Central cardiovascular effects of L-DOPA and clonidine in the lizard, Agama caudospinosa.
Topics: Animals; Benserazide; Blood Pressure; Blood-Brain Barrier; Brain; Carbidopa; Catecholamines; Clonidine; Heart Rate; Hemodynamics; Levodopa; Lizards; Myocardium | 1982 |
New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline).
Topics: Adult; Aged; Benserazide; Carbidopa; Choline; Cytidine Diphosphate Choline; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1982 |
Levodopa in borderline disorders.
Topics: Borderline Personality Disorder; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Personality Disorders | 1982 |
L-DOPA produces regional changes in glucose utilization which form discrete anatomic patterns in motor nuclei and the hypothalamus of rats.
Topics: Animals; Brain; Carbidopa; Corpus Striatum; Deoxyglucose; Glucose; Hypothalamus; Levodopa; Male; Motor Activity; Rats; Rats, Inbred Strains; Substantia Nigra | 1982 |
Pharmacology of blepharospasm-oromandibular dystonia syndrome.
Topics: Aged; Benztropine; Blepharospasm; Carbidopa; Deanol; Drug Therapy, Combination; Electromyography; Eyelid Diseases; Humans; Jaw Diseases; Levodopa; Male; Middle Aged; Movement Disorders; Syndrome | 1980 |
Drug holiday and management of Parkinson disease.
Topics: Aged; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1980 |
Thyroid function in Parkinson disease.
Topics: Aged; Carbidopa; Humans; Hypothyroidism; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Thyroid Diseases; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 1981 |
The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig.
Topics: Animals; Apomorphine; Behavior, Animal; Carbidopa; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Stereotyped Behavior; Time Factors | 1981 |
Study of the neural basis of circling behavior induced by L-dopa in lesioned entopeduncular cats.
Topics: Animals; Carbidopa; Cats; Caudate Nucleus; Dominance, Cerebral; Female; Globus Pallidus; Humans; Levodopa; Male; Motor Cortex; Neural Pathways; Neurons; Pons; Putamen; Somatosensory Cortex; Stereotyped Behavior | 1982 |
Alternate day levodopa therapy in parkinsonism.
Topics: Aged; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1982 |
Drug-induced asterixis in Parkinson disease.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Muscle Contraction; Muscular Diseases; Parkinson Disease; Posture | 1982 |
Electroretinography (ERG) as a tool of investigation in human psychopharmacology. Electroretinographic changes induced by a combination of carbi-dopa and levo-dopa.
Topics: Adult; Carbidopa; Drug Combinations; Electroretinography; Humans; Levodopa; Male; Psychopharmacology; Retina | 1980 |
Bilateral vocal cord paralysis in Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tracheotomy; Vocal Cord Paralysis | 1981 |
Method of addition of bromocriptine to the drug regime of patients with advanced Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1981 |
Evaluation of two inhibitory tests (nomifensine and L-dopa + carbidopa) for the diagnosis of hyperprolactinaemic states.
Topics: Adenoma; Adolescent; Adult; Carbidopa; Diagnosis, Differential; Female; Humans; Isoquinolines; Levodopa; Male; Middle Aged; Nomifensine; Pituitary Neoplasms; Polycystic Ovary Syndrome; Prolactin | 1980 |
Parkinson's disease: new treatments.
Topics: Acetylcholine; Amantadine; Apomorphine; Bromocriptine; Carbidopa; Counseling; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Manifestations; Parkinson Disease; Physical Therapy Modalities; Receptors, Dopamine; Thalamus | 1981 |
Carbidopa-levodopa ratio in Parkinson's disease.
Topics: Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1981 |
Dopaminergic regulation of growth hormone (GH) secretion in normal man: correlation of L-dopa and dopamine levels with the GH response.
Topics: Adolescent; Adult; Carbidopa; Dopamine; Growth Hormone; Humans; Kinetics; Levodopa; Male; Prolactin | 1981 |
Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
Topics: Adult; Aged; Carbidopa; Circadian Rhythm; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Receptors, Dopamine; Reference Values | 1981 |
Growth hormone and prolactin secretion in liver cirrhosis: evidence for dopaminergic dysfunction.
Topics: Adult; Brain; Carbidopa; Female; Growth Hormone; Humans; Levodopa; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prolactin; Receptors, Dopamine | 1981 |
[Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone].
Topics: Aged; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Trazodone | 1981 |
A case of sporadic juvenile Parkinson's disease.
Topics: Adult; Aging; Carbidopa; Female; Humans; Levodopa; Parkinson Disease | 1981 |
Dopamine release in rat striatum after administration of L-dope as studied with in vivo electrochemistry.
Topics: 4-Butyrolactone; Amphetamine; Animals; Carbidopa; Corpus Striatum; Dopamine; Electrochemistry; Haloperidol; Levodopa; Male; Pargyline; Rats; Rats, Inbred Strains | 1981 |
Cardiac effects of pergolide.
Topics: Aged; Antiparkinson Agents; Arrhythmias, Cardiac; Carbidopa; Drug Therapy, Combination; Ergolines; Heart; Heart Rate; Humans; Levodopa; Middle Aged; Pergolide | 1981 |
[The combination of L-dopa and carbidopa in therapy of a case of familial juvenile parkinsonism].
Topics: Adult; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease | 1981 |
On the localization and mediation of the centrally induced hyperactive urinary bladder response to L-dopa in the rat.
Topics: Animals; Carbidopa; Cervical Vertebrae; Levodopa; Lumbar Vertebrae; Male; Parasympathetic Nervous System; Rats; Rats, Inbred Strains; Urinary Bladder | 1981 |
Dystonic foot response of Parkinsonism.
Topics: Aged; Carbidopa; Dystonia; Foot Diseases; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1980 |
Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Effect of dopamine on length of gestation and on the release of fetal oxytocin in rats.
Topics: Animals; Animals, Newborn; Brain; Carbidopa; Dopamine; Drug Interactions; Female; Fetus; Gestational Age; Labor, Obstetric; Levodopa; Oxytocin; Pituitary Gland; Pregnancy; Rats | 1980 |
Low dose perphenazine and levodopa/carbidopa therapy in a patient with Parkinsonism and a psychotic illness.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Perphenazine; Psychotic Disorders | 1980 |
Sinemet - 25/100.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1980 |
Evidence for dopamine as an inhibitor of vasoprotein release in man.
Topics: Adult; Arginine Vasopressin; Blood Pressure; Carbidopa; Depression, Chemical; Dopamine; Female; Heart Rate; Humans; Levodopa; Male; Posture; Secretory Rate | 1980 |
Further experiences with low doses of bromocriptine in Parkinson's disease.
Topics: Bromocriptine; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease | 1980 |
The role of bromocriptine in the treatment of Parkinson's disease.
Topics: Bromocriptine; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Middle Aged; Parkinson Disease | 1980 |
A comparative study of bromocriptine and levodopa in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Differential sensitivity of spontaneously hypertensive rats to the hypothermic effect of dopaminergic drugs.
Topics: Animals; Apomorphine; Blood Pressure; Body Temperature; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Hypertension; Levodopa; Male; Rats | 1980 |
The effect of levodopa with carbidopa (Sinemet R) on the metabolic response to semistarvation.
Topics: Adaptation, Physiological; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Metabolism; Carbidopa; Diet, Reducing; Drug Combinations; Energy Intake; Female; Humans; Levodopa; Middle Aged; Obesity; Triiodothyronine | 1980 |
Effect of central nervous system dopaminergic activation on prolactin secretion in man: evidence for a common central defect in hyperprolactinemic patients with and without radiological signs of pituitary tumors.
Topics: Adolescent; Adult; Carbidopa; Female; Humans; Kinetics; Levodopa; Nomifensine; Pituitary Neoplasms; Prolactin | 1980 |
Effect of pyridoxal 5-phosphate on carbidopa and decarboxylation of levodopa.
Topics: Apoenzymes; Carbidopa; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Decarboxylation; Hydroxylamines; Levodopa; Pyridoxal Phosphate; Tyrosine Decarboxylase | 1980 |
Central nervous system-mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia.
Topics: Adenoma; Adolescent; Adult; Animals; Carbidopa; Cimetidine; Female; Guanidines; Humans; Levodopa; Male; Metoclopramide; Pituitary Neoplasms; Postpartum Period; Pregnancy; Prolactin; Rats; Sex Factors | 1980 |
Failure of carbidopa and L-dopa to suppress the prolactin stimulating effect of sulpiride in normal man.
Topics: Adult; Carbidopa; Humans; Levodopa; Male; Prolactin; Sulpiride | 1980 |
Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Topics: Aged; Amine Oxidase (Copper-Containing); Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carbidopa; Cross-Sectional Studies; Dialysis; Drug Synergism; Enzyme Inhibitors; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease | 1995 |
Higher environmental temperature-induced increase of body temperature: involvement of central opioidergic-GABAergic interaction.
Topics: Animals; Body Temperature; Body Temperature Regulation; Carbidopa; Dopamine Agents; Dopamine Antagonists; Endorphins; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; Haloperidol; Hot Temperature; Levodopa; Male; Narcotic Antagonists; Parasympathetic Nervous System; Rats; Receptors, Opioid | 1995 |
Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amidines; Animals; Biogenic Monoamines; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Microdialysis; Neostriatum; Nitriles; Pyridones; Rats; Rats, Wistar; Stereotaxic Techniques; Tryptophan; Tyrosine | 1994 |
Dopamine and serotonin turnover rate in the retina of rabbit, rat, goldfish, and Eugerres plumieri: light effects in goldfish and rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; alpha-Methyltyrosine; Animals; Carbidopa; Dopamine; Fenclonine; Goldfish; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Light; Male; Methyltyrosines; Pargyline; Perciformes; Rabbits; Rats; Rats, Sprague-Dawley; Retina; Serotonin; Species Specificity | 1994 |
Sinemet and brain injury: functional versus statistical change and suggestions for future research designs.
Topics: Aged; Brain Damage, Chronic; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Glasgow Coma Scale; Head Injuries, Closed; Humans; Levodopa; Neurologic Examination; Neuropsychological Tests | 1995 |
Restless legs syndrome.
Topics: Carbidopa; Dopamine Agents; Humans; Levodopa; Male; Middle Aged; Peripheral Nervous System Diseases; Psychomotor Agitation; Restless Legs Syndrome; Syndrome | 1995 |
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 1995 |
Upper airway obstruction in Parkinson's disease.
Topics: Airway Obstruction; Carbidopa; Dopamine Antagonists; Fasting; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sleep Apnea Syndromes | 1995 |
Rapid degradation of 3,4-dihydroxyphenylalanine in plasma samples containing ethylenediaminetetraacetic acid.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Blood Specimen Collection; Carbidopa; Chelating Agents; Dihydroxyphenylalanine; Dopamine Agents; Edetic Acid; Humans; Levodopa; Temperature | 1995 |
Delayed onset generalised dystonia after cyanide poisoning.
Topics: Adult; Carbidopa; Drug Overdose; Drug Therapy, Combination; Dystonia; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Neurologic Examination; Potassium Cyanide; Putamen; Suicide, Attempted | 1995 |
Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period.
Topics: Body Temperature; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Menstrual Cycle; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease | 1993 |
Parkinsonism and bipolar affective disorder.
Topics: Aged; Antiparkinson Agents; Bipolar Disorder; Carbidopa; Clonazepam; Dopamine; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Lithium Carbonate; Male; Parkinson Disease, Secondary | 1995 |
Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease.
Topics: Adult; Aged; Biperiden; Carbidopa; Evaluation Studies as Topic; Humans; Levodopa; Middle Aged; Neurotransmitter Agents; Parkinson Disease; Treatment Outcome | 1994 |
Adverse reactions to Sinemet CR.
Topics: Aged; Antiparkinson Agents; Carbidopa; Confusion; Delayed-Action Preparations; Drug Combinations; Dyskinesia, Drug-Induced; Hallucinations; Humans; Levodopa | 1995 |
Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat.
Topics: Animals; Base Sequence; Behavior, Animal; Carbidopa; Enkephalins; Female; Gene Expression Regulation, Enzymologic; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Molecular Sequence Data; Neostriatum; Oligonucleotide Probes; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Tachykinins | 1995 |
The levodopa test in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Geriatric Assessment; Humans; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Reaction Time; Walking | 1995 |
Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.
Topics: Affect; Aged; Anxiety; Arousal; Carbidopa; Depression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1995 |
Use of Sinemet in locked-in syndrome: a report of two cases.
Topics: Adult; Carbidopa; Child; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Male; Quadriplegia | 1995 |
Clozapine therapeutic plunge in patient with Parkinson's disease.
Topics: Carbidopa; Clozapine; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Psychotic Disorders | 1995 |
Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders.
Topics: Adult; Aged; Carbidopa; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Intracranial Arteriosclerosis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Olivopontocerebellar Atrophies; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive; Tomography, X-Ray Computed; Treatment Outcome; Xenon | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Agonists; Ergolines; Female; Fetal Tissue Transplantation; Forelimb; Functional Laterality; Levodopa; Motor Activity; Movement Disorders; Norepinephrine; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Transplantation, Heterotopic | 1995 |
Contemporaneous bilateral postero-ventral pallidotomy for early onset "juvenile type" Parkinson's disease. Case report.
Topics: Antiparkinson Agents; Brain Mapping; Carbidopa; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Postoperative Complications | 1994 |
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Depression; Desipramine; Dihydroxyphenylalanine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Levodopa; Male; Motor Activity; Nitriles; Nitrophenols; Rats; Rats, Wistar; Swimming; Tolcapone | 1995 |
MRI and PET studies of manganese-intoxicated monkeys.
Topics: Animals; Carbidopa; Corpus Striatum; Deoxyglucose; Drug Therapy, Combination; Dystonia; Fluorodeoxyglucose F18; Globus Pallidus; Glucose; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Male; Manganese Poisoning; Parkinson Disease, Secondary; Raclopride; Salicylamides; Substantia Nigra; Tomography, Emission-Computed | 1995 |
[Preparation of a levodopa/carbidopa solution in ascorbic acid (citridopa) and chromatographic and electrochemical assessment of its stability over 24 hours].
Topics: Ascorbic Acid; Carbidopa; Chromatography, High Pressure Liquid; Drug Stability; Humans; Levodopa; Solutions; Time Factors | 1995 |
The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study.
Topics: Animals; Carbidopa; Catechols; Dogs; Extracellular Space; Levodopa; Male; Microdialysis; Muscle, Skeletal; Nitriles; Premedication | 1995 |
Anticholinergic effects in a depressed parkinsonian patient.
Topics: Aged; Benztropine; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome | 1995 |
Delusions of infestation during delirium in a patient with restless legs syndrome.
Topics: Aged; Carbidopa; Delirium; Delusions; Female; Humans; Levodopa; Pneumonia; Restless Legs Syndrome; Thioridazine | 1995 |
Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Frail Elderly; Hallucinations; Humans; Levodopa; Male; Mental Status Schedule; Parkinson Disease; Severity of Illness Index | 1995 |
Hereditary parkinsonism with multiple system degeneration: beneficial effect of anticholinergics, but not of levodopa.
Topics: Adult; Amantadine; Basal Ganglia; Carbidopa; Cerebellar Ataxia; Cholinergic Antagonists; Consanguinity; Drug Resistance; Female; Genes, Recessive; Globus Pallidus; Homovanillic Acid; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Pedigree; Trihexyphenidyl | 1994 |
Adrenal medulla and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Carbidopa; Catecholamines; Disease Models, Animal; Drug Combinations; Humans; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary | 1994 |
Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro.
Topics: Animals; Bromocriptine; Carbidopa; Corpus Striatum; Desipramine; Dopamine; Free Radical Scavengers; Hydroxyl Radical; Injections, Intraventricular; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine | 1994 |
Leg pain and numbness in an elderly man.
Topics: Aged; Aged, 80 and over; Bed Rest; Carbidopa; Humans; Leg; Levodopa; Male; Pain; Paresthesia; Parkinson Disease; Posture; Radiography; Spinal Stenosis | 1995 |
Levodopa administration to normal rats: influence on striatal oxidized glutathione concentration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Carbidopa; Corpus Striatum; Dose-Response Relationship, Drug; Glutathione; Glutathione Disulfide; Kinetics; Levodopa; Male; Rats; Rats, Sprague-Dawley; Time Factors | 1994 |
Familial levodopa-responsive parkinsonian-pyramidal syndrome.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Carbidopa; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Pedigree | 1994 |
Anticholinergics and dyskinesia.
Topics: Aged; Biperiden; Carbidopa; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Tremor; Trihexyphenidyl | 1994 |
Dopa-responsive dystonia and normalization of soleus H-reflex test results with treatment.
Topics: Adult; Carbidopa; Drug Combinations; Dystonia; Female; H-Reflex; Humans; Levodopa; Male; Middle Aged; Muscle, Skeletal | 1995 |
Parkinson's disease: reorganization of the reach to grasp movement in response to perturbation of the distal motor patterning.
Topics: Aged; Antiparkinson Agents; Attention; Carbidopa; Drug Combinations; Female; Hand Strength; Humans; Kinesthesis; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Orientation; Parkinson Disease; Psychomotor Performance; Reaction Time; Selegiline; Size Perception | 1994 |
Dopa-responsive dystonia simulating cerebral palsy.
Topics: Adolescent; Adult; Biopterins; Carbidopa; Cerebral Palsy; Child; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Dystonia; Female; Follow-Up Studies; Homovanillic Acid; Humans; Levodopa; Male; Neopterin; Neurologic Examination; Parkinson Disease, Secondary | 1994 |
Levodopa in pregnancy.
Topics: Adult; Carbidopa; Female; Humans; Levodopa; Lymphoma, Non-Hodgkin; Parkinson Disease, Secondary; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 1995 |
Enantiomeric separation and determination of antiparkinsonian drugs by reversed-phase ligand-exchange high-performance liquid chromatography.
Topics: Carbidopa; Chromatography, High Pressure Liquid; Levodopa; Ligands; Spectrophotometry, Ultraviolet; Stereoisomerism | 1994 |
Peripheral catecholamine output in Parkinson's disease: effects of drug treatment.
Topics: Adrenal Medulla; Aged; Carbidopa; Catecholamines; Corpus Striatum; Epinephrine; Female; Humans; Levodopa; Male; Metanephrine; Middle Aged; Norepinephrine; Parkinson Disease; Vanilmandelic Acid | 1995 |
Chronic administration does not alter the pharmacokinetic profile of L-dopa in the rat.
Topics: Administration, Oral; Animals; Body Weight; Carbidopa; Dopa Decarboxylase; Drug Administration Schedule; Injections, Intra-Arterial; Levodopa; Liver; Male; Rats; Rats, Wistar; Time Factors | 1993 |
Portable device for quantifying parkinsonian wrist rigidity.
Topics: Adult; Aged; Antiparkinson Agents; Antipsychotic Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Muscle Tonus; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Psychotic Disorders; Risk Factors; Transducers | 1994 |
Hyponatraemia and dopaminergic agents.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Female; Humans; Hyponatremia; Levodopa | 1994 |
A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
Topics: Amphetamine; Animals; Brain; Carbidopa; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Combinations; Functional Laterality; Immunohistochemistry; Levodopa; Male; Mesencephalon; Models, Neurological; Motor Activity; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Tyrosine 3-Monooxygenase | 1994 |
Parkinson's disease: making the diagnosis, selecting drug therapies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cholinergic Antagonists; Diagnosis, Differential; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1994 |
3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
Topics: Animals; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Levodopa; Male; Methyldopa; Motor Activity; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra | 1994 |
[Catecholamines and the dopamine-beta-hydroxylase activity of the blood plasma in motor pathology in children: the role of central and peripheral mechanisms].
Topics: Adolescent; Carbidopa; Catecholamines; Child; Chromatography, High Pressure Liquid; Dopamine Agonists; Dopamine beta-Hydroxylase; Drug Combinations; Female; Humans; Levodopa; Male; Movement Disorders; Spectrophotometry | 1994 |
First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Female; Gastric Emptying; Gastrointestinal Transit; Humans; Levodopa; Middle Aged; Parkinson Disease; Postoperative Complications; Vagotomy; Vagus Nerve | 1994 |
Punding on levodopa.
Topics: Aged; Brain; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Male; Parkinson Disease; Stereotyped Behavior | 1994 |
Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome).
Topics: Airway Obstruction; Antiparkinson Agents; Botulinum Toxins; Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dystonia; Electromyography; Genes, Recessive; Humans; Injections, Intramuscular; Laryngeal Diseases; Levodopa; Male; Middle Aged; Parkinson Disease; Respiration Disorders; Respiratory Insufficiency; Respiratory Sounds; Sex Chromosome Aberrations; X Chromosome | 1994 |
Therapy of patients with Parkinson's disease.
Topics: Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 1994 |
Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration.
Topics: Absorption; Administration, Oral; Animals; Carbidopa; Chromatography, High Pressure Liquid; Half-Life; Injections, Intra-Arterial; Injections, Intraperitoneal; Injections, Intravenous; Intestinal Absorption; Intubation, Gastrointestinal; Levodopa; Male; Models, Biological; Rats; Rats, Sprague-Dawley; Tyrosine | 1994 |
Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome.
Topics: Adolescent; Adult; Brain Diseases; Carbidopa; Child; Chromosome Aberrations; Chromosome Disorders; Consanguinity; Dementia; Electromyography; Extrapyramidal Tracts; Female; Globus Pallidus; Humans; Immobilization; Levodopa; Magnetic Resonance Imaging; Male; Pedigree; Syndrome | 1994 |
Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Carbidopa; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinson Disease, Secondary; Psychomotor Performance; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Dopaminergic treatment of restless legs and rebound phenomenon.
Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Prospective Studies; Restless Legs Syndrome; Substance Withdrawal Syndrome | 1993 |
Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes.
Topics: Aged; Biogenic Monoamines; Carbidopa; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 1993 |
Drugs for Parkinson's disease.
Topics: Carbidopa; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Selegiline | 1993 |
Management of neuroleptic malignant syndrome--a series of eight cases.
Topics: Adolescent; Adult; Bromocriptine; Carbidopa; Dantrolene; Dopamine Agents; Drug Combinations; Female; Humans; India; Levodopa; Male; Muscular Diseases; Neuroleptic Malignant Syndrome | 1993 |
Hyponatraemia due to amantadine hydrochloride and L-dopa/carbidopa.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Combinations; Humans; Hyponatremia; Levodopa; Male | 1993 |
Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.
Topics: Amidines; Amphetamine; Animals; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Clorgyline; Drug Interactions; Drug Synergism; Levodopa; Male; Methylation; Nitriles; Nitrophenols; Pyridones; Rats; Rats, Wistar; Tolcapone | 1993 |
Individualizing therapy in patients with disabling Parkinson's disease symptoms.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 1994 |
The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Dogs; Dopamine; Extracellular Space; Half-Life; Injections, Intravenous; Levodopa; Male; Microdialysis; Muscles; Tyrosine | 1993 |
Chronic administration does not alter the accumulation of L-dopa into muscle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Carbidopa; Dopamine; Drug Therapy, Combination; Homovanillic Acid; Levodopa; Long-Term Care; Male; Metabolic Clearance Rate; Muscles; Rats; Rats, Wistar | 1994 |
Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Chorea; Circadian Rhythm; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Limbic System; Long-Term Care; Male; Mesencephalon; Middle Aged; Parkinson Disease; Pilot Projects; Psychoses, Substance-Induced; Receptors, Dopamine D2; Remoxipride | 1994 |
Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetamides; Analysis of Variance; Animals; Anticonvulsants; Antiparkinson Agents; Brain; Carbidopa; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors | 1994 |
Dopaminergic hallucinosis with fluoxetine in Parkinson's disease.
Topics: Aged; Bromocriptine; Carbidopa; Fluoxetine; Hallucinations; Humans; Levodopa; Male; Parkinson Disease; Visual Perception | 1993 |
Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease.
Topics: Administration, Oral; Aged; Carbidopa; Colloids; Female; Humans; Infusion Pumps; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Motor Skills; Parkinson Disease | 1993 |
Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.
Topics: Aged; Bromocriptine; Carbidopa; Hallucinations; Humans; Levodopa; Parkinson Disease; Pergolide; Polysomnography; Sleep; Sleep, REM | 1993 |
The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dietary Proteins; Drug Administration Schedule; Drug Combinations; Eating; Female; Humans; Intestinal Absorption; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease | 1993 |
Combination therapy for PD.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 1993 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyclic AMP; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred F344; Receptors, Dopamine D1; Receptors, Dopamine D2; Sensitivity and Specificity; Substantia Nigra; Time Factors | 1993 |
Continuous duodenal infusions of levodopa.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Duodenum; Female; Humans; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Patient Education as Topic | 1993 |
Tetrahydrobiopterin deficiency and an international database of patients.
Topics: 5-Hydroxytryptophan; Alcohol Oxidoreductases; Biomarkers; Biopterins; Carbidopa; Child; Dihydropteridine Reductase; GTP Cyclohydrolase; Humans; Hydro-Lyases; Information Systems; Levodopa; Metabolism, Inborn Errors; Phenylalanine; Phenylketonurias; Phosphorus-Oxygen Lyases; Pterins; Registries | 1993 |
Levodopa pharmacodynamics.
Topics: Carbidopa; Drug Combinations; Drugs, Generic; Humans; Levodopa; Parkinson Disease; United States; United States Food and Drug Administration | 1994 |
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Tyrosine | 1993 |
Retrospective study of drug response in 87 patients with progressive supranuclear palsy.
Topics: Amitriptyline; Carbidopa; Humans; Imipramine; Levodopa; Retrospective Studies; Supranuclear Palsy, Progressive | 1993 |
Simultaneous monitoring of levodopa, dopamine and their metabolites in skeletal muscle and subcutaneous tissue in different pharmacological conditions using microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Chromatography, High Pressure Liquid; Dialysis; Dogs; Dopamine; Electrochemistry; Extracellular Space; Injections, Intravenous; Levodopa; Male; Methyldopa; Muscles; Skin | 1993 |
Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.
Topics: Carbidopa; Female; Follow-Up Studies; Humans; Levodopa; Male; Minnesota; Parkinson Disease; Parkinson Disease, Secondary; Survival Analysis; Survival Rate; Time Factors | 1993 |
End-of-dose dystonia in Parkinson's disease.
Topics: Adult; Carbidopa; Dystonia; Humans; Infusions, Intravenous; Levodopa; Middle Aged; Parkinson Disease; Selegiline; Substance Withdrawal Syndrome | 1993 |
Mycoplasma pneumoniae infection may cause striatal lesions leading to acute neurologic dysfunction.
Topics: Carbidopa; Caudate Nucleus; Child; Corpus Striatum; Erythromycin; Humans; Levodopa; Magnetic Resonance Imaging; Male; Meningitis, Bacterial; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Putamen | 1993 |
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
Topics: Benserazide; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Motor Activity; Movement Disorders; Neurologic Examination; Ocular Motility Disorders; Parkinson Disease; Parkinson Disease, Secondary; Supranuclear Palsy, Progressive | 1993 |
Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings.
Topics: Animals; Benserazide; Benzophenones; Brain; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Erythrocytes; Homovanillic Acid; Humans; Levodopa; Male; Nitrophenols; Peripheral Nerves; Rats; S-Adenosylhomocysteine; S-Adenosylmethionine; Tolcapone | 1993 |
Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Male; Middle Aged; Motor Activity; Neurologic Examination; Parkinson Disease; Risk Factors | 1993 |
Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clozapine; Dementia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Psychoses, Substance-Induced | 1993 |
Age influences magnitude but not duration of response to levodopa.
Topics: Adult; Age Factors; Aged; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Substantia Nigra | 1993 |
Developing a stable bilateral model of parkinsonism in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Feeding Behavior; Female; Injections, Intra-Arterial; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease, Secondary | 1993 |
Rehabilitation of patients with Hallervorden-Spatz syndrome.
Topics: Activities of Daily Living; Adult; Carbidopa; Drug Therapy, Combination; Exercise Therapy; Humans; Levodopa; Male; Movement Disorders; Pantothenate Kinase-Associated Neurodegeneration; Patient Care Team | 1993 |
The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
Topics: Aged; Carbidopa; Dopamine; Dose-Response Relationship, Drug; Droxidopa; Female; Gait; Humans; Levodopa; Male; Middle Aged; Norepinephrine; Parkinson Disease | 1993 |
Extrapyramidal syndrome responsive to dopaminergic treatment following recovery from central pontine myelinolysis.
Topics: Basal Ganglia Diseases; Biperiden; Carbidopa; Chlorthalidone; Coma; Drug Therapy, Combination; Female; Humans; Hypertension; Hyponatremia; Levodopa; Lisuride; Middle Aged; Neurologic Examination; Parkinson Disease, Secondary; Pons; Quadriplegia; Saline Solution, Hypertonic; Tomography, X-Ray Computed | 1993 |
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed-Action Preparations; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 1993 |
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease.
Topics: Acetazolamide; Adult; Carbidopa; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Menstruation Disturbances; Neurologic Examination; Parkinson Disease | 1993 |
Response to L-DOPA in multiple system atrophy.
Topics: Adult; Aged; Carbidopa; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Movement Disorders; Muscle Rigidity; Olivopontocerebellar Atrophies; Parkinson Disease; Tremor | 1993 |
The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Electrocardiography; Half-Life; Homovanillic Acid; Humans; Levodopa; Male; Nitriles; Reference Values; Tyrosine | 1993 |
Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography.
Topics: Adsorption; Aluminum Oxide; Antiparkinson Agents; Carbidopa; Cation Exchange Resins; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Drug Combinations; Electrochemistry; Humans; Levodopa; Parkinson Disease; Resins, Synthetic; Silanes; Tetrahydropapaveroline | 1993 |
Benign paroxysmal tonic upgaze of childhood with ataxia. A neuro-ophthalmological syndrome of familial origin?
Topics: Age Factors; Ataxia; Carbidopa; Eye Movements; Family; Humans; Infant; Levodopa; Male; Movement Disorders; Ocular Motility Disorders; Posture; Sleep; Syndrome | 1993 |
Worsening of postural tremor in patients with levodopa-induced dyskinesia: a quantitative analysis.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Posture; Tremor | 1993 |
Locally formed dopamine modulates renal Na-Pi co-transport through DA1 and DA2 receptors.
Topics: Adenylate Cyclase Toxin; Animals; Benserazide; Bromocriptine; Calcium; Carbidopa; Carrier Proteins; Cell Line; Cyclic AMP; Dopamine; Kidney Tubules, Proximal; Kinetics; Levodopa; Opossums; Parathyroid Hormone; Pertussis Toxin; Phosphates; Receptors, Dopamine D1; Receptors, Dopamine D2; Sodium; Sodium-Phosphate Cotransporter Proteins; Symporters; Virulence Factors, Bordetella | 1995 |
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E | 1995 |
[Changes in the indices of standing and walking in patients with infantile cerebral palsy under the influence of low doses of Nakom].
Topics: Adolescent; Antiparkinson Agents; Carbidopa; Cerebral Palsy; Child; Dose-Response Relationship, Drug; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Posture; Walking | 1995 |
A 61-year-old man with Parkinson's disease.
Topics: 1-Naphthylamine; Antiparkinson Agents; Carbidopa; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Family Practice; Humans; Levodopa; Male; Middle Aged; Neurology; Neuroprotective Agents; Parkinson Disease; Selegiline; Sertraline; Vitamin E | 1996 |
Cytosine arabinoside and amphotericin B-induced parkinsonism.
Topics: Amphotericin B; Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Lung Diseases; Middle Aged; Parkinson Disease, Secondary | 1996 |
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study.
Topics: Animals; Basal Ganglia; Brain; Carbidopa; Chlorides; Gliosis; Globus Pallidus; Levodopa; Macaca mulatta; Male; Manganese Compounds; Manganese Poisoning; Parkinson Disease, Secondary; Poisoning; Substantia Nigra | 1996 |
Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts.
Topics: Adult; Amantadine; Antiparkinson Agents; Autopsy; Basal Ganglia; Brain Tissue Transplantation; Carbidopa; Cell Division; Cerebral Ventricles; Corpus Striatum; Embryo, Mammalian; Fetal Tissue Transplantation; Fetus; Gestational Age; Graft Survival; Humans; Levodopa; Male; Mesencephalon; Middle Aged; Parkinson Disease; Transplantation, Homologous | 1996 |
Sinemet in locked-in syndrome.
Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Male; Quadriplegia; Terminology as Topic | 1996 |
Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dopamine; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1996 |
Dopa-responsive dystonia: clinical and family study in Taiwanese.
Topics: Adult; Carbidopa; Drug Therapy, Combination; Dystonia; Female; Humans; Levodopa; Pedigree | 1996 |
[Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 1996 |
Neutrophil function, nitric oxide, and blood oxidative stress in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catalase; Drug Therapy, Combination; Erythrocytes; Female; Free Radicals; Humans; Hydrogen Peroxide; Levodopa; Luminescent Measurements; Male; Middle Aged; Neutrophils; Nitric Oxide; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species; Superoxide Dismutase | 1996 |
Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Brain; Carbidopa; Drug Therapy, Combination; Female; Handwriting; Humans; Levodopa; Male; Microcomputers; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Signal Processing, Computer-Assisted; Treatment Outcome | 1996 |
High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pergolide | 1996 |
Augmentation of the restless legs syndrome with carbidopa/levodopa.
Topics: Carbidopa; Clinical Protocols; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Periodicity; Restless Legs Syndrome; Severity of Illness Index | 1996 |
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurologic Examination; Parkinson Disease, Secondary | 1995 |
[The prolactin and thyrotropic hormone content of the blood plasma in neostriatal dysfunction].
Topics: Basal Ganglia Diseases; Carbidopa; Dopamine Agonists; Dopamine Antagonists; Drug Combinations; Haloperidol; Humans; Immunoenzyme Techniques; Levodopa; Neostriatum; Prolactin; Thyrotropin; Time Factors | 1995 |
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use.
Topics: Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Drug Stability; Drug Storage; Humans; Levodopa; Light; Parkinson Disease; Temperature; Time Factors | 1996 |
Slow increase of homovanillic acid in cerebrospinal fluid after levodopa administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Homovanillic Acid; Humans; Hydrocephalus; Levodopa; Male; Middle Aged | 1996 |
Amantadine-induced "vocal" myoclonus.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Dysarthria; Female; Humans; Levodopa; Myoclonus; Neurologic Examination; Parkinson Disease; Verbal Behavior | 1996 |
Levodopa in pregnancy.
Topics: Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications; Risk Factors | 1996 |
Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia.
Topics: Adolescent; Adult; Calcium Channel Blockers; Carbidopa; Dopamine; Female; Humans; Hyperprolactinemia; Levodopa; Male; Middle Aged; Prolactin; Verapamil | 1996 |
Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease | 1995 |
Dopamine produced from L-DOPA is degraded by endogenous monoamine oxidase in neurons of the dorsal raphe nucleus of the rat: an immunohistochemical study.
Topics: Animals; Carbidopa; Dopamine; Enzyme Inhibitors; Immunohistochemistry; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Pargyline; Raphe Nuclei; Rats; Rats, Sprague-Dawley | 1996 |
[The brain catecholaminergic system during the long-term correction of hereditary arterial hypertension].
Topics: Animals; Brain; Brain Chemistry; Carbidopa; Dopamine; Dopamine Agents; Drug Combinations; Drug Evaluation, Preclinical; Hypertension; Levodopa; Male; Norepinephrine; Rats; Rats, Inbred SHR; Receptors, Catecholamine; Time Factors | 1996 |
In vivo microdialysis to determine the relative pharmacokinetics of drugs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benserazide; Brain Chemistry; Carbidopa; Chromatography, High Pressure Liquid; Dopamine; Drug Interactions; Electrochemistry; Homovanillic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Microdialysis; Neostriatum; Rats; Rats, Wistar | 1996 |
Mapping drug-induced changes in cerebral R2* by Multiple Gradient Recalled Echo functional MRI.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbidopa; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Parkinson Disease, Secondary | 1996 |
Supplement: treatment for Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1995 |
Circadian phase dependent pharmacokinetics of L-dopa, its main metabolites (3-OMD, HVA, DOPAC) and carbidopa in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Area Under Curve; Carbidopa; Circadian Rhythm; Half-Life; Homovanillic Acid; Levodopa; Male; Methyldopa; Rats; Rats, Wistar | 1996 |
Familial akathisia and depression treated with nefazodone.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Depressive Disorder; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Piperazines; Restless Legs Syndrome; Selective Serotonin Reuptake Inhibitors; Triazoles | 1996 |
Intrafamilial variability in Machado-Joseph disease.
Topics: Adult; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Genes, Dominant; Humans; Levodopa; Machado-Joseph Disease; Male; Neurologic Examination; Phenotype | 1996 |
Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian rat.
Topics: Amino Acid Oxidoreductases; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Benzoates; Benzoic Acid; Carbidopa; Female; Food Preservatives; Levodopa; Locomotion; Parkinson Disease, Secondary; Phenylpyruvic Acids; Rats; Rats, Sprague-Dawley | 1996 |
[Brain catecholamines and the hypothalamo-hypophyseal-adrenocortical system in hereditary arterial hypertension].
Topics: Aging; Animals; Blood Pressure; Brain; Brain Chemistry; Carbidopa; Catecholamines; Dopamine Agonists; Drug Combinations; Female; Hypertension; Hypothalamo-Hypophyseal System; Levodopa; Male; Pituitary-Adrenal System; Rats; Rats, Inbred SHR; Rats, Wistar; Stress, Psychological | 1996 |
Carbidopa/levodopa in the treatment of neuroleptic malignant syndrome.
Topics: Adult; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome | 1997 |
Protective effect of carbidopa on hydroxyl radical generation in the rat striatum by dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Dopamine; Dopamine Agents; Free Radicals; Hydroxides; Levodopa; Male; Microdialysis; Neostriatum; Neuroprotective Agents; Rats; Rats, Wistar; Sodium Salicylate | 1996 |
Triphasic waves in serotonin syndrome.
Topics: 1-Naphthylamine; Aged; Amantadine; Antiparkinson Agents; Brain Diseases; Carbidopa; Drug Combinations; Drug Therapy, Combination; Electroencephalography; Hallucinations; Humans; Levodopa; Male; Myoclonus; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Sertraline; Syndrome | 1997 |
Comparison of utilization of Sinemet and Parkinson's disease mortality as surrogate indicators of Parkinson's disease in the United States.
Topics: Antiparkinson Agents; Carbidopa; Demography; Drug Combinations; Drug Utilization; Humans; Levodopa; Linear Models; Parkinson Disease; United States | 1997 |
Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Pergolide; Restless Legs Syndrome; Severity of Illness Index; Treatment Outcome | 1996 |
Hydrocephalic parkinsonism due to Paget's disease of bone: dramatic improvement following ventriculoperitoneal shunt and temporary levodopa/carbidopa therapy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Hydrocephalus; Levodopa; Neurologic Examination; Osteitis Deformans; Parkinson Disease, Secondary; Ventriculoperitoneal Shunt | 1997 |
Levodopa in pregnancy.
Topics: Abortion, Spontaneous; Adult; Antiparkinson Agents; Carbidopa; Drug Combinations; Dystonia; Female; Humans; Infant, Newborn; Levodopa; Male; Pregnancy; Pregnancy Complications | 1997 |
The nurse's role in clinical trials.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials, Phase IV as Topic; Drug Combinations; Humans; Job Description; Levodopa; Nursing Care; Parkinson Disease | 1996 |
Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task.
Topics: Animals; Antiparkinson Agents; Appetitive Behavior; Brain Mapping; Carbidopa; Corpus Striatum; Dominance, Cerebral; Dopamine; Drug Combinations; Levodopa; Male; Mental Recall; Motor Skills; Oxidopamine; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reinforcement Schedule | 1997 |
Henoch-Schönlein syndrome induced by carbidopa/levodopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; IgA Vasculitis; Levodopa; Male | 1997 |
Validation of a rodent model of Parkinson's Disease: evidence of a therapeutic window for oral Sinemet.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Stereotyped Behavior | 1996 |
Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Autoradiography; Biomarkers; Carbidopa; Female; Functional Laterality; Immunohistochemistry; Levodopa; Motor Activity; Neurons; Neurotoxins; Oxidopamine; Radioimmunoassay; Rats; Rats, Wistar; Substantia Nigra; Sulfur Radioisotopes; Tegmentum Mesencephali; Tyrosine 3-Monooxygenase | 1997 |
Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
Topics: Adult; Aged; Amino Acids; Antiparkinson Agents; Brain; Carbidopa; Circadian Rhythm; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Severity of Illness Index; Time Factors | 1997 |
Acanthocytosis and spinocerebellar degeneration: a new association?
Topics: Acanthocytes; Adult; Anticonvulsants; Antiparkinson Agents; Carbidopa; Cerebellum; Clonazepam; Drug Therapy, Combination; Humans; Levodopa; Magnetic Resonance Imaging; Male; Spinocerebellar Degenerations; Videotape Recording; Vitamin E | 1997 |
Microdialysis-HPLC for plasma levodopa and metabolites monitoring in parkinsonian patients.
Topics: Aged; Carbidopa; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; Kinetics; Levodopa; Microdialysis; Middle Aged; Parkinson Disease | 1997 |
The combined use of amantadine and l-dopa/carbidopa in the treatment of chronic brain injury.
Topics: Amantadine; Behavior; Brain Injuries; Carbidopa; Chronic Disease; Cognition; Drug Therapy, Combination; Female; Humans; Levodopa; Mental Status Schedule; Middle Aged; Neuropsychological Tests | 1997 |
Flow injection spectrophotometric determination of L-Dopa and carbidopa in pharmaceutical formulations using a crude extract of sweet potato root [Ipomoea batatas (L.) Lam.] as enzymatic source.
Topics: Carbidopa; Dihydroxyphenylalanine; Levodopa; Spectrophotometry; Technology, Pharmaceutical; Vegetables | 1997 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
Amine precursor uptake and decarboxylation: significance for processing of the rat gastrin precursor.
Topics: Adrenergic Uptake Inhibitors; Animals; Biogenic Amines; Carbidopa; Decarboxylation; Dopamine Agents; Gastric Mucosa; Gastrins; Hydrogen-Ion Concentration; Levodopa; Male; Microscopy, Electron; Precipitin Tests; Protein Precursors; Protons; Rats; Rats, Wistar; Reserpine | 1997 |
The stability of carbidopa in solution.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Stability; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease; Solutions | 1997 |
Stability of levodopa/carbidopa solutions.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Stability; Humans; Levodopa; Reference Standards; Solutions | 1997 |
(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Dopamine Antagonists; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Posture; Raclopride; Salicylamides | 1997 |
Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Cerebral Ventricles; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; Glial Cell Line-Derived Neurotrophic Factor; Injections, Intraventricular; Levodopa; Macaca mulatta; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Parkinson Disease, Secondary; Stereotyped Behavior | 1997 |
[The effect of low doses of nakom on the hormonal secretion of the hypothalamo-hypophyseal-adrenal system in patients with infantile cerebral palsy].
Topics: Adolescent; Adrenal Cortex Hormones; Carbidopa; Cerebral Palsy; Child; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hypothalamic Hormones; Hypothalamo-Hypophyseal System; Levodopa; Male; Pituitary Hormones; Pituitary-Adrenal System | 1996 |
Different effects of levodopa and apomorphine on blink reflex recovery cycle in essential blepharospasm.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Blepharospasm; Blinking; Carbidopa; Dopamine; Dopamine Agonists; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Reaction Time; Synaptic Transmission | 1997 |
Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures.
Topics: Animals; Animals, Newborn; Carbidopa; Cell Survival; Coculture Techniques; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Glutathione; Levodopa; Mesencephalon; Nerve Growth Factors; Neurons; Rats; Tyrosine 3-Monooxygenase | 1997 |
Effects of L-DOPA/carbidopa administration on the levels of L-DOPA, other amino acids and related compounds in the plasma, brain and heart of the rat.
Topics: Amino Acids; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Brain Stem; Carbidopa; Cerebellum; Cerebral Cortex; Enzyme Inhibitors; Levodopa; Male; Mesencephalon; Myocardium; Rats; Rats, Sprague-Dawley | 1997 |
Use of carbidopa-levodopa in a patient with hydrocephalus and frozen movement.
Topics: Adult; Antiparkinson Agents; Basal Ganglia; Carbidopa; Cerebral Ventricles; Drug Therapy, Combination; Humans; Hydrocephalus; Levodopa; Male; Parkinson Disease, Secondary; Regional Blood Flow; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Ventriculoperitoneal Shunt | 1997 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Lisuride; Parkinson Disease; Reaction Time | 1994 |
Automated determination of levodopa and carbidopa in plasma by high-performance liquid chromatography-electrochemical detection using an on-line flow injection analysis sample pretreatment unit.
Topics: Animals; Antiparkinson Agents; Automation; Carbidopa; Chromatography, High Pressure Liquid; Dogs; Electrochemistry; Flow Injection Analysis; Levodopa; Male; Methyldopa; Reference Standards | 1997 |
Treatment with AC pulsed electromagnetic fields improves the response to levodopa in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Circadian Rhythm; Combined Modality Therapy; Drug Combinations; Electromagnetic Fields; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
[Body fat loss in patients with Parkinson's disease].
Topics: Adipose Tissue; Aged; Aged, 80 and over; Antiparkinson Agents; Body Mass Index; Body Weight; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Levodopa; Male; Movement Disorders; Nitriles; Severity of Illness Index | 1997 |
Coexistence of tics and parkinsonism: evidence for non-dopaminergic mechanisms in tic pathogenesis.
Topics: Aged; Carbidopa; Dopamine; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tic Disorders; Treatment Outcome | 1997 |
Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice.
Topics: Animals; Bromocriptine; Carbidopa; Catalepsy; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Kinetics; Levodopa; Male; Mice; Motor Activity | 1997 |
Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Humans; Inappropriate ADH Syndrome; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Trihexyphenidyl | 1998 |
Square-wave action dystonia in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Dominance, Cerebral; Drug Combinations; Dystonia; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1998 |
Hyperprolactinemia, a tool in treatment control of tetrahydrobiopterin deficiency: endocrine studies in an affected girl.
Topics: Adolescent; Biopterins; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Follicle Stimulating Hormone; Human Growth Hormone; Humans; Hydrocortisone; Hyperprolactinemia; Insulin; Levodopa; Luteinizing Hormone; Melatonin; Phenylketonurias; Phosphorus-Oxygen Lyases; Prolactin | 1998 |
[Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dopamine; Dopamine Agents; Drug Synergism; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Nitrophenols; Rats; Rats, Wistar; Tolcapone | 1998 |
The co-ordination and phasing of a bilateral prehension task. The influence of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Functional Laterality; Hand Strength; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reaction Time; Reference Values | 1998 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Levodopa; Nitrophenols; North America; Parkinson Disease; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
[Vascular parkinsonism].
Topics: Antiparkinson Agents; Brain Ischemia; Carbidopa; Drug Combinations; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Ultrasonography, Doppler, Transcranial | 1998 |
Quality of life and Parkinson's disease: the CR FIRST Study.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Emotions; Humans; Levodopa; Parkinson Disease; Quality of Life; Social Isolation; Treatment Outcome | 1998 |
Levodopa in human breast milk: clinical implications.
Topics: Adult; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Lactation; Levodopa; Milk, Human; Osmolar Concentration; Parkinson Disease | 1998 |
Pharmacologic management of movement disorder after midbrain haemorrhage.
Topics: Activities of Daily Living; Adult; Brain Neoplasms; Carbidopa; Cavernous Sinus; Central Nervous System Stimulants; Cerebral Hemorrhage; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Hemangioma, Cavernous; Humans; Levodopa; Male; Mesencephalon; Methamphetamine; Movement Disorders; Substance-Related Disorders | 1998 |
Orthostatic tremor: an electrophysiological analysis.
Topics: Aged; Antiparkinson Agents; Carbidopa; Central Nervous System Diseases; Clonazepam; Drug Combinations; Electroencephalography; Electromyography; Evoked Potentials; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Neurons; Muscle, Skeletal; Neural Conduction; Posture; Treatment Outcome; Tremor | 1998 |
Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Carbon Radioisotopes; Corpus Striatum; Dopamine; Enzyme Inhibitors; gamma-Aminobutyric Acid; Globus Pallidus; Hydrazines; Kinetics; Levodopa; Male; Microdialysis; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Salicylamides; Time Factors; Tomography, Emission-Computed | 1998 |
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs.
Topics: Animals; Benzophenones; Biological Transport; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Electrolytes; Enzyme Inhibitors; Female; Intestinal Mucosa; Intestinal Secretions; Intestines; Levodopa; Nitrophenols; Tolcapone | 1998 |
Biochemical hallmarks of tyrosine hydroxylase deficiency.
Topics: Adolescent; Age Factors; Biomarkers; Carbidopa; Child; Child, Preschool; Dopamine Agents; Drug Therapy, Combination; Dystonia; Female; Humans; Infant; Levodopa; Male; Reference Values; Specimen Handling; Tyrosine 3-Monooxygenase | 1998 |
Early dopaminergic drug-induced hallucinations in parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Follow-Up Studies; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1998 |
Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias.
Topics: Adult; Aged; Carbidopa; Case-Control Studies; Cerebrovascular Circulation; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Thalamus; Tomography, Emission-Computed | 1998 |
[A case of impending neuroleptic malignant syndrome associated with Shy-Drager syndrome].
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Fludrocortisone; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Shy-Drager Syndrome | 1998 |
[Amoxapine-induced pseudopheochromocytoma. Apropos of a case].
Topics: Adrenal Gland Neoplasms; Adrenergic Uptake Inhibitors; Aged; Amoxapine; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Drug Combinations; Drug Interactions; Epinephrine; Female; Humans; Levodopa; Norepinephrine; Pheochromocytoma | 1998 |
Reversible parkinsonism induced by prolonged treatment with valproate.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Remission Induction; Seizures; Valproic Acid | 1998 |
My doctor prescribed Sinemet for my restless legs and it was a catastrophe. Why did you recommend it in a recent article?
Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Restless Legs Syndrome | 1998 |
Dopaminergic therapy in acute encephalitis lethargica.
Topics: Acute Disease; Adolescent; Apomorphine; Carbidopa; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Parkinson Disease, Postencephalitic | 1999 |
Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Psychomotor Disorders; Treatment Outcome | 1999 |
Dopa responsive dystonia in a girl with vitiligo.
Topics: Adolescent; Anti-Dyskinesia Agents; Carbidopa; Circadian Rhythm; Dopamine Agents; Drug Combinations; Dystonia; Female; Follow-Up Studies; Humans; Levodopa; Vitiligo | 1998 |
L-dopa and cancer anorexia.
Topics: Anorexia; Carbidopa; Dopamine Agents; Humans; Levodopa; Male; Parkinson Disease; Urinary Bladder Neoplasms | 1999 |
In vivo effects of new inhibitors of catechol-O-methyl transferase.
Topics: Animals; Benzylidene Compounds; Carbidopa; Catalepsy; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Levodopa; Male; Mice; Motor Activity; Nitro Compounds; Rats; Rats, Sprague-Dawley; Reserpine; Vinyl Compounds | 1999 |
Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs.
Topics: Adult; Antiparkinson Agents; Brain Edema; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levodopa; Magnetic Resonance Imaging; Male; Methanol; Parkinson Disease, Secondary; Putamen; Tomography, X-Ray Computed | 1999 |
Effects of dopaminergic agents and of an NMDA receptor antagonist on motor coordination in Lurcher mutant mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Carbidopa; Dextromethorphan; Dopamine Agonists; Dopamine Antagonists; Female; Levodopa; Male; Mice; Mice, Neurologic Mutants; Olivopontocerebellar Atrophies; Psychomotor Performance; Receptors, N-Methyl-D-Aspartate | 1999 |
Principal component analysis of the dynamic response measured by fMRI: a generalized linear systems framework.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Mapping; Carbidopa; Dopamine Agents; Female; Levodopa; Linear Models; Macaca mulatta; Magnetic Resonance Imaging; Mathematics; Models, Statistical; Parkinson Disease, Secondary; Regression Analysis; Systems Analysis | 1999 |
Reduction in terminal excitability of nigrostriatal dopaminergic neurons in rats following chronic L-dopa administration.
Topics: Animals; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Evoked Potentials; Levodopa; Male; Neurons; Rats; Rats, Sprague-Dawley | 1999 |
Acute overdosage and intoxication with carbidopa/levodopa can be detected in the subacute stage by measurement of 3-o-methyldopa.
Topics: Aged; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Overdose; Humans; Levodopa; Male; Time Factors; Tyrosine | 1999 |
A novel mutation in the GTP cyclohydrolase I gene associated with a broad range of clinical presentations in a family with autosomal dominant dopa-responsive dystonia.
Topics: Antiparkinson Agents; Carbidopa; DNA; Dystonia; Exons; Genes, Dominant; GTP Cyclohydrolase; Humans; Jews; Levodopa; Point Mutation; Polymorphism, Genetic; Polymorphism, Single-Stranded Conformational | 1999 |
[High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Pramipexole; Thiazoles | 1999 |
Feeding behavior in dopamine-deficient mice.
Topics: Animals; Behavior, Animal; Brain; Carbidopa; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Feeding Behavior; Levodopa; Mice; Mice, Inbred C57BL; Motor Activity; Receptors, Dopamine D1; Receptors, Dopamine D2; Time Factors | 1999 |
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone | 1999 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders | 1999 |
Amelioration of sensory limb discomfort of restless legs syndrome by pallidotomy.
Topics: Anticonvulsants; Carbidopa; Disease Progression; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Treatment Outcome | 1999 |
Successful orchestration of antiparkinsonian pharmacotherapy.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Comorbidity; Disease Progression; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacists | 1999 |
Neuroendocrine responses to levodopa in multiple system atrophy (MSA).
Topics: Adult; Aged; Antiparkinson Agents; Blood Glucose; Carbidopa; Dopamine; Drug Combinations; Female; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Insulin-Like Growth Factor I; Levodopa; Male; Middle Aged; Multiple System Atrophy; Reference Values; Thyrotropin | 1999 |
Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Carbidopa; Carbon Radioisotopes; Corpus Striatum; Dihydroxyphenylalanine; Drug Combinations; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Raclopride; Receptors, Dopamine D2; Tomography, Emission-Computed | 1999 |
Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Interactions; Enzyme Inhibitors; Extracellular Space; Haloperidol; Homovanillic Acid; Levodopa; Male; Microdialysis; Nitrophenols; Piperazines; Rats; Rats, Wistar; Time Factors; Tolcapone; Visual Cortex | 1999 |
The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 2000 |
The effect of pregnancy in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; Levodopa; Neurologic Examination; Parkinson Disease; Pregnancy; Pregnancy Complications; Quality of Life | 2000 |
Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Rotation; Substantia Nigra; Sympatholytics | 2000 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2000 |
Simultaneous determination of levodopa, carbidopa and their metabolites in human plasma and urine samples using LC-EC.
Topics: Carbidopa; Chromatography, High Pressure Liquid; Dopamine Agents; Humans; Levodopa | 2000 |
Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection.
Topics: Adult; Antiparkinson Agents; Biological Availability; Carbidopa; Chromatography, High Pressure Liquid; Dopamine Agents; Female; Humans; Levodopa; Male | 2000 |
Parkinsonism, dystonia, and hemiatrophy.
Topics: Adolescent; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Child; Child, Preschool; Dominance, Cerebral; Drug Therapy, Combination; Dystonia; Humans; Infant; Infant, Newborn; Levodopa; Magnetic Resonance Imaging; Muscular Atrophy; Neurologic Examination; Parkinson Disease; Putamen; Treatment Outcome | 2000 |
Simultaneous stimulation of growth hormone, adrenocorticotropin and cortisol with L-dopa/L-carbidopa and propranolol in children of short stature.
Topics: Adolescent; Adrenocorticotropic Hormone; Carbidopa; Child; Child, Preschool; Dopamine Agents; Drug Synergism; Female; Growth Disorders; Growth Hormone; Humans; Hydrocortisone; Levodopa; Male; Pituitary Function Tests; Propranolol | 2000 |
Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Confusion; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Nitrophenols; Substance Withdrawal Syndrome; Tolcapone | 2000 |
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Catheterization; Caudate Nucleus; Cell Line; Dependovirus; Dopamine; Drug Administration Routes; Drug Combinations; Fluorine Radioisotopes; Genetic Therapy; Genetic Vectors; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Neurons; Parkinson Disease, Secondary; Prodrugs; Putamen; Tomography, Emission-Computed; Tyrosine; Tyrosine 3-Monooxygenase | 2000 |
Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Humans; Levodopa; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic | 2000 |
Variable absorption of carbidopa affects both peripheral and central levodopa metabolism.
Topics: Absorption; Adult; Aged; Antiparkinson Agents; Brain; Carbidopa; Child; Homovanillic Acid; Humans; Levodopa; Middle Aged | 2000 |
A possible association between exposure to n-hexane and parkinsonism.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Electromyography; Evoked Potentials, Auditory, Brain Stem; Evoked Potentials, Somatosensory; Hexanes; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Occupational Diseases; Parkinsonian Disorders; Selegiline; Solvents | 2000 |
Quality control of benserazide-levodopa and carbidopa-levodopa tablets by capillary zone electrophoresis.
Topics: Benserazide; Carbidopa; Electrophoresis, Capillary; Levodopa; Molecular Structure; Quality Control | 2000 |
Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents.
Topics: Antipsychotic Agents; Carbidopa; Dopamine Agonists; Drug Therapy, Combination; Female; Gambling; Humans; Impulsive Behavior; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Risperidone; Treatment Outcome | 2000 |
Influence of dopamine energic pharmacology drugs on secretion of the adrenocorticotropic hormone from the hypophysis.
Topics: Adrenocorticotropic Hormone; Animals; Bromocriptine; Carbidopa; Dopamine; Dopamine Agents; Drug Therapy, Combination; Levodopa; Male; Pituitary Gland; Rats; Rats, Wistar | 2000 |
Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls.
Topics: Aged; Antiparkinson Agents; Carbidopa; Case-Control Studies; Diagnosis, Computer-Assisted; Diagnosis, Differential; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinson Disease; Postural Balance; Posture; Severity of Illness Index; Supranuclear Palsy, Progressive | 2000 |
Dopa-induced blood flow responses in nonhuman primates.
Topics: Anesthetics, Dissociative; Animals; Antiparkinson Agents; Arousal; Carbidopa; Cerebrovascular Circulation; Dopamine; Frontal Lobe; Gyrus Cinguli; Ketamine; Levodopa; Macaca nemestrina; Male; Papio; Parkinson Disease; Putamen; Temporal Lobe; Tomography, Emission-Computed | 2000 |
Response to levodopa challenge in Tourette syndrome.
Topics: Adult; Carbidopa; Dopamine; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Pilot Projects; Severity of Illness Index; Single-Blind Method; Tourette Syndrome; Treatment Outcome | 2000 |
First measured plasma concentration value as C(max); impact on the C(max) confidence interval in bioequivalence studies.
Topics: Absorption; Adolescent; Adult; Anti-HIV Agents; Carbidopa; Computer Simulation; Confidence Intervals; Cross-Over Studies; Delayed-Action Preparations; Dopamine Agents; Drug Combinations; Humans; Individuality; Levodopa; Middle Aged; Models, Biological; Monte Carlo Method; Randomized Controlled Trials as Topic; Therapeutic Equivalency; Zidovudine | 2000 |
Case report: successful use of rectally administered levodopa-carbidopa.
Topics: Administration, Oral; Administration, Rectal; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Deglutition Disorders; Female; Humans; Levodopa; Parkinson Disease; Patient Compliance | 2001 |
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hydroxyl Radical; Levodopa; Male; Microdialysis; Nitriles; Nitrophenols; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar; Tolcapone | 2001 |
Pharmacological evidence for stimulation of growth hormone secretion by a central noradrenergic system in dogs.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Carbidopa; Catecholamines; Clonidine; Dogs; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Growth Hormone; Hypothalamo-Hypophyseal System; Injections, Intraventricular; Levodopa; Male; Neurons; Norepinephrine; Pimozide; Receptors, Adrenergic; Sympathetic Nervous System | 1976 |
Molecular analysis and long-term follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency.
Topics: Adolescent; Adult; Antioxidants; Biopterins; Carbidopa; Child; Child, Preschool; DNA Mutational Analysis; Dopamine Agents; Female; Follow-Up Studies; Genotype; Heterozygote; Homozygote; Humans; Infant; Infant, Newborn; Levodopa; Male; Mutation; Phenotype; Phenylketonurias; Phosphorus-Oxygen Lyases; Pterins; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2001 |
Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carbidopa; Decarboxylation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Levodopa; Male; Microdialysis; Neostriatum; Parkinson Disease; Rats; Rats, Wistar | 2001 |
L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells.
Topics: Antioxidants; Apoptosis; Ascorbic Acid; bcl-X Protein; Buthionine Sulfoximine; Carbidopa; Cell Differentiation; Culture Media, Conditioned; Culture Media, Serum-Free; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glutathione; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Levodopa; Neuroblastoma; Neuroglia; Neurons; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 2001 |
Atypical presentation of dopa-responsive dystonia: generalized hypotonia and proximal weakness.
Topics: Carbidopa; Child; Chromosome Aberrations; Chromosome Disorders; Circadian Rhythm; Drug Combinations; Dystonic Disorders; Gait; Genes, Dominant; GTP Cyclohydrolase; Humans; Levodopa; Male; Muscle Hypotonia; Muscle Weakness; Neurologic Examination; Point Mutation; Treatment Outcome | 2001 |
Post-stroke violent adventitial movement responsive to levo-dopa/carbi-dopa therapy.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Movement Disorders; Stroke; Treatment Outcome; Tremor | 2001 |
Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; Animals; Benzazepines; Brain Diseases; Carbidopa; Carrier Proteins; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine D2 Receptor Antagonists; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Malonates; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuropeptides; Oxidopamine; Rats; Rats, Wistar; Reactive Oxygen Species; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Reserpine; Succinate Dehydrogenase; Sulpiride; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2001 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Interactions; Homovanillic Acid; Hydroxyindoleacetic Acid; Hypokinesia; Immunohistochemistry; Isoquinolines; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Serotonin; Stereoisomerism; Substantia Nigra; Tetrahydroisoquinolines; Tyrosine 3-Monooxygenase | 2001 |
Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Binding Sites; Carbidopa; Crystallography, X-Ray; Dopa Decarboxylase; Drug Design; Humans; Kidney; Levodopa; Ligands; Models, Molecular; Parkinson Disease; Pliability; Protein Structure, Secondary; Swine | 2001 |
Interactions between deep brain stimulation and levodopa in Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electric Stimulation Therapy; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease; Reaction Time; Subthalamic Nucleus; Walking | 2001 |
Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Topics: Animals; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cerebral Cortex; Corpus Striatum; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Levodopa; Macaca fascicularis; Mazindol; Neural Pathways; Nitriles; Oxidative Stress; Reference Values; RNA, Messenger; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Periodic limb movement disorder : a clinical and polysomnographic study.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Carbidopa; Clonazepam; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Polysomnography; Retreatment | 2001 |
Chronic akinetic mutism after mesencephalic-diencephalic infarction: remediated with dopaminergic medications.
Topics: Adult; Akinetic Mutism; Carbidopa; Cerebral Infarction; Chronic Disease; Diencephalon; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Neuropsychological Tests; Pergolide | 2001 |
Life-threatening parkinsonism induced by kava-kava.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Kava; Levodopa; Middle Aged; Parkinsonian Disorders; Tremor | 2002 |
Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Anesthesia; Animals; Carbidopa; Catechol O-Methyltransferase; Corpus Striatum; Dopamine; Dopamine Agents; Female; Homovanillic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Methyldopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Norepinephrine | 2002 |
[Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Circadian Rhythm; Drug Tolerance; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2002 |
Duodenal levodopa infusion in Parkinson's disease--long-term experience.
Topics: Adult; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Duodenoscopy; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time | 2001 |
Entacapone in restless legs syndrome.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Middle Aged; Neurologic Examination; Nitriles; Restless Legs Syndrome | 2002 |
Bruxism as presenting feature of Parkinson's disease.
Topics: Antiparkinson Agents; Bruxism; Carbidopa; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Interactions; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Carbidopa; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Levodopa; Male; Parkinson Disease, Secondary; Recombinant Proteins; Treatment Outcome | 2002 |
Role of sphingosine synthesis inhibition in transcutaneous delivery of levodopa.
Topics: Acyltransferases; Administration, Cutaneous; Animals; beta-Alanine; Carbidopa; Dopamine Agents; Drug Stability; Enzyme Inhibitors; Female; Levodopa; Male; Rats; Rats, Wistar; Serine C-Palmitoyltransferase; Skin; Skin Absorption; Solvents; Sphingosine | 2002 |
[Hallucinations caused by paroxetine in combined usage of levodopa-carbidopa].
Topics: Antidepressive Agents, Second-Generation; Antiparkinson Agents; Carbidopa; Drug Interactions; Hallucinations; Levodopa; Parkinson Disease; Paroxetine | 2002 |
Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report.
Topics: Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Electromyography; Essential Tremor; Female; Humans; Levodopa; Neurologic Examination; Parkinson Disease; Posture; Receptors, Dopamine | 2002 |
[The use of amantadine sulfate in combined therapy of Parkinson's disease].
Topics: Aged; Amantadine; Carbidopa; Dopamine Agents; Drug Combinations; Drug Therapy, Combination; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2002 |
Levodopa-responsive rubral (Holmes') tremor.
Topics: Adult; Antiparkinson Agents; Ataxia; Carbidopa; Cerebral Hemorrhage; Dominance, Cerebral; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Mesencephalon; Neurologic Examination; Tomography, X-Ray Computed; Treatment Outcome | 2002 |
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Electrodes, Implanted; Female; Globus Pallidus; Levodopa; Neurons; Organic Chemicals; Parkinsonian Disorders | 2002 |
[Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Synergism; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Olanzapine: a proarrhythmic drug?
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Carbidopa; Electrocardiography; Female; Humans; Levodopa; Long QT Syndrome; Olanzapine; Pirenzepine; Psychoses, Substance-Induced; Risk Factors | 2002 |
Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Binding Sites; Binding, Competitive; Brain; Carbidopa; Clonidine; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonists; Enzyme Inhibitors; Female; Isoquinolines; Kinetics; Lactation; Levodopa; Male; Mazindol; Median Eminence; Methyldopa; Pituitary Gland; Pituitary Gland, Posterior; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reserpine | 2003 |
Effect of promoters on cellular immune response induced by recombinant fowlpox virus expressing multi-epitope polypeptides from HIV-1.
Topics: Animals; Carbidopa; CD8-Positive T-Lymphocytes; Cell Line; Chickens; Drug Combinations; Epitopes; Epitopes, T-Lymphocyte; Female; Fowlpox virus; Gene Expression Regulation, Viral; HIV Antigens; Immunity, Cellular; Levodopa; Mice; Peptides; Promoter Regions, Genetic; Recombinant Fusion Proteins; Recombination, Genetic; T-Lymphocytes, Cytotoxic; Vaccinia virus | 2002 |
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Cytoplasm; Drug Combinations; Indoles; Levodopa; Male; Microscopy, Immunoelectron; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Synaptic Membranes; Tyrosine 3-Monooxygenase | 2002 |
Clozapine withdrawal symptoms in a Parkinson's disease patient.
Topics: Aged; Antipsychotic Agents; Carbidopa; Clozapine; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Hallucinations; Humans; Levodopa; Male; Neurologic Examination; Parkinson Disease; Parkinson Disease, Secondary; Substance Withdrawal Syndrome | 2002 |
Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Female; Hip; Humans; Knee; Levodopa; Lower Extremity; Male; Middle Aged; Muscle Weakness; Muscle, Skeletal; Parkinson Disease; Posture; Random Allocation; Severity of Illness Index | 2003 |
Neonatal dopa-responsive extrapyramidal syndrome in twins with recessive GTPCH deficiency.
Topics: Adolescent; Antiparkinson Agents; Basal Ganglia Diseases; Carbidopa; Dopamine Agents; Dystonia; Female; Follow-Up Studies; Genes, Recessive; GTP Cyclohydrolase; Homozygote; Humans; Infant, Newborn; Infant, Newborn, Diseases; Levodopa; Metabolism, Inborn Errors; Muscle Rigidity; Mutation; Reflex, Abnormal; Remission Induction; Treatment Outcome; Tremor | 2003 |
Reversal of parkinsonism following liver transplantation.
Topics: Acute Disease; Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Gait Disorders, Neurologic; Humans; Immunosuppressive Agents; Levodopa; Liver Cirrhosis; Liver Transplantation; Male; Parkinsonian Disorders; Remission Induction; Treatment Outcome; Tremor | 2003 |
[A preliminary report of the effect of levodopa and carbidopa for childhood amblyopia].
Topics: Adolescent; Amblyopia; Carbidopa; Child; Child, Preschool; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Scotoma; Visual Acuity | 1998 |
Role of adenosine in drug-induced catatonia in mice.
Topics: Adenosine; Animals; Antiparkinson Agents; Brain; Carbidopa; Catatonia; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Levodopa; Male; Mice; Motor Activity; Perphenazine | 2002 |
Viral encephalitis complicated by neuroleptic malignant syndrome in a 7-year-old girl.
Topics: Anticonvulsants; Carbidopa; Child; Dopamine Agents; Drug Therapy, Combination; Encephalitis, Viral; Epilepsy, Tonic-Clonic; Female; Haloperidol; Humans; Hypnotics and Sedatives; Levodopa; Neuroleptic Malignant Syndrome; Psychomotor Agitation | 2003 |
Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Basal Ganglia; Carbidopa; Dopamine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Reading; Speech Production Measurement; Stuttering | 2003 |
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Nitriles; Parkinsonian Disorders; Pulse Therapy, Drug; Substantia Nigra; Time Factors | 2003 |
Rapid intravenous loading of levodopa for human research: clinical results.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease; Tourette Syndrome | 2003 |
Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy.
Topics: Antiparkinson Agents; Atrophy; Carbidopa; Combined Modality Therapy; Contraindications; Deglutition Disorders; Diagnosis, Differential; Dysarthria; Electric Stimulation Therapy; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Microelectrodes; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pons; Putamen; Subthalamic Nucleus | 2003 |
L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients.
Topics: Adenosine Diphosphate; Aged; Arylsulfotransferase; Biotransformation; Blood Platelets; Carbidopa; Catechol O-Methyltransferase; Dose-Response Relationship, Drug; Drug Combinations; Erythrocytes; Female; Humans; Levodopa; Male; Methylation; Middle Aged; Parkinson Disease; S-Adenosylmethionine; Sulfates | 2003 |
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Apomorphine; Cannabinoids; Carbidopa; Cell Line, Tumor; Dronabinol; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rotation; Substantia Nigra | 2003 |
[Respiratory regulation during adaptation to intermittent hypoxia in patients with Parkinson disease].
Topics: Adaptation, Physiological; Carbidopa; Dopamine Agents; Humans; Levodopa; Middle Aged; Oxygen; Parkinson Disease; Respiratory Mechanics | 2003 |
Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Benzopyrans; Carbidopa; Cocaine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Female; Grooming; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Oxazines; Pyrroles; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3; Stereotyped Behavior | 2003 |
Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment.
Topics: Antimetabolites, Antineoplastic; Antiparkinson Agents; Carbidopa; Child; Cytarabine; Humans; Levodopa; Male; Parkinson Disease, Secondary | 2003 |
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Topics: Animals; Antiparkinson Agents; Callithrix; Carbidopa; Chlorobenzenes; Cyclobutanes; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Postural Balance; Stereotyped Behavior | 2004 |
Split spinal cord malformation in an elderly patient: case report.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Carbidopa; Clonazepam; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Low Back Pain; Magnetic Resonance Imaging; Movement Disorders; Spinal Dysraphism; Tomography, X-Ray Computed | 2004 |
Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; DNA Mutational Analysis; Drug Combinations; Dystonic Disorders; Exercise; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Phenotype; Semen; Ubiquitin-Protein Ligases; Videotape Recording | 2004 |
Levodopa-responsive aromatic L-amino acid decarboxylase deficiency.
Topics: Adolescent; Adult; Alanine; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Binding Sites; Carbidopa; Chromatography, High Pressure Liquid; Developmental Disabilities; DNA Mutational Analysis; Drug Combinations; Electrochemistry; Family Health; Female; Glycine; Humans; Levodopa; Male; Models, Structural; Point Mutation; Protein Binding; Protein Conformation | 2004 |
Apraxia of lid opening: dose-dependent response to carbidopa-levodopa.
Topics: Aged; Apraxia, Ideomotor; Blepharospasm; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Eyelid Diseases; Eyelids; Female; Humans; Levodopa; Lewy Body Disease; Time Factors | 2004 |
Drug adherence in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chronic Disease; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Female; Humans; Levodopa; Male; Medication Systems; Parkinson Disease; Patient Compliance; Surveys and Questionnaires | 2004 |
Stalevo for Parkinson's disease.
Topics: Carbidopa; Catechols; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Nausea; Nitriles; Parkinson Disease | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide | 2004 |
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 2004 |
Markedly asymmetrical parkinsonism as a leading feature of adult-onset Huntington's disease.
Topics: Adult; Alleles; Antiparkinson Agents; Carbidopa; Cognition Disorders; Diagnosis, Differential; Drug Combinations; Humans; Huntington Disease; Levodopa; Male; Neuropsychological Tests; Parkinsonian Disorders; Pedigree; Severity of Illness Index | 2004 |
Levodopa with carbidopa diminishes glycogen concentration, glycogen synthase activity, and insulin-stimulated glucose transport in rat skeletal muscle.
Topics: Animals; Carbidopa; Dopamine Agents; Drug Synergism; Glucose; Glucose Tolerance Test; Glycogen; Glycogen Synthase; Hypoglycemic Agents; Insulin; Insulin Resistance; Levodopa; Male; Muscle, Skeletal; Rats; Rats, Wistar | 2004 |
[Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson's disease].
Topics: Aged; Amino Acids; Carbidopa; Drug Therapy, Combination; Electroencephalography; Evoked Potentials; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Treatment Outcome | 2004 |
Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
Topics: Age Factors; Animals; Behavior, Animal; Benzazepines; Carbidopa; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Antagonists; Dopamine beta-Hydroxylase; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Gene Expression; Haloperidol; In Situ Hybridization; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Neurotensin; Pyrazoles; Quinolines; Receptors, Neurotensin; RNA, Messenger; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase | 2004 |
Superficial siderosis of the central nervous system associated with parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Central Nervous System Diseases; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Siderosis | 2004 |
Pathophysiology of parkinsonism due to hydrocephalus.
Topics: Adult; Antiparkinson Agents; Brain Mapping; Carbidopa; Caudate Nucleus; Cerebral Ventricles; Drug Combinations; Equipment Failure; Humans; Hydrocephalus; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Neurologic Examination; Parkinsonian Disorders; Positron-Emission Tomography; Postoperative Complications; Putamen; Ventriculoperitoneal Shunt | 2004 |
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Subcutaneous; Levodopa; Locomotion; Male; MPTP Poisoning; Nitriles; Severity of Illness Index; Substantia Nigra; Time Factors | 2005 |
A young onset Parkinson's patient: a case study.
Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Dibenzothiazepines; Disease Progression; Dyskinesias; Humans; Levodopa; Male; Motor Skills; Nurse's Role; Parkinson Disease; Patient Advocacy; Patient Education as Topic; Quality of Life; Quetiapine Fumarate; Rhabdomyolysis; Severity of Illness Index; Social Support; Treatment Outcome | 2004 |
Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment.
Topics: Adult; Brain Injuries; Carbidopa; Consciousness; Dopamine Agents; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement; Persistent Vegetative State; Prospective Studies; Time Factors; Treatment Outcome | 2004 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Enzyme Activation; Ergolines; Glutathione; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Neurotoxicity Syndromes; Oxidopamine; Thiobarbituric Acid Reactive Substances | 2005 |
[18F]FDOPA PET and clinical features in parkinsonism due to manganism.
Topics: Adult; Antiparkinson Agents; Brain; Carbidopa; Drug Combinations; Female; Fluorodeoxyglucose F18; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Manganese Poisoning; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats.
Topics: Animals; Biotransformation; Carbidopa; Drug Evaluation, Preclinical; Levodopa; Male; Microspheres; Parkinsonian Disorders; Rats | 2005 |
Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Fees, Pharmaceutical; Humans; Levodopa; Parkinson Disease | 2005 |
Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Female; Gait; Humans; Levodopa; Male; Middle Aged; Motor Skills; Motor Skills Disorders; Parkinson Disease; Severity of Illness Index; Speech Acoustics; Time Factors | 2005 |
[Use of tremonorm in treatment of Parkinson's disease: outpatient experience of Moscow Municipal Health Care Service].
Topics: Carbidopa; Data Interpretation, Statistical; Drug Combinations; Dyspepsia; Humans; Levodopa; Mental Status Schedule; Moscow; Outpatients; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2004 |
Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Dyskinesias; France; Gastrointestinal Diseases; Humans; Levodopa; Parkinson Disease | 2005 |
Signal transduction pathways of nitric oxide release in primary microglial culture challenged with gram-positive bacterial constituent, lipoteichoic acid.
Topics: Animals; Antibodies; Blotting, Western; Carbidopa; Cells, Cultured; Dose-Response Relationship, Drug; Drug Combinations; Eye Proteins; Fluorescent Antibody Technique; gamma-Synuclein; Gene Expression Regulation; I-kappa B Proteins; Indoles; Lectins; Levodopa; Lipopolysaccharide Receptors; Lipopolysaccharides; Microglia; Nerve Tissue Proteins; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Wistar; Signal Transduction; Teichoic Acids; Time Factors | 2005 |
6-pyruvoyl-tetrahydropterin synthase deficiency with mild hyperphenylalaninemia.
Topics: 5-Hydroxytryptophan; Biopterins; Carbidopa; Cerebral Palsy; Child; Developmental Disabilities; Diagnostic Errors; Dopamine Agents; Female; Humans; Levodopa; Movement Disorders; Phenylalanine; Phenylketonurias; Phosphorus-Oxygen Lyases; Seizures | 2005 |
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Carbidopa; Catechols; Child; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; United Kingdom | 2005 |
[Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Intubation, Gastrointestinal; Levodopa; Parkinson Disease | 2005 |
Effects of deep brain stimulation and medication on strength, bradykinesia, and electromyographic patterns of the ankle joint in Parkinson's disease.
Topics: Ankle Joint; Antiparkinson Agents; Biomechanical Phenomena; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Electrodes, Implanted; Electromyography; Humans; Hypokinesia; Isometric Contraction; Levodopa; Muscle Weakness; Muscle, Skeletal; Parkinson Disease; Reference Values; Signal Processing, Computer-Assisted; Statistics as Topic; Torque; Treatment Outcome; Tremor | 2006 |
Psychiatric sequelae of Parkinson disease: a case report.
Topics: Antiparkinson Agents; Cabergoline; Carbidopa; Compulsive Behavior; Drug Combinations; Ergolines; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Offenses | 2006 |
Hydrosoluble fiber (Plantago ovata husk) and levodopa II: experimental study of the pharmacokinetic interaction in the presence of carbidopa.
Topics: Administration, Oral; Animals; Area Under Curve; Carbidopa; Dietary Fiber; Levodopa; Metabolic Clearance Rate; Models, Animal; Models, Biological; Phytotherapy; Plantago; Rabbits | 2005 |
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2006 |
[Continuous treatment with levodopa of Parkinson disease].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Humans; Infusion Pumps; Levodopa; Middle Aged; Parkinson Disease | 2005 |
Hemiparkinsonism with a discrete lacunar infarction in the contralateral substantia nigra.
Topics: Antiparkinson Agents; Brain Stem Infarctions; Carbidopa; Cerebral Infarction; Diagnosis, Differential; Dominance, Cerebral; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Substantia Nigra; Tomography, Emission-Computed, Single-Photon | 2006 |
Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Carbidopa; Cell Count; Cells, Cultured; Dihydroergocryptine; Dopamine; Dopamine Agents; Dopamine Antagonists; Drug Synergism; Female; Lactic Acid; Levodopa; Mice; Neuroglia; Neurons; Pregnancy; Sulpiride; Tyrosine 3-Monooxygenase | 2006 |
Augmentation of artistic productivity in Parkinson's disease.
Topics: Antiparkinson Agents; Art; Carbidopa; Creativity; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Frontal Lobe; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Poetry as Topic | 2006 |
Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
Topics: Administration, Oral; Aged; Carbidopa; Disease Progression; Dopamine Agents; Drug Combinations; Female; Humans; Intestinal Pseudo-Obstruction; Intestine, Small; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Substance Withdrawal Syndrome; Treatment Failure | 2005 |
Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dopa Decarboxylase; Dopamine Agents; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Levodopa; Longitudinal Studies; Male; Middle Aged; Models, Biological; Parkinson Disease | 2005 |
Familial dopa-responsive cervical dystonia.
Topics: Adolescent; Adult; Antiparkinson Agents; Carbidopa; Child; Child, Preschool; Female; Humans; Islam; Levodopa; Male; Pedigree; Siblings; Torticollis | 2006 |
Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Calibration; Carbidopa; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Levodopa; Tyrosine | 2006 |
Effective treatment with levodopa and carbidopa for hypomyelination with atrophy of the basal ganglia and cerebellum.
Topics: Administration, Oral; Antiparkinson Agents; Atrophy; Basal Ganglia; Carbidopa; Cerebellum; Child, Preschool; Demyelinating Diseases; Diagnosis, Differential; Drug Therapy, Combination; Dystonia; Fluorodeoxyglucose F18; Humans; Levodopa; Magnetic Resonance Imaging; Male; Positron-Emission Tomography; Spinocerebellar Degenerations; Treatment Outcome | 2006 |
OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Dominance, Cerebral; Drug Therapy, Combination; Dyskinesias; Electrodes, Implanted; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Secondary Prevention; Stereotaxic Techniques; Substance Withdrawal Syndrome; Subthalamic Nucleus | 2006 |
Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Dopamine Agents; Drug Administration Routes; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Predictive Value of Tests; Treatment Outcome | 2006 |
Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome.
Topics: Adrenergic beta-Antagonists; Aged; Anxiety Disorders; Benzodiazepines; Carbidopa; Central Nervous System Agents; Cerebellar Ataxia; Cholinesterase Inhibitors; Dopamine Agonists; Female; Fragile X Syndrome; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Tremor | 2006 |
[Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
Topics: Anxiety; Benzothiazoles; Carbidopa; Delayed-Action Preparations; Depression; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Receptors, Dopamine D1; Thiazoles; Treatment Outcome | 2006 |
Levodopa can worsen tremor associated with dystonia.
Topics: Aged; Antiparkinson Agents; Carbidopa; Diagnostic Errors; Drug Combinations; Dystonia; Female; Humans; Levodopa; Neurologic Examination; Parkinsonian Disorders; Psychomotor Performance; Tremor | 2006 |
The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing.
Topics: Animals; Carbidopa; Drug Combinations; Female; Fracture Healing; Levodopa; Rats; Rats, Sprague-Dawley | 2006 |
Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy.
Topics: Acetaminophen; Acyclovir; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiparkinson Agents; Antiviral Agents; Anxiety; Carbidopa; Ceftriaxone; Cervical Vertebrae; Depression; Dexamethasone; Diazepam; Doxepin; Electroconvulsive Therapy; Humans; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Oxycodone; Pain; Parkinson Disease; Selegiline; Spinal Injuries | 2006 |
[Case of juvenile parkinsonism in pregnancy].
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Contraindications; Dopamine Agents; Dopamine Agonists; Ergolines; Family Planning Services; Female; Humans; Infant, Newborn; Levodopa; Parkinsonian Disorders; Pramipexole; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiazoles | 2006 |
D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminase.
Topics: Animals; Carbidopa; D-Amino-Acid Oxidase; Dihydroxyphenylalanine; Enzyme Inhibitors; Kidney; Levodopa; Mice; Rats; Rats, Sprague-Dawley; Sodium Benzoate | 2006 |
Sepiapterin reductase deficiency: clinical presentation and evaluation of long-term therapy.
Topics: 5-Hydroxytryptophan; Adolescent; Alcohol Oxidoreductases; Antidepressive Agents, Second-Generation; Carbidopa; Child; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Metabolism, Inborn Errors; Treatment Outcome | 2006 |
Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Basal Ganglia; Carbidopa; Ethylene Glycol; Female; Humans; Levodopa; Male; Methanol; Necrosis; Parkinson Disease, Secondary; Respiratory Insufficiency; Tomography, X-Ray Computed | 2007 |
Cerebral folate deficiency and folinic acid treatment in hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) syndrome.
Topics: Antiparkinson Agents; Atrophy; Basal Ganglia; Brain Diseases, Metabolic; Carbidopa; Cerebellum; Demyelinating Diseases; Dystonia; Female; Folic Acid Deficiency; Humans; Leucovorin; Levodopa; Male; Syndrome; Tetrahydrofolates; Treatment Outcome; Vitamin B Complex | 2007 |
Carbidopa/levodopa-responsive myoclonus.
Topics: Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Myoclonus | 2007 |
Skin rash associated with Sinemet does not equal levodopa allergy.
Topics: Aged; Antiparkinson Agents; Carbidopa; Coloring Agents; Drug Combinations; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Skin; Withholding Treatment | 2007 |
Simultaneous kinetic determination of levodopa and carbidopa by H-point standard addition method.
Topics: Antiparkinson Agents; Carbidopa; Ethanol; Excipients; Hydrogen-Ion Concentration; Kinetics; Levodopa; Osmolar Concentration; Oxidation-Reduction; Pharmaceutical Preparations; Phenanthrolines; Sensitivity and Specificity; Solubility; Spectrophotometry; Surface-Active Agents; Tablets; Temperature | 2007 |
Panic attack like episodes possibly associated with pramipexole therapy in Parkinson's disease.
Topics: Anxiety Disorders; Benzothiazoles; Carbidopa; Central Nervous System; Diazepam; Dopamine Agonists; Dose-Response Relationship, Drug; Female; GABA Agonists; Humans; Levodopa; Middle Aged; Panic Disorder; Parkinson Disease; Pramipexole; Self Administration | 2007 |
Simultaneous spectrophotometric determination of levodopa and carbidopa in pharmaceutical formulations and water samples by using mean centering of ratio spectra and H-point standard addition methods.
Topics: 4-Aminobenzoic Acid; Carbidopa; Levodopa; Pharmaceutical Preparations; Spectrum Analysis | 2007 |
I couldn't sleep at all last night.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Restless Legs Syndrome; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2005 |
Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Levodopa; Male; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra | 2007 |
Fracture risk associated with parkinsonism and anti-Parkinson drugs.
Topics: Adult; Age Factors; Antiparkinson Agents; Carbidopa; Case-Control Studies; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Female; Fractures, Bone; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Risk Factors; Sex Factors; Time Factors | 2007 |
[Association between amytrophic lateral sclerosis and Parkinson's disease].
Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cabergoline; Carbidopa; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Riluzole; Time Factors; Tomography, X-Ray Computed | 2007 |
Simultaneous kinetic-spectrophotometric determination of carbidopa, levodopa and methyldopa in the presence of citrate with the aid of multivariate calibration and artificial neural networks.
Topics: Calibration; Carbidopa; Citric Acid; Humans; Hydrogen-Ion Concentration; Kinetics; Levodopa; Methyldopa; Neural Networks, Computer; Spectrophotometry | 2007 |
Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
Topics: Acute Disease; Antipsychotic Agents; Brief Psychiatric Rating Scale; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Thiazoles | 2008 |
Simultaneous determination of levodopa and carbidopa in levodopa-carbidopa tablets by ATR-FTIR spectrometry.
Topics: Antiparkinson Agents; Carbidopa; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Drug Combinations; Levodopa; Spectroscopy, Fourier Transform Infrared; Tablets | 2007 |
Acute overdose with controlled-release levodopa-carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine; Drug Combinations; Drug Overdose; Epinephrine; Humans; Kinetics; Levodopa; Male; Middle Aged; Norepinephrine; Psychomotor Agitation; Psychoses, Substance-Induced; Tachycardia | 2008 |
Dopa-responsive dystonia presenting as delayed and awkward gait.
Topics: Carbidopa; Child, Preschool; Dopamine Agonists; Drug Combinations; Dystonic Disorders; Gait Disorders, Neurologic; GTP Cyclohydrolase; Humans; Levodopa; Male; Mutation; Pedigree | 2008 |
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Cholinergic Antagonists; Dopamine Agonists; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Selegiline; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2008 |
Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients.
Topics: 5-Hydroxytryptophan; Aromatic Amino Acid Decarboxylase Inhibitors; Biomarkers; Carbidopa; Child, Preschool; Dietary Proteins; Dihydropteridine Reductase; Dopa Decarboxylase; Dopamine Agents; Drug Monitoring; Drug Therapy, Combination; Enzyme Inhibitors; Genetic Predisposition to Disease; Humans; Infant; Infant, Newborn; Italy; Levodopa; Monoamine Oxidase Inhibitors; Mutation; Neonatal Screening; Neurologic Examination; Phenotype; Phenylketonurias; Prolactin; Selegiline; Time Factors; Treatment Outcome | 2008 |
The hydrosoluble fiber Plantago ovata husk improves levodopa (with carbidopa) bioavailability after repeated administration.
Topics: Administration, Oral; Analysis of Variance; Animals; Area Under Curve; Biological Availability; Carbidopa; Dietary Fiber; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Levodopa; Metabolic Clearance Rate; Models, Animal; Plantago; Rabbits; Time Factors | 2008 |
Simultaneous determination of levodopa and carbidopa by synchronous fluorescence spectrometry using double scans.
Topics: Carbidopa; Levodopa; Pharmaceutical Preparations; Sensitivity and Specificity; Spectrometry, Fluorescence; Time Factors | 2008 |
Altered behavioural and neurochemical profile of L-DOPA following deuterium substitutions in the molecule.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Carbidopa; Deuterium; Dopamine; Dopamine Agents; Levodopa; Male; Microdialysis; Motor Activity; Rats; Rats, Wistar; Time Factors | 2008 |
Flow-batch technique for the simultaneous enzymatic determination of levodopa and carbidopa in pharmaceuticals using PLS and successive projections algorithm.
Topics: Algorithms; Buffers; Carbidopa; Catechol Oxidase; Computer Simulation; Ipomoea batatas; Least-Squares Analysis; Levodopa; Linear Models; Oxidation-Reduction; Pharmaceutical Preparations; Phosphates; Spectrophotometry; Time Factors | 2008 |
Response of motor complications in Cockayne syndrome to carbidopa-levodopa.
Topics: Adolescent; Carbidopa; Cockayne Syndrome; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Movement Disorders | 2008 |
Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dystonic Disorders; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Tropanes | 2008 |
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
Topics: Aged; Antiparkinson Agents; Azepines; Benzothiazoles; Cabergoline; Carbidopa; Catatonia; Catechols; Drug Therapy, Combination; Electroconvulsive Therapy; Ergolines; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2009 |
Case studies in the advancement of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary | 2008 |
Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Benzothiazoles; Brain; Carbidopa; Dopamine Agents; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Severity of Illness Index; Time Factors; Tomography, Emission-Computed, Single-Photon; Tropanes | 2009 |
Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Compulsive Behavior; Dopamine Agonists; Female; Gambling; Humans; Indoles; Levodopa; Libido; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies | 2009 |
Cyclosporine-induced parkinsonism.
Topics: Antiparkinson Agents; Brain; Carbidopa; Cyclosporine; Fatal Outcome; Hematoma, Subdural; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Stem Cell Transplantation | 2009 |
Effects of Plantago ovata husk on levodopa (with Carbidopa) bioavailability in rabbits with autonomic gastrointestinal disorders.
Topics: Animals; Autonomic Nervous System; Biological Availability; Carbidopa; Gastrointestinal Diseases; Levodopa; Plantago; Rabbits | 2009 |
Simultaneous kinetic-spectrofluorometric determination of levodopa and carbidopa using partial least-squares regression.
Topics: Antiparkinson Agents; Carbidopa; Cerium; Fluorescence; Hydrogen-Ion Concentration; Kinetics; Least-Squares Analysis; Levodopa; Oxidation-Reduction; Pharmaceutical Preparations; Spectrometry, Fluorescence; Sulfuric Acids; Temperature | 2009 |
Restless legs syndrome.
Topics: Algorithms; Amines; Analgesics, Opioid; Benzodiazepines; Carbidopa; Causality; Cyclohexanecarboxylic Acids; Dopamine Agents; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives; Levodopa; Middle Aged; Oxycodone; Practice Guidelines as Topic; Restless Legs Syndrome; Treatment Outcome | 2009 |
Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Carbidopa; Drug Therapy, Combination; Follow-Up Studies; Gambling; Humans; Levodopa; Male; Parkinson Disease; Pramipexole | 2009 |
[Long term experience with Stalevo in Szeged, Hungary].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Resistance; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Levodopa/carbidopa/entacapone in Parkinson's disease.
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Catechols; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2009 |
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Dihydroxyphenylalanine; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Tyrosine | 2009 |
Cavernous hemangioma: a rare cause for secondary parkinsonism: a case report.
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Carbidopa; Female; Globus Pallidus; Hemangioma, Cavernous, Central Nervous System; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Putamen; Tomography, X-Ray Computed; Treatment Failure | 2009 |
The effect of memantine and levodopa/carbidopa on the responses of phrenic nerve-diaphragm preparations from aged rats.
Topics: Aging; Animals; Carbidopa; Diaphragm; Electric Stimulation; Gallamine Triethiodide; Gene Expression Regulation; Levodopa; Male; Memantine; Muscle Contraction; Neostigmine; Neuromuscular Blockade; Phrenic Nerve; Protein Subunits; Rats; Receptors, Nicotinic; RNA, Messenger | 2009 |
Importance of membrane-bound catechol-O-methyltransferase in L-DOPA metabolism: a pharmacokinetic study in two types of Comt gene modified mice.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Blotting, Western; Carbidopa; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Female; Immunohistochemistry; Isoenzymes; Levodopa; Male; Mice; Mice, Knockout; Sex Factors; Time Factors | 2009 |
Caffeic acid improves the bioavailability of L-dopa in rabbit plasma.
Topics: Animals; Caffeic Acids; Carbidopa; Coumaric Acids; Levodopa; Rabbits; Tyrosine | 2010 |
Sildenafil induced choreoathetosis in men with Parkinson's disease.
Topics: Antiparkinson Agents; Athetosis; Carbidopa; Chorea; Drug Combinations; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2010 |
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Callithrix; Carbidopa; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Motor Activity; MPTP Poisoning; Pramipexole; Time Factors | 2010 |
Biochemical alterations of dopamine receptor responses following chronic L-dopa therapy.
Topics: Adenylyl Cyclases; Animals; Carbidopa; Corpus Striatum; Dopamine; Drug Interactions; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Methoxyhydroxyphenylglycol; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Spiperone | 1980 |
Quantitative analysis of levodopa, carbidopa and methyldopa in human plasma samples using HPLC-DAD combined with second-order calibration based on alternating trilinear decomposition algorithm.
Topics: Algorithms; Calibration; Carbidopa; Chemistry Techniques, Analytical; Chromatography; Chromatography, High Pressure Liquid; Humans; Levodopa; Methyldopa; Models, Chemical; Reproducibility of Results; Solvents | 2010 |
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Callithrix; Carbidopa; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Female; Levodopa; Male; Methyldopa; Motor Activity; Movement Disorders | 2010 |
Oral administration of a tri-therapy for central pattern generator activation in paraplegic mice: proof-of-concept of efficacy.
Topics: Administration, Oral; Animals; Biological Clocks; Buspirone; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Gait Disorders, Neurologic; Levodopa; Male; Mice; Paraplegia; Serotonin Receptor Agonists; Spinal Cord | 2010 |
Evaluation and optimization of preparative variables for controlled-release floating microspheres of levodopa/carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Drug Compounding; Kinetics; Levodopa; Microscopy, Electron, Scanning; Microspheres; Particle Size; Solubility | 2010 |
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Carbidopa; Catechols; Cohort Studies; Dosage Forms; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Compliance; Retrospective Studies; Tablets | 2010 |
Tremor following ischemic stroke of the posterior thalamus.
Topics: Carbidopa; Dopamine Agents; Female; Humans; Hypercholesterolemia; Hypertension; Levodopa; Magnetic Resonance Imaging; Middle Aged; Stroke; Thalamus; Tremor | 2010 |
Levodopa-responsive parkinsonism after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Subarachnoid Hemorrhage; Substantia Nigra | 2010 |
Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain; Carbidopa; Catechol O-Methyltransferase; Dopamine; Drug Combinations; Extracellular Space; Female; Levodopa; Male; Methylation; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Mutation; Phenotype; Sensory Gating; Sex Factors; Social Dominance | 2010 |
An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Enteral Nutrition; Food-Drug Interactions; Humans; Intensive Care Units; Length of Stay; Levodopa; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease | 2010 |
Kinetic approach for the enzymatic determination of levodopa and carbidopa assisted by multivariate curve resolution-alternating least squares.
Topics: Calibration; Carbidopa; Catechol Oxidase; Equipment Design; Ipomoea batatas; Kinetics; Least-Squares Analysis; Levodopa; Multivariate Analysis; Pharmaceutical Preparations; Reference Values; Spectrophotometry | 2010 |
Simultaneous voltammetric determination of levodopa, carbidopa and benserazide in pharmaceuticals using multivariate calibration.
Topics: Algorithms; Benserazide; Calibration; Carbidopa; Dopamine Agents; Drug Combinations; Electrochemical Techniques; Electrodes; Excipients; Levodopa | 2010 |
Oxidative stress and aminopeptidases in Parkinson's disease patients with and without treatment.
Topics: Aged; Aminopeptidases; Antiparkinson Agents; Carbidopa; Case-Control Studies; Female; Humans; Lactates; Levodopa; Lipid Peroxides; Lipids; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 2011 |
[The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off].
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Combinations; Female; Humans; Hungary; Levodopa; Male; Middle Aged; Observation; Parkinson Disease; Quality of Life; Treatment Outcome | 2010 |
Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia.
Topics: Antiparkinson Agents; Carbidopa; Child, Preschool; Deficiency Diseases; Drug Combinations; Female; Follow-Up Studies; GTP Cyclohydrolase; Humans; Infant; Levodopa; Male; Mutation; Neurotransmitter Agents; Phenylketonurias | 2011 |
Carbidopa/levodopa pharmacy errors in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Medication Errors; Parkinson Disease; Pharmacies; Prospective Studies | 2010 |
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States | 2010 |
Delayed-onset parkinsonian tremor following a mesencephalic lesion.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Electromyography; Female; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurologic Examination; Parkinson Disease; Tegmentum Mesencephali; Tremor | 2011 |
Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenum; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Severity of Illness Index; Treatment Outcome | 2011 |
Transfusion of defibrinated blood in P.O.W. camps at Chungkai and Nakom Paton, Thailand.
Topics: Blood Transfusion; Carbidopa; Drug Combinations; Humans; Levodopa; Military Medicine; Military Personnel; Prisoners; Prisoners of War; Thailand; Warfare | 1946 |
Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Topics: Antiparkinson Agents; Calibration; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Drug Combinations; Humans; Levodopa; Methyldopa; Nitriles; Reproducibility of Results; Solid Phase Extraction | 2011 |
Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.
Topics: Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Drug Costs; Duodenum; Government Agencies; Humans; Levodopa; Models, Economic; Parkinson Disease; Reimbursement Mechanisms; Sweden; Treatment Outcome | 2010 |
Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine | 2010 |
Behavioural and pharmacological examinations in a transgenic mouse model of early-onset torsion dystonia.
Topics: Amphetamines; Animals; Anxiety; Behavior, Animal; Carbidopa; Chromans; Disease Models, Animal; Dystonia; Levodopa; Locomotion; Mice; Mice, Transgenic; Quinpirole; Raclopride | 2011 |
The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Levodopa; Nitriles; Parkinson Disease; Patient Compliance; Retrospective Studies | 2011 |
Transient executive dysfunction following STNDBS in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Deep Brain Stimulation; Executive Function; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Time Factors | 2011 |
A tale of two tauopathies.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Tauopathies | 2011 |
[Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease].
Topics: Adult; Aged; Carbidopa; Catechols; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2011 |
Hemiparkinsonism-hemiatrophy syndrome.
Topics: Adult; Antiparkinson Agents; Atrophy; Benzothiazoles; Biperiden; Carbidopa; Cerebral Cortex; Cerebral Ventricles; Dopamine Agonists; Drug Combinations; Humans; Indans; Levodopa; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Pramipexole; Tomography, X-Ray Computed | 2011 |
Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.
Topics: Aged; Arginine Vasopressin; Benzothiazoles; Carbidopa; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole | 2011 |
Three year follow up of levodopa plus carbidopa treatment in a prevalent cohort of patients with Parkinson's disease in Hai, Tanzania.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Retrospective Studies; Tanzania | 2011 |
Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Carbidopa; Dipeptides; Female; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Tyrosine | 2011 |
Deletion in the tyrosine hydroxylase gene in a patient with a mild phenotype.
Topics: Antiparkinson Agents; Carbidopa; DNA Mutational Analysis; Drug Combinations; Female; Homovanillic Acid; Humans; Infant; Levodopa; Movement Disorders; Phenotype; Sequence Deletion; Tyrosine 3-Monooxygenase; Video Recording | 2011 |
Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Disability Evaluation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Subthalamic Nucleus; Treatment Outcome | 2011 |
A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.
Topics: Aged; Aging; Antiparkinson Agents; Carbidopa; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Female; Hand Strength; Humans; Isometric Contraction; Levodopa; Longitudinal Studies; Male; Middle Aged; Muscle Strength; Neuropsychological Tests; Parkinson Disease; Positron-Emission Tomography; Psychomotor Performance; Radiopharmaceuticals; Reaction Time; Retrospective Studies; Sex Characteristics; Tongue | 2011 |
Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Blotting, Western; Carbidopa; Carrier Proteins; Disease Models, Animal; Drosophila; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Motor Activity; Nerve Degeneration; Nerve Tissue Proteins; Neurotoxicity Syndromes; Parkinson Disease; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
In-vivo evaluation of prolonged release bilayer tablets of anti-Parkinson drugs in Göttingen minipigs.
Topics: Acetophenones; Animals; Antiparkinson Agents; Area Under Curve; Carbidopa; Delayed-Action Preparations; Drug Carriers; Levodopa; Swine; Swine, Miniature; Tablets; Technology, Pharmaceutical | 2011 |
Severe weight loss in a young Parkinson's disease patient: a multidisciplinary approach to diagnosis and treatment.
Topics: Antiparkinson Agents; Carbidopa; Caregivers; Disease Progression; Domestic Violence; Drug Combinations; Eating; Female; Humans; Hypertrichosis; Levodopa; Middle Aged; Nutritional Status; Parkinson Disease; Weight Loss | 2011 |
Levodopa-induced breathing, cognitive and behavioral changes in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Drug Combinations; Humans; Levodopa; Male; Mental Disorders; Parkinson Disease; Respiration Disorders | 2011 |
Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Delusions; Drug Combinations; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales | 2011 |
Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance.
Topics: Aged; Benserazide; Benzothiazoles; Carbidopa; Cues; Deep Brain Stimulation; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Psychomotor Performance; Reaction Time; Subthalamic Nucleus | 2011 |
A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Gels; Humans; Levodopa; Parkinson Disease; Quality-Adjusted Life Years; United Kingdom | 2011 |
Malnutritional neuropathy under intestinal levodopa infusion.
Topics: Aged; Carbidopa; Humans; Infusions, Parenteral; Levodopa; Male; Malnutrition; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Polyneuropathies | 2012 |
Parkinsonism and dropped head: dystonia, myopathy or both?
Topics: Aged; Carbidopa; Drug Combinations; Dystonic Disorders; Electromyography; Female; Head Movements; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Muscular Diseases; Parkinsonian Disorders; Retrospective Studies | 2012 |
Development and validation of a high-performance liquid chromatography-electrospray ionization-MS/MS method for the simultaneous quantitation of levodopa and carbidopa in human plasma.
Topics: Administration, Oral; Carbidopa; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Levodopa; Male; Methyldopa; Reproducibility of Results; Sensitivity and Specificity; Tablets; Tandem Mass Spectrometry | 2011 |
Ocular motor and sensory function in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Combined Modality Therapy; Convergence, Ocular; Deep Brain Stimulation; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Ocular Motility Disorders; Oculomotor Muscles; Parkinson Disease; Prospective Studies; Quality of Life; Sensation; Surveys and Questionnaires; Visual Acuity | 2012 |
Duodopa infusion treatment: a point of view from the gastroenterologist.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastroenterology; Gels; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Parkinson Disease | 2011 |
Lees' syndrome: a case series.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Syndrome | 2011 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biomarkers; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopa Decarboxylase; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Japan; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome; Tyrosine | 2011 |
Westphal variant Huntington disease and refractory catatonia: a case report.
Topics: Adult; Amantadine; Carbidopa; Catatonia; Combined Modality Therapy; Dopamine Agents; Drug Combinations; Drug Resistance; Electroconvulsive Therapy; Female; Humans; Huntington Disease; Levodopa | 2011 |
Parkinson's disease patients cannot get their dopamine replacement: the 8-Sinemet limit.
Topics: Carbidopa; Dopamine; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2012 |
Nasogastric medication for perioperative Parkinson's rigidity during anaesthesia emergence.
Topics: Amantadine; Anesthesia; Anesthesia Recovery Period; Anesthesia, General; Antiparkinson Agents; Carbidopa; Drug Combinations; Fracture Fixation, Internal; Fractures, Bone; Humans; Humerus; Intraoperative Awareness; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Perioperative Care | 2011 |
Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Carbidopa; Caregivers; Drug Combinations; Duodenostomy; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Spouses; Stress, Psychological; Surveys and Questionnaires | 2012 |
Trichophagia affects response to duodenal levodopa/carbidopa gel administration.
Topics: Aged; Antiparkinson Agents; Carbidopa; Compulsive Behavior; Drug Administration Routes; Drug Therapy, Combination; Duodenum; Feeding Behavior; Hair; Humans; Levodopa; Male; Parkinson Disease | 2012 |
Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Burning Mouth Syndrome; Carbidopa; Dopamine; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Pramipexole | 2012 |
Oral formulations of L-dopa and continuous dopaminergic stimulation.
Topics: Animals; Antiparkinson Agents; Carbidopa; Dopamine Agents; Drug Delivery Systems; Female; Humans; Levodopa; Male; Parkinson Disease | 2012 |
Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2012 |
Application of nanosized MCM-41 to fabrication of a nanostructured electrochemical sensor for the simultaneous determination of levodopa and carbidopa.
Topics: Calibration; Carbidopa; Electrochemical Techniques; Electrodes; Levodopa; Limit of Detection; Microscopy, Electron, Scanning; Nanostructures; X-Ray Diffraction | 2012 |
Electrocatalytic oxidation and voltammetric determination of levodopa in the presence of carbidopa at the surface of a nanostructure based electrochemical sensor.
Topics: Antiparkinson Agents; Biosensing Techniques; Carbidopa; Carbon; Electrochemical Techniques; Humans; Hydrogen-Ion Concentration; Levodopa; Metal Nanoparticles; Metalloporphyrins; Oxidation-Reduction; Titanium | 2012 |
Levodopa in combination with carbidopa does not affect plasma arginine vasopressin levels in treatment-naïve older patients with Parkinson's disease: A before-after study.
Topics: Arginine Vasopressin; Carbidopa; Controlled Before-After Studies; Humans; Levodopa; Parkinson Disease | 2012 |
Voltammetric detection of L-dopa and carbidopa on graphene modified glassy carbon interfaces.
Topics: Carbidopa; Electrochemistry; Glass; Graphite; Hydrazines; Hydrogen-Ion Concentration; Levodopa; Nanostructures; Oxides | 2013 |
Finasteride attenuates pathological gambling in patients with Parkinson disease.
Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games | 2012 |
A clinically silent, but severe, duodenal complication of duodopa infusion.
Topics: Aged; Bezoars; Carbidopa; Drug Combinations; Duodenum; Humans; Infusion Pumps, Implantable; Levodopa; Male | 2012 |
Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 2012 |
Dopamine dysregulation syndrome including mania related to coadministration of droxidopa.
Topics: Aggression; Antiparkinson Agents; Behavior, Addictive; Benzothiazoles; Bipolar Disorder; Carbidopa; Droxidopa; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Neurotoxicity Syndromes; Parkinson Disease; Pramipexole; Treatment Outcome | 2012 |
Neuroleptic malignant syndrome associated with the use of carbidopa/levodopa for dystonia in persons with cerebral palsy.
Topics: Carbidopa; Cerebral Palsy; Child; Dopamine Agents; Drug Therapy, Combination; Dystonia; Follow-Up Studies; Humans; Levodopa; Male; Neuroleptic Malignant Syndrome | 2012 |
Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Cysteine; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome.
Topics: Cabergoline; Carbidopa; Cognitive Behavioral Therapy; Dopamine Agonists; Drug Combinations; Ergolines; Gambling; Humans; Indoles; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2011 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Subthalamus | 2012 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dyskinesia, Drug-Induced; Dystonia; Female; Foot Diseases; Humans; Levodopa; Middle Aged; Neurologic Examination; Nitriles; Parkinson Disease | 2013 |
Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Disability Evaluation; Drug Combinations; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Quality of Life; Statistics, Nonparametric | 2013 |
Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under duodopa® therapy.
Topics: Aged; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Seizures; Treatment Outcome; Vitamin B 6; Vitamin B 6 Deficiency | 2013 |
DYT16: the original cases.
Topics: Adolescent; Adult; Age of Onset; Anti-Dyskinesia Agents; Antiparkinson Agents; Baclofen; Biperiden; Botulinum Toxins; Carbidopa; Child; Child, Preschool; Cholinergic Antagonists; Drug Combinations; Drug Resistance; Dystonia; Dystonic Disorders; Female; Humans; Levodopa; Male; Middle Aged; Muscle Relaxants, Central; Mutation; Parkinsonian Disorders; Pedigree; Phenotype; RNA-Binding Proteins; Speech Disorders; Trihexyphenidyl; Young Adult | 2012 |
[A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2012 |
Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Anticonvulsants; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Valproic Acid | 2013 |
Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Cell Line, Tumor; Cell Survival; Comet Assay; DNA Damage; Dopa Decarboxylase; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Hydrogen Peroxide; Levodopa; Neuroblastoma; Oxidants; Oxidative Stress; Reactive Oxygen Species; Time Factors | 2012 |
Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
Topics: Antiparkinson Agents; Carbidopa; Costs and Cost Analysis; Deep Brain Stimulation; Health Resources; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Spain; Surveys and Questionnaires | 2013 |
Drug-induced burning mouth syndrome: a new clinico-pathological entity?
Topics: Antiparkinson Agents; Burning Mouth Syndrome; Carbidopa; Female; Humans; Levodopa; Parkinson Disease | 2012 |
Isolated extra pontine myelinolysis presenting as acute onset parkinsonism.
Topics: Acute Disease; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Middle Aged; Myelinolysis, Central Pontine; Parkinson Disease, Secondary; Saline Solution, Hypertonic | 2012 |
Assuring the quality of next-generation sequencing in clinical laboratory practice.
Topics: Carbidopa; Chromosome Mapping; Drug Combinations; Levodopa; Practice Guidelines as Topic; Quality Assurance, Health Care; Sequence Analysis, DNA; United States | 2012 |
Is blinking of the eyes affected in extrapyramidal disorders? An interesting observation in a patient with Wilson disease.
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Blinking; Carbidopa; Ceruloplasmin; Drug Therapy, Combination; Female; Hepatolenticular Degeneration; Humans; Levodopa; Penicillamine; Trihexyphenidyl; Zinc Sulfate | 2012 |
Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrointestinal Diseases; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease | 2012 |
Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antiparkinson Agents; Carbidopa; Catechin; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Disease Models, Animal; Excitatory Amino Acid Agonists; Fluoresceins; Glial Fibrillary Acidic Protein; Hippocampus; Hydroxybenzoates; In Vitro Techniques; Kainic Acid; Levodopa; Male; Methylation; Mice; Nerve Degeneration; Neurons; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors; Tyrosine | 2013 |
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Biotransformation; Carbidopa; Chemistry, Pharmaceutical; Drug Combinations; Female; Gels; Germany; Humans; Infusion Pumps; Intestinal Absorption; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Tyrosine | 2013 |
Perioperative medication withholding in patients with Parkinson's disease: a retrospective electronic health records review.
Topics: Aged; Antiparkinson Agents; Carbidopa; Comorbidity; Drug Combinations; Electronic Health Records; Female; Half-Life; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies; Surgical Procedures, Operative | 2013 |
Chaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Chromatography, Reverse-Phase; Drug Contamination; Levodopa; Nitriles; Particle Size; Reproducibility of Results; Sensitivity and Specificity; Trifluoroacetic Acid | 2013 |
Anti-allodynic effects of levodopa in neuropathic rats.
Topics: Animals; Carbidopa; Dopamine Agents; Hyperalgesia; Levodopa; Male; Neuralgia; Rats; Rats, Sprague-Dawley; Rotarod Performance Test | 2013 |
Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies.
Topics: Antiparkinson Agents; Basal Ganglia; Carbidopa; Disability Evaluation; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index | 2013 |
Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Carbidopa; Catechols; Clozapine; Diagnosis, Differential; Fluphenazine; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2014 |
Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Socioeconomic Factors; Spain | 2014 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline | 2013 |
Extended-release carbidopa-levodopa in Parkinson's disease.
Topics: Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Motor Skills Disorders; Parkinson Disease | 2013 |
Mydriasis in a Parkinson disease patient on low-dose carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Mydriasis; Parkinson Disease | 2013 |
Development and validation of a simple and sensitive method for quantification of levodopa and carbidopa in rat and monkey plasma using derivatization and UPLC-MS/MS.
Topics: Animals; Calibration; Carbidopa; Chromatography, High Pressure Liquid; Haplorhini; Levodopa; Limit of Detection; Rats; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry | 2013 |
Heterotopic ossification following distal radius fractures in a patient with Parkinson disease treated with levodopa-carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Causality; Drug Combinations; Fracture Fixation, Internal; Humans; Levodopa; Male; Middle Aged; Ossification, Heterotopic; Parkinson Disease; Radiography; Radius Fractures | 2013 |
Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Dose-Response Relationship, Drug; Female; Gels; Humans; Infusions, Parenteral; Intestines; Levodopa; Male; Middle Aged; Patient Outcome Assessment; Polyneuropathies; Prospective Studies; Weight Loss | 2013 |
[Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013].
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Drug Administration Schedule; Drug Therapy, Combination; Gels; Humans; Intestines; Levodopa; Parkinson Disease | 2013 |
Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Callithrix; Carbidopa; Cholinergic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Statistics, Nonparametric | 2014 |
Letter regarding "Heterotopic ossification following distal radius fractures in a patient with Parkinson disease treated with levodopa-carbidopa".
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Ossification, Heterotopic; Parkinson Disease | 2013 |
In reply.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Ossification, Heterotopic; Parkinson Disease | 2013 |
[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Livedo Reticularis; Parkinson Disease | 2014 |
Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Guillain-Barre Syndrome; Humans; Levodopa; Parkinson Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2014 |
Brief case report: dopa-responsive dystonia.
Topics: Adult; Carbidopa; Dopamine Agonists; Drug Combinations; Dystonia; Female; Humans; Insurance, Life; Levodopa | 2013 |
Nano composite system based on coumarin derivative-titanium dioxide nanoparticles and ionic liquid: determination of levodopa and carbidopa in human serum and pharmaceutical formulations.
Topics: Carbidopa; Carbon; Catalysis; Chemistry, Pharmaceutical; Coumarins; Electrochemical Techniques; Electrodes; Humans; Hydrogen-Ion Concentration; Ionic Liquids; Levodopa; Metal Nanoparticles; Nanocomposites; Oxidation-Reduction; Titanium | 2013 |
Drugs for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 2013 |
Dopamine receptor dysregulation in hippocampus of aged rats underlies chronic pulsatile L-Dopa treatment induced cognitive and emotional alterations.
Topics: Age Factors; Anhedonia; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cognition Disorders; Drug Combinations; Emotions; Hippocampus; Levodopa; Male; Mental Disorders; Motor Activity; Neurons; Rats, Wistar; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Dopamine D5; Spatial Learning | 2014 |
Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Effects of hypothalamic dopamine (DA) on salsolinol (SAL)-induced prolactin (PRL) secretion in male goats.
Topics: Animals; Carbidopa; Dopamine; Goats; Hypothalamus; Injections, Intravenous; Isoquinolines; Levodopa; Male; Photoperiod; Prolactin; Stimulation, Chemical; Time Factors | 2014 |
Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report.
Topics: Adolescent; Amantadine; Carbidopa; Cerebral Palsy; Cognition Disorders; Dopamine Agonists; Dopamine Antagonists; Drug Combinations; Haloperidol; Humans; Levodopa; Male; Psychomotor Disorders | 2013 |
Jejunal levodopa infusion in Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Intestinal levodopa infusion: the Belgian experience.
Topics: Aged; Antiparkinson Agents; Belgium; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 2014 |
Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Chromatography, Reverse-Phase; Cysteine; Dipeptides; Drug Delivery Systems; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2014 |
Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Drug Administration Routes; Drug Combinations; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Patient Selection; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2014 |
Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Carbidopa; Catalase; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Peroxidase; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Melatonin; Mice; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase | 2013 |
Simultaneous estimation of levodopa and carbidopa by RP-HPLC using a fluorescence detector: its application to a pharmaceutical dosage form.
Topics: Carbidopa; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Levodopa; Molecular Conformation; Spectrometry, Fluorescence | 2014 |
Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Cognitive Dysfunction; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
GCH1 heterozygous mutation identified by whole-exome sequencing as a treatable condition in a patient presenting with progressive spastic paraplegia.
Topics: Adult; Carbidopa; Codon, Nonsense; Dopamine Agonists; Drug Combinations; Dystonic Disorders; Exome; Female; GTP Cyclohydrolase; Heterozygote; Humans; Levodopa; Phenotype; Sequence Analysis, DNA; Spastic Paraplegia, Hereditary; Treatment Outcome | 2014 |
Parkinson disease: Intestinal levodopa infusion in PD--the first randomized trial.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?
Topics: Adipose Tissue; Amino Acids; Animals; Antigens, CD; Brain; Brain-Derived Neurotrophic Factor; Carbidopa; Cell Differentiation; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Drug Combinations; Female; Gene Expression; Genes, sry; Levodopa; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Ovariectomy; Parkinson Disease; Rats, Sprague-Dawley; Rotenone; Transforming Growth Factor beta; Tyrosine 3-Monooxygenase | 2014 |
Effect of levodopa and carbidopa on non-motor symptoms and signs of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.
Topics: Animals; Carbidopa; Drugs, Chinese Herbal; Gastric Emptying; Ghrelin; Levodopa; Male; Oligopeptides; Parkinson Disease, Secondary; Postprandial Period; Rats, Sprague-Dawley; Receptors, Ghrelin | 2014 |
Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Parkinson Disease; Polyneuropathies; Vitamin B 12 | 2014 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, Animal; Drug Combinations; Levodopa; Minocycline; Motor Activity; Oxidopamine; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Sympatholytics; Vitamin E; Zebrafish; Zebrafish Proteins | 2014 |
Direct endoscopic jejunosotomy for the administration of levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gels; Humans; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease | 2014 |
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Nitrophenols; Parkinson Disease; Psychomotor Performance; Statistics, Nonparametric; Tolcapone; Treatment Outcome | 2014 |
Gastric bezoar complication of Duodopa(®) therapy in Parkinson's disease, treated with Coca-Cola(®).
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Carbonated Beverages; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Stomach | 2014 |
Synthesis of ZnO nanorods and their application in the construction of a nanostructure-based electrochemical sensor for determination of levodopa in the presence of carbidopa.
Topics: Acrylates; Carbidopa; Carbon; Dopamine Agents; Electrochemical Techniques; Electrodes; Levodopa; Limit of Detection; Nanotubes; Oxidation-Reduction; Tablets; Zinc Oxide | 2014 |
A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.
Topics: Aged; Antiparkinson Agents; Carbidopa; Chromatography, Liquid; Drug Monitoring; Drug Stability; Female; Humans; Hydrophobic and Hydrophilic Interactions; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2014 |
Successful treatment of dopamine dysregulation syndrome with valproic acid.
Topics: Antimanic Agents; Carbidopa; Compulsive Behavior; Dopamine Agonists; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Valproic Acid | 2014 |
Levodopa-carbidopa intestinal gel (LCIG) infusion during pregnancy and delivery: first documented case.
Topics: Adult; Antiparkinson Agents; Carbidopa; Female; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease; Pregnancy; Treatment Outcome | 2014 |
Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease | 2014 |
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Cost-Benefit Analysis; Deep Brain Stimulation; Drug Administration Schedule; Gels; Germany; Humans; Injections, Subcutaneous; Levodopa; Markov Chains; Models, Econometric; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years | 2015 |
Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.
Topics: Antioxidants; Carbidopa; Cells, Cultured; DNA Damage; Humans; Levodopa; Lymphocytes; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 2015 |
Teaching NeuroImages: Pisa syndrome in Parkinson disease.
Topics: Aged; Carbidopa; Drug Combinations; Dystonia; Humans; Indoles; Levodopa; Male; Parkinson Disease; Posture; Scoliosis | 2014 |
Towards an expert system for accurate diagnosis and progress monitoring of Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Biomarkers; Carbidopa; Deep Brain Stimulation; Disease Progression; Drug Therapy, Combination; Expert Systems; Humans; Levodopa; Parkinson Disease; Sensitivity and Specificity | 2015 |
Effects of hypothalamic dopamine on growth hormone-releasing hormone-induced growth hormone secretion and thyrotropin-releasing hormone-induced prolactin secretion in goats.
Topics: Animals; Carbidopa; Dopamine; Female; Goats; Growth Hormone; Growth Hormone-Releasing Hormone; Hypothalamus; Injections, Intravenous; Levodopa; Male; Prolactin; Stimulation, Chemical; Thyrotropin-Releasing Hormone | 2015 |
Serotonin syndrome in stroke patients.
Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Indoles; Levodopa; Male; Middle Aged; Serotonin Syndrome; Stroke | 2015 |
[Levodopa-responsive dystonia: Segawa's disease. Report of a case with late onset].
Topics: Adult; Age of Onset; Botulinum Toxins, Type A; Carbidopa; Consanguinity; Drug Resistance; Drug Therapy, Combination; Dystonic Disorders; Female; Genetic Counseling; GTP Cyclohydrolase; Humans; Levodopa | 2014 |
Parkinsonism after external ventricular drainage in a patient with intraventricular hemorrhage.
Topics: Activities of Daily Living; Carbidopa; Caudate Nucleus; Cerebral Ventricles; Drainage; Drug Combinations; Female; Humans; Intracranial Hemorrhages; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinson Disease, Secondary; Positron-Emission Tomography; Predictive Value of Tests; Putamen; Radiopharmaceuticals; Recovery of Function; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tropanes; Ventriculoperitoneal Shunt | 2015 |
24 h Levodopa-carbidopa intestinal gel may reduce falls and "unresponsive" freezing of gait in Parkinson's disease.
Topics: Accidental Falls; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait Disorders, Neurologic; Gels; Humans; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors | 2015 |
Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.
Topics: Benzophenones; Blood Chemical Analysis; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Nitriles; Nitrophenols; Quality Control; Reproducibility of Results; Tandem Mass Spectrometry; Tolcapone; Tyrosine | 2015 |
Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Gels; Humans; Jejunum; Levodopa; Parkinson Disease | 2015 |
Making sense: Dopamine activates conscious self-monitoring through medial prefrontal cortex.
Topics: Adult; Awareness; Brain Waves; Carbidopa; Consciousness; Dopamine; Dopamine Agonists; Double-Blind Method; Drug Combinations; Humans; Judgment; Levodopa; Magnetoencephalography; Male; Metacognition; Neuropsychological Tests; Prefrontal Cortex; Self Concept; Young Adult | 2015 |
Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
Topics: Animals; Antiparkinson Agents; Astrocytes; Carbidopa; Corpus Striatum; Gliosis; Levodopa; Male; Maze Learning; Memory Disorders; Memory, Short-Term; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Prefrontal Cortex; Rats, Wistar; Spatial Memory | 2015 |
[Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Gels; Humans; Hungary; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Selection; Quality of Life; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Continuous levodopa infusion is better—for now.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model.
Topics: Carbidopa; Drug Combinations; Gels; Humans; Jejunum; Levodopa; Outpatients; Parkinson Disease | 2015 |
New and emerging treatments for Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Carbidopa; Chromatography, High Pressure Liquid; Corpus Striatum; Dependovirus; Dopamine; Electrochemical Techniques; Genetic Therapy; Genetic Vectors; Humans; Immunohistochemistry; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2015 |
Capgras delusion for animals and inanimate objects in Parkinson's Disease: a case report.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Capgras Syndrome; Carbidopa; Clozapine; Cognitive Dysfunction; Delusions; Dibenzothiazepines; Dogs; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Parkinson Disease; Pets; Plants; Quetiapine Fumarate | 2015 |
Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Italy; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2015 |
Knotting of Duodopa® duodenal infusion system.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catheterization; Catheters; Drug Combinations; Duodenum; Equipment Failure; Female; Humans; Infusion Pumps; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
In vivo protective effect of Uridine, a pyrimidine nucleoside, on genotoxicity induced by Levodopa/Carbidopa in mice.
Topics: Animals; Bone Marrow Cells; Carbidopa; Comet Assay; Dopamine Agents; Levodopa; Male; Mice, Inbred BALB C; Micronucleus Tests; Protective Agents; Uridine | 2015 |
Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Duodenum; Dyskinesia, Drug-Induced; Dyskinesias; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Registries; Spain; Treatment Outcome | 2015 |
Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Anhedonia; Apathy; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Substance Withdrawal Syndrome | 2015 |
Depression, anxiety and non-motor symptoms on initiation of intrajejunal levodopa/carbidopa therapy.
Topics: Adult; Aged; Antiparkinson Agents; Anxiety; Carbidopa; Depression; Drug Combinations; Female; Humans; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Time Factors | 2016 |
Electroencephalographic lateralization, clinical correlates and pharmacological response in untreated Parkinson's disease.
Topics: Aged; Alpha Rhythm; Antiparkinson Agents; Beta Rhythm; Carbidopa; Drug Combinations; Electroencephalography; Female; Frontal Lobe; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Occipital Lobe; Parkinson Disease; Severity of Illness Index | 2015 |
The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.
Topics: Animals; Antiparkinson Agents; Brain Stem; Calpain; Carbidopa; Cell Death; Cell Line; Corpus Striatum; Dopaminergic Neurons; Drug Therapy, Combination; Histone Acetyltransferases; Levodopa; Lithium Chloride; Male; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Rats; Tyrosine 3-Monooxygenase | 2015 |
Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.
Topics: Antiparkinson Agents; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Suicide in Parkinson's Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel.
Topics: Antiparkinson Agents; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Dissociative disorder manifesting for underlying adolescent hemi-parkinsonism: New chronology for old mummies.
Topics: Adult; Age of Onset; Antiparkinson Agents; Carbidopa; Dissociative Disorders; Drug Combinations; Female; Humans; Levodopa; Parkinsonian Disorders; Young Adult | 2015 |
Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Carbidopa; Equipment Failure; Female; Follow-Up Studies; Gastric Bypass; Gastroscopy; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Safety; Postoperative Complications; Prospective Studies; Treatment Outcome; Vascular Access Devices | 2016 |
Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Delivery Systems; Humans; Infusions, Parenteral; Levodopa; Male; Parkinson Disease | 2015 |
Visual Acuity Improvement of Amblyopia in an Adult With Levodopa/Carbidopa Treatment.
Topics: Administration, Oral; Amblyopia; Carbidopa; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Visual Acuity | 2015 |
Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dyskinesias; Female; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Quality of Life | 2016 |
Delayed chorea after recovery from severe akinetic-rigid parkinsonism caused by extrapontine myelinolysis.
Topics: Carbidopa; Chorea; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Myelinolysis, Central Pontine; Parkinsonian Disorders | 2015 |
Continuous duodenal levodopa infusion in a patient with Crohn's disease and small bowel surgery - Case report.
Topics: Antiparkinson Agents; Carbidopa; Crohn Disease; Drug Combinations; Duodenum; Humans; Intestine, Small; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Female; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease | 2015 |
Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
Topics: Behavior, Addictive; Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Syndrome | 2015 |
Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder.
Topics: Brain; Brain Diseases; Carbidopa; Child; Dopamine; Humans; Levodopa; Male; Parkinsonian Disorders; Polymorphism, Single Nucleotide; Serotonin | 2016 |
Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Prospective Studies | 2016 |
Gas-phase acidity and dynamics of the protonation processes of carbidopa and levodopa. A QM/QD study.
Topics: Carbidopa; Drug Design; Levodopa; Models, Chemical; Models, Molecular; Molecular Conformation; Protons | 2016 |
Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Topics: Animals; Brain; Carbidopa; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Enzyme Inhibitors; Levodopa; Macaca fascicularis; MPTP Poisoning; Parkinson Disease, Secondary; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Presynaptic; Tyrosine | 2016 |
Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Duodenum; Female; Gels; Humans; Infusions, Parenteral; Intubation, Gastrointestinal; Levodopa; Long-Term Care; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Quality of Life | 2015 |
Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Parkinson Disease; Prospective Studies | 2016 |
Reply to letter: Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Male; Parkinson Disease | 2016 |
The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Quality of Life; Retrospective Studies; Romania | 2016 |
Compensatory striatal-cerebellar connectivity in mild-moderate Parkinson's disease.
Topics: Aged; Brain Mapping; Carbidopa; Caudate Nucleus; Cerebellum; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Motor Activity; Motor Cortex; Neural Pathways; Parkinson Disease; Putamen; Severity of Illness Index | 2016 |
Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Over Studies; Diet; Double-Blind Method; Female; Glycine max; Humans; Levodopa; Male; Middle Aged; Mucuna; Parkinson Disease | 2016 |
Possible serotonin syndrome with carbidopa-levodopa and linezolid.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Linezolid; Serotonin Agents; Serotonin Syndrome | 2016 |
DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Topics: Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Central Nervous System Stimulants; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotation; Sympatholytics; Time Factors | 2016 |
Simultaneous estimation of levodopa, carbidopa and 3-oxymethyldopa in rat plasma using HPLC-ECD.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Electrochemical Techniques; Levodopa; Limit of Detection; Male; Rats; Rats, Wistar; Tyrosine | 2016 |
Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers.
Topics: Adult; Carbidopa; Catechols; Cocaine; Cocaine-Related Disorders; Drug Interactions; Face; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Smoke; Young Adult | 2016 |
A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole.
Topics: Antiparkinson Agents; Benzothiazoles; Carbidopa; Drug Combinations; Drug Therapy, Combination; Edema; Humans; Leg; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Treatment Outcome | 2016 |
24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Muscle Rigidity; Outcome Assessment, Health Care; Parkinson Disease; Sleep Wake Disorders | 2016 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
Tremor in progressive supranuclear palsy.
Topics: Aged; Carbidopa; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Retrospective Studies; Supranuclear Palsy, Progressive; Tremor | 2016 |
Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
Topics: Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Humans; Levodopa; Parkinson Disease; Physicians | 2016 |
Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa.
Topics: Antiparkinson Agents; Carbidopa; Caregivers; Clinical Trials as Topic; Databases, Bibliographic; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2016 |
What Is Not in the Name? Dopa-Responsive Dystonia May Respond to More Than L-Dopa.
Topics: 5-Hydroxytryptophan; Adolescent; Anti-Dyskinesia Agents; Carbidopa; Diseases in Twins; Dopamine Agonists; Drug Combinations; Dystonia; Female; Humans; Levodopa; Male; Metabolism, Inborn Errors; Psychomotor Disorders; Serotonin Agents | 2016 |
Restless leg syndrome and its treatment.
Topics: Amines; Carbidopa; Cyclohexanecarboxylic Acids; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Renal Dialysis; Restless Legs Syndrome | 2016 |
Advanced therapies in Parkinson's disease: Long-term retrospective study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Thalamus; Treatment Outcome | 2016 |
Outpatient titration of carbidopa/levodopa enteral suspension (Duopa).
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Outpatients; Parkinson Disease; Suspensions; Treatment Outcome | 2017 |
Endoscopic alternative to buried bumper syndrome secondary to Duodopa
Topics: Aged; Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Device Removal; Drug Combinations; Emergencies; Equipment Design; Foreign-Body Migration; Gastroscopes; Gastroscopy; Gastrostomy; Humans; Infusion Pumps, Implantable; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed | 2017 |
Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.
Topics: Animals; Caproates; Capsules; Carbidopa; Catechols; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Humans; Hydrophobic and Hydrophilic Interactions; Lactones; Levodopa; Microscopy, Confocal; Nitriles; Parkinson Disease; Polyesters | 2016 |
Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Combinations; Female; Gels; Health Care Costs; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric; Visual Analog Scale | 2016 |
Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2016 |
A potential case of remission of Parkinson's disease.
Topics: Aged; Brain; Carbidopa; Dopamine; Drug Combinations; Humans; Levodopa; Male; Meditation; Parkinson Disease; Psychophysiology; Remission Induction | 2016 |
Wearable Sensors for Advanced Therapy Referral in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monitoring, Ambulatory; Parkinson Disease; Referral and Consultation; Retrospective Studies; Severity of Illness Index | 2016 |
Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Italy; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life | 2016 |
Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Dopamine; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Psychotic Disorders | 2016 |
Plantar cutaneous function in Parkinson's disease patients ON and OFF L-dopa.
Topics: Aged; Carbidopa; Discrimination, Psychological; Drug Combinations; Electromyography; Female; Foot; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Physical Stimulation; Reflex, Abnormal; Touch; Touch Perception; Vibration | 2016 |
Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Spain | 2016 |
Choosing an Advanced Therapy in Parkinson's Disease; is it an Evidence-Based Decision in Current Practice?
Topics: Apomorphine; Carbidopa; Caregivers; Clinical Decision-Making; Consumer Health Information; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Evidence-Based Practice; Humans; Levodopa; Neurologists; Parkinson Disease; Patient Preference; Qualitative Research | 2016 |
Levodopa/carbidopa intestinal gel therapy for advanced Parkinson Disease: AN early toxic effect for small nerve fibers?
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2016 |
Authors' Reply to Lambarth: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Intestines; Levodopa; Parkinson Disease; Review Literature as Topic | 2016 |
Investigation of different spectrophotometric and chemometric methods for determination of entacapone, levodopa and carbidopa in ternary mixture.
Topics: Calibration; Carbidopa; Catechols; Least-Squares Analysis; Levodopa; Limit of Detection; Nitriles; Principal Component Analysis; Reproducibility of Results; Spectrophotometry | 2017 |
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Duodenum; Dyskinesias; Endoscopes, Gastrointestinal; Humans; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed; Weight Loss | 2016 |
Jejunal catheter placement for levodopa-carbidopa infusion in a patient with Billroth I gastrectomy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Gastrectomy; Gastroenterostomy; Humans; Infusion Pumps; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease | 2016 |
Comparison of Nanoemulsion and Aqueous Micelle Systems of Paliperidone for Intranasal Delivery.
Topics: Administration, Intranasal; Animals; Carbidopa; Drug Delivery Systems; Emulsions; Levodopa; Mice; Micelles; Motor Activity; Nanoparticles; Paliperidone Palmitate | 2017 |
Beneficial anti-Parkinson effects of camel milk in Chlorpromazineinduced animal model: Behavioural and histopathological study.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Camelus; Carbidopa; Catalepsy; Chlorpromazine; Drug Combinations; Female; Levodopa; Male; Milk; Parkinsonian Disorders; Rats, Wistar; Time Factors | 2016 |
Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Female; Gastrostomy; Humans; Infusions, Parenteral; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease | 2017 |
Jejunitis secondary to Duodopa® probe, a different complication.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Female; Humans; Infusion Pumps, Implantable; Jejunal Diseases; Levodopa; Parkinson Disease | 2016 |
Cathecol-O-methyltransferase inhibitors: another possibly useful pharmacological tool for treating Parkinson's disease in pregnancy?
Topics: Adult; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cesarean Section; Female; Gestational Age; Humans; Infant, Newborn; Levodopa; Nitriles; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2017 |
Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index | 2017 |
Fahr's Disease Presenting as Late-Onset Levodopa-Responsive Parkinsonism.
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Calcinosis; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Neurodegenerative Diseases | 2017 |
Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Tablets | 2017 |
Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2017 |
Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Disability Evaluation; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2017 |
Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
Topics: Age Factors; Antiparkinson Agents; Bifidobacterium; Carbidopa; Case-Control Studies; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Confounding Factors, Epidemiologic; Diet; Drug Combinations; Dysbiosis; Female; Fruit; Gastrointestinal Microbiome; Humans; Lactobacillaceae; Levodopa; Male; Parkinson Disease; Pasteurellaceae; Risk Factors; RNA, Ribosomal, 16S; Sex Factors; United States; Vegetables; Verrucomicrobia | 2017 |
Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.
Topics: Algorithms; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Decision Support Systems, Clinical; Drug Combinations; Drug Therapy, Combination; Humans; Infusion Pumps; Levodopa; Parkinson Disease | 2017 |
Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up.
Topics: Antiparkinson Agents; Carbidopa; Disease Progression; Drug Combinations; Female; Gels; Health Surveys; Humans; Intestines; Italy; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Retrospective Studies; Substance Withdrawal Syndrome | 2017 |
Prevalence and burden of dysautonomia in advanced Parkinson's disease.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Deep Brain Stimulation; Drug Combinations; Female; Humans; Levodopa; Logistic Models; Male; Parkinson Disease; Prevalence; Primary Dysautonomias; Severity of Illness Index; Subthalamic Nucleus; Surveys and Questionnaires | 2017 |
First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tablets | 2017 |
Delayed O-methylation of l-DOPA in MB-COMT-deficient mice after oral administration of l-DOPA and carbidopa.
Topics: Animals; Carbidopa; Catechol O-Methyltransferase; Levodopa; Methylation; Mice; Mice, Mutant Strains | 2018 |
Small bowel obstruction secondary to distal migration of the intestinal probe in a patient with an endoscopic gastrostomy for continuous carbidopa-levodopa infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Foreign-Body Migration; Gastrostomy; Humans; Ileal Diseases; Ileum; Intestinal Obstruction; Levodopa | 2018 |
SCL20A2 mutation mimicking fluctuating Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Mutation; Parkinson Disease; Sodium-Phosphate Cotransporter Proteins, Type III | 2017 |
Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Carbidopa; Drug Carriers; Drug Combinations; Drug Liberation; Levodopa; Male; Micelles; Nanoparticles; Permeability; Rabbits; Rats, Sprague-Dawley; Skin Absorption; Surface Properties; Swine; Transdermal Patch | 2017 |
Quantitation of levodopa and carbidopa in rat plasma by LC-MS/MS: The key role of ion-pairing reversed-phase chromatography.
Topics: Animals; Carbidopa; Chromatography, Reverse-Phase; Dopamine Agents; Fluorocarbons; Levodopa; Limit of Detection; Liquid-Liquid Extraction; Pentanoic Acids; Rats; Tandem Mass Spectrometry | 2017 |
A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinsonian Disorders; Polysomnography; Severity of Illness Index; Sleep Wake Disorders; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2017 |
Use of advanced therapies for Parkinson's disease in Norway.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Drug Utilization; Gels; Healthcare Disparities; Humans; Infusions, Parenteral; Levodopa; Norway; Parkinson Disease; Patient Education as Topic | 2017 |
Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
Topics: Aged; Antiparkinson Agents; Ascorbic Acid; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2017 |
Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Peripheral Nervous System Diseases; Vitamin B Complex | 2017 |
Hypothalamic dopamine is required for salsolinol-induced prolactin secretion in goats.
Topics: Animals; Carbidopa; Dopamine; Dopamine D2 Receptor Antagonists; Drug Combinations; Female; Goats; Haloperidol; Hypothalamus; Injections, Intravenous; Isoquinolines; Levodopa; Prolactin; Thyrotropin-Releasing Hormone | 2017 |
Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System Diseases; Pilot Projects; Prospective Studies; Vitamin B Complex; Vitamin D Deficiency | 2017 |
An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life | 2017 |
Central conduction abnormalities in patients receiving levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Central Nervous System; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Neural Conduction; Parkinson Disease; Peripheral Nervous System; Polyneuropathies; Prospective Studies | 2017 |
Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Crohn Disease; Donepezil; Drug Combinations; Fluid Therapy; Humans; Indans; Kidney Calculi; Levodopa; Male; Parkinson Disease; Piperidines; Severity of Illness Index; Sulfasalazine; Ultrasonography | 2017 |
Enteral feeding in Parkinson's patients receiving levodopa/carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Gels; Humans; Levodopa; Male; Parkinson Disease | 2017 |
Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Treatment Outcome; Weight Loss | 2017 |
Cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Barium; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Radiography; Stomach Diseases | 2017 |
Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Levodopa; Molecular Structure; Nitriles | 2017 |
Clinical Metabolomics to Segregate Aromatic Amino Acid Decarboxylase Deficiency From Drug-Induced Metabolite Elevations.
Topics: Amino Acid Metabolism, Inborn Errors; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Child; Child, Preschool; Cohort Studies; Dopamine; Dopamine Agonists; Drug Combinations; Edetic Acid; Female; Humans; Infant; Levodopa; Male; Metabolic Networks and Pathways; Metabolomics; Vanilmandelic Acid | 2017 |
Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Drug Monitoring; Female; Gels; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Quality of Life; Spain; Time; Treatment Outcome | 2017 |
Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report.
Topics: Aged; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Ninety-day Local Tolerability and Toxicity Study of ND0612, a Novel Formulation of Levodopa/Carbidopa, Administered by Subcutaneous Continuous Infusion in Minipigs.
Topics: Animals; Carbidopa; Dopamine Agonists; Drug Combinations; Drug Evaluation, Preclinical; Drug Tolerance; Female; Infusions, Subcutaneous; Injection Site Reaction; Levodopa; Male; Necrosis; Swine; Swine, Miniature; Toxicity Tests, Chronic | 2017 |
The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Female; Gels; Health Expenditures; Health Resources; Humans; Ireland; Levodopa; Male; Markov Chains; Parkinson Disease; Quality-Adjusted Life Years | 2017 |
Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Telemedicine; Time Factors; Treatment Outcome; Video Recording | 2017 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Parkinson Disease; Registries | 2017 |
Dopaminergic tone does not influence pain levels during placebo interventions in patients with chronic neuropathic pain.
Topics: Adult; Aged; Anesthetics, Local; Carbidopa; Chronic Pain; Dopamine; Dopamine Agents; Drug Combinations; Female; Haloperidol; Humans; Levodopa; Lidocaine; Male; Middle Aged; Motivation; Neuralgia; Placebo Effect; Placebos; Psychological Tests; Retrospective Studies; Suggestion | 2018 |
Levodopa-carbidopa intestinal gel therapy after deep brain stimulation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2018 |
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biological Availability; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; HeLa Cells; Humans; Levodopa; Male; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Permeability; Picolinic Acids; Prodrugs; Solubility; Structure-Activity Relationship | 2017 |
Post encephalitic parkinsonism following dengue viral infection.
Topics: Aged; Antibodies, Viral; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Immunoglobulin M; Levodopa; Male; Parkinson Disease, Postencephalitic; Severe Dengue; Sri Lanka | 2017 |
l-Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition; Deep Brain Stimulation; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome | 2017 |
Case 38-2017. A 20-Year-Old Woman with Seizures and Progressive Dystonia.
Topics: Basal Ganglia Diseases; Biotin; Brain; Carbidopa; Diagnosis, Differential; Drug Combinations; Dystonia; Female; Humans; Levodopa; Macula Lutea; Magnetic Resonance Imaging; Membrane Transport Proteins; Metabolism, Inborn Errors; Mutation; Optic Nerve; Seizures; Thiamine; Young Adult | 2017 |
Patient Preferences for Device-Aided Treatments Indicated for Advanced Parkinson Disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Choice Behavior; Deep Brain Stimulation; Drug Combinations; Drug Delivery Systems; Duodenum; Equipment Design; Female; Humans; Infusion Pumps; Internet; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Preference; Surveys and Questionnaires; United States | 2017 |
Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome.
Topics: 5-Hydroxytryptophan; Adolescent; Brain; Carbidopa; Dopamine; Drug Combinations; Humans; Intellectual Disability; Levodopa; Male; Mutation; p21-Activated Kinases; Psychotropic Drugs; Self-Injurious Behavior; Serotonin; Syndrome | 2018 |
Neither Cholinergic Nor Dopaminergic Enhancement Improve Spatial Working Memory Precision in Humans.
Topics: Acetylcholine; Adolescent; Adult; Carbidopa; Donepezil; Dopamine; Double-Blind Method; Drug Combinations; Female; Humans; Indans; Levodopa; Male; Memory, Short-Term; Neuropsychological Tests; Nootropic Agents; Piperidines; Psychometrics; Spatial Memory; Treatment Failure; Visual Perception; Young Adult | 2017 |
Continuous intestinal infusion of levodopa-carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community.
Topics: Antiparkinson Agents; Carbidopa; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Spain | 2021 |
Report: Preparation of levodopa/carbidopa compound drug resins.
Topics: Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Stability; Ion Exchange Resins; Levodopa; Technology, Pharmaceutical | 2018 |
Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait Disorders, Neurologic; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2018 |
Prelemniscal Lesion for Selective Improvement of Parkinson Disease Tremor.
Topics: Aged; Carbidopa; Drug Combinations; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome; Tremor; Ventral Thalamic Nuclei | 2018 |
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Glucagon-Like Peptide 1; Levodopa; Linagliptin; Mice; Mice, Inbred BALB C; NF-kappa B; Parkinsonian Disorders; Toll-Like Receptor 4; Transforming Growth Factor beta1 | 2018 |
Duodopa nasoduodenal tube at intrabronchial position.
Topics: Aged; Bronchi; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Humans; Intubation, Gastrointestinal; Levodopa | 2018 |
Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia.
Topics: Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Middle Aged | 2018 |
A wrinkle in ON-time - A GI structural abnormality confounding levodopa therapy with Duodopa rescue; a case study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Hernia, Hiatal; Humans; Levodopa; Male; Parkinson Disease | 2018 |
Clinical trials in ophthalmology, do we do what we must?
Topics: Adult; Amblyopia; Carbidopa; Child; Clinical Trials as Topic; Eye Diseases; Eye Protective Devices; Fibrinolysin; Helsinki Declaration; Human Experimentation; Humans; Intravitreal Injections; Levodopa; Ophthalmology; Peptide Fragments; Quality of Life; Retinal Perforations; Risk Assessment | 2018 |
Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Apomorphine; Carbidopa; Caregivers; Cost of Illness; Cross-Sectional Studies; Drug Combinations; Family; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Satisfaction; Quality of Life; Socioeconomic Factors; Surveys and Questionnaires; Treatment Outcome | 2018 |
Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Caregivers; Comorbidity; Cost of Illness; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Psychotropic Drugs; Quality of Life; Severity of Illness Index; Sleep; Treatment Outcome | 2018 |
Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Denmark; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies; Sweden | 2018 |
Jejunal pulling syndrome: A peculiar LCIG complication.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Drug Combinations; Gastric Bypass; Gels; Humans; Infusions, Parenteral; Intestinal Volvulus; Jejunum; Levodopa; Male; Parkinson Disease | 2018 |
Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease.
Topics: Animals; Brain; Carbidopa; Catalepsy; Chlorpromazine; Disease Models, Animal; Drug Combinations; Hydrogen-Ion Concentration; Levodopa; Parkinsonian Disorders; Rats; Water | 2018 |
Levodopa-carbidopa intestinal gel: is the naso-jejunal phase a redundant convention?
Topics: Administration, Intranasal; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Jejunostomy; Jejunum; Length of Stay; Levodopa; Male; Middle Aged; Parkinson Disease | 2018 |
Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Activities of Daily Living; Age Factors; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Europe; Female; Gels; Humans; International Cooperation; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2018 |
Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry.
Topics: Accelerometry; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Parkinson Disease; Precision Medicine; Quality of Life; Single-Blind Method; Tablets; Treatment Outcome | 2018 |
Acute cholecystitis induced by surgery for levodopa-carbidopa intestinal gel therapy: Possible relationship to pre-existing gallstones.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cholecystitis, Acute; Drug Combinations; Gallstones; Humans; Infusions, Parenteral; Jejunostomy; Levodopa; Male; Parkinson Disease | 2018 |
Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Biological Availability; Brain Chemistry; Capsules; Carbidopa; Catechols; Dopamine; Drug Compounding; Female; Hydrophobic and Hydrophilic Interactions; Levodopa; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Nitriles; Parkinson Disease | 2018 |
Micellar HPLC-UV method for the simultaneous determination of levodopa, carbidopa and entacapone in pharmaceuticals and human plasma.
Topics: Adult; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Humans; Levodopa; Limit of Detection; Linear Models; Male; Nitriles; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets | 2018 |
Lesson of the month 2: An unusual adverse reaction associated with pramipexole.
Topics: Carbidopa; Dermatitis, Phototoxic; Dopamine Agonists; Drug Combinations; Drug Substitution; Humans; Levodopa; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Pramipexole | 2018 |
Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Case-Control Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Parkinson Disease; Tablets; Young Adult | 2018 |
Independent effects of age and levodopa on reversal learning in healthy volunteers.
Topics: Adult; Aged; Aging; Carbidopa; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Drug Combinations; Humans; Levodopa; Punishment; Reversal Learning; Reward; Young Adult | 2018 |
[Outpatient establishment and initial management of treatment with intraduodenal levodopa-carbidopa infusion in advanced Parkinson's disease].
Topics: Aged; Algorithms; Ambulatory Care; Antiparkinson Agents; Carbidopa; Clinical Protocols; Disease Management; Drug Combinations; Duodenum; Female; Gastrostomy; Humans; Infusions, Parenteral; Intestinal Absorption; Intubation, Gastrointestinal; Levodopa; Male; Parkinson Disease | 2018 |
Assessment of Duodopa
Topics: Aged; Antiparkinson Agents; Carbidopa; Caregivers; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2018 |
Phytobezoar and duodenal ulcer as complication of Duodopa therapy in a patient affected by Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bezoars; Carbidopa; Catheters, Indwelling; Drug Combinations; Duodenal Ulcer; Endoscopy, Digestive System; Gastrostomy; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Tomography, X-Ray Computed | 2018 |
Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antiparkinson Agents; Carbidopa; Consensus; Drug Combinations; Europe; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Specialization; Young Adult | 2018 |
Levodopa-Carbidopa-Related Rash in Parkinson's Disease: A Case Series.
Topics: Adult; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Exanthema; Female; Humans; Levodopa; Middle Aged; Parkinson Disease | 2018 |
[Levodopa-carbidopa intestinal gel treatment introduced by surgical gastrostomy in a patient of Parkinson's disease after Billroth II gastrojejunostomy].
Topics: Aged; Antiparkinson Agents; Carbidopa; Dosage Forms; Drug Combinations; Drug Compounding; Duodenal Ulcer; Gastric Bypass; Gastrostomy; Gels; Humans; Levodopa; Male; Parkinson Disease; Treatment Outcome | 2018 |
The effect of continuous levodopa treatment during the afternoon hours.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Time Factors | 2019 |
Possible modulation of concurrent Parkinson's disease in the management of metastatic GIST: a review of two cases.
Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Levodopa; Liver Neoplasms; Male; Parkinson Disease; Severity of Illness Index; Stomach Neoplasms | 2018 |
[Vitamin B6 deficiency caused by the use of levodopa].
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Tablets; Vitamin B 6 Deficiency | 2018 |
Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Droxidopa; Drug Combinations; Female; Humans; Hypotension, Orthostatic; Kidney; Levodopa; Male; Middle Aged; Norepinephrine | 2019 |
Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Weight Loss | 2019 |
Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cost of Illness; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2019 |
Proposition of zinc supplementation during levodopa-carbidopa intestinal gel treatment.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Administration Routes; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Prospective Studies; Zinc | 2018 |
A case of Perry Syndrome responding to intestinal infusion of carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Depression; Drug Combinations; Female; Gels; Humans; Hypoventilation; Infusions, Parenteral; Jejunostomy; Levodopa; Middle Aged; Parkinsonian Disorders | 2019 |
Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose.
Topics: Aged; Carbidopa; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Patient Preference; Retrospective Studies | 2019 |
Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2018 |
Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Gels; Health Expenditures; Health Services; Health Status; Humans; Infusion Pumps, Implantable; Levodopa; Markov Chains; Models, Econometric; Parkinson Disease; Quality-Adjusted Life Years; Scotland; Severity of Illness Index; Wales | 2019 |
Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.
Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Registries | 2019 |
Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2019 |
Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2019 |
Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience.
Topics: Actigraphy; Administration, Oral; Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Carbidopa; Drug Combinations; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Wearable Electronic Devices | 2019 |
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Levodopa; Liraglutide; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Wistar; Rotenone; Sitagliptin Phosphate | 2019 |
A Man Made Manic: Levodopa-Carbidopa-Induced Mania in Traumatic Brain Injury.
Topics: Bipolar Disorder; Brain Injuries, Traumatic; Carbidopa; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Male; Middle Aged | 2019 |
[Analysis of PEG-J associated complications in 14 adult patients treated with levodopa-carbidopa intestinal gel].
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Diseases; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastrostomy; Gels; Humans; Intestinal Perforation; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Peritonitis; Retrospective Studies; Skin Diseases; Surgical Stomas | 2019 |
Managing treatment fluctuations in Parkinson disease: "On" again-, "off" again.
Topics: Carbidopa; Catechols; Humans; Levodopa; Nitriles; Parkinson Disease | 2019 |
Schlafen 12 mediates the effects of butyrate and repetitive mechanical deformation on intestinal epithelial differentiation in human Caco-2 intestinal epithelial cells.
Topics: Butyric Acid; Caco-2 Cells; Carbidopa; Carrier Proteins; Cell Differentiation; Dose-Response Relationship, Drug; Drug Combinations; Epithelial Cells; Gastrointestinal Motility; Gene Expression; Humans; Intestines; Levodopa; Peristalsis; Sucrase-Isomaltase Complex | 2019 |
[Complications and troubleshooting at the initial introduction of Levodopa-carbidopa continuous infusion gel therapy: A single-center study].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gastrostomy; Gels; Glycosides; Humans; Infusion Pumps; Intubation; Levodopa; Male; Middle Aged; Parkinson Disease; Pregnanes; Retrospective Studies; Skin Diseases, Infectious | 2019 |
Does levodopa have a disease-modifying effect in Parkinson's disease? Evidence from a delayed-start trial.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Parkinson Disease | 2019 |
Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
Topics: Administration, Mucosal; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gait; Gels; Humans; Intestinal Mucosa; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance | 2019 |
Acute parkinsonism as an unexpected consequence of pituitary adenoma resection: A case report.
Topics: Adenoma; Adult; Carbidopa; Drug Combinations; Female; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Myelinolysis, Central Pontine; Parkinsonian Disorders; Pituitary Neoplasms | 2019 |
Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Catalepsy; Chlorpromazine; Corpus Striatum; Diclofenac; Dopamine; Female; Levodopa; Male; Motor Activity; Neuroprotective Agents; Rats; Rats, Wistar | 2019 |
Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Drug Therapy, Combination; Fever; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2019 |
Dopamine dysregulation syndrome induced by proxy.
Topics: Aged; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Substance-Related Disorders; Syndrome | 2019 |
Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Carbidopa; Cognitive Dysfunction; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Drug Substitution; Electronic Health Records; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Technique and outcome of percutaneous endoscopic transgastric jejunostomy for continuous infusion of levodopa-carbidopa intestinal gel for treatment of Parkinson's disease.
Topics: Aged; Aged, 80 and over; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Female; Gels; Humans; Jejunostomy; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Retrospective Studies; Treatment Outcome | 2019 |
Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusion Pumps; Italy; Jejunum; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prospective Studies; Retrospective Studies; Treatment Outcome | 2019 |
Inhaled levodopa (Inbrija) for Parkinson's disease.
Topics: Administration, Inhalation; Antiparkinson Agents; Carbidopa; Drug Combinations; Dry Powder Inhalers; Humans; Levodopa; Parkinson Disease; Treatment Outcome | 2019 |
3D cloves bud like Gd doped ZnO strewn rGO hybrid for highly selective determination of l-dopa in the presence of carbidopa and ascorbic acid.
Topics: Ascorbic Acid; Carbidopa; Equipment Design; Graphite; Humans; Hydrogen-Ion Concentration; Levodopa; Limit of Detection; Mucuna; Nanocomposites; Nanoparticles; Reproducibility of Results; Seeds; Urinalysis; X-Ray Diffraction; Zinc Oxide | 2019 |
Levodopa/carbidopa intestinal gel infusion can improve camptocormia in Parkinson's disease.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Muscular Atrophy, Spinal; Parkinson Disease; Spinal Curvatures; Treatment Outcome | 2019 |
Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Germany; Humans; Infusions, Parenteral; Infusions, Subcutaneous; Levodopa; Neurology; Parkinson Disease; Practice Patterns, Physicians' | 2019 |
Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastrostomy; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Registries; Retrospective Studies | 2019 |
Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies | 2019 |
[Chronic inflammatory demyelinating polyradiculoneuropathy associated with treatment using intraduodenal infusion of levodopa-carbidopa].
Topics: Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Dopamine; Drug Combinations; Duodenum; Female; Folic Acid; Humans; Infusions, Parenteral; Levodopa; Metabolic Networks and Pathways; Methionine; Middle Aged; Parkinson Disease; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2019 |
Endoscopic management of duodenal levodopa-carbidopa therapy of advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenoscopy; Female; Gastrostomy; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine | 2019 |
Investigating Stochastic Differential Equations Modelling for Levodopa Infusion in Patients with Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Models, Biological; Parkinson Disease; Precision Medicine; Stochastic Processes | 2020 |
Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2019 |
Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cause of Death; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Prognosis; Retrospective Studies | 2020 |
Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catheters, Indwelling; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Endoscopy, Gastrointestinal; Female; France; Gastrostomy; Gels; Humans; Infusion Pumps; Intestinal Absorption; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2020 |
Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience
Topics: Activities of Daily Living; Aged; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reproducibility of Results | 2020 |
Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel.
Topics: Aged; Antiparkinson Agents; Carbidopa; Case-Control Studies; Cross-Sectional Studies; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gels; Humans; Intestines; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2019 |
Neurochemical supplementation in patients with depressed levels of participation after brain tumor surgery: Rationale and preliminary results.
Topics: Adult; Basal Ganglia; Brain; Brain Neoplasms; Carbidopa; Dietary Supplements; Drug Combinations; Female; Frontal Lobe; Humans; Levodopa; Male; Methylphenidate; Middle Aged; Patient Participation; Postoperative Period; Retrospective Studies | 2020 |
Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinsonian Disorders; Sensitivity and Specificity; Severity of Illness Index; Tremor | 2020 |
Clinical Trial Highlights - Infusion Therapies.
Topics: Apomorphine; Carbidopa; Clinical Trials as Topic; Dopamine Agonists; Drug Combinations; Gels; Humans; Infusion Pumps, Implantable; Infusions, Subcutaneous; Jejunum; Levodopa; Parkinson Disease | 2020 |
Transient parkinsonism associated with acute Legionnaires' disease.
Topics: Adult; Anti-Bacterial Agents; Antiparkinson Agents; Carbidopa; Ciprofloxacin; Drug Combinations; Drug Therapy, Combination; Dysarthria; Humans; Legionella; Legionnaires' Disease; Levodopa; Male; Parkinsonian Disorders; Respiratory Insufficiency | 2020 |
Supplementary management with Pycnogenol® in Parkinson's disease to prevent cognitive impairment.
Topics: Carbidopa; Cognition; Cognitive Dysfunction; Dietary Supplements; Drug Combinations; Female; Free Radicals; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Registries | 2020 |
An Evaluation of the Effects of Pyridoxal Phosphate in Chlorpromazineinduced Parkinsonism using Mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Body Weight; Carbidopa; Chlorpromazine; Diet; Drug Combinations; Eating; Grooming; Levodopa; Lipid Peroxidation; Mice; Motor Activity; Parkinson Disease, Secondary; Pyridoxal Phosphate | 2020 |
Child Neurology: A young child with an undiagnosed case of dystonia responsive to l-dopa.
Topics: Anti-Dyskinesia Agents; Carbidopa; Child, Preschool; Diagnosis, Differential; Drug Combinations; Dystonic Disorders; Humans; Levodopa; Male | 2020 |
Istradefylline (Nourianz) for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Drug Administration Schedule; Humans; Levodopa; Parkinson Disease; Purines | 2020 |
"On-State" Freezing of Gait: Insights and Treatment With Levodopa Intestinal Gel Infusion.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gait; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Parkinson Disease | 2020 |
A rapid liquid chromatography/tandem mass spectrometry method for simultaneous determination of levodopa, carbidopa, entacapone and their six related compounds in film-coated tablets.
Topics: Carbidopa; Catechols; Chromatography, High Pressure Liquid; Levodopa; Limit of Detection; Linear Models; Nitriles; Reproducibility of Results; Tablets; Tandem Mass Spectrometry | 2020 |
Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gait; Gels; Humans; Levodopa; Parkinson Disease; Pilot Projects; Posture | 2020 |
The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infant, Newborn; Levodopa; Male; Parkinson Disease; Quality of Life | 2020 |
Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Infusions, Parenteral; Italy; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease; Patient Dropouts; Sex Factors | 2020 |
Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Italy; Levodopa; Parkinson Disease; Quality of Life | 2020 |
[Movement Disorders: What Are You Doing? What Can We Do?]
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Dopamine Agonists; Essential Tremor; Humans; Levodopa; Parkinson Disease | 2020 |
Outcome of Parkinson's Disease Patients Affected by COVID-19.
Topics: Aged; Aged, 80 and over; Betacoronavirus; Carbidopa; Coronavirus Infections; COVID-19; Female; Humans; Levodopa; Male; Pandemics; Parkinson Disease; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Case Report: Dengue Virus-Triggered Parkinsonism in an Adolescent.
Topics: Adolescent; Antiparkinson Agents; Brain; Carbidopa; Dengue; Diffusion Magnetic Resonance Imaging; Drug Combinations; Electroencephalography; Humans; India; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Treatment Outcome | 2020 |
Levodopa infusion in Parkinson's disease: Individual quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Caregivers; Cost of Illness; Drug Combinations; Female; Humans; Infusions, Parenteral; Jejunum; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Prospective Studies; Psychomotor Performance; Quality of Life; Treatment Outcome | 2020 |
Biphasic Levodopa-Induced Freezing of Gait in Parkinson's Disease.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinson Disease | 2020 |
[New Therapeutic Options for the Individualised Titration of Levodopa].
Topics: Antiparkinson Agents; Carbidopa; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2021 |
Pearls and Oy-sters: Vitamin B
Topics: Aged, 80 and over; Antiparkinson Agents; Carbidopa; Electroencephalography; Epilepsy; Fatal Outcome; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Status Epilepticus; Vitamin B 6 Deficiency | 2020 |
Levodopa-carbidopa intestinal gel is an option in Parkinson's disease with hyponatremia induced by dopamine agonists.
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Gels; Humans; Hyponatremia; Levodopa; Parkinson Disease | 2020 |
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2020 |
Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?
Topics: Aged; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cost Savings; Delivery of Health Care; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Retrospective Studies | 2020 |
Quality Improvement in Parkinson's Disease: A Successful Program to Enhance Timely Administration of Levodopa in the Hospital.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Hospital Departments; Hospitalization; Hospitals, Urban; Humans; Length of Stay; Levodopa; Male; Middle Aged; Parkinson Disease; Process Assessment, Health Care; Quality Improvement; Time Factors | 2020 |
Levodopa Positively Affects Neovascular Age-Related Macular Degeneration.
Topics: Aged; Aged, 80 and over; Carbidopa; Cohort Studies; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Macular Degeneration; Male; Middle Aged; Pilot Projects; Treatment Outcome | 2021 |
Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data.
Topics: Aged; Carbidopa; Dopamine Agonists; Drug Combinations; Female; Gels; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Levodopa; Male; Medication Adherence; Middle Aged; Parkinson Disease | 2020 |
EQUIDopa: A responsive web application for the levodopa equivalent dose calculator.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2020 |
Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2020 |
Neurochemical, neurobehavioral and histochemical effects of therapeutic dose of l-dopa on striatal neurons in rats: Protective effect of virgin coconut oil.
Topics: Animals; Behavior, Animal; Carbidopa; Coconut Oil; Corpus Striatum; Levodopa; Male; Neurons; Neuroprotective Agents; Parkinson Disease; Rats, Sprague-Dawley | 2020 |
Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
Topics: Abdomen, Acute; Aged; Carbidopa; Catheterization; Deglutition Disorders; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Dysarthria; Dyskinesias; Endoscopy; Female; Gait; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome; Turkey | 2021 |
Intrajejunal vs oral levodopa-carbidopa therapy in Parkinson disease: A retrospective cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carbidopa; Cohort Studies; Drug Combinations; Female; Humans; Injections; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Romania | 2020 |
Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrointestinal Microbiome; Gels; Humans; Levodopa; Metabolome; Parkinson Disease; RNA, Ribosomal, 16S | 2021 |
Intestinal burying of the jejunal-tube of a PEG-J levodopa-carbidopa release system for Parkinson's disease. Successful endoscopic management.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Jejunum; Levodopa; Parkinson Disease | 2021 |
Parkinson Disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Drug Combinations; Family Practice; Humans; Levodopa; Parkinson Disease; Physical Therapy Modalities | 2020 |
Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gait Disorders, Neurologic; Gels; Humans; Italy; Levodopa; Parkinson Disease; Quality of Life | 2021 |
Real-world assessment of the impact of "OFF" episodes on health-related quality of life among patients with Parkinson's disease in the United States.
Topics: Aged; Carbidopa; Cross-Sectional Studies; Drug Combinations; Female; Health Status; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Regression Analysis; Surveys and Questionnaires; Symptom Flare Up; United States | 2021 |
Device-aided therapies for advanced Parkinson disease: insights from an international survey.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Parkinson Disease | 2021 |
Melanocytic Hyperactivation Simulating an Acral Lentiginous Melanoma in a Patient With Parkinson Disease Treated by Levodopa.
Topics: Aged; Antiparkinson Agents; Carbidopa; Diagnosis, Differential; Drug Combinations; Female; Humans; Hyperpigmentation; Levodopa; Melanins; Melanocytes; Melanoma; Parkinson Disease; Predictive Value of Tests; Skin; Skin Neoplasms; Skin Pigmentation; Treatment Outcome | 2021 |
Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Dopaminergic Neurons; Drug Combinations; Electroencephalography; Insulin-Like Growth Factor I; Levodopa; Male; Medial Forebrain Bundle; Mesenchymal Stem Cell Transplantation; Motor Activity; Nerve Growth Factor; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Substantia Nigra; Wharton Jelly | 2021 |
Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19.
Topics: Blood Coagulation; Brain Diseases; Carbidopa; Central Nervous System Stimulants; Cognitive Dysfunction; COVID-19; Critical Care; Drug Combinations; Humans; Hypokinesia; Ischemic Stroke; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Modafinil; Rehabilitation; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Ventilator Weaning | 2021 |
Buried Bumper Syndrome: A common complication of levodopa intestinal infusion for Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Endoscopy, Gastrointestinal; Enteral Nutrition; Equipment Failure; Female; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Parkinson Disease; Postoperative Complications; Prospective Studies; Retrospective Studies | 2021 |
Effect of levodopa/carbidopa on stress response in zebrafish.
Topics: Adrenal Glands; alpha-Methyltyrosine; Animals; Carbidopa; Dopamine; Dopamine Agonists; Dopaminergic Neurons; Drug Combinations; Enzyme Inhibitors; Female; Hydrocortisone; Hypothalamo-Hypophyseal System; Levodopa; Male; Stress, Physiological; Tyrosine 3-Monooxygenase; Zebrafish; Zebrafish Proteins | 2021 |
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2021 |
Monozygotic twins with DYT-TOR1A showing jerking movements and levodopa responsiveness.
Topics: Adolescent; Carbidopa; Dopamine Agents; Drug Combinations; Dystonic Disorders; Humans; Levodopa; Male; Molecular Chaperones; Twins, Monozygotic | 2021 |
Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens.
Topics: Administration, Topical; Animals; Animals, Newborn; Biomarkers; Carbidopa; Chickens; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Injections, Intraperitoneal; Levodopa; Male; Mitosis; Myopia; Ophthalmic Solutions; Sensory Deprivation; Vitreous Body | 2021 |
Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Cohort Studies; Colitis, Microscopic; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2021 |
Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Body Weight; Carbidopa; Catalase; Catalepsy; Disease Models, Animal; Dopamine; Drug Combinations; Female; Glutathione; Levodopa; Locomotion; Male; Mesencephalon; Muscular Diseases; Oxidative Stress; Parkinson Disease; Postural Balance; Rats, Sprague-Dawley; Rotenone; Superoxides; Thiobarbituric Acid Reactive Substances; Vanillic Acid | 2021 |
Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2021 |
The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinson's Disease Population.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Parkinson Disease; Social Values | 2020 |
[Optimal dose of levodopa-carbidopa intestinal gel in the treatment of diphasic dyskinesia and freezing of gait].
Topics: Activities of Daily Living; Carbidopa; Dyskinesias; Gait; Gait Disorders, Neurologic; Humans; Levodopa; Middle Aged; Parkinson Disease | 2021 |
Exogenous glutathione exerts a therapeutic effect in ischemic stroke rats by interacting with intrastriatal dopamine.
Topics: Animals; Carbidopa; Cytokines; Disease Models, Animal; Dopamine; Glutathione; Homocystine; Infarction, Middle Cerebral Artery; Ischemic Stroke; Levodopa; Male; Oxidative Stress; Proteomics; Rats; Rats, Wistar; Reperfusion Injury; Tyrosine 3-Monooxygenase; Up-Regulation | 2022 |
Impact of an Augmented Reality Navigation System (SIRIO) on Bone Percutaneous Procedures: A Comparative Analysis with Standard CT-Guided Technique.
Topics: Augmented Reality; Carbidopa; Drug Combinations; Humans; Image-Guided Biopsy; Levodopa; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrointestinal Microbiome; Gels; Humans; Levodopa; Parkinson Disease | 2022 |
Body mass index variations in patients with Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion: A case control study versus standard of care and subthalamic nucleus deep brain stimulation.
Topics: Antiparkinson Agents; Body Mass Index; Carbidopa; Case-Control Studies; Deep Brain Stimulation; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Standard of Care; Subthalamic Nucleus | 2021 |
The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastric Bypass; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2021 |
Secondary biogenic amine deficiencies: genetic etiology, therapeutic interventions, and clinical effects.
Topics: Adolescent; Adult; Biogenic Amines; Carbidopa; Child; Child, Preschool; Drug Combinations; Female; Humans; Kinesins; Levodopa; Male; Neurotransmitter Agents; p21-Activated Kinases; Young Adult | 2021 |
Per-oral image guided gastrojejunostomy insertion for levodopa-carbidopa intestinal gel in Parkinson's disease is safe and may be advantageous.
Topics: Aged; Antiparkinson Agents; Carbidopa; Digestive System Surgical Procedures; Drug Combinations; Female; Gastrostomy; Gels; Humans; Jejunum; Levodopa; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parkinson Disease; Surgery, Computer-Assisted | 2021 |
Scalable Asymmetric Syntheses of Foslevodopa and Foscarbidopa Drug Substances for the Treatment of Parkinson's Disease.
Topics: Carbidopa; Humans; Hydrogenation; Levodopa; Parkinson Disease; Pharmaceutical Preparations | 2022 |
Surgical treatment of buried bumper syndrome in patients with Parkinson´s disease and duodenal levodopa/carbidopa infusion therapy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Enteral Nutrition; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2021 |
Measuring General Expectations of Advanced Stage Treatment Outcomes in Parkinson's Disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Levodopa; Male; Middle Aged; Motivation; Parkinson Disease; Prognosis; Treatment Outcome | 2021 |
Effect of catechin and commercial preparation of green tea essence on the pharmacokinetics of l-dopa in rabbits.
Topics: Animals; Biological Availability; Carbidopa; Catechin; Catechol O-Methyltransferase; Chromatography, Liquid; Herb-Drug Interactions; Levodopa; Male; Rabbits; Reproducibility of Results; Tandem Mass Spectrometry; Tea; Tyrosine | 2021 |
Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2021 |
Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial.
Topics: Acute Coronary Syndrome; Aspirin; Carbidopa; Drug Combinations; Humans; Levodopa; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel.
Topics: Antiparkinson Agents; Carbidopa; Gels; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2021 |
Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study).
Topics: Acute Disease; Carbidopa; COVID-19; Drug Combinations; Heart Failure; Humans; Levodopa; Pandemics; Retrospective Studies; SARS-CoV-2 | 2022 |
Melanochrome-based colorimetric assay for quantitative detection of levodopa in co-presence of carbidopa and its application to relevant anti-Parkinson drugs.
Topics: Antiparkinson Agents; Carbidopa; Colorimetry; Drug Combinations; Humans; Levodopa; Parkinson Disease; Tablets | 2022 |
Modulation of dopamine tone induces frequency shifts in cortico-basal ganglia beta oscillations.
Topics: Action Potentials; Animals; Basal Ganglia; Beta Rhythm; Carbidopa; Cerebral Cortex; Chlorocebus aethiops; Dopamine; Electrodes, Implanted; Eye-Tracking Technology; Female; Humans; Levodopa; Magnetic Resonance Imaging; Nerve Net; Organic Chemicals; Parkinson Disease; Parkinsonian Disorders; Pupil; Stereotaxic Techniques | 2021 |
Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
Topics: Activities of Daily Living; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2022 |
Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats.
Topics: Animals; Bacteria; Carbidopa; Cross-Sectional Studies; Gastrointestinal Microbiome; Gastrointestinal Motility; Humans; Levodopa; Parkinson Disease; Rats; Tyrosine Decarboxylase | 2022 |
Recessive GCH1 Deficiency Causing DOPA-Responsive Dystonia Diagnosed by Reported Negative Exome.
Topics: Carbidopa; Child; Dopamine Agonists; Drug Combinations; Dystonic Disorders; Exome; Exome Sequencing; GTP Cyclohydrolase; Humans; Levodopa; Male | 2022 |
Spinocerebellar ataxia type 3: response to levodopa infusion in two cases.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Machado-Joseph Disease; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders | 2022 |
[Adverse effects and complications of continuous intestinal infusion of levodopa-carbidopa in a cohort of patients with Parkinson's disease in a tertiary hospital].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Tertiary Care Centers | 2022 |
Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; United States; United States Food and Drug Administration | 2022 |
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Drug Combinations; Gels; Humans; Levodopa; Neurodegenerative Diseases; Parkinson Disease; Quality of Life | 2022 |
[Real-time 3D reconstruction CT-jejunography guided direct percutaneous endoscopic jejunostomy for levodopa-carbidopa intestinal gel treatment in a patient with prior gastrojejunostomy].
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gastric Bypass; Gels; Humans; Imaging, Three-Dimensional; Jejunostomy; Levodopa; Tomography, X-Ray Computed | 2022 |
Letter to the editor, "Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications".
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2022 |
Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Pain; Parkinson Disease | 2022 |
Continuous Dopaminergic Stimulation Improves Cortical Maladaptive Changes in Advanced Parkinson's Disease.
Topics: Carbidopa; Dopamine; Dyskinesias; Humans; Levodopa; Motor Cortex; Parkinson Disease | 2022 |
The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2022 |
A rare complication of jejunal extension of a percutaneous endoscopic gastrostomy tube for levodopa-carbidopa intestinal gel administration.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrostomy; Gels; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2022 |
Refractory status epilepticus due to vitamin B
Topics: Carbidopa; Humans; Levodopa; Parkinson Disease; Status Epilepticus; Vitamin B 6; Vitamins | 2022 |
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Homocysteine; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2022 |
Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts.
Topics: Aged; Anemia; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Myelodysplastic Syndromes; Parkinson Disease; Pyridoxine; Vitamin B 6; Vitamin B 6 Deficiency | 2022 |
Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE-PD observational study.
Topics: Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Severity of Illness Index | 2022 |
Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide.
Topics: Antiparkinson Agents; Ascorbic Acid; Carbidopa; Humans; Levodopa; Magnesium Oxide; Parkinson Disease | 2022 |
Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Retrospective Studies | 2022 |
Up-regulated expression of miRNA-29b in patients with Parkinson's disease on levodopa gel infusion.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Infusions, Parenteral; Levodopa; MicroRNAs; Parkinson Disease | 2023 |
Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson's disease on levodopa/carbidopa intestinal gel infusion.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies; Weight Loss | 2022 |
Ten-year trends of the characteristics in patients with advanced Parkinson's disease at the time of intestinal gel therapy introduction
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gels; Humans; Levodopa; Male; Neurodegenerative Diseases; Parkinson Disease; Retrospective Studies | 2022 |
Adverse effects of levodopa/carbidopa intrajejunal gel treatment: A single-center long-term follow-up study.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Follow-Up Studies; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life | 2022 |
Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Drug Combinations; Homocysteine; Humans; Levodopa; Parkinson Disease; Pilot Projects; Quality of Life; Tolcapone | 2022 |
Application of net analyte signal and principal component regression for rapid simultaneous determination of Levodopa and carbidopa in commercial pharmaceutical formulation and breast (human) milk sample using spectrophotometric method.
Topics: Animals; Calibration; Carbidopa; Drug Compounding; Female; Humans; Least-Squares Analysis; Levodopa; Milk; Spectrophotometry | 2022 |
Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa-carbidopa intestinal gel infusion: Analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS).
Topics: Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Parkinson Disease; Quality of Life; Retrospective Studies | 2022 |
How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Gait Disorders, Neurologic; Gels; Humans; Levodopa; Middle Aged; Parkinson Disease; Posture | 2023 |
Phytoconstituents of Datura metel extract improved motor coordination in haloperidol-induced cataleptic mice: Dual-target molecular docking and behavioural studies.
Topics: alpha-Synuclein; Animals; Antioxidants; Antiparkinson Agents; Atropine Derivatives; Carbidopa; Cholinergic Antagonists; Datura metel; Dopa Decarboxylase; Haloperidol; Levodopa; Methanol; Mice; Molecular Docking Simulation; Parkinson Disease; Phytochemicals; Plant Extracts; Scopolamine | 2023 |
Neurologists' preferences for device-aided therapy for advanced Parkinson's disease in Japan.
Topics: Antiparkinson Agents; Bayes Theorem; Carbidopa; Humans; Japan; Levodopa; Neurologists; Parkinson Disease | 2023 |
Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring.
Topics: Aged; Antiparkinson Agents; Carbidopa; Female; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies | 2022 |
Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.
Topics: Carbidopa; Drugs, Generic; Humans; Levodopa; Solubility; Therapeutic Equivalency | 2022 |
Revisiting levodopa for advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Humans; Levodopa; Parkinson Disease | 2022 |
Determination of the motor status of patients with advanced Parkinson's disease under levodopa-carbidopa intestinal gel using a machine learning model.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2023 |
Impact of concomitant use of opicapone during levodopa-carbidopa intestinal gel treatment.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Oxadiazoles | 2023 |
Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy.
Topics: Animals; Carbidopa; Catalepsy; Dopamine; Levodopa; Parkinson Disease; Rats | 2022 |
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: long-term results from COSMOS.
Topics: Antiparkinson Agents; Carbidopa; Cross-Sectional Studies; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome.
Topics: Carbidopa; Enteral Nutrition; Gastrostomy; Humans; Levodopa; Parkinson Disease | 2023 |
Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Humans; Learning; Levodopa; Parkinson Disease; Time Factors | 2023 |
The impact of dysphagia in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel.
Topics: Antiparkinson Agents; Carbidopa; Deglutition Disorders; Dementia; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 2023 |
3-Methoxytyrosine as an indicator of dopaminergic manipulation in equine plasma.
Topics: Animals; Carbidopa; Catechol O-Methyltransferase; Catechols; Dopamine; Horses; Levodopa | 2023 |
Diagnosis of autism in a rare case of tyrosine hydroxylase deficiency: a case report.
Topics: Autism Spectrum Disorder; Autistic Disorder; Carbidopa; Child, Preschool; Humans; Language Development Disorders; Levodopa; Male | 2023 |
New-onset impulse control disorders after treatment with levodopa-carbidopa intestinal gel in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Disruptive, Impulse Control, and Conduct Disorders; Humans; Levodopa; Parkinson Disease | 2023 |
Levodopa/carbidopa intestinal gel via percutaneous endoscopic transgastric jejunostomy in advanced Parkinson's disease: hitting two birds with one stone?
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Jejunostomy; Levodopa; Parkinson Disease | 2023 |
Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Prospective Studies | 2023 |
Fecal microbiota transplantation for Parkinson's disease using levodopa - carbidopa intestinal gel percutaneous endoscopic gastro-jejeunal tube.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Fecal Microbiota Transplantation; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
Development and Validation of a New LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Levodopa, Levodopa Methyl Ester, and Carbidopa in Human Plasma Samples.
Topics: Carbidopa; Chromatography, Liquid; Humans; Levodopa; Male; Middle Aged; Reproducibility of Results; Tandem Mass Spectrometry | 2023 |
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Prospective Studies; Quality of Life | 2023 |
Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2023 |
Response to 'Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out'.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease; Polyneuropathies | 2023 |
Development of an immediate release excipient composition for 3D printing via direct powder extrusion in a hospital.
Topics: Carbidopa; Drug Liberation; Excipients; Hospitals; Levodopa; Powders; Printing, Three-Dimensional; Tablets; Technology, Pharmaceutical | 2023 |
Are Parkinson's disease patients referred too late for device-aided therapies and how can better informed and earlier referrals be encouraged?
Topics: Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Classification of l-DOPA pharmacokinetics shapes and creating a predictive model.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2023 |
Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson's Disease Treatment.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Jejunostomy; Levodopa; Parkinson Disease; Quality of Life | 2023 |
Human equivalent doses of L-DOPA rescues retinal morphology and visual function in a murine model of albinism.
Topics: Albinism; Animals; Carbidopa; Disease Models, Animal; Humans; Levodopa; Mice; Mice, Inbred C57BL | 2023 |
Antinociceptive effects of carbidopa levodopa on normal rats and Parkinson's disease mice.
Topics: Analgesics; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Humans; Levodopa; Mice; Pain; Parkinson Disease; Rats | 2023 |
Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Subcutaneous; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies | 2023 |
Quantitative Colorimetric Sensing of Carbidopa in Anti-Parkinson Drugs Based on Selective Reaction with Indole-3-Carbaldehyde.
Topics: Antiparkinson Agents; Carbidopa; Colorimetry; Humans; Levodopa; Quality of Life; Reproducibility of Results | 2023 |